

Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults

Alimentary Pharmacology and Therapeutics

34, 274-285

DOI: [10.1111/j.1365-2036.2011.04724.x](https://doi.org/10.1111/j.1365-2036.2011.04724.x)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Vitamin E for Nonalcoholic Fatty Liver Disease. <i>Nutrition in Clinical Practice</i> , 2011, 26, 636-637.	1.1	1
2	Differential effects of shiitake- and white button mushroom-supplemented diets on hepatic steatosis in C57BL/6 mice. <i>Food and Chemical Toxicology</i> , 2011, 49, 3074-3080.	1.8	20
3	Overexpression of 11 β -hydroxysteroid dehydrogenase type 1 in visceral adipose tissue and portal hypercortisolism in nonalcoholic fatty liver disease. <i>Liver International</i> , 2012, 32, 392-399.	1.9	42
5	Prognosis and staging of non-alcoholic fatty liver disease. <i>BMJ: British Medical Journal</i> , 2011, 343, d7302-d7302.	2.4	8
6	Critical care outcomes. <i>Current Opinion in Critical Care</i> , 2011, 17, 493-494.	1.6	2
7	Nonalcoholic steatohepatitis. <i>Current Opinion in Lipidology</i> , 2011, 22, 479-488.	1.2	98
8	Beneficial Effects of <i>Ocimum gratissimum</i> Aqueous Extract on Rats with CCl ₄ -Induced Acute Liver Injury. <i>Evidence-based Complementary and Alternative Medicine</i> , 2012, 2012, 1-9.	0.5	23
9	Excess body fat in obese and normal-weight subjects. <i>Nutrition Research Reviews</i> , 2012, 25, 150-161.	2.1	130
10	Nonalcoholic fatty liver disease and vascular risk. <i>Current Opinion in Cardiology</i> , 2012, 27, 420-428.	0.8	53
11	Serum biomarkers in nonalcoholic steatohepatitis: value for assessing drug effects?. <i>Biomarkers in Medicine</i> , 2012, 6, 743-757.	0.6	9
12	Prevalence of cirrhosis in patients with thrombocytopenia who receive bone marrow biopsy. <i>Saudi Journal of Gastroenterology</i> , 2012, 18, 257.	0.5	24
13	Management of Nonalcoholic Fatty Liver Disease. <i>JAMA - Journal of the American Medical Association</i> , 2012, 308, 608-16.	3.8	18
14	The Association between Nonalcoholic Fatty Liver Disease, Metabolic Syndrome and Arterial Stiffness in Nondiabetic, Nonhypertensive Individuals. <i>Cardiology</i> , 2012, 123, 54-61.	0.6	51
15	Nonalcoholic Fatty Liver Disease in Lean Individuals in the United States. <i>Medicine (United States)</i> , 2012, 91, 319-327.	0.4	441
16	Triangulated Mal-Signaling in Alzheimer's Disease: Roles of Neurotoxic Ceramides, ER Stress, and Insulin Resistance Reviewed. <i>Journal of Alzheimer's Disease</i> , 2012, 30, S231-S249.	1.2	78
17	Fatty Liver: A Link to Cardiovascular Disease – Its Natural History, Pathogenesis, and Treatment. <i>Methodist DeBakey Cardiovascular Journal</i> , 2021, 8, 21.	0.5	14
18	High ambulatory blood pressure values associated with non-alcoholic fatty liver in middle-aged adults. <i>Journal of Hypertension</i> , 2012, 30, 2015-2019.	0.3	32
19	Nonalcoholic Fatty Liver Disease. <i>Journal of Clinical Gastroenterology</i> , 2012, 46, 272-284.	1.1	124

#	ARTICLE	IF	CITATIONS
20	The Role of Nutrients in the Development, Progression, and Treatment of Nonalcoholic Fatty Liver Disease. <i>Journal of Clinical Gastroenterology</i> , 2012, 46, 457-467.	1.1	96
21	Recent Advances on Stearoyl-Coa Desaturase Regulation in Fatty Liver Diseases. <i>Current Drug Metabolism</i> , 2012, 13, 1454-1463.	0.7	20
22	Essential roles of growth hormone (GH) and insulin-like growth factor-I (IGF-I) in the liver [Review]. <i>Endocrine Journal</i> , 2012, 59, 955-962.	0.7	74
23	Pediatric nonalcoholic fatty liver disease: a multidisciplinary approach. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2012, 9, 152-161.	8.2	99
24	Review article: the reversibility of cirrhosis. <i>Alimentary Pharmacology and Therapeutics</i> , 2012, 36, 824-832.	1.9	63
25	Review article: is non-alcoholic fatty liver disease a spectrum, or are steatosis and non-alcoholic steatohepatitis distinct conditions?. <i>Alimentary Pharmacology and Therapeutics</i> , 2012, 36, 815-823.	1.9	173
26	Prevalence and risk factors for non-alcoholic fatty liver disease in Asian people who are not obese. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2012, 27, 1555-1560.	1.4	174
27	The Diagnosis and Management of Non-alcoholic Fatty Liver Disease: Practice Guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. <i>Gastroenterology</i> , 2012, 142, 1592-1609.	0.6	1,486
28	Human serum proteome analysis: new source of markers in metabolic disorders. <i>Biomarkers in Medicine</i> , 2012, 6, 759-773.	0.6	21
29	Does fructose consumption contribute to non-alcoholic fatty liver disease?. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2012, 36, 554-560.	0.7	85
30	Describing the role of ethnicity in the progression of NAFLD: Easier said than done?. <i>Hepatology</i> , 2012, 56, 2005-2005.	3.6	2
31	Reducing the load: The evolution and management of obesity and nonalcoholic steatohepatitis before liver transplantation. <i>Liver Transplantation</i> , 2012, 18, S52-S58.	1.3	17
32	Noninvasive Assessment of Nonalcoholic Fatty Liver Disease in Obese or Overweight Patients. <i>Clinical Gastroenterology and Hepatology</i> , 2012, 10, 1162-1168.	2.4	65
33	Serum parameters predict the severity of ultrasonographic findings in non-alcoholic fatty liver disease. <i>Hepatobiliary and Pancreatic Diseases International</i> , 2012, 11, 513-520.	0.6	32
34	Prevalence and Indicators of Portal Hypertension in Patients With Nonalcoholic Fatty Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2012, 10, 1028-1033.e2.	2.4	76
35	Nonalcoholic Fatty Liver Disease: A Nutritional Approach. <i>Metabolic Syndrome and Related Disorders</i> , 2012, 10, 161-166.	0.5	22
36	Serum interleukin 1 receptor antagonist as an independent marker of non-alcoholic steatohepatitis in humans. <i>Journal of Hepatology</i> , 2012, 56, 663-670.	1.8	87
37	Evaluation of inflammatory and angiogenic factors in patients with non-alcoholic fatty liver disease. <i>Cytokine</i> , 2012, 59, 442-449.	1.4	100

#	ARTICLE	IF	CITATIONS
38	Serum proteomics for biomarker discovery in nonalcoholic fatty liver disease. <i>Clinica Chimica Acta</i> , 2012, 413, 1190-1193.	0.5	12
39	Leptin in the Liver: A Toxic or Beneficial Mix?. <i>Cell Metabolism</i> , 2012, 16, 1-2.	7.2	14
40	Management of nonalcoholic fatty liver disease: Role of bariatric surgery. <i>Clinical Liver Disease</i> , 2012, 1, 119-121.	1.0	0
41	Hepatic steatosis and steatohepatitis in human immunodeficiency virus/hepatitis C virus-coinfected patients. <i>Hepatology</i> , 2012, 56, 1261-1270.	3.6	37
42	Food restriction and refeeding induces changes in lipid pathways and fat deposition in the adipose and hepatic tissues in rats with diet-induced obesity. <i>Experimental Physiology</i> , 2012, 97, 882-894.	0.9	24
43	Prevalence and factors associated with nonalcoholic fatty liver disease in shanghai work-units. <i>BMC Gastroenterology</i> , 2012, 12, 123.	0.8	77
44	Non-alcoholic fatty liver disease. <i>Journal of Diabetes</i> , 2012, 4, 266-280.	0.8	46
45	Assessment of non-alcoholic fatty liver disease using serum total cell death and apoptosis markers. <i>Alimentary Pharmacology and Therapeutics</i> , 2012, 36, 1057-1066.	1.9	61
46	Nonalcoholic Fatty Liver Disease/Steatohepatitis: Epidemiology, Pathogenesis, Clinical Presentation and Treatment. <i>Digestive Diseases</i> , 2012, 30, 158-162.	0.8	165
47	The potential role of fatty liver in paediatric metabolic syndrome: a distinct phenotype with high metabolic risk?. <i>Pediatric Obesity</i> , 2012, 7, e75-80.	1.4	26
48	Epidemiology and Natural History of Non-alcoholic Fatty Liver Disease. <i>Journal of Clinical and Experimental Hepatology</i> , 2012, 2, 135-144.	0.4	70
49	Management of Non-alcoholic Fatty Liver Disease and Steatohepatitis. <i>Journal of Clinical and Experimental Hepatology</i> , 2012, 2, 156-173.	0.4	32
50	Role of Obesity and Lipotoxicity in the Development of Nonalcoholic Steatohepatitis: Pathophysiology and Clinical Implications. <i>Gastroenterology</i> , 2012, 142, 711-725.e6.	0.6	711
51	Increased insulinogenic index is an independent determinant of nonalcoholic fatty liver disease activity score in patients with normal glucose tolerance. <i>Digestive and Liver Disease</i> , 2012, 44, 935-939.	0.4	4
52	The lipid accumulation product is highly related to serum alanine aminotransferase level in male adults. <i>Nutrition Research</i> , 2012, 32, 581-587.	1.3	8
53	The Diagnosis and Management of Non-alcoholic Fatty Liver Disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. <i>American Journal of Gastroenterology</i> , 2012, 107, 811-826.	0.2	359
54	Metabolic syndrome and risk factors for non-alcoholic fatty liver disease. <i>Arquivos De Gastroenterologia</i> , 2012, 49, 89-96.	0.3	158
55	Causative role of gut microbiota in non-alcoholic fatty liver disease pathogenesis. <i>Frontiers in Cellular and Infection Microbiology</i> , 2012, 2, 132.	1.8	44

#	ARTICLE	IF	CITATIONS
56	Transient elastography in non-alcoholic fatty liver disease. <i>Annals of Hepatology</i> , 2012, 11, 172-178.	0.6	48
57	Ursodeoxycholic acid for nonalcoholic steatohepatitis. <i>European Journal of Gastroenterology and Hepatology</i> , 2012, 24, 1.	0.8	11
58	Disruption of phospholipid and bile acid homeostasis in mice with nonalcoholic steatohepatitis. <i>Hepatology</i> , 2012, 56, 118-129.	3.6	215
59	The diagnosis and management of non-alcoholic fatty liver disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. <i>Hepatology</i> , 2012, 55, 2005-2023.	3.6	2,935
61	Sulfated oxysterols as candidates for the treatment of nonalcoholic fatty liver disease. <i>Metabolism: Clinical and Experimental</i> , 2012, 61, 755-758.	1.5	4
62	Review article: fructose in non-alcoholic fatty liver disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2012, 35, 1135-1144.	1.9	54
63	Cirrhosis and mortality risks of biopsy-verified alcoholic pure steatosis and steatohepatitis: a nationwide registry-based study. <i>Alimentary Pharmacology and Therapeutics</i> , 2012, 35, 1336-1342.	1.9	55
64	Correlation between liver histology and novel magnetic resonance imaging in adult patients with non-alcoholic fatty liver disease – MRI accurately quantifies hepatic steatosis in NAFLD. <i>Alimentary Pharmacology and Therapeutics</i> , 2012, 36, 22-29.	1.9	285
65	Review article: non-alcoholic fatty liver disease and osteoporosis – clinical and molecular crosstalk. <i>Alimentary Pharmacology and Therapeutics</i> , 2012, 36, 345-352.	1.9	74
66	Updated thresholds for serum alanine aminotransferase level in a large-scale population study composed of 34,346 subjects. <i>Alimentary Pharmacology and Therapeutics</i> , 2012, 36, 560-568.	1.9	55
67	Assessment of inflammation and fibrosis in non-alcoholic fatty liver disease by imaging-based techniques. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2012, 27, 1281-1292.	1.4	30
68	Molecular signature of adipose tissue in patients with both Non-Alcoholic Fatty Liver Disease (NAFLD) and Polycystic Ovarian Syndrome (PCOS). <i>Journal of Translational Medicine</i> , 2013, 11, 133.	1.8	59
69	Desmosterol in human nonalcoholic steatohepatitis. <i>Hepatology</i> , 2013, 58, 976-982.	3.6	42
70	From NAFLD to NASH to cirrhosis – new insights into disease mechanisms. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2013, 10, 627-636.	8.2	502
71	NAFLD Fibrosis Score: Is It Ready for Wider Use in Clinical Practice and for Clinical Trials?. <i>Gastroenterology</i> , 2013, 145, 717-719.	0.6	9
72	Ultrasonographic Quantification of Hepatic Renal Echogenicity Difference in Hepatic Steatosis Diagnosis. <i>Digestive Diseases and Sciences</i> , 2013, 58, 2993-3000.	1.1	20
73	Diagnosis and management of non-alcoholic fatty liver disease and related metabolic disorders: Consensus statement from the Study Group of Liver and Metabolism, Chinese Society of Endocrinology (éžé... ç²¼æ€Œ,,è,æ€Œç–...äžç,ä	0.8	97
74	Vitamin E and changes in serum alanine aminotransferase levels in patients with non-alcoholic steatohepatitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2013, 38, 134-143.	1.9	163

#	ARTICLE	IF	CITATIONS
75	Identifying Practice Gaps to Optimize Medical Care for Patients with Nonalcoholic Fatty Liver Disease. <i>Digestive Diseases and Sciences</i> , 2013, 58, 2809-2816.	1.1	44
76	Association between novel ¹ H-MRI-estimated pancreatic fat and liver histology-determined steatosis and fibrosis in non-alcoholic fatty liver disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2013, 37, 630-639.	1.9	104
78	Nonalcoholic fatty liver disease: an emerging threat to obese and diabetic individuals. <i>Annals of the New York Academy of Sciences</i> , 2013, 1281, 106-122.	1.8	216
79	Association Between High-Normal Levels of Alanine Aminotransferase and Risk Factors for Atherogenesis. <i>Gastroenterology</i> , 2013, 145, 1271-1279.e3.	0.6	79
80	Non-alcoholic steatohepatitis: A non-invasive diagnosis by analysis of exhaled breath. <i>Journal of Hepatology</i> , 2013, 58, 543-548.	1.8	51
82	Exploration of a symptoms experience in people with obesity-related nonalcoholic fatty liver disease. <i>Nursing Outlook</i> , 2013, 61, 242-251.e2.	1.5	3
83	Association of Sleep Disorders with Nonalcoholic Fatty Liver Disease (NAFLD): A Population-based Study. <i>Journal of Clinical and Experimental Hepatology</i> , 2013, 3, 181-185.	0.4	35
84	Potential treatment of human nonalcoholic fatty liver disease with long-chain omega-3 polyunsaturated fatty acids. <i>Nutrition Reviews</i> , 2013, 71, 753-771.	2.6	33
86	Liver disease and malnutrition. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2013, 27, 619-629.	1.0	50
87	Gut microbiota and non-alcoholic fatty liver disease: new insights. <i>Clinical Microbiology and Infection</i> , 2013, 19, 338-348.	2.8	196
88	Nonalcoholic Fatty Liver Disease. <i>Journal of Parenteral and Enteral Nutrition</i> , 2013, 37, 787-793.	1.3	24
89	Nonalcoholic Fatty Liver Disease and the Metabolic Syndrome. <i>Nutrition in Clinical Practice</i> , 2013, 28, 40-51.	1.1	52
90	Gastrointestinal Complications of Diabetes. <i>Endocrinology and Metabolism Clinics of North America</i> , 2013, 42, 809-832.	1.2	24
91	Characterization of gut microbiomes in nonalcoholic steatohepatitis (NASH) patients: A connection between endogenous alcohol and NASH. <i>Hepatology</i> , 2013, 57, 601-609.	3.6	1,321
92	The Prevalence and Clinical Correlates of Nonalcoholic Fatty Liver Disease (NAFLD) in African Americans: The Multiethnic Study of Atherosclerosis (MESA). <i>Digestive Diseases and Sciences</i> , 2013, 58, 2392-2398.	1.1	43
93	Revising the Upper Limit of Normal for Levels of Serum Alanine Aminotransferase in a Middle Eastern Population with Normal Liver Histology. <i>Digestive Diseases and Sciences</i> , 2013, 58, 2369-2375.	1.1	17
94	Expression of genes for microRNA-processing enzymes is altered in advanced non-alcoholic fatty liver disease. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2013, 28, 1410-1415.	1.4	33
95	Obesity, insulin resistance, NASH and hepatocellular carcinoma. <i>Seminars in Cancer Biology</i> , 2013, 23, 483-491.	4.3	128

#	ARTICLE	IF	CITATIONS
96	Metformin decreases hepatocellular carcinoma risk in a dose-dependent manner: population-based and in vitro studies. <i>Gut</i> , 2013, 62, 606-615.	6.1	352
97	A novel noninvasive index for nonalcoholic steatohepatitis: a pilot study. <i>Biomarkers</i> , 2013, 18, 607-613.	0.9	16
98	Validation of terminal peptide of procollagen III for the detection and assessment of nonalcoholic steatohepatitis in patients with nonalcoholic fatty liver disease. <i>Hepatology</i> , 2013, 57, 103-111.	3.6	103
99	In patients with non-alcoholic fatty liver disease, metabolically abnormal individuals are at a higher risk for mortality while metabolically normal individuals are not. <i>Metabolism: Clinical and Experimental</i> , 2013, 62, 352-360.	1.5	141
100	An ALTer Ego of Serum ALT: Is It More Than a Marker of Liver Inflammation?. <i>Gastroenterology</i> , 2013, 145, 1191-1193.	0.6	3
101	Nonalcoholic Steatohepatitis. <i>Surgical Pathology Clinics</i> , 2013, 6, 227-257.	0.7	5
102	Nrf2 Activators Attenuate the Progression of Nonalcoholic Steatohepatitis-Related Fibrosis in a Dietary Rat Model. <i>Molecular Pharmacology</i> , 2013, 84, 62-70.	1.0	115
103	From NAFLD in clinical practice to answers from guidelines. <i>Journal of Hepatology</i> , 2013, 59, 859-871.	1.8	304
104	The association between TCM syndromes and SCAP polymorphisms in subjects with non-alcoholic fatty liver disease. <i>European Journal of Integrative Medicine</i> , 2013, 5, 386-392.	0.8	3
105	Statins Are Associated With a Reduced Risk of Hepatocellular Cancer: A Systematic Review and Meta-analysis. <i>Gastroenterology</i> , 2013, 144, 323-332.	0.6	392
106	<i>Helicobacter pylori</i> infection in patients with nonalcoholic fatty liver disease. <i>Metabolism: Clinical and Experimental</i> , 2013, 62, 121-126.	1.5	130
107	Review article: the diagnosis of non-alcoholic fatty liver disease – availability and accuracy of non-invasive methods. <i>Alimentary Pharmacology and Therapeutics</i> , 2013, 37, 392-400.	1.9	156
108	Excess S-adenosylmethionine reroutes phosphatidylethanolamine towards phosphatidylcholine and triglyceride synthesis. <i>Hepatology</i> , 2013, 58, 1296-1305.	3.6	100
109	Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2013, 10, 330-344.	8.2	1,381
110	Nonalcoholic Fatty Liver Disease: Current Issues and Novel Treatment Approaches. <i>Drugs</i> , 2013, 73, 1-14.	4.9	139
111	Non-alcoholic fatty liver disease contributes to hepatocarcinogenesis in non-cirrhotic liver: A clinical and pathological study. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2013, 28, 848-854.	1.4	101
112	Effects of Antihypertensive and Triglyceride Lowering Agents on Splenocyte Apoptosis in Rats with Fatty Liver. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2013, 113, 37-42.	1.2	2
113	Anthropometric and Clinical Factors Associated with Mortality in Subjects with Nonalcoholic Fatty Liver Disease. <i>Digestive Diseases and Sciences</i> , 2013, 58, 1132-1140.	1.1	58

#	ARTICLE	IF	CITATIONS
114	Inflammasome biology in fibrogenesis. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2013, 1832, 979-988.	1.8	54
115	Prevalence and Risk Factors for the Development of Nonalcoholic Fatty Liver Disease in a Nonobese Chinese Population: the Zhejiang Zhenhai Study. <i>American Journal of Gastroenterology</i> , 2013, 108, 1299-1304.	0.2	146
116	Unconjugated bilirubin, a potent endogenous antioxidant, is decreased in patients with nonalcoholic steatohepatitis and advanced fibrosis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2013, 28, 1202-1208.	1.4	55
117	Gastrointestinal complications of obesity: Non-alcoholic fatty liver disease (NAFLD) and its sequelae. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2013, 27, 195-208.	2.2	61
118	The Genetic Architecture of Liver Enzyme Levels: GGT, ALT and AST. <i>Behavior Genetics</i> , 2013, 43, 329-339.	1.4	113
119	Serum osteopontin levels as a predictor of portal inflammation in patients with nonalcoholic fatty liver disease. <i>Digestive and Liver Disease</i> , 2013, 45, 58-62.	0.4	21
120	Pediatric Nonalcoholic Fatty Liver Disease. <i>Nutrition in Clinical Practice</i> , 2013, 28, 448-458.	1.1	29
121	Omega-3 polyunsaturated fatty acids for non-alcoholic fatty liver disease. <i>The Cochrane Library</i> , 0, , .	1.5	1
122	The genetics of NAFLD. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2013, 10, 645-655.	8.2	297
123	Risk factors for intrahepatic cholangiocarcinoma: Association between metformin use and reduced cancer risk. <i>Hepatology</i> , 2013, 57, 648-655.	3.6	120
124	Interaction of Type 2 diabetes and nonalcoholic fatty liver disease. <i>Expert Review of Gastroenterology and Hepatology</i> , 2013, 7, 405-407.	1.4	9
125	Insulin Resistance Increases MRI-Estimated Pancreatic Fat in Nonalcoholic Fatty Liver Disease and Normal Controls. <i>Gastroenterology Research and Practice</i> , 2013, 2013, 1-8.	0.7	42
126	Paediatric Non-Alcoholic Fatty Liver Disease: Impact on Patients and Mothers' Quality of Life. <i>Hepatitis Monthly</i> , 2013, 13, e7871.	0.1	19
127	Hepatic Fatty Acid Trafficking: Multiple Forks in the Road. <i>Advances in Nutrition</i> , 2013, 4, 697-710.	2.9	115
128	The Relationship between Intestinal Motility and Interstitial Cells of Cajal in Nonalcoholic Fatty Liver Mice. <i>Hepatitis Monthly</i> , 2013, 13, e13674.	0.1	1
129	Non Alcoholic Fatty Liver Disease in Southern Iran: A Population Based Study. <i>Hepatitis Monthly</i> , 2013, 13, e9248.	0.1	84
130	Major Histocompatibility Class II Pathway Is Not Required for the Development of Nonalcoholic Fatty Liver Disease in Mice. <i>International Journal of Endocrinology</i> , 2013, 2013, 1-12.	0.6	4
131	Diabetes and Risk of Cancer. <i>ISRN Oncology</i> , 2013, 2013, 1-16.	2.1	83

#	ARTICLE	IF	CITATIONS
132	Fetuin-A mRNA expression is elevated in NASH compared with NAFL patients. <i>Clinical Science</i> , 2013, 125, 391-400.	1.8	52
133	Expression of Inflammation-Related Genes Is Altered in Gastric Tissue of Patients with Advanced Stages of NAFLD. <i>Mediators of Inflammation</i> , 2013, 2013, 1-10.	1.4	5
134	Noninvasive detection of hepatic steatosis in patients without ultrasonographic evidence of fatty liver using the controlled attenuation parameter evaluated with transient elastography. <i>European Journal of Gastroenterology and Hepatology</i> , 2013, 25, 1330-1334.	0.8	32
135	Dietary treatment of nonalcoholic steatohepatitis. <i>Current Opinion in Gastroenterology</i> , 2013, 29, 170-176.	1.0	17
136	C/EBP Homologous Protein-induced Macrophage Apoptosis Protects Mice from Steatohepatitis. <i>Journal of Biological Chemistry</i> , 2013, 288, 18624-18642.	1.6	78
137	Leptin's Role in Lipodystrophic and Nonlipodystrophic Insulin-Resistant and Diabetic Individuals. <i>Endocrine Reviews</i> , 2013, 34, 377-412.	8.9	212
138	Metformin suppresses hepatocellular carcinoma cell growth through induction of cell cycle G1/G0 phase arrest and p21CIP and p27KIP expression and downregulation of cyclin D1 in vitro and in vivo. <i>Oncology Reports</i> , 2013, 30, 2449-2457.	1.2	65
139	Surveillance for early diagnosis of hepatocellular carcinoma: How best to do it?. <i>World Journal of Gastroenterology</i> , 2013, 19, 8808.	1.4	72
140	Clinical Characteristics and Time Trends in Etiology of Hepatocellular Cancer in Germany. <i>Digestion</i> , 2013, 87, 147-159.	1.2	34
141	PNPLA3-Associated Steatohepatitis: Toward a Gene-Based Classification of Fatty Liver Disease. <i>Seminars in Liver Disease</i> , 2013, 33, 369-379.	1.8	81
142	The role of endocannabinoids system in fatty liver disease and therapeutic potentials. <i>Saudi Journal of Gastroenterology</i> , 2013, 19, 144.	0.5	39
144	Role of vascular endothelial growth factor in the pathophysiology of nonalcoholic steatohepatitis in two rodent models. <i>Hepatology</i> , 2013, 57, 1793-1805.	3.6	74
145	Toxicant-associated Steatohepatitis. <i>Toxicologic Pathology</i> , 2013, 41, 343-360.	0.9	161
148	Piloting a multidisciplinary clinic for the management of non-alcoholic fatty liver disease: initial 5-year experience. <i>Frontline Gastroenterology</i> , 2013, 4, 263-269.	0.9	23
150	Mechanisms in endocrinology: Non-alcoholic fatty liver disease in common endocrine disorders. <i>European Journal of Endocrinology</i> , 2013, 169, R27-R37.	1.9	80
151	Aquaporin-9 downregulation prevents steatosis in oleic acid-induced non-alcoholic fatty liver disease cell models. <i>International Journal of Molecular Medicine</i> , 2013, 32, 1159-1165.	1.8	22
152	Adiponectin, bile acids, and burnt-out nonalcoholic steatohepatitis: New light on an old paradox. <i>Hepatology</i> , 2013, 57, 2106-2109.	3.6	10
153	Association between noninvasive fibrosis markers and mortality among adults with nonalcoholic fatty liver disease in the United States. <i>Hepatology</i> , 2013, 57, 1357-1365.	3.6	614

#	ARTICLE	IF	CITATIONS
154	Hepatocyte caspase-8 is an essential modulator of steatohepatitis in rodents. <i>Hepatology</i> , 2013, 57, 2189-2201.	3.6	89
155	<i>Solute carrier family 2 member 1</i> is involved in the development of nonalcoholic fatty liver disease. <i>Hepatology</i> , 2013, 57, 505-514.	3.6	25
156	Nonalcoholic steatohepatitis in nonalcoholic fatty liver disease patients of Bangladesh. <i>World Journal of Hepatology</i> , 2013, 5, 281.	0.8	34
157	Common Carotid Intima-media Thickness in Patients with Non-alcoholic Fatty Liver Disease: A Population-based Case-control Study. <i>Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi, The</i> , 2013, 62, 344.	0.2	25
158	Sex steroids and sex hormone-binding globulin in postmenopausal women with nonalcoholic fatty liver disease. <i>Hormones</i> , 2013, 12, 405-416.	0.9	49
159	Comparison of the relationships of alcoholic and nonalcoholic fatty liver with hypertension, diabetes mellitus, and dyslipidemia. <i>Journal of Clinical Biochemistry and Nutrition</i> , 2013, 52, 82-88.	0.6	4
160	Inverse Association between Hepatitis B Virus Infection and Fatty Liver Disease: A Large-Scale Study in Populations Seeking for Check-Up. <i>PLoS ONE</i> , 2013, 8, e72049.	1.1	76
161	Molecular Interactions between NAFLD and Xenobiotic Metabolism. <i>Frontiers in Genetics</i> , 2013, 4, 2.	1.1	55
162	Nutritional Management of Insulin Resistance in Nonalcoholic Fatty Liver Disease (NAFLD). <i>Nutrients</i> , 2013, 5, 4093-4114.	1.7	58
163	Current Concepts and Management Approaches in Nonalcoholic Fatty Liver Disease. <i>Scientific World Journal, The</i> , 2013, 2013, 1-10.	0.8	67
164	S-Allyl cysteine improves nonalcoholic fatty liver disease in type 2 diabetes Otsuka Long-Evans Tokushima Fatty rats via regulation of hepatic lipogenesis and glucose metabolism. <i>Journal of Clinical Biochemistry and Nutrition</i> , 2013, 53, 94-101.	0.6	26
165	Primary care practitioners survey of non-alcoholic fatty liver disease. <i>Annals of Hepatology</i> , 2013, 12, 758-765.	0.6	59
166	Adipocytokines and cytokeratin-18 in patients with nonalcoholic fatty liver disease: Introduction of CHA index. <i>Annals of Hepatology</i> , 2013, 12, 749-757.	0.6	29
167	What about non-alcoholic fatty liver disease as a new criterion to define metabolic syndrome?. <i>World Journal of Gastroenterology</i> , 2013, 19, 3375.	1.4	147
168	Non-Invasive Assessment of Hepatic Steatosis in Patients with NAFLD Using Controlled Attenuation Parameter and 1H-MR Spectroscopy. <i>PLoS ONE</i> , 2014, 9, e91987.	1.1	130
169	Traditional but Not HIV-Related Factors Are Associated with Nonalcoholic Fatty Liver Disease in Asian Patients with HIV-1 Infection. <i>PLoS ONE</i> , 2014, 9, e87596.	1.1	42
170	Lipotoxic Effect of p21 on Free Fatty Acid-Induced Steatosis in L02 Cells. <i>PLoS ONE</i> , 2014, 9, e96124.	1.1	11
171	Non-“Laboratory-Based Self-Assessment Screening Score for Non-Alcoholic Fatty Liver Disease: Development, Validation and Comparison with Other Scores. <i>PLoS ONE</i> , 2014, 9, e107584.	1.1	90

#	ARTICLE	IF	CITATIONS
172	MR Quantification of Total Liver Fat in Patients with Impaired Glucose Tolerance and Healthy Subjects. PLoS ONE, 2014, 9, e111283.	1.1	29
173	Identification of Novel Clinical Factors Associated with Hepatic Fat Accumulation in Extreme Obesity. Journal of Obesity, 2014, 2014, 1-8.	1.1	13
174	The Effect of tert-Butyl Hydroperoxide-Induced Oxidative Stress on Lean and Steatotic Rat Hepatocytes In Vitro. Oxidative Medicine and Cellular Longevity, 2014, 2014, 1-12.	1.9	100
175	Non-Alcoholic Fatty Liver Disease. Deutsches Arzteblatt International, 2014, 111, 447-52.	0.6	134
176	Radiologic evaluation of nonalcoholic fatty liver disease. World Journal of Gastroenterology, 2014, 20, 7392.	1.4	330
177	The Influence of Dietary Fat on Liver Fat Accumulation. Nutrients, 2014, 6, 5018-5033.	1.7	100
178	The Role of Dietary Sugars and De novo Lipogenesis in Non-Alcoholic Fatty Liver Disease. Nutrients, 2014, 6, 5679-5703.	1.7	113
179	Recent advances in dietary supplementation, in treating non-alcoholic fatty liver disease. World Journal of Hepatology, 2014, 7, 204.	0.8	62
180	Role of endoplasmic reticulum stress in the pathogenesis of nonalcoholic fatty liver disease. World Journal of Gastroenterology, 2014, 20, 1768.	1.4	235
181	Review of nonalcoholic fatty liver disease in women with polycystic ovary syndrome. World Journal of Gastroenterology, 2014, 20, 14172.	1.4	69
182	Surgical treatment of nonalcoholic fatty liver disease in severely obese patients. Hepatic Medicine: Evidence and Research, 2014, 6, 103.	0.9	8
183	Modern approach to the clinical management of non-alcoholic fatty liver disease. World Journal of Gastroenterology, 2014, 20, 8341.	1.4	61
184	Gender and racial differences in nonalcoholic fatty liver disease. World Journal of Hepatology, 2014, 6, 274.	0.8	242
185	A Review of Fatty Liver/NASH and Liver Cirrhosis: Genetics, Prevention, Nutritional, Behavioral Modification, Exercise, Pharmaceutical, Biophysics and Biotech Therapy. Journal of Liver, 2014, 3, .	0.3	1
186	Non-alcoholic fatty liver disease: What the clinician needs to know. World Journal of Gastroenterology, 2014, 20, 12956.	1.4	154
187	Pharmacologic Management of Non-Alcoholic Fatty Liver Disease. Advances in Pharmacoeconomics & Drug Safety, 2014, 03, .	0.1	1
188	The Role of Interleukin-6 and Interleukin-8 Gene Polymorphisms in Non-Alcoholic Steatohepatitis. Hepatitis Monthly, 2014, 14, e24635.	0.1	12
189	Experimental models of non-alcoholic fatty liver disease in rats. World Journal of Gastroenterology, 2014, 20, 8364.	1.4	149

#	ARTICLE	IF	CITATIONS
190	Effect of resistance training on non-alcoholic fatty-liver disease a randomized-clinical trial. <i>World Journal of Gastroenterology</i> , 2014, 20, 4382.	1.4	115
191	The prevalence of nonalcoholic fatty liver disease in the Americas. <i>Annals of Hepatology</i> , 2014, 13, 166-178.	0.6	122
192	Nonalcoholic fatty liver disease and aging: Epidemiology to management. <i>World Journal of Gastroenterology</i> , 2014, 20, 14185.	1.4	227
193	Role of the PNPLA3 I148M Polymorphism in Nonalcoholic Fatty Liver Disease and Fibrosis in Korea. <i>Digestive Diseases and Sciences</i> , 2014, 59, 2967-2974.	1.1	33
194	Serum amylase levels are decreased in Chinese non-alcoholic fatty liver disease patients. <i>Lipids in Health and Disease</i> , 2014, 13, 185.	1.2	11
195	Association between non-alcoholic fatty liver disease and arterial stiffness in the non-obese, non-hypertensive, and non-diabetic young and middle-aged Chinese population. <i>Journal of Zhejiang University: Science B</i> , 2014, 15, 879-887.	1.3	26
196	Astaxanthin lowers plasma TAG concentrations and increases hepatic antioxidant gene expression in diet-induced obesity mice. <i>British Journal of Nutrition</i> , 2014, 112, 1797-1804.	1.2	62
197	<i>TLR4</i> Gene Polymorphism in Patients with Nonalcoholic Fatty Liver Disease in Comparison to Healthy Controls. <i>Metabolic Syndrome and Related Disorders</i> , 2014, 12, 165-170.	0.5	33
198	Non-alcoholic fatty liver disease in obese adults: clinical aspects and current management strategies. <i>Clinical Obesity</i> , 2014, 4, 243-253.	1.1	31
199	A comparison of FibroMeter, NAFLD Score, NAFLD fibrosis score, and transient elastography as noninvasive diagnostic tools for hepatic fibrosis in patients with biopsy-proven non-alcoholic fatty liver disease. <i>Scandinavian Journal of Gastroenterology</i> , 2014, 49, 1343-1348.	0.6	43
200	Evolving Concepts in the Pathogenesis of NASH: Beyond Steatosis and Inflammation. <i>International Journal of Molecular Sciences</i> , 2014, 15, 8591-8638.	1.8	285
201	Mitochondrial nuclear genome interactions in non-alcoholic fatty liver disease in mice. <i>Biochemical Journal</i> , 2014, 461, 223-232.	1.7	41
202	Role of Mitochondria in Nonalcoholic Fatty Liver Disease. <i>International Journal of Molecular Sciences</i> , 2014, 15, 8713-8742.	1.8	271
203	Cannabinoid Receptor 1 Gene Polymorphisms and Nonalcoholic Fatty Liver Disease in Women with Polycystic Ovary Syndrome and in Healthy Controls. <i>International Journal of Endocrinology</i> , 2014, 2014, 1-8.	0.6	20
204	Endocannabinoid Receptors Gene Expression in Morbidly Obese Women with Nonalcoholic Fatty Liver Disease. <i>BioMed Research International</i> , 2014, 2014, 1-7.	0.9	25
205	Triglyceride is strongly associated with nonalcoholic fatty liver disease among markers of hyperlipidemia and diabetes. <i>Biomedical Reports</i> , 2014, 2, 633-636.	0.9	89
206	Management of fatty liver disease with the metabolic syndrome. <i>Expert Review of Gastroenterology and Hepatology</i> , 2014, 8, 487-500.	1.4	26
207	Inhibiting Monoacylglycerol Acyltransferase 1 Ameliorates Hepatic Metabolic Abnormalities but Not Inflammation and Injury in Mice. <i>Journal of Biological Chemistry</i> , 2014, 289, 30177-30188.	1.6	40

#	ARTICLE	IF	CITATIONS
208	Histologically proven nonalcoholic fatty liver disease and clinically related factors in recipients after liver transplantation. <i>Clinical Transplantation</i> , 2014, 28, 521-529.	0.8	50
209	The Effect of miRNA-122 in Regulating Fat Deposition in a Cell Line Model. <i>Journal of Cellular Biochemistry</i> , 2014, 115, 839-846.	1.2	10
210	Endotoxemia unrequired in the pathogenesis of pediatric nonalcoholic steatohepatitis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2014, 29, 1292-1298.	1.4	57
211	A positive feedback loop between RIP3 and JNK controls nonalcoholic steatohepatitis. <i>EMBO Molecular Medicine</i> , 2014, 6, 1062-1074.	3.3	253
212	3,3'-diindolylmethane alleviates steatosis and the progression of NASH partly through shifting the imbalance of Treg/Th17 cells to Treg dominance. <i>International Immunopharmacology</i> , 2014, 23, 489-498.	1.7	47
213	Addressing liver disease in the UK: a blueprint for attaining excellence in health care and reducing premature mortality from lifestyle issues of excess consumption of alcohol, obesity, and viral hepatitis. <i>Lancet, The</i> , 2014, 384, 1953-1997.	6.3	492
214	Effects of Soothing Liver and Invigorating Spleen Recipe on Lipid Metabolism Disorders in Kupffer Cells of NAFLD Rats by LXRI±/SREBP-1c Signal Pathway. <i>Chinese Herbal Medicines</i> , 2014, 6, 297-304.	1.2	4
215	Inhibition of ceramide <i>de novo</i> synthesis reduces liver lipid accumulation in rats with nonalcoholic fatty liver disease. <i>Liver International</i> , 2014, 34, 1074-1083.	1.9	109
216	Association between aspirin use and the prevalence of nonalcoholic fatty liver disease: a cross-sectional study from the Third National Health and Nutrition Examination Survey. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 40, 1066-1073.	1.9	49
217	Lipoprotein subclass metabolism in nonalcoholic steatohepatitis. <i>Journal of Lipid Research</i> , 2014, 55, 2676-2684.	2.0	59
218	Hypoadiponectinaemia in nonalcoholic fatty liver disease obese women is associated with infrequent intake of dietary sucrose and fatty foods. <i>Journal of Human Nutrition and Dietetics</i> , 2014, 27, 301-312.	1.3	8
219	Chemoprevention of nonalcoholic fatty liver disease by dietary natural compounds. <i>Molecular Nutrition and Food Research</i> , 2014, 58, 147-171.	1.5	77
220	Non-high density lipoprotein cholesterol independently predicts new onset of nonalcoholic fatty liver disease. <i>Liver International</i> , 2014, 34, e128-35.	1.9	48
221	Accumulation of ¹⁸ F-FDG in the Liver in Hepatic Steatosis. <i>American Journal of Roentgenology</i> , 2014, 203, 643-648.	1.0	52
222	The relationship between advanced oxidation protein products (AOPP) and biochemical and histopathological findings in patients with nonalcoholic steatohepatitis. <i>Journal of Digestive Diseases</i> , 2014, 15, 131-136.	0.7	12
223	Clinical, anthropometric, biochemical, and histological characteristics of nonobese nonalcoholic fatty liver disease patients of Bangladesh. <i>Indian Journal of Gastroenterology</i> , 2014, 33, 452-457.	0.7	57
224	Non-Alcoholic Fatty Liver and Metabolic Syndrome in Children: A Vicious Circle. <i>Hormone Research in Paediatrics</i> , 2014, 82, 283-289.	0.8	34
225	Nonalcoholic fatty liver disease (NAFLD) in the Veterans Administration population: development and validation of an algorithm for NAFLD using automated data. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 40, 949-954.	1.9	31

#	ARTICLE	IF	CITATIONS
226	Noninvasive Biomarkers of Liver Fibrosis: Clinical Applications and Future Directions. <i>Current Pathobiology Reports</i> , 2014, 2, 245-256.	1.6	30
227	Body composition variables as predictors of NAFLD by ultrasound in obese children and adolescents. <i>BMC Pediatrics</i> , 2014, 14, 25.	0.7	29
228	Dietary pulp from <i>Fructus Schisandra Chinensis</i> supplementation reduces serum/hepatic lipid and hepatic glucose levels in mice fed a normal or high cholesterol/bile salt diet. <i>Lipids in Health and Disease</i> , 2014, 13, 46.	1.2	13
229	Remembering the forgotten non-communicable diseases. <i>BMC Medicine</i> , 2014, 12, 200.	2.3	82
230	Serum alanine aminotransferase predicts interventricular septum thickness and left ventricular mass in patients with nonalcoholic fatty liver disease. <i>European Journal of Gastroenterology and Hepatology</i> , 2014, 26, 654-660.	0.8	12
231	State of the art. <i>Current Opinion in Gastroenterology</i> , 2014, 30, 223-237.	1.0	26
232	A Bayesian approach to an integrated multimodal noninvasive diagnosis of definitive nonalcoholic steatohepatitis in the spectrum of nonalcoholic fatty liver disease. <i>European Journal of Gastroenterology and Hepatology</i> , 2014, 26, 1292-1295.	0.8	7
233	Prevalence and factors associated with liver steatosis as measured by transient elastography with controlled attenuation parameter in HIV-infected patients. <i>Aids</i> , 2014, 28, 1279-1287.	1.0	59
234	Contributions of metabolic dysregulation and inflammation to nonalcoholic steatohepatitis, hepatic fibrosis, and cancer. <i>Current Opinion in Oncology</i> , 2014, 26, 100-107.	1.1	74
235	Effects of resveratrol in experimental and clinical non-alcoholic fatty liver disease. <i>World Journal of Hepatology</i> , 2014, 6, 188.	0.8	51
236	Epidemiology of Nonalcoholic Fatty Liver Disease. <i>Korean Journal of Medicine</i> , 2014, 86, 399.	0.1	8
237	Insulin sensitizers for the treatment of non-alcoholic fatty liver disease. <i>World Journal of Hepatology</i> , 2014, 6, 199.	0.8	66
238	Serum Cytokeratin-18 Is Associated with NOX2-Generated Oxidative Stress in Patients with Nonalcoholic Fatty Liver. <i>International Journal of Hepatology</i> , 2014, 2014, 1-6.	0.4	15
239	World Gastroenterology Organisation Global Guidelines. <i>Journal of Clinical Gastroenterology</i> , 2014, 48, 467-473.	1.1	319
240	Effects of Antihypertensive and Triglyceride-Lowering Agents on Hepatic Copper Concentrations in Rats with Fatty Liver Disease. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2014, 115, 545-551.	1.2	5
241	Low normal thyroid function attenuates serum alanine aminotransferase elevations in the context of metabolic syndrome and insulin resistance in white people. <i>Clinical Biochemistry</i> , 2014, 47, 1028-1032.	0.8	13
242	Resveratrol Does Not Benefit Patients With Nonalcoholic Fatty Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2014, 12, 2092-2103.e6.	2.4	237
243	Effects of bayberry juice on inflammatory and apoptotic markers in young adults with features of non-alcoholic fatty liver disease. <i>Nutrition</i> , 2014, 30, 198-203.	1.1	80

#	ARTICLE	IF	CITATIONS
244	The Role of Medications for the Management of Patients with NAFLD. <i>Clinics in Liver Disease</i> , 2014, 18, 73-89.	1.0	27
246	Comparison of interobserver agreement of magnetic resonance elastography with histopathological staging of liver fibrosis. <i>Abdominal Imaging</i> , 2014, 39, 283-290.	2.0	45
247	The changing role of beta-blocker therapy in patients with cirrhosis. <i>Journal of Hepatology</i> , 2014, 60, 643-653.	1.8	109
248	Coffee enhances the expression of chaperones and antioxidant proteins in rats with nonalcoholic fatty liver disease. <i>Translational Research</i> , 2014, 163, 593-602.	2.2	57
249	Nonalcoholic fatty liver disease and bariatric surgery in adolescents. <i>Seminars in Pediatric Surgery</i> , 2014, 23, 49-57.	0.5	21
250	Utilization of FibroScan in Clinical Practice. <i>Current Gastroenterology Reports</i> , 2014, 16, 372.	1.1	101
251	Hepatic Steatosis and Steatohepatitis: Are they Really Two Distinct Entities?. <i>Current Hepatology Reports</i> , 2014, 13, 151-158.	0.4	22
252	New and Improved Imaging Modalities for NAFLD. <i>Current Hepatology Reports</i> , 2014, 13, 88-96.	0.4	1
253	Review article: the endocannabinoid system in liver disease, a potential therapeutic target. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 39, 790-801.	1.9	39
254	The impact of cereal grain consumption on the development and severity of non-alcoholic fatty liver disease. <i>European Journal of Nutrition</i> , 2014, 53, 1727-1735.	1.8	37
255	Irisin in patients with nonalcoholic fatty liver disease. <i>Metabolism: Clinical and Experimental</i> , 2014, 63, 207-217.	1.5	179
256	Hemostasis in Liver Disease: Implications of New Concepts for Perioperative Management. <i>Transfusion Medicine Reviews</i> , 2014, 28, 107-113.	0.9	108
257	Necessity for timely noninvasive diagnosis of nonalcoholic fatty liver disease. <i>Metabolism: Clinical and Experimental</i> , 2014, 63, 161-167.	1.5	69
258	Adipokines in Nonalcoholic Fatty Liver Disease. , 2014, , 249-283.		2
259	Accelerated Infant Weight Gain and Risk for Nonalcoholic Fatty Liver Disease in Early Adulthood. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014, 99, 1189-1195.	1.8	46
261	Are oxidative stress mechanisms the common denominator in the progression from hepatic steatosis towards nonalcoholic steatohepatitis (NASH)?. <i>Liver International</i> , 2014, 34, e180-90.	1.9	93
262	Utility and appropriateness of the fatty liver inhibition of progression (FLIP) algorithm and steatosis, activity, and fibrosis (SAF) score in the evaluation of biopsies of nonalcoholic fatty liver disease. <i>Hepatology</i> , 2014, 60, 565-575.	3.6	491
263	Dietary Sugar and Body Weight: Have We Reached a Crisis in the Epidemic of Obesity and Diabetes?. <i>Diabetes Care</i> , 2014, 37, 950-956.	4.3	329

#	ARTICLE	IF	CITATIONS
264	Introduction to Integrative Weight Management. , 2014, , 1-8.		1
266	Randomized, Vitamin E-Controlled Trial of Bicyclol Plus Metformin in Non-Alcoholic Fatty Liver Disease Patients with Impaired Fasting Glucose. <i>Clinical Drug Investigation</i> , 2014, 34, 1-7.	1.1	31
267	Metabolic Phenotyping and Systems Biology Approaches to Understanding Metabolic Syndrome and Fatty Liver Disease. <i>Gastroenterology</i> , 2014, 146, 46-62.	0.6	153
268	Obesity and Liver Disease. <i>Clinics in Liver Disease</i> , 2014, 18, 1-18.	1.0	103
269	Brain metabolic dysfunction at the core of Alzheimer's disease. <i>Biochemical Pharmacology</i> , 2014, 88, 548-559.	2.0	374
271	M30 Does Not Predict the Severity of Hepatosteatosis, Whereas Adiponectin Level Declined With Increase of ALT and the Severity of Hepatic Steatosis. <i>Journal of Clinical Laboratory Analysis</i> , 2014, 28, 381-385.	0.9	3
272	Non-alcoholic fatty liver disease: the role of nuclear receptors and circadian rhythmicity. <i>Liver International</i> , 2014, 34, 1133-1152.	1.9	56
273	Altered levels of serum sphingomyelin and ceramide containing distinct acyl chains in young obese adults. <i>Nutrition and Diabetes</i> , 2014, 4, e141-e141.	1.5	125
274	Circulating Triacylglycerol Signatures in Nonalcoholic Fatty Liver Disease Associated With the I148M Variant in PNPLA3 and With Obesity. <i>Diabetes</i> , 2014, 63, 312-322.	0.3	58
275	Fructose, high-fructose corn syrup, sucrose, and nonalcoholic fatty liver disease or indexes of liver health: a systematic review and meta-analysis , , . <i>American Journal of Clinical Nutrition</i> , 2014, 100, 833-849.	2.2	204
276	Role of white adipose lipolysis in the development of NASH induced by methionine- and choline-deficient diet. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , 2014, 1841, 1596-1607.	1.2	60
277	Non-alcoholic fatty liver disease. <i>BMJ, The</i> , 2014, 349, g4596-g4596.	3.0	253
278	Cell Death and Cell Death Responses in Liver Disease: Mechanisms and Clinical Relevance. <i>Gastroenterology</i> , 2014, 147, 765-783.e4.	0.6	587
279	Novel equation to determine the hepatic triglyceride concentration in humans by MRI: diagnosis and monitoring of NAFLD in obese patients before and after bariatric surgery. <i>BMC Medicine</i> , 2014, 12, 137.	2.3	20
280	NLRP3 inflammasome activation is required for fibrosis development in NAFLD. <i>Journal of Molecular Medicine</i> , 2014, 92, 1069-1082.	1.7	394
281	Nonalcoholic fatty liver disease: a frequent condition in type 2 diabetic patients. <i>Wiener Klinische Wochenschrift</i> , 2014, 126, 335-340.	1.0	12
282	Liver steatosis (LS) evaluated through chemical-shift magnetic resonance imaging liver enzymes in morbid obesity; effect of weight loss obtained with intragastric balloon gastric banding. <i>Acta Diabetologica</i> , 2014, 51, 361-368.	1.2	41
283	Obesity and the liver: nonalcoholic fatty liver disease. <i>Translational Research</i> , 2014, 164, 312-322.	2.2	59

#	ARTICLE	IF	CITATIONS
284	Non-alcoholic fatty liver disease, obesity and the metabolic syndrome. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2014, 28, 637-653.	1.0	332
285	Relationships Between Diabetes and Cognitive Impairment. <i>Endocrinology and Metabolism Clinics of North America</i> , 2014, 43, 245-267.	1.2	63
286	A Dietary Restriction Influences the Progression But Not the Initiation of MSG-Induced Nonalcoholic Steatohepatitis. <i>Journal of Medicinal Food</i> , 2014, 17, 374-383.	0.8	20
287	Natural History of Hepatic Steatosis: Observed Outcomes for Subsequent Liver and Cardiovascular Complications. <i>American Journal of Roentgenology</i> , 2014, 202, 752-758.	1.0	68
288	Evaluation of Aroclor 1260 exposure in a mouse model of diet-induced obesity and non-alcoholic fatty liver disease. <i>Toxicology and Applied Pharmacology</i> , 2014, 279, 380-390.	1.3	85
289	Susceptibility-weighted MR Imaging in the Grading of Liver Fibrosis: A Feasibility Study. <i>Radiology</i> , 2014, 270, 149-158.	3.6	37
290	Relationship between glucose metabolism and non-alcoholic fatty liver disease severity in morbidly obese women. <i>Journal of Endocrinological Investigation</i> , 2014, 37, 739-744.	1.8	11
291	Expression of energy metabolism related genes in the gastric tissue of obese individuals with non-alcoholic fatty liver disease. <i>BMC Gastroenterology</i> , 2014, 14, 72.	0.8	5
292	L-arginine conjugates of bile acids-a possible treatment for non-alcoholic fatty liver disease. <i>Lipids in Health and Disease</i> , 2014, 13, 69.	1.2	14
293	Dietary determinants of hepatic steatosis and visceral adiposity in overweight and obese youth at risk of type 2 diabetes. <i>American Journal of Clinical Nutrition</i> , 2014, 99, 804-812.	2.2	79
294	Non-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome. <i>Lancet Diabetes and Endocrinology</i> , 2014, 2, 901-910.	5.5	938
295	Coffee, alcohol and other beverages in relation to cirrhosis mortality: The Singapore Chinese Health Study. <i>Hepatology</i> , 2014, 60, 661-669.	3.6	51
296	Review of Treatment Options for Nonalcoholic Fatty Liver Disease. <i>Medical Clinics of North America</i> , 2014, 98, 55-72.	1.1	31
297	P806 PREVALENCE AND DETERMINANTS OF FATTY LIVER IN NORMAL WEIGHT AND OVERWEIGHT YOUNG ADULTS. THE CARDIOVASCULAR RISK IN YOUNG FINNS STUDY. <i>Journal of Hepatology</i> , 2014, 60, S339.	1.8	0
298	Apoptotic and anti-apoptotic seromarkers for assessment of disease severity of non-alcoholic steatohepatitis. <i>Arab Journal of Gastroenterology</i> , 2014, 15, 6-11.	0.4	16
299	Cyanidin-3-O- β -glucoside protects primary mouse hepatocytes against high glucose-induced apoptosis by modulating mitochondrial dysfunction and the PI3K/Akt pathway. <i>Biochemical Pharmacology</i> , 2014, 90, 135-144.	2.0	54
300	Host Genetic Variants in Obesity-Related Nonalcoholic Fatty Liver Disease. <i>Clinics in Liver Disease</i> , 2014, 18, 249-267.	1.0	8
301	Paraoxonase 1 and oxidative stress in paediatric non-alcoholic steatohepatitis. <i>Liver International</i> , 2014, 34, 110-117.	1.9	30

#	ARTICLE	IF	CITATIONS
302	The Diagnostic Accuracy of Transient Elastography for the Diagnosis of Liver Fibrosis in Bariatric Surgery Candidates with Suspected NAFLD. <i>Obesity Surgery</i> , 2014, 24, 1693-1701.	1.1	75
303	Relationship Between Changes in Serum Levels of Keratin 18 and Changes in Liver Histology in Children and Adults With Nonalcoholic Fatty Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2014, 12, 2121-2130.e2.	2.4	97
304	MRI evaluation of fatty liver in day to day practice: Quantitative and qualitative methods. <i>Egyptian Journal of Radiology and Nuclear Medicine</i> , 2014, 45, 619-626.	0.3	6
305	Associations between nonalcoholic fatty liver disease and subclinical atherosclerosis in middle-aged adults: The Coronary Artery Risk Development in Young Adults Study. <i>Atherosclerosis</i> , 2014, 235, 599-605.	0.4	129
306	A population-based study on the prevalence of NASH using scores validated against liver histology. <i>Journal of Hepatology</i> , 2014, 60, 839-846.	1.8	107
308	CEUS and Fibroscan in non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. <i>World Journal of Hepatology</i> , 2014, 6, 496.	0.8	25
309	Clinical approaches to non-alcoholic fatty liver disease. <i>World Journal of Gastroenterology</i> , 2014, 20, 1712.	1.4	111
310	Adipokines and proinflammatory cytokines, the key mediators in the pathogenesis of nonalcoholic fatty liver disease. <i>World Journal of Gastroenterology</i> , 2014, 20, 18070.	1.4	260
311	Ethnicity and the diagnosis gap in liver disease: a population-based study. <i>British Journal of General Practice</i> , 2014, 64, e694-e702.	0.7	39
312	Debate: A bridge too far-liver transplantation for nonalcoholic steatohepatitis will overwhelm the organ supply. <i>Liver Transplantation</i> , 2014, 20, S32-S37.	1.3	14
313	Liver Transplantation for NASH-Related Cirrhosis. <i>Current Surgery Reports</i> , 2015, 3, 1.	0.4	0
314	Non-alcoholic fatty liver disease among sasang constitutional types: a population-based study in Korea. <i>BMC Complementary and Alternative Medicine</i> , 2015, 15, 399.	3.7	9
315	Obesity and the extent of liver damage among adult New Zealanders: findings from a national survey. <i>Obesity Science and Practice</i> , 2015, 1, 67-77.	1.0	10
316	Systematic review: microbial dysbiosis and nonalcoholic fatty liver disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 42, 1051-1063.	1.9	167
317	Intrahepatic transplantation of adipose-derived stem cells attenuates the progression of non-alcoholic fatty liver disease in rats. <i>Molecular Medicine Reports</i> , 2015, 12, 3725-3733.	1.1	22
318	Non-alcoholic fatty liver disease. Role of primary care physicians. <i>Medicina Clínica (English Edition)</i> , 2015, 145, 112-114.	0.1	0
319	ZJU index: a novel model for predicting nonalcoholic fatty liver disease in a Chinese population. <i>Scientific Reports</i> , 2015, 5, 16494.	1.6	72
320	Liver steatosis is a risk factor for hepatotoxicity in patients with inflammatory bowel disease under immunosuppressive treatment. <i>European Journal of Gastroenterology and Hepatology</i> , 2015, 27, 698-704.	0.8	28

#	ARTICLE	IF	CITATIONS
321	Measurements of serum procollagen-III peptide and M30 do not improve the diagnostic accuracy of transient elastography for the detection of hepatic fibrosis in patients with nonalcoholic fatty liver disease. <i>European Journal of Gastroenterology and Hepatology</i> , 2015, 27, 667-671.	0.8	10
322	Mechanism of the development of nonalcoholic steatohepatitis after pancreaticoduodenectomy. <i>BBA Clinical</i> , 2015, 3, 168-174.	4.1	26
323	Risk of de novo post-transplant type 2 diabetes in patients undergoing liver transplant for non-alcoholic steatohepatitis. <i>BMC Gastroenterology</i> , 2015, 15, 175.	0.8	27
324	Change in fatty liver status and 5-year risk of incident metabolic syndrome: a retrospective cohort study. <i>Clinical Hypertension</i> , 2015, 21, 22.	0.7	4
325	De novo hepatic steatosis drives atherogenic risk in liver transplantation recipients. <i>Liver Transplantation</i> , 2015, 21, 1395-1402.	1.3	31
326	Association of weight gain since age 20 with nonalcoholic fatty liver disease in normal weight individuals. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2015, 30, 909-917.	1.4	14
327	Intimate association of visceral obesity with nonalcoholic fatty liver disease in healthy Asians: A case-control study. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2015, 30, 1666-1672.	1.4	35
328	Eicosapentaenoic and docosahexaenoic acid-enriched high fat diet delays the development of fatty liver in mice. <i>Lipids in Health and Disease</i> , 2015, 14, 74.	1.2	27
329	Progression of non-alcoholic steatosis to steatohepatitis and fibrosis parallels cumulative accumulation of danger signals that promote inflammation and liver tumors in a high fat cholesterol-sugar diet model in mice. <i>Journal of Translational Medicine</i> , 2015, 13, 193.	1.8	100
330	Global publication trends and research hotspots of nonalcoholic fatty liver disease: a bibliometric analysis and systematic review. <i>SpringerPlus</i> , 2015, 4, 776.	1.2	21
331	An overview of the genetics, mechanisms and management of NAFLD and ALD. <i>Clinical Medicine</i> , 2015, 15, s77-s82.	0.8	23
332	Is it time to advance pediatric NAFLD diagnosis to the magnetic resonance imaging era?. <i>Hepatology</i> , 2015, 61, 1779-1780.	3.6	5
333	Patatin-like phospholipase 3 (rs738409) gene polymorphism is associated with increased liver enzymes in obese adolescents and metabolic syndrome in all ages. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 42, 99-105.	1.9	35
334	Assessing inflammatory liver injury in an acute CCl ₄ model using dynamic 3D metabolic imaging of hyperpolarized [1- ¹³ C]pyruvate. <i>NMR in Biomedicine</i> , 2015, 28, 1671-1677.	1.6	48
335	Practical approach to nonalcoholic fatty liver disease in patients with diabetes. <i>Diabetic Medicine</i> , 2015, 32, 1121-1133.	1.2	15
336	Validation of the Fatty Liver Index for Nonalcoholic Fatty Liver Disease in Middle-Aged and Elderly Chinese. <i>Medicine (United States)</i> , 2015, 94, e1682.	0.4	132
337	Noninvasive estimation of disease activity and liver fibrosis in nonalcoholic fatty liver disease using anthropometric and biochemical characteristics, including insulin, insulin resistance, and 13C-methionine breath test. <i>European Journal of Gastroenterology and Hepatology</i> , 2015, 27, 1137-1143.	0.8	8
338	1148M variant in PNPLA3 reduces central adiposity and metabolic disease risks while increasing nonalcoholic fatty liver disease. <i>Liver International</i> , 2015, 35, 2537-2546.	1.9	27

#	ARTICLE	IF	CITATIONS
339	Genome-wide analysis of long noncoding RNA expression profiles in patients with non-alcoholic fatty liver disease. <i>IUBMB Life</i> , 2015, 67, 847-852.	1.5	53
340	CX3CR1 is a gatekeeper for intestinal barrier integrity in mice: Limiting steatohepatitis by maintaining intestinal homeostasis. <i>Hepatology</i> , 2015, 62, 1405-1416.	3.6	94
342	The combined effects of alcohol consumption and body mass index on hepatic steatosis in a general population sample of European men and women. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 41, 467-476.	1.9	49
343	Low-fasting triglyceride levels are associated with non-invasive markers of advanced liver fibrosis among adults in the United States. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 42, 106-116.	1.9	21
344	Prevalence and risk factors for biopsy-proven non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in a prospective cohort of adult patients with gallstones. <i>Liver International</i> , 2015, 35, 1983-1991.	1.9	23
345	High-fructose Intake in Obesity-related Nonalcoholic Fatty Liver Disease. , 2015, 05, .		2
346	Effect of vitamin E in nonalcoholic fatty liver disease with metabolic syndrome: A propensity score-matched cohort study. <i>Clinical and Molecular Hepatology</i> , 2015, 21, 379.	4.5	17
347	Physical activity as a treatment of non-alcoholic fatty liver disease: A systematic review. <i>World Journal of Hepatology</i> , 2015, 7, 2041.	0.8	55
348	Association of nonalcoholic fatty liver disease and liver cancer. <i>World Journal of Gastroenterology</i> , 2015, 21, 913.	1.4	20
349	Elevated Serum Gamma-glutamyl Transpeptidase Levels and Fatty Liver Strongly Predict the Presence of Carotid Plaque. <i>Journal of Atherosclerosis and Thrombosis</i> , 2015, 22, 1051-1060.	0.9	5
350	Cardiovascular risk across the histological spectrum and the clinical manifestations of non-alcoholic fatty liver disease: An update. <i>World Journal of Gastroenterology</i> , 2015, 21, 6820-6834.	1.4	120
351	Genetic background in nonalcoholic fatty liver disease: A comprehensive review. <i>World Journal of Gastroenterology</i> , 2015, 21, 11088.	1.4	66
352	Development of non-alcoholic fatty liver disease scoring system among adult medical check-up patients: a large cross-sectional and prospective validation study. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2015, 8, 213.	1.1	27
353	Low-Normal Thyroid Function and Novel Cardiometabolic Biomarkers. <i>Nutrients</i> , 2015, 7, 1352-1377.	1.7	39
354	Problems of Long Survival Following Surgery in Patients with NonBNonC-HCC: Comparison with HBV and HCV Related-HCC. <i>Journal of Cancer</i> , 2015, 6, 438-447.	1.2	17
355	Liver fibrosis in non-alcoholic fatty liver disease - diagnostic challenge with prognostic significance. <i>World Journal of Gastroenterology</i> , 2015, 21, 11077.	1.4	132
356	Non-alcohol fatty liver disease in Asia: Prevention and planning. <i>World Journal of Hepatology</i> , 2015, 7, 1788.	0.8	60
357	Peroxisome proliferator-activated receptor-delta agonist ameliorated inflammasome activation in nonalcoholic fatty liver disease. <i>World Journal of Gastroenterology</i> , 2015, 21, 12787.	1.4	51

#	ARTICLE	IF	CITATIONS
358	P2X7 Receptor as a Key Player in Oxidative Stress-Driven Cell Fate in Nonalcoholic Steatohepatitis. <i>Oxidative Medicine and Cellular Longevity</i> , 2015, 2015, 1-7.	1.9	23
359	Sorafenib prevents liver fibrosis in a non-alcoholic steatohepatitis (NASH) rodent model. <i>Brazilian Journal of Medical and Biological Research</i> , 2015, 48, 408-414.	0.7	20
360	Does Lysosomal Acid Lipase Reduction Play a Role in Adult Non-Alcoholic Fatty Liver Disease?. <i>International Journal of Molecular Sciences</i> , 2015, 16, 28014-28021.	1.8	18
361	Oxidative Stress and Inflammation in Hepatic Diseases: Therapeutic Possibilities of N-Acetylcysteine. <i>International Journal of Molecular Sciences</i> , 2015, 16, 30269-30308.	1.8	171
362	Dietary Patterns Modulate the Risk of Non-Alcoholic Fatty Liver Disease in Chinese Adults. <i>Nutrients</i> , 2015, 7, 4778-4791.	1.7	74
363	Nutritional Modulation of Non-Alcoholic Fatty Liver Disease and Insulin Resistance. <i>Nutrients</i> , 2015, 7, 9127-9138.	1.7	117
364	Incidence and Risk Factors of Non-Alcoholic Fatty Liver Disease among Non-Obese Patients Attending at Department of Gastroenterology, BSMMU. <i>Journal of Medicine (Bangladesh)</i> , 2015, 16, 89-92.	0.1	1
365	External Validation of Fatty Liver Index for Identifying Ultrasonographic Fatty Liver in a Large-Scale Cross-Sectional Study in Taiwan. <i>PLoS ONE</i> , 2015, 10, e0120443.	1.1	105
366	The hop constituent xanthohumol exhibits hepatoprotective effects and inhibits the activation of hepatic stellate cells at different levels. <i>Frontiers in Physiology</i> , 2015, 6, 140.	1.3	43
367	Kinetic Studies to Elucidate Impaired Metabolism of Triglyceride-rich Lipoproteins in Humans. <i>Frontiers in Physiology</i> , 2015, 6, 342.	1.3	11
368	Management of hepatocellular carcinoma with portal vein thrombosis. <i>World Journal of Gastroenterology</i> , 2015, 21, 3462.	1.4	90
369	Gut Microbiota: Association with NAFLD and Metabolic Disturbances. <i>BioMed Research International</i> , 2015, 2015, 1-9.	0.9	55
370	Hugan Qingzhi Exerts Anti-Inflammatory Effects in a Rat Model of Nonalcoholic Fatty Liver Disease. <i>Evidence-based Complementary and Alternative Medicine</i> , 2015, 2015, 1-13.	0.5	20
371	The Influence of Metabolic Factors for Nonalcoholic Fatty Liver Disease in Women. <i>BioMed Research International</i> , 2015, 2015, 1-8.	0.9	27
372	Developmental Programming of Nonalcoholic Fatty Liver Disease: The Effect of Early Life Nutrition on Susceptibility and Disease Severity in Later Life. <i>BioMed Research International</i> , 2015, 2015, 1-12.	0.9	46
373	Comparative Study on the Cytoprotective Effects of Activated Protein C Treatment in Nonsteatotic and Steatotic Livers under Ischemia-Reperfusion Injury. <i>BioMed Research International</i> , 2015, 2015, 1-13.	0.9	7
374	Treatment of Nonalcoholic Steatohepatitis in Adults: Present and Future. <i>Gastroenterology Research and Practice</i> , 2015, 2015, 1-14.	0.7	25
375	The Crosstalk between Hypoxia and Innate Immunity in the Development of Obesity-Related Nonalcoholic Fatty Liver Disease. <i>BioMed Research International</i> , 2015, 2015, 1-8.	0.9	15

#	ARTICLE	IF	CITATIONS
376	The nuclear receptor FXR, but not LXR, up-regulates bile acid transporter expression in non-alcoholic fatty liver disease. <i>Annals of Hepatology</i> , 2015, 14, 487-493.	0.6	65
377	Treatment of Nonalcoholic Fatty Liver Disease: The Role of Medical, Surgical, and Endoscopic Weight Loss. <i>Journal of Clinical and Translational Hepatology</i> , 2015, 3, 230-238.	0.7	36
378	Nonalcoholic fatty liver disease and polycystic ovary syndrome. <i>Annals of Hepatology</i> , 2015, 14, 941-943.	0.6	3
379	Bile acid receptors and nonalcoholic fatty liver disease. <i>World Journal of Hepatology</i> , 2015, 7, 2811.	0.8	64
380	Oxidative stress: New insights on the association of non-alcoholic fatty liver disease and atherosclerosis. <i>World Journal of Hepatology</i> , 2015, 7, 1325.	0.8	152
381	Characteristics of hepatocellular carcinoma in cirrhotic and non-cirrhotic non-alcoholic fatty liver disease. <i>World Journal of Gastroenterology</i> , 2015, 21, 1189.	1.4	105
382	Role of diet on non-alcoholic fatty liver disease: An updated narrative review. <i>World Journal of Hepatology</i> , 2015, 7, 575.	0.8	52
383	Visceral Adipose Tissue Area as an Independent Risk Factor for Elevated Liver Enzyme in Nonalcoholic Fatty Liver Disease. <i>Medicine (United States)</i> , 2015, 94, e573.	0.4	25
384	Editorial: call to screen for <scp>NAFLD</scp> and <scp>NASH</scp> in psoriasis. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 41, 492-493.	1.9	1
385	EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis. <i>Journal of Hepatology</i> , 2015, 63, 237-264.	1.8	1,463
386	Long-Term Outcomes of Nonalcoholic Fatty Liver Disease. <i>Current Hepatology Reports</i> , 2015, 14, 69-76.	0.4	13
387	NADPH Oxidase-Derived Peroxynitrite Drives Inflammation in Mice and Human Nonalcoholic Steatohepatitis via TLR4-Lipid Raft Recruitment. <i>American Journal of Pathology</i> , 2015, 185, 1944-1957.	1.9	38
388	Prevalence of Nonalcoholic Fatty Liver Disease and Economy. <i>Digestive Diseases and Sciences</i> , 2015, 60, 3194-3202.	1.1	99
389	Pathogenesis of Hepatocellular Carcinoma Development in Non-alcoholic Fatty Liver Disease. <i>Current Hepatology Reports</i> , 2015, 14, 119-127.	0.4	15
390	Recent insights on the role of cholesterol in non-alcoholic fatty liver disease. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2015, 1852, 1765-1778.	1.8	221
391	Hepatic steatosis and cardiovascular disease outcomes: An analysis of the Framingham Heart Study. <i>Journal of Hepatology</i> , 2015, 63, 470-476.	1.8	165
392	Treatment and survival of non-alcoholic steatohepatitis associated hepatocellular carcinoma. <i>BMC Cancer</i> , 2015, 15, 210.	1.1	87
393	Utility of Ultrasound, Transaminases, and Visual Inspection to Assess Nonalcoholic Fatty Liver Disease in Bariatric Surgery Patients. <i>Obesity Surgery</i> , 2015, 25, 2368-2375.	1.1	37

#	ARTICLE	IF	CITATIONS
394	Pattern and profile of chronic liver disease in acute on chronic liver failure. <i>Hepatology International</i> , 2015, 9, 366-372.	1.9	21
395	Cost-utility analysis of nonalcoholic steatohepatitis screening. <i>European Radiology</i> , 2015, 25, 3282-3294.	2.3	51
396	Shared Symptoms and Putative Biological Mechanisms in Chronic Liver Disease. <i>Biological Research for Nursing</i> , 2015, 17, 222-229.	1.0	4
397	Intestinal FXR: A New Therapeutic Target for Nonalcoholic Fatty Liver Disease. <i>Journal of Clinical and Experimental Hepatology</i> , 2015, 5, 264-266.	0.4	1
398	The measurement of acoustic impedance of the cells cultured with five kinds of the fatty acid. , 2015, , .		0
399	Docosahexaenoic Acid and Its Role in G-Protein-Coupled Receptor 120 Activation in Children Affected by Nonalcoholic Fatty Liver Disease. <i>Endocrine Development</i> , 2016, 30, 29-36.	1.3	7
400	Liraglutide reduces fatty degeneration in hepatic cells via the AMPK/SREBP1 pathway. <i>Experimental and Therapeutic Medicine</i> , 2015, 10, 1777-1783.	0.8	10
401	Gut microbiota and non-alcoholic fatty liver disease. <i>Hepatobiliary and Pancreatic Diseases International</i> , 2015, 14, 572-581.	0.6	61
402	Changing epidemiology of hepatocellular carcinoma in Asia. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2015, 29, 919-928.	1.0	121
403	miR-21 regulates triglyceride and cholesterol metabolism in non-alcoholic fatty liver disease by targeting HMGCR. <i>International Journal of Molecular Medicine</i> , 2015, 35, 847-853.	1.8	113
404	Non-Alcoholic Steatohepatitis-Related Hepatocellular Carcinoma: A Growing Epidemic?. <i>Digestive Diseases</i> , 2015, 33, 642-647.	0.8	17
405	Risk for Nonalcoholic Fatty Liver Disease in Young Adults Born Preterm. <i>Hormone Research in Paediatrics</i> , 2015, 84, 199-205.	0.8	14
406	Blood redox status is associated with the likelihood of nonalcoholic fatty liver disease irrespectively of diet's total antioxidant capacity. <i>Nutrition Research</i> , 2015, 35, 41-48.	1.3	23
407	A comparison of the cardiometabolic profile of black South Africans with suspected non-alcoholic fatty liver disease (NAFLD) and excessive alcohol use. <i>Alcohol</i> , 2015, 49, 165-172.	0.8	8
408	Fatty liver indices in the multiethnic United States National Health and Nutrition Examination Survey. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 41, 65-76.	1.9	245
409	Increased risk of non-alcoholic fatty liver disease after diagnosis of celiac disease. <i>Journal of Hepatology</i> , 2015, 62, 1405-1411.	1.8	82
410	Flaxseed oil containing flaxseed oil ester of plant sterol attenuates high-fat diet-induced hepatic steatosis in apolipoprotein-E knockout mice. <i>Journal of Functional Foods</i> , 2015, 13, 169-182.	1.6	12
411	Metformin and metabolic diseases: a focus on hepatic aspects. <i>Frontiers of Medicine</i> , 2015, 9, 173-186.	1.5	69

#	ARTICLE	IF	CITATIONS
412	The effect of ezetimibe on NAFLD. <i>Atherosclerosis Supplements</i> , 2015, 17, 27-34.	1.2	19
413	Prevalence of Suspected Nonalcoholic Fatty Liver Disease in Hispanic/Latino Individuals Differs by Heritage. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 569-576.	2.4	89
414	The efficacy and safety of statins for the treatment of non-alcoholic fatty liver disease. <i>Digestive and Liver Disease</i> , 2015, 47, 4-11.	0.4	121
415	Ultrasound elastography: liver. <i>Abdominal Imaging</i> , 2015, 40, 698-708.	2.0	24
416	Nonalcoholic Steatohepatitis Is the Second Leading Etiology of Liver Disease Among Adults Awaiting Liver Transplantation in the United States. <i>Gastroenterology</i> , 2015, 148, 547-555.	0.6	1,506
417	Clinical features of hepatocellular carcinoma associated with nonalcoholic fatty liver disease: a review of human studies. <i>Clinical Journal of Gastroenterology</i> , 2015, 8, 1-9.	0.4	69
418	Temporal Trends of Nonalcoholic Fatty Liver Disease-Related Hepatocellular Carcinoma in the Veteran Affairs Population. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 594-601.e1.	2.4	215
419	A concise review of non-alcoholic fatty liver disease. <i>Atherosclerosis</i> , 2015, 239, 192-202.	0.4	234
420	Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. <i>Journal of Gastroenterology</i> , 2015, 50, 364-377.	2.3	203
421	FXR Agonists as Therapeutic Agents for Non-alcoholic Fatty Liver Disease. <i>Current Atherosclerosis Reports</i> , 2015, 17, 500.	2.0	96
422	PPAR α gene expression correlates with severity and histological treatment response in patients with non-alcoholic steatohepatitis. <i>Journal of Hepatology</i> , 2015, 63, 164-173.	1.8	270
423	The prevalence of <sc>NAFLD</sc> and <sc>NASH</sc> among patients with psoriasis in a tertiary care dermatology and rheumatology clinic. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 41, 293-300.	1.9	60
425	Total Body Weight Loss of $\geq 10\%$ Is Associated with Improved Hepatic Fibrosis in Patients with Nonalcoholic Steatohepatitis. <i>Digestive Diseases and Sciences</i> , 2015, 60, 1024-1030.	1.1	129
426	Beneficial effects of mineralocorticoid receptor blockade in experimental non-alcoholic steatohepatitis. <i>Liver International</i> , 2015, 35, 2129-2138.	1.9	48
427	Non-alcoholic fatty liver disease in 2015. <i>World Journal of Hepatology</i> , 2015, 7, 1450.	0.8	160
428	Recommendations for Diagnosis, Referral for Liver Biopsy, and Treatment of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis. <i>Mayo Clinic Proceedings</i> , 2015, 90, 1233-1246.	1.4	214
429	Liver Enzyme Levels and Hepatic Iron Content in Fatty Liver. <i>Academic Radiology</i> , 2015, 22, 714-721.	1.3	7
431	Nonalcoholic Fatty Liver Disease Review: Diagnosis, Treatment, and Outcomes. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 2062-2070.	2.4	267

#	ARTICLE	IF	CITATIONS
432	Impact of Steatosis on Prognosis of Patients with Early-Stage Hepatocellular Carcinoma After Hepatic Resection. <i>Annals of Surgical Oncology</i> , 2015, 22, 2253-2261.	0.7	31
433	Resilience in Organ Transplantation: An Application of the Connorâ€Davidson Resilience Scale (CDâ€RISC) With Liver Transplant Candidates. <i>Journal of Personality Assessment</i> , 2015, 97, 487-493.	1.3	26
434	Interactions of Hepatitis B Virus Infection with Nonalcoholic Fatty Liver Disease: Possible Mechanisms and Clinical Impact. <i>Digestive Diseases and Sciences</i> , 2015, 60, 3513-3524.	1.1	36
435	Serum ferritin levels predict histological severity in patients with nonalcoholic fatty liver disease in India. <i>Indian Journal of Gastroenterology</i> , 2015, 34, 200-208.	0.7	9
436	Diets rich in fructose, fat or fructose and fat alter intestinal barrier function and lead to the development of nonalcoholic fatty liver disease over time. <i>Journal of Nutritional Biochemistry</i> , 2015, 26, 1183-1192.	1.9	134
437	Strategies, models and biomarkers in experimental non-alcoholic fatty liver disease research. <i>Progress in Lipid Research</i> , 2015, 59, 106-125.	5.3	130
438	The Influence of the Gut Microbiome on Obesity, Metabolic Syndrome and Gastrointestinal Disease. <i>Clinical and Translational Gastroenterology</i> , 2015, 6, e91.	1.3	177
439	Low- and high-density lipoprotein subclasses in subjects with nonalcoholic fatty liver disease. <i>Journal of Clinical Lipidology</i> , 2015, 9, 576-582.	0.6	56
440	Hepatocyte-specific Bid depletion reduces tumor development by suppressing inflammation-related compensatory proliferation. <i>Cell Death and Differentiation</i> , 2015, 22, 1985-1994.	5.0	25
441	Nonalcoholic Fatty Liver Disease and Type 2 Diabetes: Common Pathophysiologic Mechanisms. <i>Current Diabetes Reports</i> , 2015, 15, 607.	1.7	102
442	Automatic quantification of lobular inflammation and hepatocyte ballooning in nonalcoholic fatty liver disease liver biopsies. <i>Human Pathology</i> , 2015, 46, 767-775.	1.1	33
443	Sustained proliferation in cancer: Mechanisms and novel therapeutic targets. <i>Seminars in Cancer Biology</i> , 2015, 35, S25-S54.	4.3	468
444	Clinical Model for NASH and Advanced Fibrosis in Adult Patients With Diabetes and NAFLD: Guidelines for Referral in NAFLD. <i>Diabetes Care</i> , 2015, 38, 1347-1355.	4.3	162
445	Usefulness of ultrasonographic estimation of preperitoneal and subcutaneous fat thickness in the diagnosis of nonalcoholic fatty liver disease in diabetic patients. <i>Journal of Medical Ultrasonics (2001)</i> , 2015, 42, 357-363.	0.6	9
446	Age Impacts Ability of Aspartateâ€Alanine Aminotransferase Ratio to Predict Advanced Fibrosis in Nonalcoholic Fatty Liver Disease. <i>Digestive Diseases and Sciences</i> , 2015, 60, 1825-1831.	1.1	18
447	A study of gender-wise risk association between fatty liver and metabolic syndrome components (Asia-Pacific criteria) in a South Indian urban cohort. <i>Indian Journal of Gastroenterology</i> , 2015, 34, 38-42.	0.7	6
448	Prevalence of hypothyroidism in nonalcoholic fatty liver disease in patients attending a tertiary hospital in western India. <i>Indian Journal of Gastroenterology</i> , 2015, 34, 169-173.	0.7	26
449	Non-alcoholic fatty liver disease: when to intervene and with what. <i>Clinical Medicine</i> , 2015, 15, 186-190.	0.8	17

#	ARTICLE	IF	CITATIONS
451	Helicobacter pylori infection is not associated with fatty liver disease including non-alcoholic fatty liver disease: a large-scale cross-sectional study in Japan. BMC Gastroenterology, 2015, 15, 25.	0.8	80
452	Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis. Gastroenterology, 2015, 149, 367-378.e5.	0.6	1,592
453	Lowering the dietary omega-6: omega-3 does not hinder nonalcoholic fatty-liver disease development in a murine model. Nutrition Research, 2015, 35, 449-459.	1.3	27
454	Nonalcoholic Steatohepatitis (NASH) Is Associated with a Decline in Pancreatic Beta Cell (β^2 -Cell) Function. Digestive Diseases and Sciences, 2015, 60, 2529-2537.	1.1	28
455	Gut Microbiota and Metabolic Diseases: From Pathogenesis to Therapeutic Perspective. Molecular and Integrative Toxicology, 2015, , 199-234.	0.5	7
456	Ketone body production is differentially altered in steatosis and nonalcoholic steatohepatitis in obese humans. Liver International, 2015, 35, 1853-1861.	1.9	62
457	Trends in Outpatient Resource Utilizations and Outcomes for Medicare Beneficiaries With Nonalcoholic Fatty Liver Disease. Journal of Clinical Gastroenterology, 2015, 49, 222-227.	1.1	43
458	Comparison of noninvasive scores for the detection of advanced fibrosis in patients with nonalcoholic fatty liver disease. European Journal of Gastroenterology and Hepatology, 2015, 27, 137-141.	0.8	36
460	Association between serum free fatty acid levels and nonalcoholic fatty liver disease: a cross-sectional study. Scientific Reports, 2014, 4, 5832.	1.6	131
461	Nonalcoholic Fatty Liver Disease as a Risk Factor of Arterial Stiffness Measured by the Cardioankle Vascular Index. Medicine (United States), 2015, 94, e654.	0.4	27
462	A systematic review of the prevalence of mildly abnormal liver function tests and associated health outcomes. European Journal of Gastroenterology and Hepatology, 2015, 27, 1-7.	0.8	54
463	Macrophage activation marker soluble CD163 and nonalcoholic fatty liver disease in morbidly obese patients undergoing bariatric surgery. Journal of Gastroenterology and Hepatology (Australia), 2015, 30, 1293-1300.	1.4	53
464	Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. Hepatology Research, 2015, 45, 363-377.	1.8	149
465	Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. Hepatology, 2015, 61, 1547-1554.	3.6	1,683
466	Trihalomethane exposure and biomonitoring for the liver injury indicator, alanine aminotransferase, in the United States population (NHANES 1999-2006). Science of the Total Environment, 2015, 521-522, 226-234.	3.9	23
467	Combining metformin therapy with caloric restriction for the management of type 2 diabetes and nonalcoholic fatty liver disease in obese rats. Applied Physiology, Nutrition and Metabolism, 2015, 40, 1038-1047.	0.9	35
468	JTP-103237, a monoacylglycerol acyltransferase inhibitor, prevents fatty liver and suppresses both triglyceride synthesis and de novo lipogenesis. Journal of Pharmacological Sciences, 2015, 128, 150-157.	1.1	9
469	Multicenter investigation of lifestyle-related diseases and visceral disorders in thalidomide embryopathy at around 50 years of age. Birth Defects Research Part A: Clinical and Molecular Teratology, 2015, 103, 787-793.	1.6	8

#	ARTICLE	IF	CITATIONS
470	HÁGADO GRASO NO ALCOHÁ“LICO. Revista MÃ©dica ClÃ©nica Las Condes, 2015, 26, 600-612.	0.2	0
471	Influence of ethnicity on the distribution of genetic polymorphisms associated with risk of chronic liver disease in South American populations. BMC Genetics, 2015, 16, 93.	2.7	25
472	Non-Alcoholic Steatohepatitis: Limited Available Treatment Options but Promising Drugs in Development and Recent Progress Towards a Regulatory Approval Pathway. Drugs, 2015, 75, 1373-1392.	4.9	61
473	Association Between Patatin-Like Phospholipase Domain Containing 3 Gene (PNPLA3) Polymorphisms and Nonalcoholic Fatty Liver Disease: A HuGE Review and Meta-Analysis. Scientific Reports, 2015, 5, 9284.	1.6	106
474	Lipid-Induced Hepatocyte-Derived Extracellular Vesicles Regulate Hepatic Stellate Cells via MicroRNA Targeting Peroxisome Proliferator-Activated Receptor- β . Cellular and Molecular Gastroenterology and Hepatology, 2015, 1, 646-663.e4.	2.3	170
475	Clinical, biochemical and histological differences between <sc>HIV</sc> associated <sc>NAFLD</sc> and primary <sc>NAFLD</sc>: a caseâ€“control study. Alimentary Pharmacology and Therapeutics, 2015, 41, 368-378.	1.9	106
476	Impact of nonâ€“alcoholic fatty liver disease on liver volume in humans. Hepatology Research, 2015, 45, 210-219.	1.8	16
477	Hepatic fat, not visceral fat, is associated with gallbladder polyps: A study of 2643 healthy subjects. Journal of Gastroenterology and Hepatology (Australia), 2015, 30, 767-774.	1.4	13
478	Nonalcoholic Fatty Liver Disease. Seminars in Liver Disease, 2015, 35, 203-206.	1.8	6
479	The Genetics of Nonalcoholic Fatty Liver Disease: Spotlight on PNPLA3 and TM6SF2. Seminars in Liver Disease, 2015, 35, 270-290.	1.8	135
480	Sarcopaenia is associated with NAFLD independently of obesity and insulin resistance: Nationwide surveys (KNHANES 2008â€“2011). Journal of Hepatology, 2015, 63, 486-493.	1.8	264
482	Nonalcoholic fatty liver disease â€“ current status and future directions. Journal of Digestive Diseases, 2015, 16, 541-557.	0.7	80
483	Associations between dietary intake and the presence of the metabolic syndrome in patients with nonâ€“alcoholic fatty liver disease. Journal of Human Nutrition and Dietetics, 2015, 28, 409-415.	1.3	25
484	Similar Reduction of Cholesterol-Adjusted Vitamin E Serum Levels in Simple Steatosis and Non-Alcoholic Steatohepatitis. Clinical and Translational Gastroenterology, 2015, 6, e113.	1.3	25
485	Sex-Specific Differences in Hepatic Fat Oxidation and Synthesis May Explain the Higher Propensity for NAFLD in Men. Journal of Clinical Endocrinology and Metabolism, 2015, 100, 4425-4433.	1.8	108
486	Epidemiological modifiers of non-alcoholic fatty liver disease: Focus on high-risk groups. Digestive and Liver Disease, 2015, 47, 997-1006.	0.4	368
487	Current and Future Burden of Chronic Nonmalignant Liver Disease. Clinical Gastroenterology and Hepatology, 2015, 13, 2031-2041.	2.4	111
488	Caring for children with NAFLD and navigating their care into adulthood. Nature Reviews Gastroenterology and Hepatology, 2015, 12, 617-628.	8.2	17

#	ARTICLE	IF	CITATIONS
489	Docosahexaenoic acid attenuates Western diet-induced hepatic fibrosis in Ldlr mice by targeting the TGF β 2-Smad3 pathway. <i>Journal of Lipid Research</i> , 2015, 56, 1936-1946.	2.0	39
490	Tissue Inhibitors of Metalloproteinase-1 and 2 and Obesity Related Non-Alcoholic Fatty Liver Disease: Is There a Relationship?. <i>Digestion</i> , 2015, 92, 130-137.	1.2	32
491	Nonalcoholic Fatty Liver Disease and Vascular Function. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2015, 35, 1284-1291.	1.1	68
492	Potential for Dietary ω -3 Fatty Acids to Prevent Nonalcoholic Fatty Liver Disease and Reduce the Risk of Primary Liver Cancer. <i>Advances in Nutrition</i> , 2015, 6, 694-702.	2.9	64
493	Reduced Lysosomal Acid Lipase Activity in Adult Patients With Non-alcoholic Fatty Liver Disease. <i>EBioMedicine</i> , 2015, 2, 750-754.	2.7	51
494	Relative contributions of L-FABP, SCP-2/SCP-x, or both to hepatic biliary phenotype of female mice. <i>Archives of Biochemistry and Biophysics</i> , 2015, 588, 25-32.	1.4	9
495	Longitudinal Changes in Liver Fat Content in Asymptomatic Adults: Hepatic Attenuation on Unenhanced CT as an Imaging Biomarker for Steatosis. <i>American Journal of Roentgenology</i> , 2015, 205, 1167-1172.	1.0	34
496	The association of hepatitis C virus infection and post-liver transplant diabetes: data from 17,000 HCV-infected transplant recipients. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 41, 209-217.	1.9	17
497	Is there a rationale for treatment of chronic liver disease with antithrombotic therapy?. <i>Blood Reviews</i> , 2015, 29, 127-136.	2.8	36
498	Obesity depresses the anti-inflammatory HSP70 pathway, contributing to NAFLD progression. <i>Obesity</i> , 2015, 23, 120-129.	1.5	87
499	Noninvasive Diagnosis of Nonalcoholic Fatty Liver Disease and Quantification of Liver Fat Using a New Quantitative Ultrasound Technique. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 1337-1345.e6.	2.4	200
500	Prevalence and determinants of fatty liver in normal-weight and overweight young adults. The Cardiovascular Risk in Young Finns Study. <i>Annals of Medicine</i> , 2015, 47, 40-46.	1.5	35
501	Coffee consumption and nonalcoholic fatty liver onset: a prospective study in the general population. <i>Translational Research</i> , 2015, 165, 428-436.	2.2	65
502	Risk of non-alcoholic fatty liver disease in patients with psoriasis: a systematic review and meta-analysis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2015, 29, 656-662.	1.3	116
503	Liver Disease in the Adolescent. <i>Clinics in Liver Disease</i> , 2015, 19, 171-185.	1.0	6
504	Bioinformatics and database resources in hepatology. <i>Journal of Hepatology</i> , 2015, 62, 712-719.	1.8	31
505	The pan-caspase inhibitor Emricasan (IDN6556) decreases liver injury and fibrosis in a murine model of non-alcoholic steatohepatitis. <i>Liver International</i> , 2015, 35, 953-966.	1.9	231
506	Diagnosis and classification of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis: Current concepts and remaining challenges. <i>Hepatology Research</i> , 2015, 45, 20-28.	1.8	84

#	ARTICLE	IF	CITATIONS
507	Nutrition Status of Patients With Chronic Hepatitis B or C. <i>Nutrition in Clinical Practice</i> , 2015, 30, 290-296.	1.1	10
508	Leptin in nonalcoholic fatty liver disease: A narrative review. <i>Metabolism: Clinical and Experimental</i> , 2015, 64, 60-78.	1.5	170
509	Astaxanthin prevents TGF β ² 1-induced pro-fibrogenic gene expression by inhibiting Smad3 activation in hepatic stellate cells. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 2015, 1850, 178-185.	1.1	81
510	Chronic Liver Disease in the Human Immunodeficiency Virus Patient. <i>Clinics in Liver Disease</i> , 2015, 19, 1-22.	1.0	25
511	Severity of Nonalcoholic Fatty Liver Disease and Progression to Cirrhosis Are Associated With Atherogenic Lipoprotein Profile. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 1000-1008.e3.	2.4	164
512	Measurement of liver stiffness as a noninvasive method for diagnosis of nonalcoholic fatty liver disease. <i>Hepatology Research</i> , 2015, 45, 142-151.	1.8	47
513	Use of noninvasive serum glycan markers to distinguish nonalcoholic steatohepatitis from simple steatosis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2015, 30, 528-534.	1.4	26
514	Lipids Nutrition and Epigenetic Modification in Obesity-Related Co-Morbidities * *All authors equally contributed to draft the manuscript. All authors gave final approval of the version to be published. Disclosure statement: The authors declare that there are no conflicts of interest., 2016, , 85-110.		4
515	Cardiovascular Disease Risk Factors among Non-Alcoholic Fatty Liver Disease Patients at Makkah, Kingdom of Saudi Arabia. <i>Global Journal of Health Science</i> , 2016, 8, 45.	0.1	0
517	Association between hepatitis B and metabolic syndrome: Current state of the art. <i>World Journal of Gastroenterology</i> , 2016, 22, 155.	1.4	41
518	Insulin resistance in development and progression of nonalcoholic fatty liver disease. <i>World Journal of Gastrointestinal Pathophysiology</i> , 2016, 7, 211.	0.5	74
519	Nonalcoholic Fatty Liver Disease in Canadian First Nations and Non-First Nations Patients. <i>Canadian Journal of Gastroenterology and Hepatology</i> , 2016, 2016, 1-6.	0.8	5
520	Intrahepatic Fat Content and Markers of Hepatic Fibrosis in Obese Children. <i>International Journal of Endocrinology</i> , 2016, 2016, 1-10.	0.6	2
521	Prevalence and sonographic changes compatible with fatty liver disease in patients referred for abdominal ultrasound examination in Aracaju, SE. <i>Radiologia Brasileira</i> , 2016, 49, 1-5.	0.3	9
522	Rural Residency has a Protective Effect and Marriage is a Risk Factor for NAFLD. <i>Hepatitis Monthly</i> , 2016, 16, e38357.	0.1	4
523	Nonalcoholic fatty liver disease as a multi-systemic disease. <i>World Journal of Gastroenterology</i> , 2016, 22, 4079.	1.4	100
524	Hepatokines and non-alcoholic fatty liver disease. <i>Acta Biochimica Polonica</i> , 2016, 63, .	0.3	32
525	The Relationship between 10-Year Cardiovascular Risk Calculated Using the Pooled Cohort Equation and the Severity of Non-Alcoholic Fatty Liver Disease. <i>Endocrinology and Metabolism</i> , 2016, 31, 86.	1.3	24

#	ARTICLE	IF	CITATIONS
526	The Western-Style Diet, Calcium Deficiency and Chronic Disease. <i>Journal of Nutrition & Food Sciences</i> , 2016, 06, .	1.0	6
527	Can Pharmacologic Therapy Induce Histologic Improvement in Non-alcoholic Steatohepatitis?. <i>Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi, The</i> , 2016, 67, 286.	0.2	0
528	Emerging role of obeticholic acid in the management of nonalcoholic fatty liver disease. <i>World Journal of Gastroenterology</i> , 2016, 22, 9039.	1.4	31
529	Fibroscan Compared to FIB-4, APRI, and AST/ALT Ratio for Assessment of Liver Fibrosis in Saudi Patients With Nonalcoholic Fatty Liver Disease. <i>Hepatitis Monthly</i> , 2016, 16, e38346.	0.1	40
531	Body Roundness Index and Waist-to-Height Ratio are Strongly Associated With Non-Alcoholic Fatty Liver Disease: A Population-Based Study. <i>Hepatitis Monthly</i> , 2016, 16, e39575.	0.1	39
532	Prevalence of and risk factors for non-alcoholic fatty liver disease in a Chinese population: An 8-year follow-up study. <i>World Journal of Gastroenterology</i> , 2016, 22, 3663.	1.4	32
533	Liver fibrosis and hepatic stellate cells: Etiology, pathological hallmarks and therapeutic targets. <i>World Journal of Gastroenterology</i> , 2016, 22, 10512.	1.4	429
534	Albumin Binding Function: The Potential Earliest Indicator for Liver Function Damage. <i>Gastroenterology Research and Practice</i> , 2016, 2016, 1-7.	0.7	10
535	Associations between White Blood Cell Count and the Development of Incidental Nonalcoholic Fatty Liver Disease. <i>Gastroenterology Research and Practice</i> , 2016, 2016, 1-6.	0.7	27
536	Computed Tomography Measurement of Hepatic Steatosis: Prevalence of Hepatic Steatosis in a Canadian Population. <i>Canadian Journal of Gastroenterology and Hepatology</i> , 2016, 2016, 1-7.	0.8	37
537	Preclinical Models for Investigation of Herbal Medicines in Liver Diseases: Update and Perspective. <i>Evidence-based Complementary and Alternative Medicine</i> , 2016, 2016, 1-26.	0.5	8
538	<i>AÃ§ai</i> (<i>Euterpe oleracea</i> Mart.) Upregulates Paraoxonase 1 Gene Expression and Activity with Concomitant Reduction of Hepatic Steatosis in High-Fat Diet-Fed Rats. <i>Oxidative Medicine and Cellular Longevity</i> , 2016, 2016, 1-13.	1.9	25
539	A Guide to Non-Alcoholic Fatty Liver Disease in Childhood and Adolescence. <i>International Journal of Molecular Sciences</i> , 2016, 17, 947.	1.8	129
540	NAFLD and Chronic Kidney Disease. <i>International Journal of Molecular Sciences</i> , 2016, 17, 562.	1.8	142
541	Garcinoic Acid. <i>Studies in Natural Products Chemistry</i> , 2016, 51, 435-481.	0.8	7
542	Comparisons of dietary intake in Japanese with non-alcoholic fatty liver disease and type 2 diabetes mellitus. <i>Journal of Clinical Biochemistry and Nutrition</i> , 2016, 59, 215-219.	0.6	9
543	Pathology of Non-Alcoholic Fatty Liver Disease. <i>International Journal of Digestive Diseases</i> , 2016, 2, .	0.2	10
544	Relationship between Methyl Tertiary Butyl Ether Exposure and Non-Alcoholic Fatty Liver Disease: A Cross-Sectional Study among Petrol Station Attendants in Southern China. <i>International Journal of Environmental Research and Public Health</i> , 2016, 13, 946.	1.2	5

#	ARTICLE	IF	CITATIONS
545	Hepatoprotective Effects of Chinese Medicinal Herbs: A Focus on Anti-Inflammatory and Anti-Oxidative Activities. <i>International Journal of Molecular Sciences</i> , 2016, 17, 465.	1.8	107
546	PNPLA3 Expression Is Related to Liver Steatosis in Morbidly Obese Women with Non-Alcoholic Fatty Liver Disease. <i>International Journal of Molecular Sciences</i> , 2016, 17, 630.	1.8	18
547	Nutritional Strategies for the Individualized Treatment of Non-Alcoholic Fatty Liver Disease (NAFLD) Based on the Nutrient-Induced Insulin Output Ratio (NIOR). <i>International Journal of Molecular Sciences</i> , 2016, 17, 1192.	1.8	23
548	Molecular Pathogenesis of NASH. <i>International Journal of Molecular Sciences</i> , 2016, 17, 1575.	1.8	150
549	Is Western Diet-Induced Nonalcoholic Steatohepatitis in Ldlr ^{-/-} Mice Reversible?. <i>PLoS ONE</i> , 2016, 11, e0146942.	1.1	35
550	Efficacy of Resveratrol Supplementation against Non-Alcoholic Fatty Liver Disease: A Meta-Analysis of Placebo-Controlled Clinical Trials. <i>PLoS ONE</i> , 2016, 11, e0161792.	1.1	33
551	Discrimination of Nonalcoholic Steatohepatitis Using Transient Elastography in Patients with Nonalcoholic Fatty Liver Disease. <i>PLoS ONE</i> , 2016, 11, e0157358.	1.1	62
552	The Association between Non-Invasive Hepatic Fibrosis Markers and Cardiometabolic Risk Factors in the Framingham Heart Study. <i>PLoS ONE</i> , 2016, 11, e0157517.	1.1	25
553	Novel Molecular Mechanisms in the Development of Non-Alcoholic Steatohepatitis. <i>Diabetes and Metabolism Journal</i> , 2016, 40, 1.	1.8	53
554	Clinical guidelines of non-alcoholic fatty liver disease: A systematic review. <i>World Journal of Gastroenterology</i> , 2016, 22, 8226.	1.4	29
555	Autophagy in Non-Alcoholic Fatty Liver Disease (NAFLD). , 0, , .		7
556	Fatty liver is associated with an increased risk of diabetes and cardiovascular disease - Evidence from three different disease models: NAFLD, HCV and HIV. <i>World Journal of Gastroenterology</i> , 2016, 22, 9674.	1.4	93
557	Prediction and Diagnosis of Non-Alcoholic Fatty Liver Disease (NAFLD) and Identification of Its Associated Factors Using the Classification Tree Method. <i>Iranian Red Crescent Medical Journal</i> , 2016, 18, e32858.	0.5	23
558	Anti-obesity and anti-hepatosteatorosis effects of dietary scopoletin in high-fat diet fed mice. <i>Journal of Functional Foods</i> , 2016, 25, 433-446.	1.6	14
559	Epidemiology of nonalcoholic fatty liver disease: A primer. <i>Clinical Liver Disease</i> , 2016, 7, 106-108.	1.0	21
560	Identification of novel noninvasive markers for diagnosing nonalcoholic steatohepatitis and related fibrosis by data mining. <i>Hepatology</i> , 2016, 63, 462-473.	3.6	33
561	Liver stiffness in nonalcoholic fatty liver disease: A comparison of supersonic shear imaging, FibroScan, and ARFI with liver biopsy. <i>Hepatology</i> , 2016, 63, 1817-1827.	3.6	388
562	Liver Disease in Pediatric Patients With Ataxia Telangiectasia. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2016, 62, 550-555.	0.9	28

#	ARTICLE	IF	CITATIONS
563	Follicle-stimulating hormone is associated with non-alcoholic fatty liver disease in Chinese women over 55 years old. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2016, 31, 1196-1202.	1.4	29
564	The invasion of fatty liver disease in liver transplantation. <i>Transplant International</i> , 2016, 29, 416-417.	0.8	4
565	Hepatocellular carcinoma in noncirrhotic livers is associated with steatosis rather than steatohepatitis: potential implications for pathogenesis. <i>European Journal of Gastroenterology and Hepatology</i> , 2016, 28, 955-962.	0.8	14
566	Acetylcholine induces fibrogenic effects via M2/M3 acetylcholine receptors in non-alcoholic steatohepatitis and in primary human hepatic stellate cells. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2016, 31, 475-483.	1.4	13
567	Dietary fatty acids and risk of hepatocellular carcinoma in the Singapore Chinese health study. <i>Liver International</i> , 2016, 36, 893-901.	1.9	33
568	Dietary Saturated Fat Promotes Development of Hepatic Inflammation Through Toll-Like Receptor 4 in Mice. <i>Journal of Cellular Biochemistry</i> , 2016, 117, 1613-1621.	1.2	20
569	Systematic transcriptome analysis reveals elevated expression of alcohol-metabolizing genes in <sc>NAFLD</sc> livers. <i>Journal of Pathology</i> , 2016, 238, 531-542.	2.1	40
570	Effect of cocoa in diabetes: the potential of the pancreas and liver as key target organs, more than an antioxidant effect?. <i>International Journal of Food Science and Technology</i> , 2016, 51, 829-841.	1.3	10
571	An Overview of Mouse Models of Nonalcoholic Steatohepatitis: From Past to Present. <i>Current Protocols in Mouse Biology</i> , 2016, 6, 185-200.	1.2	40
572	Development and validation of a noninvasive prediction model for nonalcoholic steatohepatitis resolution after lifestyle intervention. <i>Hepatology</i> , 2016, 63, 1875-1887.	3.6	50
573	Association of noninvasive quantitative decline in liver fat content on MRI with histologic response in nonalcoholic steatohepatitis. <i>Therapeutic Advances in Gastroenterology</i> , 2016, 9, 692-701.	1.4	123
574	Pharmacogenomic and personalized approaches to tackle nonalcoholic fatty liver disease. <i>Pharmacogenomics</i> , 2016, 17, 1273-1288.	0.6	13
575	Male 11 β -HSD1 Knockout Mice Fed Trans-Fats and Fructose Are Not Protected From Metabolic Syndrome or Nonalcoholic Fatty Liver Disease. <i>Endocrinology</i> , 2016, 157, 3493-3504.	1.4	16
576	Treatment of Non-alcoholic Fatty Liver Disease with Curcumin: A Randomized Placebo-controlled Trial. <i>Phytotherapy Research</i> , 2016, 30, 1540-1548.	2.8	316
577	Shared genetic effects between hepatic steatosis and fibrosis: A prospective twin study. <i>Hepatology</i> , 2016, 64, 1547-1558.	3.6	64
578	Role of intrahepatic B cells in non-alcoholic fatty liver disease by secreting pro-inflammatory cytokines and regulating intrahepatic T cells. <i>Journal of Digestive Diseases</i> , 2016, 17, 464-474.	0.7	32
579	Changes in liver steatosis evaluated by transient elastography with the controlled attenuation parameter in <sc>HIV</sc>-infected patients. <i>HIV Medicine</i> , 2016, 17, 766-773.	1.0	23
580	Elevated serum ferritin is associated with increased mortality in non-alcoholic fatty liver disease after 16 years of follow-up. <i>Liver International</i> , 2016, 36, 1688-1695.	1.9	54

#	ARTICLE	IF	CITATIONS
581	Ethnic and Gender Differences in the Prevalence of Nonalcoholic Steatohepatitis Among Bariatric Surgery Patients. <i>Bariatric Surgical Patient Care</i> , 2016, 11, 153-157.	0.1	1
582	Heterozygous <i>Hfe</i> gene deletion leads to impaired glucose homeostasis, but not liver injury in mice fed a high-calorie diet. <i>Physiological Reports</i> , 2016, 4, e12837.	0.7	5
583	Epidemiology of nonalcoholic steatohepatitis and hepatocellular carcinoma. <i>Clinical Liver Disease</i> , 2016, 8, 119-122.	1.0	23
584	American Association of Clinical Endocrinologists and American College of Endocrinology Comprehensive Clinical Practice Guidelines For Medical Care of Patients with Obesity. <i>Endocrine Practice</i> , 2016, 22, 1-203.	1.1	952
585	Telomere Dysfunction in Nonalcoholic Fatty Liver Disease and Cryptogenic Cirrhosis. <i>Cytogenetic and Genome Research</i> , 2016, 150, 93-99.	0.6	41
586	CXCL10-Mediates Macrophage, but not Other Innate Immune Cells-Associated Inflammation in Murine Nonalcoholic Steatohepatitis. <i>Scientific Reports</i> , 2016, 6, 28786.	1.6	99
587	Probiotics and Liver Disease. <i>Journal of Clinical Gastroenterology</i> , 2016, 50, S188-S190.	1.1	12
588	Higher Mortality and Survival Benefit in Obese Patients Awaiting Liver Transplantation. <i>Transplantation</i> , 2016, 100, 2648-2655.	0.5	45
592	Impact of dietary fat on the development of non-alcoholic fatty liver disease in <i>Ldlr</i> mice. <i>Proceedings of the Nutrition Society</i> , 2016, 75, 1-9.	0.4	36
593	Association between white blood cell count and non-alcoholic fatty liver disease in urban Han Chinese: a prospective cohort study. <i>BMJ Open</i> , 2016, 6, e010342.	0.8	30
594	Peripheral insulin resistance predicts liver damage in nondiabetic subjects with nonalcoholic fatty liver disease. <i>Hepatology</i> , 2016, 63, 107-116.	3.6	67
595	Novel Pharmacotherapy Options for NASH. <i>Digestive Diseases and Sciences</i> , 2016, 61, 1398-1405.	1.1	35
596	Relationship between non-alcoholic fatty liver disease, metabolic syndrome and insulin resistance in Korean adults: A cross-sectional study. <i>Clinica Chimica Acta</i> , 2016, 458, 12-17.	0.5	14
597	Non-alcoholic steatohepatitis and liver transplantation. <i>Digestive and Liver Disease</i> , 2016, 48, 587-591.	0.4	18
598	Relationship of epicardial fat thickness and nonalcoholic fatty liver disease to coronary artery calcification: From the CAESAR study. <i>Journal of Clinical Lipidology</i> , 2016, 10, 619-626.e1.	0.6	26
599	Review of current and potential future pharmacological treatments in nonalcoholic steatohepatitis. <i>Clinical Liver Disease</i> , 2016, 7, 11-14.	1.0	1
600	2D AMESING multi-echo 31P-MRSI of the liver at 7T allows transverse relaxation assessment and T2-weighted averaging for improved SNR. <i>Magnetic Resonance Imaging</i> , 2016, 34, 219-226.	1.0	4
601	Obesity and colorectal liver metastases: Mechanisms and management. <i>Surgical Oncology</i> , 2016, 25, 246-251.	0.8	20

#	ARTICLE	IF	CITATIONS
602	Association between exposures to brominated trihalomethanes, hepatic injury and type II diabetes mellitus. <i>Environment International</i> , 2016, 92-93, 486-493.	4.8	9
603	Metabolically Healthy Obesity and the Development of Nonalcoholic Fatty Liver Disease. <i>American Journal of Gastroenterology</i> , 2016, 111, 1133-1140.	0.2	158
604	Investigating the role of cortisol and growth hormone in fatty liver development: fatty liver index in patients with pituitary adenomas. <i>Pituitary</i> , 2016, 19, 461-471.	1.6	14
605	EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. <i>Diabetologia</i> , 2016, 59, 1121-1140.	2.9	485
606	EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. <i>Journal of Hepatology</i> , 2016, 64, 1388-1402.	1.8	3,403
607	Significant Association Between Gallstone Disease and Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis. <i>Digestive Diseases and Sciences</i> , 2016, 61, 2389-2396.	1.1	47
608	Development and Validation of the Framingham Steatosis Index to Identify Persons With Hepatic Steatosis. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, 1172-1180.e2.	2.4	76
609	Nonalcoholic Fatty Liver Disease: Pathogenesis and Disease Spectrum. <i>Annual Review of Pathology: Mechanisms of Disease</i> , 2016, 11, 451-496.	9.6	449
610	Global Epidemiology of Nonalcoholic Fatty Liver Disease and Perspectives on US Minority Populations. <i>Digestive Diseases and Sciences</i> , 2016, 61, 1214-1225.	1.1	130
611	EASL-EASD-EASO Clinical Practice Guidelines for the Management of Non-Alcoholic Fatty Liver Disease. <i>Obesity Facts</i> , 2016, 9, 65-90.	1.6	371
612	Nonalcoholic Steatohepatitis and Liver Transplantation. <i>Current Hepatology Reports</i> , 2016, 15, 113-116.	0.4	1
613	Interleukin-18-deficient mice develop dyslipidemia resulting in nonalcoholic fatty liver disease and steatohepatitis. <i>Translational Research</i> , 2016, 173, 101-114.e7.	2.2	30
614	Nonalcoholic Fatty Liver Disease: Prognosis and Progression of Disease. <i>Current Hepatology Reports</i> , 2016, 15, 117-124.	0.4	1
615	Efficacy and safety study of cenicriviroc for the treatment of non-alcoholic steatohepatitis in adult subjects with liver fibrosis: CENTAUR Phase 2b study design. <i>Contemporary Clinical Trials</i> , 2016, 47, 356-365.	0.8	178
616	Extrahepatic Manifestations of Nonalcoholic Fatty Liver Disease. <i>Current Hepatology Reports</i> , 2016, 15, 75-85.	0.4	87
617	Ethnicity matters: A Systematic Review and Meta-Analysis of the Non-Linear Relationship Between Alcohol Consumption and Prevalence and Incidence of Hepatic Steatosis. <i>EBioMedicine</i> , 2016, 8, 317-330.	2.7	24
618	Changes of liver enzymes and triglyceride during the menopausal transition in Japanese women. <i>Journal of Obstetrics and Gynaecology</i> , 2016, 36, 806-811.	0.4	6
619	The association of early unexplained elevated alanine aminotransferase with large-for-gestational-age birthweight. <i>American Journal of Obstetrics and Gynecology</i> , 2016, 215, 474.e1-474.e5.	0.7	12

#	ARTICLE	IF	CITATIONS
620	The PNPLA3 rs738409 C>G polymorphism is associated with the risk of progression to cirrhosis in NAFLD patients. <i>Scandinavian Journal of Gastroenterology</i> , 2016, 51, 967-973.	0.6	20
621	Gd-EOB-DTPA-enhanced-MR imaging in the inflammation stage of nonalcoholic steatohepatitis (NASH) in mice. <i>Magnetic Resonance Imaging</i> , 2016, 34, 724-729.	1.0	25
622	Novel educational interventions in residency increase knowledge of chronic liver disease and career interest in hepatology. <i>Hepatology</i> , 2016, 64, 2210-2218.	3.6	5
623	The role of mitochondrial genomics in patients with non-alcoholic steatohepatitis (NASH). <i>BMC Medical Genetics</i> , 2016, 17, 63.	2.1	29
624	Tipping the Scales: Liver Transplant Outcomes of the Super Obese. <i>Journal of Gastrointestinal Surgery</i> , 2016, 20, 1628-1635.	0.9	14
625	Increased parenchymal damage and steatohepatitis in Caucasian non-alcoholic fatty liver disease patients with common IL1B and IL6 polymorphisms. <i>Alimentary Pharmacology and Therapeutics</i> , 2016, 44, 1253-1264.	1.9	23
626	Distinctive features of hepatocellular carcinoma in non-alcoholic fatty liver disease. <i>The Lancet Gastroenterology and Hepatology</i> , 2016, 1, 156-164.	3.7	116
627	The overall computer/mobile devices usage time is related to newly diagnosed non-alcoholic fatty liver disease: a population-based study. <i>Annals of Medicine</i> , 2016, 48, 568-576.	1.5	10
628	Sevelamer Improves Steatohepatitis, Inhibits Liver and Intestinal Farnesoid X Receptor (FXR), and Reverses Innate Immune Dysregulation in a Mouse Model of Non-alcoholic Fatty Liver Disease. <i>Journal of Biological Chemistry</i> , 2016, 291, 23058-23067.	1.6	33
629	miRNAs in non-alcoholic fatty liver disease. <i>Frontiers of Medicine</i> , 2016, 10, 389-396.	1.5	32
630	The effect of minimal dietary changes with raisins in NAFLD patients with non-significant fibrosis: a randomized controlled intervention. <i>Food and Function</i> , 2016, 7, 4533-4544.	2.1	23
631	p38 ^β and p38 ^γ reprogram liver metabolism by modulating neutrophil infiltration. <i>EMBO Journal</i> , 2016, 35, 536-552.	3.5	61
632	Hypogonadism alters cecal and fecal microbiota in male mice. <i>Gut Microbes</i> , 2016, 7, 533-539.	4.3	46
633	NAFLD and liver transplantation: Current burden and expected challenges. <i>Journal of Hepatology</i> , 2016, 65, 1245-1257.	1.8	352
634	Mapping liver fat female-dependent quantitative trait loci in collaborative cross mice. <i>Mammalian Genome</i> , 2016, 27, 565-573.	1.0	20
635	Association of Intestinal Microbiota with Metabolic Markers and Dietary Habits in Patients with Type 2 Diabetes. <i>Digestion</i> , 2016, 94, 66-72.	1.2	84
636	Efficacy of alogliptin in preventing non-alcoholic fatty liver disease progression in patients with type 2 diabetes. <i>Biomedical Reports</i> , 2016, 4, 183-187.	0.9	42
637	Impact of body fat distribution on neoadjuvant chemotherapy outcomes in advanced breast cancer patients. <i>Cancer Medicine</i> , 2016, 5, 41-48.	1.3	75

#	ARTICLE	IF	CITATIONS
638	Subclassification of fatty liver by its pathogenesis: cLEFing is believing. <i>Journal of Pathology</i> , 2016, 239, 3-5.	2.1	0
639	Elucidating Differences in the Hepatotoxic Potential of Tolcapone and Entacapone With DILIsym [®] , a Mechanistic Model of Drug-Induced Liver Injury. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2016, 5, 31-39.	1.3	61
640	Increased risk of chronic liver disease in patients with bipolar disorder: A population-based study. <i>General Hospital Psychiatry</i> , 2016, 42, 54-59.	1.2	22
641	Pharmacokinetics, Safety, and CCR2/CCR5 Antagonist Activity of Cenicriviroc in Participants With Mild or Moderate Hepatic Impairment. <i>Clinical and Translational Science</i> , 2016, 9, 139-148.	1.5	47
642	Natural antioxidants for non-alcoholic fatty liver disease: molecular targets and clinical perspectives. <i>Liver International</i> , 2016, 36, 5-20.	1.9	203
643	<i>De novo</i> lipogenesis in the liver in health and disease: more than just a shunting yard for glucose. <i>Biological Reviews</i> , 2016, 91, 452-468.	4.7	323
644	Aneuploidy and asynchronous replication in non-alcoholic fatty liver disease and cryptogenic cirrhosis. <i>Gene</i> , 2016, 593, 162-166.	1.0	4
645	Comparison of Predicted Energy Expenditure in Japanese Patients with Non-Alcoholic Fatty Liver Disease to Establish a Suitable Nutrition Intervention. <i>Journal of Nutritional Science and Vitaminology</i> , 2016, 62, 108-115.	0.2	2
646	Clinical assessment of hepatic de novo lipogenesis in non-alcoholic fatty liver disease. <i>Lipids in Health and Disease</i> , 2016, 15, 159.	1.2	65
648	Mid-infrared fibre evanescent wave spectroscopy of serum allows fingerprinting of the hepatic metabolic status in mice. <i>Analyst</i> , 2016, 141, 6259-6269.	1.7	5
649	Effect of diet based on the principles of Iranian traditional medicine on cirrhosis (a clinical trial). <i>Complementary Therapies in Medicine</i> , 2016, 29, 35-41.	1.3	2
650	Changes in blood microbiota profiles associated with liver fibrosis in obese patients: A pilot analysis. <i>Hepatology</i> , 2016, 64, 2015-2027.	3.6	230
651	Gut microbiota are linked to increased susceptibility to hepatic steatosis in low-aerobic-capacity rats fed an acute high-fat diet. <i>American Journal of Physiology - Renal Physiology</i> , 2016, 311, G166-G179.	1.6	32
652	Histological Evaluation of Non-alcoholic Fatty Liver Disease and Its Correlation with Different Noninvasive Scoring Systems with Special Reference to Fibrosis: A Single Center Experience. <i>Journal of Clinical and Experimental Hepatology</i> , 2016, 6, 291-296.	0.4	15
653	Fenofibrate nanoliposome: Preparation and its inhibitory effects on nonalcoholic fatty liver disease in mice. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2016, 12, 2449-2458.	1.7	16
654	Indications for Surgery for Obesity and Weight-Related Diseases: Position Statements from the International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO). <i>Obesity Surgery</i> , 2016, 26, 1659-1696.	1.1	228
655	Lipid phenotypes in patients with nonalcoholic fatty liver disease. <i>Metabolism: Clinical and Experimental</i> , 2016, 65, 1391-1398.	1.5	27
656	Revisión de los tratamientos farmacológicos actuales y futuros de la esteatohepatitis no alcohólica. <i>Clinical Liver Disease</i> , 2016, 8, S34-S38.	1.0	0

#	ARTICLE	IF	CITATIONS
658	Diet-induced non-alcoholic fatty liver disease affects expression of major cytochrome P450 genes in a mouse model. <i>Journal of Pharmacy and Pharmacology</i> , 2016, 68, 1567-1576.	1.2	20
659	Hepatocellular autophagy modulates the unfolded protein response and fasting-induced steatosis in mice. <i>American Journal of Physiology - Renal Physiology</i> , 2016, 311, G599-G609.	1.6	37
660	Developmental Programming of Nonalcoholic Fatty Liver Disease (NAFLD). , 2016, , 255-288.		0
661	Nonalcoholic Fatty Liver Disease. <i>Gastroenterology Clinics of North America</i> , 2016, 45, 639-652.	1.0	202
662	Gender impacts on the correlations between nonalcoholic fatty liver disease and hypertension in a Chinese population aged 45â€“60 y. <i>Clinical and Experimental Hypertension</i> , 2016, 38, 639-643.	0.5	9
663	Epidemiology of Hepatocellular Carcinoma. , 2016, , 3-24.		6
664	Microarray analysis of gene expression in liver, adipose tissue and skeletal muscle in response to chronic dietary administration of NDGA to high-fructose fed dyslipidemic rats. <i>Nutrition and Metabolism</i> , 2016, 13, 63.	1.3	11
665	Obese Mice Fed a Diet Supplemented with Enzyme-Treated Wheat Bran Display Marked Shifts in the Liver Metabolome Concurrent with Altered Gut Bacteria. <i>Journal of Nutrition</i> , 2016, 146, 2445-2460.	1.3	16
667	BMI history and risk of incident fatty liver. <i>European Journal of Gastroenterology and Hepatology</i> , 2016, 28, 1188-1193.	0.8	21
668	Nonalcoholic fatty liver is not associated with incident chronic kidney disease. <i>European Journal of Gastroenterology and Hepatology</i> , 2016, 28, 441-443.	0.8	15
669	Nonalcoholic Fatty Liver Disease: Epidemiology, Pathogenesis, Natural History, Diagnosis, and Current Treatment Options. <i>Clinical Medicine Insights Therapeutics</i> , 2016, 8, CMT.S18885.	0.4	33
670	Nonalcoholic fatty liver disease is associated with excessive calorie intake rather than a distinctive dietary pattern. <i>Medicine (United States)</i> , 2016, 95, e3887.	0.4	78
671	Prevalence of hepatic steatosis in apparently healthy medical students: a transient elastography study on the basis of a controlled attenuation parameter. <i>European Journal of Gastroenterology and Hepatology</i> , 2016, 28, 1264-1267.	0.8	18
672	Kinetics of plasma triglycerides in abdominal obesity. <i>Current Opinion in Lipidology</i> , 2017, 28, 11-18.	1.2	60
673	Gut microbiota and metabolic disease: from pathogenesis to new therapeutic strategies. <i>Reviews in Medical Microbiology</i> , 2016, 27, 141-152.	0.4	15
674	Global epidemiology of nonalcoholic fatty liver diseaseâ€”Metaâ€”analytic assessment of prevalence, incidence, and outcomes. <i>Hepatology</i> , 2016, 64, 73-84.	3.6	7,346
675	Altered Hepatic Transport by Fetal Arsenite Exposure in Dietâ€”Induced Fatty Liver Disease. <i>Journal of Biochemical and Molecular Toxicology</i> , 2016, 30, 321-330.	1.4	8
676	Significant Morbidity and Mortality Among Hospitalized End-Stage Liver Disease Patients in Medicare. <i>Journal of Pain and Symptom Management</i> , 2016, 52, 412-419.e1.	0.6	25

#	ARTICLE	IF	CITATIONS
677	Why Pursue a Fourth Year in Advanced/Transplant Hepatology?. Digestive Diseases and Sciences, 2016, 61, 1817-1818.	1.1	0
678	Natural History of Patients Presenting with Autoimmune Hepatitis and Coincident Nonalcoholic Fatty Liver Disease. Digestive Diseases and Sciences, 2016, 61, 2710-2720.	1.1	64
679	Effect of incretin therapies compared to pioglitazone and gliclazide in non-alcoholic fatty liver disease in diabetic patients not controlled on metformin alone: An observational, pilot study. EndocrinologÃa Y NutriciÃ³n (English Edition), 2016, 63, 194-201.	0.5	16
680	MRI and MRE for non-invasive quantitative assessment of hepatic steatosis and fibrosis in NAFLD and NASH: Clinical trials to clinical practice. Journal of Hepatology, 2016, 65, 1006-1016.	1.8	275
681	Acute-on-chronic and Decompensated Chronic Liver Failure. Critical Care Clinics, 2016, 32, 301-309.	1.0	15
682	Liver resection for cancer: New developments in prediction, prevention and management of postresectional liver failure. Journal of Hepatology, 2016, 65, 1217-1231.	1.8	96
683	Nighttime sleep duration and risk of nonalcoholic fatty liver disease: the Dongfeng-Tongji prospective study. Annals of Medicine, 2016, 48, 468-476.	1.5	19
684	Women with Cirrhosis. Gastroenterology Clinics of North America, 2016, 45, 345-358.	1.0	17
685	Phosphorylated heat shock protein 27 promotes lipid clearance in hepatic cells through interacting with STAT3 and activating autophagy. Cellular Signalling, 2016, 28, 1086-1098.	1.7	23
686	Awareness of nonalcoholic steatohepatitis and associated practice patterns of primary care physicians and specialists. BMC Research Notes, 2016, 9, 157.	0.6	42
688	The increasing burden of nonalcoholic fatty liver disease among young adults in the United States: A growing epidemic. Hepatology, 2016, 64, 1386-1387.	3.6	26
689	Liver injury attenuation by curcumin in a rat NASH model: an Nrf2 activation-mediated effect?. Irish Journal of Medical Science, 2016, 185, 93-100.	0.8	39
690	Serum microRNAs explain discordance of non-alcoholic fatty liver disease in monozygotic and dizygotic twins: a prospective study. Gut, 2016, 65, 1546-1554.	6.1	75
691	<i>AdipoQ</i> T45ÃG and G276ÃT Polymorphisms and Susceptibility to Nonalcoholic Fatty Liver Disease Among Asian Populations: A MetaÃAnalysis and MetaÃRegression. Journal of Clinical Laboratory Analysis, 2016, 30, 47-57.	0.9	14
692	Animal Models of Nonalcoholic Fatty Liver Disease. , 2016, , 121-145.		2
693	Global Epidemiology and Risk Factors for Nonalcoholic Fatty Liver Disease. , 2016, , 21-40.		2
694	Fatty acid metabolism is altered in non-alcoholic steatohepatitis independent of obesity. Metabolism: Clinical and Experimental, 2016, 65, 655-666.	1.5	78
695	Garlic Influences Gene Expression In Vivo and In Vitro. Journal of Nutrition, 2016, 146, 444S-449S.	1.3	14

#	ARTICLE	IF	CITATIONS
696	Placebo-controlled, randomised clinical trial: high-dose resveratrol treatment for non-alcoholic fatty liver disease. <i>Scandinavian Journal of Gastroenterology</i> , 2016, 51, 456-464.	0.6	109
697	The Framingham Heart Study – 67 years of discovery in metabolic disease. <i>Nature Reviews Endocrinology</i> , 2016, 12, 177-183.	4.3	48
698	Associations of insulin resistance, inflammation and liver synthetic function with very low-density lipoprotein: The Cardiovascular Health Study. <i>Metabolism: Clinical and Experimental</i> , 2016, 65, 92-99.	1.5	18
699	Deletion of sphingosine kinase 1 ameliorates hepatic steatosis in diet-induced obese mice: Role of PPAR β . <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , 2016, 1861, 138-147.	1.2	41
700	Comparison of the Phenotype and Approach to Pediatric vs Adult Patients With Nonalcoholic Fatty Liver Disease. <i>Gastroenterology</i> , 2016, 150, 1798-1810.	0.6	129
701	Efecto de las terapias incretínicas comparadas con pioglitazona y gliclazida en la esteatosis hepática no alcohólica de los pacientes diabéticos no controlados solo con metformina: estudio observacional piloto. <i>Endocrinología Y Nutricion: Organo De La Sociedad Espanola De Endocrinología Y Nutricion</i> , 2016, 63, 194-201.	0.8	18
702	Staging of fibrosis in experimental non-alcoholic steatohepatitis by quantitative molecular imaging in rat models. <i>Nuclear Medicine and Biology</i> , 2016, 43, 179-187.	0.3	9
703	Nonalcoholic Fatty Liver Disease is Associated with Erectile Dysfunction: A Prospective Pilot Study. <i>Journal of Sexual Medicine</i> , 2016, 13, 383-388.	0.3	14
704	Novel 3D Magnetic Resonance Elastography for the Noninvasive Diagnosis of Advanced Fibrosis in NAFLD: A Prospective Study. <i>American Journal of Gastroenterology</i> , 2016, 111, 986-994.	0.2	160
705	Gestational Diabetes Mellitus Is Strongly Associated With Non-Alcoholic Fatty Liver Disease. <i>American Journal of Gastroenterology</i> , 2016, 111, 658-664.	0.2	80
706	Clinical Presentation and Patient Evaluation in Nonalcoholic Fatty Liver Disease. <i>Clinics in Liver Disease</i> , 2016, 20, 277-292.	1.0	32
707	Quantitative succinylome analysis in the liver of non-alcoholic fatty liver disease rat model. <i>Proteome Science</i> , 2016, 14, 3.	0.7	32
708	Targeting Cell Death and Sterile Inflammation Loop for the Treatment of Nonalcoholic Steatohepatitis. <i>Seminars in Liver Disease</i> , 2016, 36, 027-036.	1.8	35
709	Epidemiology and natural history of non-alcoholic fatty liver disease. <i>Metabolism: Clinical and Experimental</i> , 2016, 65, 1017-1025.	1.5	339
710	Ginger Essential Oil Ameliorates Hepatic Injury and Lipid Accumulation in High Fat Diet-Induced Nonalcoholic Fatty Liver Disease. <i>Journal of Agricultural and Food Chemistry</i> , 2016, 64, 2062-2071.	2.4	99
711	Metabolomics Study of Roux-en-Y Gastric Bypass Surgery (RYGB) to Treat Type 2 Diabetes Patients Based on Ultraperformance Liquid Chromatography–Mass Spectrometry. <i>Journal of Proteome Research</i> , 2016, 15, 1288-1299.	1.8	48
712	Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor α and β , Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening. <i>Gastroenterology</i> , 2016, 150, 1147-1159.e5.	0.6	847
713	The Correlation Between Obesity-Related Diseases and Non-alcoholic Fatty Liver Disease in Women in the Pre-operative Evaluation for Bariatric Surgery Assessed by Transient Hepatic Elastography. <i>Obesity Surgery</i> , 2016, 26, 2089-2097.	1.1	10

#	ARTICLE	IF	CITATIONS
714	3D Printing for Liver Tissue Engineering: Current Approaches and Future Challenges. <i>Current Transplantation Reports</i> , 2016, 3, 100-108.	0.9	27
715	Chronic hepatitis B and fatty liver: Issues in clinical management. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2016, 40, 755-759.	0.7	12
716	Noninvasive diagnosis of nonalcoholic fatty liver disease: Are we there yet?. <i>Metabolism: Clinical and Experimental</i> , 2016, 65, 1087-1095.	1.5	53
717	Gut Microbiota of Nonalcoholic Fatty Liver Disease. <i>Digestive Diseases and Sciences</i> , 2016, 61, 1268-1281.	1.1	46
718	The Burden of Rehospitalization for Patients With Liver Cirrhosis. <i>Hospital Practice (1995)</i> , 2016, 44, 60-69.	0.5	15
719	Association of Nonalcoholic Fatty Liver Disease With Visceral Adiposity but Not Coronary Artery Calcification in the Elderly. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, 1337-1344.e3.	2.4	20
720	Emerging Therapies for Nonalcoholic Fatty Liver Disease. <i>Clinics in Liver Disease</i> , 2016, 20, 365-385.	1.0	8
721	Non-alcoholic fatty liver disease and liver transplantation. <i>Metabolism: Clinical and Experimental</i> , 2016, 65, 1208-1223.	1.5	40
722	Impact of high-fat diet on the proteome of mouse liver. <i>Journal of Nutritional Biochemistry</i> , 2016, 31, 10-19.	1.9	31
723	Development and Validation of an Algorithm to Identify Nonalcoholic Fatty Liver Disease in the Electronic Medical Record. <i>Digestive Diseases and Sciences</i> , 2016, 61, 913-919.	1.1	63
724	Genetic and epigenetic mechanisms of NASH. <i>Hepatology International</i> , 2016, 10, 394-406.	1.9	46
725	Practice patterns in NAFLD and NASH: real life differs from published guidelines. <i>Therapeutic Advances in Gastroenterology</i> , 2016, 9, 4-12.	1.4	72
726	Adipokines in nonalcoholic fatty liver disease. <i>Metabolism: Clinical and Experimental</i> , 2016, 65, 1062-1079.	1.5	250
727	Epidemiology of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis in the United States and the Rest of the World. <i>Clinics in Liver Disease</i> , 2016, 20, 205-214.	1.0	403
728	The Metabolic Syndrome and Its Influence on Nonalcoholic Steatohepatitis. <i>Clinics in Liver Disease</i> , 2016, 20, 225-243.	1.0	85
729	Magnetic Resonance Imaging More Accurately Classifies Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease Than Transient Elastography. <i>Gastroenterology</i> , 2016, 150, 626-637.e7.	0.6	628
730	Adzuki bean ameliorates hepatic lipogenesis and proinflammatory mediator expression in mice fed a high-cholesterol and high-fat diet to induce nonalcoholic fatty liver disease. <i>Nutrition Research</i> , 2016, 36, 90-100.	1.3	35
731	Trends in the Burden of Nonalcoholic Fatty Liver Disease in the United States Cohort of Veterans. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, 301-308.e2.	2.4	136

#	ARTICLE	IF	CITATIONS
732	Current complications and challenges in nonalcoholic steatohepatitis screening and diagnosis. Expert Review of Gastroenterology and Hepatology, 2016, 10, 63-71.	1.4	50
733	Perceptions of non-alcoholic fatty liver disease " an Asian community-based study. Gastroenterology Report, 2016, 4, 131-135.	0.6	38
734	MicroRNA changes, activation of progenitor cells and severity of liver injury in mice induced by choline and folate deficiency. Journal of Nutritional Biochemistry, 2016, 28, 83-90.	1.9	24
735	The impact of metabolic syndrome and prevalent liver disease on living donor liver transplantation: a pressing need to expand the pool. Hepatology International, 2016, 10, 347-354.	1.9	12
736	Magnetic resonance elastography for staging liver fibrosis in non-alcoholic fatty liver disease: a diagnostic accuracy systematic review and individual participant data pooled analysis. European Radiology, 2016, 26, 1431-1440.	2.3	195
737	Feasibility of a three-step magnetic resonance imaging approach for the assessment of hepatic steatosis in an asymptomatic study population. European Radiology, 2016, 26, 1895-1904.	2.3	43
738	Vitamin B5 and N-Acetylcysteine in Nonalcoholic Steatohepatitis: A Preclinical Study in a Dietary Mouse Model. Digestive Diseases and Sciences, 2016, 61, 137-148.	1.1	10
739	Adverse outcomes of pregnancy in women with non-alcoholic fatty liver disease. Liver International, 2016, 36, 268-274.	1.9	80
740	Non-alcoholic fatty liver disease resolution following sleeve gastrectomy. Surgical Endoscopy and Other Interventional Techniques, 2016, 30, 1983-1987.	1.3	32
741	Circulating leptin in non-alcoholic fatty liver disease: a systematic review and meta-analysis. Diabetologia, 2016, 59, 30-43.	2.9	186
742	Poor Inter-test Reliability Between CK18 Kits as a Biomarker of NASH. Digestive Diseases and Sciences, 2016, 61, 905-912.	1.1	17
743	Nonalcoholic Fatty Liver Disease in Latinos. Clinical Gastroenterology and Hepatology, 2016, 14, 5-12.	2.4	87
744	An assessment of racial differences in the upper limits of normal ALT levels in children and the effect of obesity on elevated values. Pediatric Obesity, 2017, 12, 363-372.	1.4	4
745	Modified thresholds for fibrosis risk scores in nonalcoholic fatty liver disease are necessary in the obese. Obesity Surgery, 2017, 27, 115-125.	1.1	30
746	Diagn3stico y cuantificaci3n de fibrosis, esteatosis y hepatosiderosis por medio de resonancia magn3tica multiparam3trica. Revista De Gastroenterolog3a De M3xico, 2017, 82, 32-45.	0.4	3
747	Serum apoB levels independently predict the development of non-alcoholic fatty liver disease: A 7-year prospective study. Liver International, 2017, 37, 1202-1208.	1.9	21
748	Effect of Korean Red Ginseng in chronic liver disease. Journal of Ginseng Research, 2017, 41, 450-455.	3.0	47
749	The natural history of streptozotocin-stimulated non-alcoholic steatohepatitis mice followed by Gd-EOB-DTPA-enhanced MRI: Comparison with simple steatosis mice. Magnetic Resonance Imaging, 2017, 38, 123-128.	1.0	3

#	ARTICLE	IF	CITATIONS
750	Derivation and validation of a scoring system for predicting nonalcoholic steatohepatitis in Taiwanese patients with severe obesity. <i>Surgery for Obesity and Related Diseases</i> , 2017, 13, 686-692.	1.0	15
751	NASH: The Ethical Dilemma. , 2017, , 213-227.		0
752	Alcohol, microbiome, life style influence alcohol and non-alcoholic organ damage. <i>Experimental and Molecular Pathology</i> , 2017, 102, 162-180.	0.9	40
753	Efficacy and safety of glucagon-like peptide-1 receptor agonists in non-alcoholic fatty liver disease: A systematic review and meta-analysis. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2017, 41, 284-295.	0.7	54
754	Gut Microbiota and Complications of Liver Disease. <i>Gastroenterology Clinics of North America</i> , 2017, 46, 155-169.	1.0	73
755	Dicer1/miR-29/HMGCR axis contributes to hepatic free cholesterol accumulation in mouse non-alcoholic steatohepatitis. <i>Acta Pharmacologica Sinica</i> , 2017, 38, 660-671.	2.8	43
756	High fat diet-induced changes of mouse hepatic transcription and enhancer activity can be reversed by subsequent weight loss. <i>Scientific Reports</i> , 2017, 7, 40220.	1.6	62
757	Effects of Bariatric Surgery on Non-alcoholic Fatty Liver Disease: Magnetic Resonance Imaging Is an Effective, Non-invasive Method to Evaluate Changes in the Liver Fat Fraction. <i>Obesity Surgery</i> , 2017, 27, 1755-1762.	1.1	19
758	Six-year changes in the prevalence of obesity and obesity-related diseases in Northeastern China from 2007 to 2013. <i>Scientific Reports</i> , 2017, 7, 41518.	1.6	23
759	An estrogen receptor $\hat{2}$ -selective agonist inhibits non-alcoholic steatohepatitis in preclinical models by regulating bile acid and xenobiotic receptors. <i>Experimental Biology and Medicine</i> , 2017, 242, 606-616.	1.1	17
760	Utility of the ELF Test for Detecting Steatohepatitis in Morbid Obese Patients with Suspicion of Nonalcoholic Fatty Liver Disease. <i>Obesity Surgery</i> , 2017, 27, 2347-2353.	1.1	17
761	Protein and Calorie Requirements Associated With the Presence of Obesity. <i>Nutrition in Clinical Practice</i> , 2017, 32, 86S-93S.	1.1	22
762	Non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in patients with HIV. <i>The Lancet Gastroenterology and Hepatology</i> , 2017, 2, 211-223.	3.7	37
763	Diagnosis and quantification of fibrosis, steatosis, and hepatic siderosis through multiparametric magnetic resonance imaging. <i>Revista De GastroenterologÁa De MÃ©xico (English Edition)</i> , 2017, 82, 32-45.	0.1	1
764	A disease-specific quality of life instrument for non-alcoholic fatty liver disease and non-alcoholic steatohepatitis: <sc>CLDQ</sc>â€œ<sc>NAFLD</sc>. <i>Liver International</i> , 2017, 37, 1209-1218.	1.9	72
765	The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement. <i>Metabolism: Clinical and Experimental</i> , 2017, 71, 17-32.	1.5	208
766	Extended Criteria Donors in Liver Transplantation. <i>Clinics in Liver Disease</i> , 2017, 21, 289-301.	1.0	128
767	Adipokine Levels Versus Hepatic Histopathology in Bariatric Surgery Patients. <i>Obesity Surgery</i> , 2017, 27, 2151-2158.	1.1	16

#	ARTICLE	IF	CITATIONS
768	Clinical risk scoring for predicting nonalcoholic fatty liver disease in metabolic syndrome patients (NAFLD-MS score). <i>Liver International</i> , 2017, 37, 1535-1543.	1.9	22
769	Association between soil heavy metals and fatty liver disease in men in Taiwan: a cross sectional study. <i>BMJ Open</i> , 2017, 7, e014215.	0.8	38
770	Efficacy and Safety of Phytosomal Curcumin in Non-Alcoholic Fatty Liver Disease: A Randomized Controlled Trial. <i>Drug Research</i> , 2017, 67, 244-251.	0.7	217
771	NAFLD-Related HCC: How Should the Shift in Epidemiology Change Our Prevention and Surveillance Strategies?. <i>Current Hepatology Reports</i> , 2017, 16, 26-32.	0.4	0
772	Nonalcoholic fatty liver disease and measures of early brain health in middle-aged adults: The CARDIA study. <i>Obesity</i> , 2017, 25, 642-651.	1.5	37
773	Choline supplementation increased total body lipid gain, while surplus methionine improved growth and amino acid retention in adult Atlantic salmon (<i>Salmo salar</i>). <i>Aquaculture Nutrition</i> , 2017, 23, 1086-1094.	1.1	8
774	Dapagliflozin decreases small dense low-density lipoprotein-cholesterol and increases high-density lipoprotein 2-cholesterol in patients with type 2 diabetes: comparison with sitagliptin. <i>Cardiovascular Diabetology</i> , 2017, 16, 8.	2.7	119
775	JPEN Journal Club 25. Study Design. <i>Journal of Parenteral and Enteral Nutrition</i> , 2017, 41, 263-265.	1.3	0
776	A model to predict the onset of nonalcoholic fatty liver disease within 2 years in elderly adults. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2017, 32, 1739-1745.	1.4	4
777	Chronic hepatitis. , 2017, , 1058-1064.e2.		0
778	Hepatic steatosis, steatohepatitis, and chemotherapy-related liver injury. , 2017, , 1065-1072.e3.		0
779	Epidemiology and Risk Factors of Nonalcoholic Fatty Liver Disease Among Patients with Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2017, 23, 998-1003.	0.9	36
780	Population Pharmacokinetics of Morphine in Patients With Nonalcoholic Steatohepatitis (NASH) and Healthy Adults. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2017, 6, 331-339.	1.3	9
781	Bile acids and bariatric surgery. <i>Molecular Aspects of Medicine</i> , 2017, 56, 75-89.	2.7	99
782	Prevalence and risk factors of nonalcoholic fatty liver disease in HIV-monoinfection. <i>Aids</i> , 2017, 31, 1621-1632.	1.0	166
783	Diagnosis of fatty liver by computed tomography coronary artery calcium score. <i>Echocardiography</i> , 2017, 34, 937-938.	0.3	7
784	Bile acids as global regulators of hepatic nutrient metabolism. <i>Liver Research</i> , 2017, 1, 10-16.	0.5	23
785	Cirrhosis Patients with Nonalcoholic Steatohepatitis Are Significantly Less Likely to Receive Surveillance for Hepatocellular Carcinoma. <i>Digestive Diseases and Sciences</i> , 2017, 62, 2174-2181.	1.1	22

#	ARTICLE	IF	CITATIONS
786	Cost-effectiveness analysis of ultrasonography screening for nonalcoholic fatty liver disease in metabolic syndrome patients. <i>Medicine (United States)</i> , 2017, 96, e6585.	0.4	21
787	Prevalence of Fatty Liver Disease and Hepatic Iron Overload in a Northeastern German Population by Using Quantitative MR Imaging. <i>Radiology</i> , 2017, 284, 706-716.	3.6	91
788	Gut Microbiome-Based Metagenomic Signature for Non-invasive Detection of Advanced Fibrosis in Human Nonalcoholic Fatty Liver Disease. <i>Cell Metabolism</i> , 2017, 25, 1054-1062.e5.	7.2	748
789	Diagnostic accuracy of serum alanine aminotransferase as biomarker for nonalcoholic fatty liver disease and insulin resistance in healthy subjects, using 3T MR spectroscopy. <i>Medicine (United States)</i> , 2017, 96, e6770.	0.4	41
790	How healthy are the "Healthy volunteers"? Penetrance of NAFLD in the biomedical research volunteer pool. <i>Hepatology</i> , 2017, 66, 825-833.	3.6	28
791	Serum vascular cell adhesion molecule-1 predicts significant liver fibrosis in non-alcoholic fatty liver disease. <i>International Journal of Obesity</i> , 2017, 41, 1207-1213.	1.6	40
792	Concentration-dependent response to pioglitazone in nonalcoholic steatohepatitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 46, 56-61.	1.9	28
793	The Liver. , 2017, , 3-22.		17
794	Hepatic Apoptosis and Necrosis. , 2017, , 47-60.		1
795	Interpreting lipoproteins in nonalcoholic fatty liver disease. <i>Current Opinion in Lipidology</i> , 2017, 28, 355-360.	1.2	24
796	Exosomes derived from palmitic acid-treated hepatocytes induce fibrotic activation of hepatic stellate cells. <i>Scientific Reports</i> , 2017, 7, 3710.	1.6	170
797	Hepatic steatosis progresses faster in HIV mono-infected than HIV/HCV co-infected patients and is associated with liver fibrosis. <i>Journal of Hepatology</i> , 2017, 67, 801-808.	1.8	70
798	Prevalence and Predictors of Significant Fibrosis Among Subjects with Transient Elastography-Defined Nonalcoholic Fatty Liver Disease. <i>Digestive Diseases and Sciences</i> , 2017, 62, 2150-2158.	1.1	18
799	Hypertension and hepatic triglycerides content. <i>Journal of Hypertension</i> , 2017, 35, 715-717.	0.3	3
800	Triglyceride glucose-body mass index is effective in identifying nonalcoholic fatty liver disease in nonobese subjects. <i>Medicine (United States)</i> , 2017, 96, e7041.	0.4	45
801	Serum cytokeratin-18 fragment levels as noninvasive marker of nonalcoholic steatohepatitis in the Chilean population. <i>GastroenterologĀ Y HepatologĀ (English Edition)</i> , 2017, 40, 388-394.	0.0	2
802	Treatment of NAFLD with diet, physical activity and exercise. <i>Journal of Hepatology</i> , 2017, 67, 829-846.	1.8	838
803	Chrelin receptor inverse agonists as a novel therapeutic approach against obesity-related metabolic disease. <i>Diabetes, Obesity and Metabolism</i> , 2017, 19, 1740-1750.	2.2	37

#	ARTICLE	IF	CITATIONS
804	Hepatic CD36 downregulation parallels steatosis improvement in morbidly obese undergoing bariatric surgery. <i>International Journal of Obesity</i> , 2017, 41, 1388-1393.	1.6	11
805	The Human Gut Microbiome in Liver Diseases. <i>Seminars in Liver Disease</i> , 2017, 37, 128-140.	1.8	30
806	Liver fat: a relevant target for dietary intervention? Summary of a Unilever workshop. <i>Journal of Nutritional Science</i> , 2017, 6, e15.	0.7	10
807	Microbiome and NAFLD: potential influence of aerobic fitness and lifestyle modification. <i>Physiological Genomics</i> , 2017, 49, 385-399.	1.0	31
808	Non-alcoholic fatty liver disease in women with polycystic ovary syndrome: systematic review and meta-analysis. <i>Journal of Endocrinological Investigation</i> , 2017, 40, 1279-1288.	1.8	116
809	Changes in drug transport and metabolism and their clinical implications in non-alcoholic fatty liver disease. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2017, 13, 625-640.	1.5	23
810	Polycystic ovary syndrome with hyperandrogenism as a risk factor for non-obese non-alcoholic fatty liver disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 45, 1403-1412.	1.9	72
811	Effect of miglitol on the suppression of nonalcoholic steatohepatitis development and improvement of the gut environment in a rodent model. <i>Journal of Gastroenterology</i> , 2017, 52, 1180-1191.	2.3	38
812	Psoriasis e hígado graso no alcohólico. <i>Actas Dermo-sifiliográficas</i> , 2017, 108, 506-514.	0.2	34
813	Retinol Binding Protein-4 Levels and Non-alcoholic Fatty Liver Disease: A community-based cross-sectional study. <i>Scientific Reports</i> , 2017, 7, 45100.	1.6	25
814	An observational study on the association of nonalcoholic fatty liver disease and metabolic syndrome with gall stone disease requiring cholecystectomy. <i>Annals of Medicine and Surgery</i> , 2017, 17, 7-13.	0.5	12
815	De Novo and Recurrence of Nonalcoholic Steatohepatitis After Liver Transplantation. <i>Clinics in Liver Disease</i> , 2017, 21, 321-335.	1.0	23
816	The Metabolic Syndrome, Oxidative Stress, and the Liver. , 2017, , 323-329.		1
817	Synbiotic supplementation in lean patients with non-alcoholic fatty liver disease: a pilot, randomised, double-blind, placebo-controlled, clinical trial. <i>British Journal of Nutrition</i> , 2017, 117, 662-668.	1.2	165
818	Nonalcoholic Fatty Liver Disease, the Gut Microbiome, and Diet. <i>Advances in Nutrition</i> , 2017, 8, 240-252.	2.9	125
819	Nutritional Approaches to Achieve Weight Loss in Nonalcoholic Fatty Liver Disease. <i>Advances in Nutrition</i> , 2017, 8, 253-265.	2.9	38
820	Patatin-like phospholipase domain-containing protein 3 (PNPLA3): A potential role in the association between liver disease and bipolar disorder. <i>Journal of Affective Disorders</i> , 2017, 209, 93-96.	2.0	9
821	Circulating sCD36 levels in patients with non-alcoholic fatty liver disease and controls. <i>International Journal of Obesity</i> , 2017, 41, 262-267.	1.6	24

#	ARTICLE	IF	CITATIONS
822	The preventive effect of sustained physical activity on incident nonalcoholic fatty liver disease. <i>Liver International</i> , 2017, 37, 919-926.	1.9	29
823	Imaging patterns and focal lesions in fatty liver: a pictorial review. <i>Abdominal Radiology</i> , 2017, 42, 1374-1392.	1.0	32
824	Protective effect of quercetin on high-fat diet-induced non-alcoholic fatty liver disease in mice is mediated by modulating intestinal microbiota imbalance and related gut-liver axis activation. <i>Free Radical Biology and Medicine</i> , 2017, 102, 188-202.	1.3	374
825	Nonalcoholic fatty liver disease and the risk of clinical cardiovascular events: A systematic review and meta-analysis. <i>Diabetes and Metabolic Syndrome: Clinical Research and Reviews</i> , 2017, 11, S209-S216.	1.8	136
826	Occurrence over time and regression of nonalcoholic fatty liver disease in type 2 diabetes. <i>Diabetes/Metabolism Research and Reviews</i> , 2017, 33, e2878.	1.7	22
827	Shiftwork Is Not Associated with Increased Risk of NAFLD: Findings from the National Health and Nutrition Examination Survey. <i>Digestive Diseases and Sciences</i> , 2017, 62, 526-533.	1.1	27
828	Acoustic Impedance Analysis with High-Frequency Ultrasound for Identification of Fatty Acid Species in the Liver. <i>Ultrasound in Medicine and Biology</i> , 2017, 43, 700-711.	0.7	21
829	Ectopic fat accumulation in the pancreas and its clinical relevance: A systematic review, meta-analysis, and meta-regression. <i>Metabolism: Clinical and Experimental</i> , 2017, 69, 1-13.	1.5	165
830	Compact bone-derived mesenchymal stem cells attenuate nonalcoholic steatohepatitis in a mouse model by modulation of CD4 cells differentiation. <i>International Immunopharmacology</i> , 2017, 42, 67-73.	1.7	22
831	Diagnosing liver fibrosis: a narrative review of current literature for dermatologists. <i>British Journal of Dermatology</i> , 2017, 177, 637-644.	1.4	8
832	Pharmacotoxicology of clinically-relevant concentrations of obeticholic acid in an organotypic human hepatocyte system. <i>Toxicology in Vitro</i> , 2017, 39, 93-103.	1.1	28
833	Sex differences in the impact of nonalcoholic fatty liver disease on cardiovascular risk factors. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2017, 27, 63-69.	1.1	12
834	Overview of Clinical Treatment Trials for NASH. <i>Current Hepatology Reports</i> , 2017, 16, 366-373.	0.4	0
835	Epidemiology of Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma. <i>Cancer Control</i> , 2017, 24, 107327481772924.	0.7	400
836	The Role of Diagnosis and Treatment of Underlying Liver Disease for the Prognosis of Primary Liver Cancer. <i>Cancer Control</i> , 2017, 24, 107327481772924.	0.7	66
837	Superior reductions in hepatic steatosis and fibrosis with co-administration of a glucagon-like peptide-1 receptor agonist and obeticholic acid in mice. <i>Molecular Metabolism</i> , 2017, 6, 1360-1370.	3.0	50
838	Early Intervention With Live Donor Liver Transplantation Reduces Resource Utilization in NASH: The Toronto Experience. <i>Transplantation Direct</i> , 2017, 3, e158.	0.8	12
839	Living With Hepatocellular Carcinoma Near the End of Life: Family Caregivers' Perspectives. <i>Oncology Nursing Forum</i> , 2017, 44, 562-570.	0.5	14

#	ARTICLE	IF	CITATIONS
840	Obstetric Outcomes in Women with Nonalcoholic Fatty Liver Disease. Metabolic Syndrome and Related Disorders, 2017, 15, 387-392.	0.5	7
841	Temporal trends, clinical patterns and outcomes of <sc>NAFLD</sc>-related <sc>HCC</sc> in patients undergoing liver resection over a 20-year period. Alimentary Pharmacology and Therapeutics, 2017, 46, 856-863.	1.9	91
842	Significant burden of nonalcoholic fatty liver disease with advanced fibrosis in the US: a cross-sectional analysis of 2011-2014 National Health and Nutrition Examination Survey. Alimentary Pharmacology and Therapeutics, 2017, 46, 974-980.	1.9	83
843	Spleen dimensions are inversely associated with lysosomal acid lipase activity in patients with non-alcoholic fatty liver disease. Internal and Emergency Medicine, 2017, 12, 1159-1165.	1.0	16
844	Angiotensin-like protein 8: An attractive biomarker for the evaluation of subjects with insulin resistance and related disorders. Diabetes Research and Clinical Practice, 2017, 133, 168-177.	1.1	13
846	Disparities Among Gastrointestinal Disorders in Research Funding From the National Institutes of Health. Gastroenterology, 2017, 153, 877-880.	0.6	4
847	NAFLD, Helicobacter species and the intestinal microbiome. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2017, 31, 657-668.	1.0	41
848	Nonalcoholic fatty liver disease, association with cardiovascular disease and treatment (II). The treatment of nonalcoholic fatty liver disease. Clínica E Investigaci3n En Arteriosclerosis (English) Tj ETQq1 1 0.78431 4 rgBT2/Overload		
849	Fragmento s3rico de citoqueratina-18 como marcador no invasivo de esteatohepatitis no alcohol3lica en poblaci3n chilena. Gastroenterolog3a Y Hepatolog3a, 2017, 40, 388-394.	0.2	6
850	The association of non-alcoholic fatty liver disease and metabolic syndrome in a Chinese population. Hepatobiliary and Pancreatic Diseases International, 2017, 16, 176-180.	0.6	18
851	Managing nonalcoholic fatty liver disease in patients living with HIV. Current Opinion in Infectious Diseases, 2017, 30, 12-20.	1.3	15
852	Resolution of donor non-alcoholic fatty liver disease following liver transplantation. Clinical Transplantation, 2017, 31, e13032.	0.8	9
853	Metabolomic characteristics of cholesterol-induced non-obese nonalcoholic fatty liver disease in mice. Scientific Reports, 2017, 7, 6120.	1.6	62
854	Liver Function in Patients With Nonalcoholic Fatty Liver Disease Randomized to Roux-en-Y Gastric Bypass Versus Sleeve Gastrectomy. Annals of Surgery, 2017, 266, 738-745.	2.1	74
855	Biochemical Profile of Nonalcoholic Fatty Liver Disease Patients in Eastern India with Histopathological Correlation. Indian Journal of Clinical Biochemistry, 2017, 32, 306-314.	0.9	7
856	The beneficial effects of resveratrol on steatosis and mitochondrial oxidative stress in HepG2 cells. Canadian Journal of Physiology and Pharmacology, 2017, 95, 1442-1453.	0.7	31
857	Sex differences in the association of HIV infection with hepatic steatosis. Aids, 2017, 31, 365-373.	1.0	22
858	Nation-wide trends in non-alcoholic steatohepatitis (NASH) in patients with and without diabetes between 2004-05 and 2014-15 in England. Diabetes Research and Clinical Practice, 2017, 132, 102-107.	1.1	4

#	ARTICLE	IF	CITATIONS
859	Family Functioning Predicts Body Mass Index and Biochemical Levels of Youths with Nonalcoholic Fatty Liver Disease. <i>Journal of Developmental and Behavioral Pediatrics</i> , 2017, 38, 155-160.	0.6	9
860	Wet Biomarker-Based Assessment of Steatosis, Inflammation, and Fibrosis in NAFLD. <i>Current Hepatology Reports</i> , 2017, 16, 308-316.	0.4	0
861	Nonalcoholic fatty liver disease in spinal and bulbar muscular atrophy. <i>Neurology</i> , 2017, 89, 2481-2490.	1.5	27
862	Hepatocellular Carcinoma in Nonalcoholic Steatohepatitis. <i>Digestive Disease Interventions</i> , 2017, 01, 066-073.	0.3	0
863	Pharmacotherapy of nonalcoholic steatohepatitis: Reflections on the existing evidence. <i>Journal of Digestive Diseases</i> , 2017, 18, 607-617.	0.7	2
864	Treatment options for nonalcoholic steatohepatitis - a safety evaluation. <i>Expert Opinion on Drug Safety</i> , 2017, 16, 903-913.	1.0	23
865	Economic evaluation of a community-based diagnostic pathway to stratify adults for non-alcoholic fatty liver disease: a Markov model informed by a feasibility study. <i>BMJ Open</i> , 2017, 7, e015659.	0.8	50
866	MANAGEMENT OF ENDOCRINE DISEASE: Polycystic ovary syndrome and nonalcoholic fatty liver disease. <i>European Journal of Endocrinology</i> , 2017, 177, R145-R158.	1.9	33
867	The ZJU index is a powerful index for identifying NAFLD in the general Chinese population. <i>Acta Diabetologica</i> , 2017, 54, 905-911.	1.2	23
868	The effect of fibroblast growth factor 15 deficiency on the development of high fat diet induced non-alcoholic steatohepatitis. <i>Toxicology and Applied Pharmacology</i> , 2017, 330, 1-8.	1.3	41
869	Liver steatosis: The new epidemic of the Third Millennium. Benign liver state or silent killer?. <i>European Journal of Internal Medicine</i> , 2017, 46, 1-5.	1.0	10
870	Insulin resistance is associated with elevated transaminases and low aspartate aminotransferase/alanine aminotransferase ratio in young adults with normal weight. <i>European Journal of Gastroenterology and Hepatology</i> , 2017, 29, 435-440.	0.8	31
871	The Association Between Nonalcoholic Fatty Liver Disease and Metabolic Abnormalities in The United States Population. <i>Journal of Clinical Gastroenterology</i> , 2017, 51, 160-166.	1.1	50
872	Burden of hepatocellular carcinoma among hispanics in South Texas: a systematic review. <i>Biomarker Research</i> , 2017, 5, 15.	2.8	19
873	Psoriasis and Nonalcoholic Fatty Liver Disease. <i>Actas Dermo-sifiliogrÁficas</i> , 2017, 108, 506-514.	0.2	17
874	Clinical and biochemical characteristics of individuals with low cholesterol syndromes: A comparison between familial hypobetalipoproteinemia and familial combined hypolipidemia. <i>Journal of Clinical Lipidology</i> , 2017, 11, 1234-1242.	0.6	34
875	The Impact of Liver Graft Injury on Cancer Recurrence Posttransplantation. <i>Transplantation</i> , 2017, 101, 2665-2670.	0.5	26
876	Antioxidant properties of tea blunt ROS-dependent lipogenesis: beneficial effect on hepatic steatosis in a high fat-high sucrose diet NAFLD obese rat model. <i>Journal of Nutritional Biochemistry</i> , 2017, 40, 95-104.	1.9	54

#	ARTICLE	IF	CITATIONS
877	Nonalcoholic Steatohepatitis. <i>Annual Review of Medicine</i> , 2017, 68, 85-98.	5.0	119
878	Intestinal gas and liver steatosis: a casual association? A prospective multicentre assessment. <i>Liver International</i> , 2017, 37, 141-147.	1.9	1
879	Drug-induced steatohepatitis. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2017, 13, 193-204.	1.5	47
880	Assessment of transient elastography in Japanese patients with non-alcoholic fatty liver disease. <i>Hepatology Research</i> , 2017, 47, 882-889.	1.8	16
881	Association between rice, bread, and noodle intake and the prevalence of non-alcoholic fatty liver disease in Japanese middle-aged men and women. <i>Clinical Nutrition</i> , 2017, 36, 1601-1608.	2.3	33
882	Association of UCP2 ^{866G>A} Polymorphism With Nonalcoholic Fatty Liver Disease in Patients From North-West of Iran. <i>Laboratory Medicine</i> , 2017, 48, 65-72.	0.8	3
883	Associations between hemoglobin concentrations and the development of incidental metabolic syndrome or nonalcoholic fatty liver disease. <i>Digestive and Liver Disease</i> , 2017, 49, 57-62.	0.4	18
884	Magnetic Resonance Elastography vs Transient Elastography in Detection of Fibrosis and Noninvasive Measurement of Steatosis in Patients With Biopsy-Proven Nonalcoholic Fatty Liver Disease. <i>Gastroenterology</i> , 2017, 152, 598-607.e2.	0.6	510
885	Detection of Steatohepatitis in a Rat Model by Using Spectroscopic Shear-Wave US Elastography. <i>Radiology</i> , 2017, 282, 726-733.	3.6	13
886	Mediterranean diet and nonalcoholic fatty liver disease: molecular mechanisms of protection. <i>International Journal of Food Sciences and Nutrition</i> , 2017, 68, 18-27.	1.3	69
887	Nonobese Fatty Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2017, 15, 474-485.	2.4	262
889	Assessment of Nonalcoholic Fatty Liver Disease in Rats Using Quantitative Dynamic Contrast-Enhanced MRI. <i>Journal of Magnetic Resonance Imaging</i> , 2017, 45, 1485-1493.	1.9	7
890	SAF score and mortality in NAFLD after up to 41 years of follow-up. <i>Scandinavian Journal of Gastroenterology</i> , 2017, 52, 87-91.	0.6	32
891	Probiotics Supplemented with Omega-3 Fatty Acids are More Effective for Hepatic Steatosis Reduction in an Animal Model of Obesity. <i>Probiotics and Antimicrobial Proteins</i> , 2017, 9, 123-130.	1.9	38
892	Alternative treatment methods attenuate the development of NAFLD: A review of resveratrol molecular mechanisms and clinical trials. <i>Nutrition</i> , 2017, 34, 108-117.	1.1	70
893	Enfermedad del h�gado graso no alcoh�lico, asociaci�n con la enfermedad cardiovascular y tratamiento (II). Tratamiento de la enfermedad del h�gado graso no alcoh�lico. <i>Cl�nica E Investigaci�n En Arteriosclerosis</i> , 2017, 29, 185-200.	0.4	6
894	Bi-directional analysis between fatty liver and cardiovascular disease risk factors. <i>Journal of Hepatology</i> , 2017, 66, 390-397.	1.8	152
895	Under-prescription of statins in patients with non-alcoholic fatty liver disease. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2017, 27, 161-167.	1.1	45

#	ARTICLE	IF	CITATIONS
896	Low hepatic copper content and PNPLA3 polymorphism in non-alcoholic fatty liver disease in patients without metabolic syndrome. <i>Journal of Trace Elements in Medicine and Biology</i> , 2017, 39, 100-107.	1.5	28
897	Effect of non-alcoholic fatty liver disease on left ventricular diastolic function and geometry in the Korean general population. <i>Hepatology Research</i> , 2017, 47, 522-532.	1.8	30
898	Fetuin-A and Risk of Diabetes Independent of Liver Fat Content. <i>American Journal of Epidemiology</i> , 2017, 185, 54-64.	1.6	17
901	Changes in Liver Steatosis After Switching From Efavirenz to Raltegravir Among Human Immunodeficiency Virus-Infected Patients With Nonalcoholic Fatty Liver Disease. <i>Clinical Infectious Diseases</i> , 2017, 65, 1012-1019.	2.9	42
902	Patients With Diabetes and Chronic Liver Disease Are at Increased Risk for Overall Mortality: A Population Study From the United States. <i>Clinical Diabetes</i> , 2017, 35, 79-83.	1.2	14
903	Does the enterolactone (ENL) affect fatty acid transporters and lipid metabolism in liver?. <i>Nutrition and Metabolism</i> , 2017, 14, 69.	1.3	12
904	Nonalcoholic fatty liver disease with cirrhosis increases familial risk for advanced fibrosis. <i>Journal of Clinical Investigation</i> , 2017, 127, 2697-2704.	3.9	137
905	In vivo photoacoustic lipid imaging in mice using the second near-infrared window. <i>Biomedical Optics Express</i> , 2017, 8, 736.	1.5	36
906	Hepatoprotective effect of calculus bovis sativus on nonalcoholic fatty liver disease in mice by inhibiting oxidative stress and apoptosis of hepatocytes. <i>Drug Design, Development and Therapy</i> , 2017, Volume 11, 3449-3460.	2.0	15
907	The Role of Growth Hormone and Insulin-Like Growth Factor-I in the Liver. <i>International Journal of Molecular Sciences</i> , 2017, 18, 1447.	1.8	138
908	A Customized Online Nutrition Guidance System Is Effective for Treating Patients with Nonalcoholic Fatty Liver Disease by Supporting Continuity of Diet Therapy at Home: A Pilot Study. <i>Internal Medicine</i> , 2017, 56, 1651-1656.	0.3	3
909	Seabuckthorn Leaves Extract and Flavonoid Glycosides Extract from Seabuckthorn Leaves Ameliorates Adiposity, Hepatic Steatosis, Insulin Resistance, and Inflammation in Diet-Induced Obesity. <i>Nutrients</i> , 2017, 9, 569.	1.7	33
910	Silibinin Restores NAD ⁺ Levels and Induces the SIRT1/AMPK Pathway in Non-Alcoholic Fatty Liver. <i>Nutrients</i> , 2017, 9, 1086.	1.7	72
911	Phyllanthus Niruri Standardized Extract Alleviates the Progression of Non-Alcoholic Fatty Liver Disease and Decreases Atherosclerotic Risk in Sprague-Dawley Rats. <i>Nutrients</i> , 2017, 9, 766.	1.7	40
912	PEGylated Curcumin Derivative Attenuates Hepatic Steatosis via CREB/PPAR- γ /CD36 Pathway. <i>BioMed Research International</i> , 2017, 2017, 1-11.	0.9	32
913	Relationship between Nonalcoholic Fatty Liver Disease and Vitamin D Nutritional Status in Extreme Obesity. <i>Canadian Journal of Gastroenterology and Hepatology</i> , 2017, 2017, 1-8.	0.8	13
914	Dahuang Zexie Decoction Protects against High-Fat Diet-Induced NAFLD by Modulating Gut Microbiota-Mediated Toll-Like Receptor 4 Signaling Activation and Loss of Intestinal Barrier. <i>Evidence-based Complementary and Alternative Medicine</i> , 2017, 2017, 1-13.	0.5	17
915	Impact of Fatty Liver on Acute Pancreatitis Severity. <i>Gastroenterology Research and Practice</i> , 2017, 2017, 1-7.	0.7	21

#	ARTICLE	IF	CITATIONS
916	Peroxisome Proliferator-Activated Receptors Associated with Nonalcoholic Fatty Liver Disease. PPAR Research, 2017, 2017, 1-8.	1.1	25
917	Intestinal hormones, gut microbiota and non-alcoholic fatty liver disease. Minerva Endocrinology, 2017, 42, 184-194.	0.6	21
918	Nonalcoholic fatty liver disease as a predictor of atrial fibrillation: a systematic review and meta-analysis. Postepy W Kardiologii Interwencyjnej, 2017, 3, 250-257.	0.1	4
919	Nonalcoholic fatty liver disease: Evolving paradigms. World Journal of Gastroenterology, 2017, 23, 6571-6592.	1.4	138
920	Clinical course of nonalcoholic fatty liver disease: an assessment of severity, progression, and outcomes. Clinical Epidemiology, 2017, Volume 9, 679-688.	1.5	37
921	Cannabis use is associated with reduced prevalence of non-alcoholic fatty liver disease: A cross-sectional study. PLoS ONE, 2017, 12, e0176416.	1.1	65
922	Non-alcoholic fatty liver disease as a risk factor for female sexual dysfunction in premenopausal women. PLoS ONE, 2017, 12, e0182708.	1.1	2
923	Prospective comparison among transient elastography, supersonic shear imaging, and ARFI imaging for predicting fibrosis in nonalcoholic fatty liver disease. PLoS ONE, 2017, 12, e0188321.	1.1	48
924	Blood lead level is associated with non-alcoholic fatty liver disease in the Yangtze River Delta region of China in the context of rapid urbanization. Environmental Health, 2017, 16, 93.	1.7	40
925	Non-HDL cholesterol and LDL cholesterol in the dyslipidemic classification in patients with nonalcoholic fatty liver disease. Lipids in Health and Disease, 2017, 16, 229.	1.2	9
926	Serum metabolites in non-alcoholic fatty-liver disease development or reversion; a targeted metabolomic approach within the PREDIMED trial. Nutrition and Metabolism, 2017, 14, 58.	1.3	22
927	Non-alcoholic fatty liver disease as a risk factor for cholangiocarcinoma: a systematic review and meta-analysis. BMC Gastroenterology, 2017, 17, 149.	0.8	90
928	MiR-149 Compromises the Reactions of Liver Cells to Fatty Acid via its Polymorphism and Increases Non-Alcoholic Fatty Liver Disease (NAFLD) Risk by Targeting Methylene Tetrahydrofolate Reductase (MTHFR). Medical Science Monitor, 2017, 23, 2299-2307.	0.5	10
929	Chronic Exposure to Low Doses of Dioxin Promotes Liver Fibrosis Development in the C57BL/6J Diet-Induced Obesity Mouse Model. Environmental Health Perspectives, 2017, 125, 428-436.	2.8	98
930	Hepatic Steatosis and Fibrosis in Obese, Dysmetabolic and Diabetic Nonhuman Primates Quantified by Noninvasive Echography. Journal of Diabetes & Metabolism, 2017, 8, .	0.2	4
931	Clinical epidemiology and disease burden of nonalcoholic fatty liver disease. World Journal of Gastroenterology, 2017, 23, 8263-8276.	1.4	514
932	Relationship between adipose tissue dysfunction, vitamin D deficiency and the pathogenesis of non-alcoholic fatty liver disease. World Journal of Gastroenterology, 2017, 23, 3407.	1.4	74
933	Sitagliptin in patients with non-alcoholic steatohepatitis: A randomized, placebo-controlled trial. World Journal of Gastroenterology, 2017, 23, 141.	1.4	121

#	ARTICLE	IF	CITATIONS
934	Bile Acids in Nonalcoholic Fatty Liver Disease: New Concepts and Therapeutic Advances. <i>Annals of Hepatology</i> , 2017, 16, S58-S67.	0.6	21
935	Testosterone, Sex Hormone-Binding Globulin and Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis. <i>Annals of Hepatology</i> , 2017, 16, 382-394.	0.6	89
936	Noninvasive imaging biomarker assessment of liver fibrosis by elastography in NAFLD. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2018, 15, 274-282.	8.2	124
937	Quantitative Elastography Methods in Liver Disease: Current Evidence and Future Directions. <i>Radiology</i> , 2018, 286, 738-763.	3.6	215
938	Evaluating feasibility and accuracy of non-invasive tests for nonalcoholic fatty liver disease in severe and morbid obesity. <i>International Journal of Obesity</i> , 2018, 42, 1900-1911.	1.6	22
939	Risk factors and metabolic abnormality of patients with non-alcoholic fatty liver disease: Either non-obese or obese Chinese population. <i>Hepatobiliary and Pancreatic Diseases International</i> , 2018, 17, 45-48.	0.6	27
940	Correlation between PPAR- α methylation level in peripheral blood and atherosclerosis of NAFLD patients with DM. <i>Experimental and Therapeutic Medicine</i> , 2018, 15, 2727-2730.	0.8	4
941	Quantitative Assessment of Liver Steatosis and Affected Pathways with Molecular Imaging and Proteomic Profiling. <i>Scientific Reports</i> , 2018, 8, 3606.	1.6	31
942	The effect of antidiabetic medications on non-alcoholic fatty liver disease (NAFLD). <i>Hormones</i> , 2018, 17, 219-229.	0.9	37
943	Nonalcoholic Fatty Liver Disease in Inflammatory Bowel Disease: Prevalence and Risk Factors. <i>Inflammatory Bowel Diseases</i> , 2018, 24, 1589-1596.	0.9	58
944	Effects of shenling baizhu powder herbal formula on intestinal microbiota in high-fat diet-induced NAFLD rats. <i>Biomedicine and Pharmacotherapy</i> , 2018, 102, 1025-1036.	2.5	86
945	Variants in the PPAR α Gene may Influence the Effect of Fat Intake on Resting Metabolic Rate in Obese Women. <i>Lipids</i> , 2018, 53, 291-300.	0.7	3
946	Nonalcoholic fatty liver disease is associated with decreased lung function. <i>Liver International</i> , 2018, 38, 2091-2100.	1.9	25
947	Update in Pediatric Gastroenterology, Hepatology and Nutrition. , 2018, , 267-311.		0
948	Impact of Smoking Cessation in Donor Candidates for Living Donor Liver Transplantation. <i>Transplantation Proceedings</i> , 2018, 50, 2593-2596.	0.3	0
949	MicroRNA-90b regulates lipid metabolism and insulin sensitivity by targeting IGF1 and ADAMTS9 in non-alcoholic fatty liver disease. <i>Journal of Cellular Biochemistry</i> , 2018, 119, 5864-5874.	1.2	31
950	Nonalcoholic fatty liver disease contributes to subclinical atherosclerosis: A systematic review and meta-analysis. <i>Hepatology Communications</i> , 2018, 2, 376-392.	2.0	91
951	Documento de consenso. Manejo de la enfermedad hepática grasa no alcohólica (EHGNA). <i>Guía de práctica clínica. Gastroenterología Y Hepatología</i> , 2018, 41, 328-349.	0.2	71

#	ARTICLE	IF	CITATIONS
952	The role of the angiotensin II type I receptor blocker telmisartan in the treatment of non-alcoholic fatty liver disease: a brief review. <i>Hypertension Research</i> , 2018, 41, 394-405.	1.5	42
953	<i>Wisteria floribunda</i> agglutinin-positive Mac-2-binding protein and type 4 collagen 7S: useful markers for the diagnosis of significant fibrosis in patients with non-alcoholic fatty liver disease. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2018, 33, 1795-1803.	1.4	34
954	Long-Term Follow-Up Study of Liver-Related Outcome After Bilio-Pancreatic Diversion in Patients with Initial, Significant Liver Damage. <i>Digestive Diseases and Sciences</i> , 2018, 63, 1946-1951.	1.1	2
955	Ratio of muscle mass to fat mass assessed by bioelectrical impedance analysis is significantly correlated with liver fat accumulation in patients with type 2 diabetes mellitus. <i>Diabetes Research and Clinical Practice</i> , 2018, 139, 122-130.	1.1	18
956	Opportunities to participate in clinical trials: awareness among liver patients. <i>Gastrointestinal Nursing</i> , 2018, 16, 30-35.	0.0	0
957	Non-alcoholic fatty liver disease: an emerging predictor of stroke risk, severity and outcome. <i>European Journal of Neurology</i> , 2018, 25, 610-611.	1.7	6
958	Repeated liver stiffness measurement compared with paired liver biopsy in patients with non-alcoholic fatty liver disease. <i>Hepatology International</i> , 2018, 12, 44-55.	1.9	27
959	Improvement of hepatic fibrosis and patient-reported outcomes in non-alcoholic steatohepatitis treated with selonsertib. <i>Liver International</i> , 2018, 38, 1849-1859.	1.9	72
960	A simple clinical model predicts incident hepatic steatosis in a community-based cohort: The Framingham Heart Study. <i>Liver International</i> , 2018, 38, 1495-1503.	1.9	34
961	Nonalcoholic fatty liver disease. <i>European Journal of Gastroenterology and Hepatology</i> , 2018, 30, 637-644.	0.8	8
962	Integration of Multi-omics Data from Mouse Diversity Panel Highlights Mitochondrial Dysfunction in Non-alcoholic Fatty Liver Disease. <i>Cell Systems</i> , 2018, 6, 103-115.e7.	2.9	124
963	Role of gut microbiota and oxidative stress in the progression of non-alcoholic fatty liver disease to hepatocarcinoma: Current and innovative therapeutic approaches. <i>Redox Biology</i> , 2018, 15, 467-479.	3.9	196
964	Future therapy for non-alcoholic fatty liver disease. <i>Liver International</i> , 2018, 38, 56-63.	1.9	42
965	Liver diseases: A major, neglected global public health problem requiring urgent actions and large-scale screening. <i>Liver International</i> , 2018, 38, 2-6.	1.9	361
966	Synergistic increase in cardiovascular risk in diabetes mellitus with nonalcoholic fatty liver disease: a meta-analysis. <i>European Journal of Gastroenterology and Hepatology</i> , 2018, 30, 631-636.	0.8	78
967	Systematic review with meta-analysis: de novo non-alcoholic fatty liver disease in liver-transplanted patients. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 47, 704-714.	1.9	46
968	MR elastography is effective for the non-invasive evaluation of fibrosis and necroinflammatory activity in patients with nonalcoholic fatty liver disease. <i>European Journal of Radiology</i> , 2018, 98, 82-89.	1.2	46
969	Alpinetin improved high fat diet-induced non-alcoholic fatty liver disease (NAFLD) through improving oxidative stress, inflammatory response and lipid metabolism. <i>Biomedicine and Pharmacotherapy</i> , 2018, 97, 1397-1408.	2.5	63

#	ARTICLE	IF	CITATIONS
970	Novel non-alcoholic steatohepatitis model with histopathological and insulin-resistant features. <i>Pathology International</i> , 2018, 68, 12-22.	0.6	17
971	Validation of goose liver fat measurement by QCT and CSE-MRI with biochemical extraction and pathology as reference. <i>European Radiology</i> , 2018, 28, 2003-2012.	2.3	22
972	Definitions, Epidemiology and Prognostication of Liver Disease. , 2018, , 75-82.		2
973	3D-printed gelatin scaffolds of differing pore geometry modulate hepatocyte function and gene expression. <i>Acta Biomaterialia</i> , 2018, 69, 63-70.	4.1	127
974	Effects of Sleeve Gastrectomy on Nonalcoholic Fatty Liver Disease in an Obese Rat Model. <i>Obesity Surgery</i> , 2018, 28, 1532-1539.	1.1	8
976	Hepatic iron concentration correlates with insulin sensitivity in nonalcoholic fatty liver disease. <i>Hepatology Communications</i> , 2018, 2, 644-653.	2.0	37
977	Randomised clinical trial: a leucine-metformin-sildenafil combination (NS vs placebo in patients with non-alcoholic fatty liver disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 47, 1639-1651.	1.9	35
978	Non-alcoholic fatty liver disease in patients with autoimmune hepatitis. <i>JGH Open</i> , 2018, 2, 54-58.	0.7	33
979	Non-invasive markers of liver fibrosis in fatty liver disease are unreliable in people of South Asian descent. <i>Frontline Gastroenterology</i> , 2018, 9, 115-121.	0.9	23
980	Active Coping and Perceived Social Support Mediate the Relationship Between Physical Health and Resilience in Liver Transplant Candidates. <i>Journal of Clinical Psychology in Medical Settings</i> , 2018, 25, 485-496.	0.8	19
981	Components of metabolic syndrome increase the risk of mortality in nonalcoholic fatty liver disease (NAFLD). <i>Medicine (United States)</i> , 2018, 97, e0214.	0.4	143
982	Fatty liver index is associated to pulse wave velocity in healthy subjects: Data from the Brisighella Heart Study. <i>European Journal of Internal Medicine</i> , 2018, 53, 29-33.	1.0	37
983	Inhibition of miR-34a-5p alleviates hypoxia-reoxygenation injury by enhancing autophagy in steatotic hepatocytes. <i>Biology Open</i> , 2018, 7, .	0.6	11
984	Ferroportin Expression in Adipocytes Does Not Contribute to Iron Homeostasis or Metabolic Responses to a High Calorie Diet. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2018, 5, 319-331.	2.3	14
985	Free-breathing liver fat quantification using a multiecho 3D stack of radial technique. <i>Magnetic Resonance in Medicine</i> , 2018, 79, 370-382.	1.9	40
986	Non-alcoholic fatty liver disease and its treatment with n-3 polyunsaturated fatty acids. <i>Clinical Nutrition</i> , 2018, 37, 37-55.	2.3	95
987	Effect of exercise training on liver function in adults who are overweight or exhibit fatty liver disease: a systematic review and meta-analysis. <i>British Journal of Sports Medicine</i> , 2018, 52, 834-843.	3.1	85
988	Systematic review and meta-analysis to determine the impact of iron depletion in dysmetabolic iron overload syndrome and non-alcoholic fatty liver disease. <i>Hepatology Research</i> , 2018, 48, E30-E41.	1.8	48

#	ARTICLE	IF	CITATIONS
989	New insight into inter-organ crosstalk contributing to the pathogenesis of non-alcoholic fatty liver disease (NAFLD). <i>Protein and Cell</i> , 2018, 9, 164-177.	4.8	92
990	Population estimates and characteristics of Australians potentially eligible for bariatric surgery: findings from the 2011-13 Australian Health Survey. <i>Australian Health Review</i> , 2018, 42, 429.	0.5	10
991	Effects of canagliflozin, an SGLT2 inhibitor, on hepatic function in Japanese patients with type 2 diabetes mellitus: pooled and subgroup analyses of clinical trials. <i>Journal of Gastroenterology</i> , 2018, 53, 140-151.	2.3	57
992	Intermittent Ischemic Preconditioning Protects Against Hepatic Ischemia-Reperfusion Injury and Extensive Hepatectomy in Steatotic Rat Liver. <i>Journal of Investigative Surgery</i> , 2018, 31, 366-377.	0.6	12
993	Exendin-4, a glucagon-like peptide-1 receptor agonist downregulates hepatic receptor for advanced glycation end products in non-alcoholic steatohepatitis rat model. <i>Archives of Physiology and Biochemistry</i> , 2018, 124, 10-17.	1.0	6
994	Omega-3 polyunsaturated fatty acids as a treatment strategy for nonalcoholic fatty liver disease. , 2018, 181, 108-125.		94
995	Weighing the risks: Morbid obesity and diabetes are associated with increased risk of death on the liver transplant waiting list. <i>Liver International</i> , 2018, 38, 553-563.	1.9	36
996	The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. <i>Hepatology</i> , 2018, 67, 328-357.	3.6	4,738
997	Soft drinks consumption is associated with nonalcoholic fatty liver disease independent of metabolic syndrome in Chinese population. <i>European Journal of Nutrition</i> , 2018, 57, 2113-2121.	1.8	22
998	Case definitions for inclusion and analysis of endpoints in clinical trials for nonalcoholic steatohepatitis through the lens of regulatory science. <i>Hepatology</i> , 2018, 67, 2001-2012.	3.6	125
999	Increased severity of liver fat content and liver fibrosis in non-alcoholic fatty liver disease correlate with epicardial fat volume in type 2 diabetes: A prospective study. <i>European Radiology</i> , 2018, 28, 1345-1355.	2.3	31
1000	Racial and Ethnic Disparities in Nonalcoholic Fatty Liver Disease Prevalence, Severity, and Outcomes in the United States: A Systematic Review and Meta-analysis. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 198-210.e2.	2.4	284
1001	Risk Factors for the Development of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis, Including Genetics. <i>Clinics in Liver Disease</i> , 2018, 22, 39-57.	1.0	35
1002	Emerging Treatments for Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis. <i>Clinics in Liver Disease</i> , 2018, 22, 189-199.	1.0	24
1003	Nonalcoholic Steatohepatitis (NASH) and Hepatic Fibrosis: Emerging Therapies. <i>Annual Review of Pharmacology and Toxicology</i> , 2018, 58, 649-662.	4.2	56
1004	Body mass index trajectories in young adulthood predict non-alcoholic fatty liver disease in middle age: The <sc>CARDIA</sc> cohort study. <i>Liver International</i> , 2018, 38, 706-714.	1.9	38
1005	Usefulness of the index of <sc>NASH</sc> â€“ <sc>ION</sc> for the diagnosis of steatohepatitis in patients with non-alcoholic fatty liver: An external validation study. <i>Liver International</i> , 2018, 38, 715-723.	1.9	22
1006	Advanced liver fibrosis but not steatosis is independently associated with albuminuria in Chinese patients with type 2 diabetes. <i>Journal of Hepatology</i> , 2018, 68, 147-156.	1.8	72

#	ARTICLE	IF	CITATIONS
1007	Clinical implications of controlled attenuation parameter in a health check-up cohort. <i>Liver International</i> , 2018, 38, 915-923.	1.9	15
1008	Performance of fibrosis prediction scores in paediatric non-alcoholic fatty liver disease. <i>Journal of Paediatrics and Child Health</i> , 2018, 54, 172-176.	0.4	33
1009	Physical activity levels and hepatic steatosis: A longitudinal follow-up study in adults. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2018, 33, 741-746.	1.4	9
1010	Optimization of region-of-interest sampling strategies for hepatic MRI proton density fat fraction quantification. <i>Journal of Magnetic Resonance Imaging</i> , 2018, 47, 988-994.	1.9	20
1011	The ASK1 inhibitor selonsertib in patients with nonalcoholic steatohepatitis: A randomized, phase 2 trial. <i>Hepatology</i> , 2018, 67, 549-559.	3.6	435
1012	Non-alcoholic Fatty Liver Disease in Morbidly Obese Individuals Undergoing Bariatric Surgery: Prevalence and Effect of the Pre-Bariatric Very Low Calorie Diet. <i>Obesity Surgery</i> , 2018, 28, 1109-1116.	1.1	40
1013	Cardiovascular Disease, Cancer, and Mortality Among People With Type 2 Diabetes and Alcoholic or Nonalcoholic Fatty Liver Disease Hospital Admission. <i>Diabetes Care</i> , 2018, 41, 341-347.	4.3	92
1014	Association of Nonalcoholic Fatty Liver Disease With Lower Brain Volume in Healthy Middle-aged Adults in the Framingham Study. <i>JAMA Neurology</i> , 2018, 75, 97.	4.5	107
1015	How bariatric surgery affects liver volume and fat density in NAFLD patients. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2018, 32, 1675-1682.	1.3	46
1016	Clinical relevance of liver histopathology and different histological classifications of NASH in adults. <i>Expert Review of Gastroenterology and Hepatology</i> , 2018, 12, 351-367.	1.4	47
1017	Nonalcoholic fatty liver disease in patients with psoriasis: a consequence of systemic inflammatory burden?. <i>British Journal of Dermatology</i> , 2018, 179, 16-29.	1.4	46
1018	Age- and Gender-Associated Liver Physiological T1rho Dynamics Demonstrated with a Clinically Applicable Single-Breathhold Acquisition. <i>SLAS Technology</i> , 2018, 23, 179-187.	1.0	15
1019	Association between urine retinol-binding protein levels and nonalcoholic fatty liver disease: A cross-sectional study in Chinese population. <i>Journal of Clinical Laboratory Analysis</i> , 2018, 32, e22359.	0.9	2
1020	Genetic deletion of the circadian clock transcription factor BMAL1 and chronic alcohol consumption differentially alter hepatic glycogen in mice. <i>American Journal of Physiology - Renal Physiology</i> , 2018, 314, G431-G447.	1.6	21
1021	DHA supplementation prevent the progression of NASH via GPR120 signaling. <i>European Journal of Pharmacology</i> , 2018, 820, 31-38.	1.7	32
1022	Optimal threshold of controlled attenuation parameter with MRI-PDFF as the gold standard for the detection of hepatic steatosis. <i>Hepatology</i> , 2018, 67, 1348-1359.	3.6	250
1023	Activation of the STING-IRF3 pathway promotes hepatocyte inflammation, apoptosis and induces metabolic disorders in nonalcoholic fatty liver disease. <i>Metabolism: Clinical and Experimental</i> , 2018, 81, 13-24.	1.5	148
1024	Serum magnesium concentration is independently associated with non-alcoholic fatty liver and non-alcoholic steatohepatitis. <i>United European Gastroenterology Journal</i> , 2018, 6, 97-103.	1.6	18

#	ARTICLE	IF	CITATIONS
1025	Low serum CTRP3 levels are associated with nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus. <i>Cytokine</i> , 2018, 106, 131-135.	1.4	15
1026	Suppressed hepatic bile acid signalling despite elevated production of primary and secondary bile acids in NAFLD. <i>Gut</i> , 2018, 67, 1881-1891.	6.1	438
1027	Complications of obesity. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2018, 111, 437-443.	0.2	155
1028	Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease. <i>Hepatology</i> , 2018, 67, 123-133.	3.6	1,474
1029	Efficacy of Probiotics and Smectite in Rats with Non-Alcoholic Fatty Liver Disease. <i>Annals of Hepatology</i> , 2018, 17, 153-161.	0.6	37
1030	HCBP6 Is Involved in the Development of Hepatic Steatosis Induced by High-Fat Diet and CCL4 in Rats. <i>Annals of Hepatology</i> , 2018, 17, 511-518.	0.6	8
1031	Fast Morphological Gallbladder Changes Triggered by a Hypercholesterolemic Diet. <i>Annals of Hepatology</i> , 2018, 17, 857-863.	0.6	3
1032	Liver Transplantation (LT) for Cryptogenic Cirrhosis (CC) and Nonalcoholic Steatohepatitis (NASH) Cirrhosis. <i>Medicine (United States)</i> , 2018, 97, e11518.	0.4	57
1033	Detection of a lipid peroxidation-induced DNA adduct across liver disease stages. <i>Hepatobiliary Surgery and Nutrition</i> , 2018, 7, 85-97.	0.7	11
1034	Life-style-induced metabolic derangement and epigenetic changes promote diabetes and oxidative stress leading to NASH and atherosclerosis severity. <i>Journal of Diabetes and Metabolic Disorders</i> , 2018, 17, 381-391.	0.8	20
1035	Elevated Liver Enzymes in Patients with Type 2 Diabetes Mellitus and Non-alcoholic Fatty Liver Disease. <i>Cureus</i> , 2018, 10, e3626.	0.2	30
1036	Canadian regulations and legal ramifications for hepatic encephalopathy: a descriptive analysis. <i>CMAJ Open</i> , 2018, 6, E575-E579.	1.1	3
1037	Omega-3 polyunsaturated fatty acid supplementation and non-alcoholic fatty liver disease. <i>Medicine (United States)</i> , 2018, 97, e12271.	0.4	89
1038	Non-alcoholic Fatty Liver Disease: What We Learn from Omics Studies. , 0, , .		0
1039	Liver transplantation for non-alcoholic fatty liver disease—a review. <i>AME Medical Journal</i> , 0, 3, 29-29.	0.4	7
1040	HIV and the Liver. , 2018, , 536-555.e7.		1
1041	Glucose-Lowering Agents in the Management of Nonalcoholic Fatty Liver Disease. <i>Journal of Korean Diabetes</i> , 2018, 19, 88.	0.1	1
1042	Health-related quality of life burden of nonalcoholic steatohepatitis: a robust pragmatic literature review. <i>Journal of Patient-Reported Outcomes</i> , 2018, 2, 28.	0.9	44

#	ARTICLE	IF	CITATIONS
1043	Molecular Basis for Pathogenesis of Steatohepatitis: Contemporary Understanding and New Insights. , O, , .		3
1044	Nonalcoholic Fatty Liver Disease: Time to Take the Bull by the Horns. Euroasian Journal of Hepato-gastroenterology, 2018, 8, 47-51.	0.1	10
1045	Inhibition of CCL19 benefits nonâ€alcoholic fatty liver disease by inhibiting TLR4/NFâ€p65 signaling. Molecular Medicine Reports, 2018, 18, 4635-4642.	1.1	9
1046	Antidiabetic Drugs in NAFLD: The Accomplishment of Two Goals at Once?. Pharmaceuticals, 2018, 11, 121.	1.7	41
1047	Non-Alcoholic Fatty Liver Disease among Type-2 Diabetes Mellitus Patients in Abha City, South Western Saudi Arabia. International Journal of Environmental Research and Public Health, 2018, 15, 2521.	1.2	19
1048	Alleviation of fatty liver in a rat model by enhancing N1-methylnicotinamide bioavailability through aldehyde oxidase inhibition. Biochemical and Biophysical Research Communications, 2018, 507, 203-210.	1.0	20
1049	Selective glucocorticoid receptor modulation prevents and reverses non-alcoholic fatty liver disease in male mice. Endocrinology, 2018, 159, 3925-3936.	1.4	27
1050	Limited scope for reproductive senescence in wild populations of a short-lived fish. Die Naturwissenschaften, 2018, 105, 68.	0.6	17
1051	Association of non-alcoholic fatty liver disease with cardiovascular disease and subclinical atherosclerosis. Archives of Medical Science, 2018, 14, 1233-1244.	0.4	39
1052	Efficacy and safety of canagliflozin in type 2 diabetes mellitus patients with biopsy-proven nonalcoholic steatohepatitis classified as stage 1–3 fibrosis. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 2018, Volume 11, 835-843.	1.1	60
1053	Lean Patients with Non-Alcoholic Fatty Liver Disease Have a Severe Histological Phenotype Similar to Obese Patients. Journal of Clinical Medicine, 2018, 7, 562.	1.0	73
1054	Portal lymphadenopathy predicts non-alcoholic steatohepatitis and advanced fibrosis in non-alcoholic fatty liver disease. PLoS ONE, 2018, 13, e0207479.	1.1	3
1055	Anti-Diabetic Medications for the Pharmacologic Management of NAFLD. Diseases (Basel, Switzerland), 2018, 6, 93.	1.0	17
1056	Hepatic Steatosis Is Associated With Adverse Molecular Signatures in Subjects Without Diabetes. Journal of Clinical Endocrinology and Metabolism, 2018, 103, 3856-3868.	1.8	24
1057	Beyond fertility: polycystic ovary syndrome and long-term health. Fertility and Sterility, 2018, 110, 794-809.	0.5	150
1058	Human hepatic 3D spheroids as a model for steatosis and insulin resistance. Scientific Reports, 2018, 8, 14297.	1.6	108
1059	Circular RNAs in Metabolic Diseases. Advances in Experimental Medicine and Biology, 2018, 1087, 275-285.	0.8	18
1060	Diethyldithiocarbamate, an antiâ€abuse drug, alleviates steatohepatitis and fibrosis in rodents through modulating lipid metabolism and oxidative stress. British Journal of Pharmacology, 2018, 175, 4480-4495.	2.7	21

#	ARTICLE	IF	CITATIONS
1061	Branched chain amino acid transaminase 1 (BCAT1) is overexpressed and hypomethylated in patients with non-alcoholic fatty liver disease who experience adverse clinical events: A pilot study. PLoS ONE, 2018, 13, e0204308.	1.1	17
1062	Treatment of NASH with Gastric Bypass. Current Gastroenterology Reports, 2018, 20, 49.	1.1	10
1063	A nonalcoholic fatty liver disease model in human induced pluripotent stem cell-derived hepatocytes, created by endoplasmic reticulum stress-induced steatosis. DMM Disease Models and Mechanisms, 2018, 11, .	1.2	44
1064	Pathogenesis of non-alcoholic fatty liver disease in children and adolescence: From "two hit theory" to "multiple hit model". World Journal of Gastroenterology, 2018, 24, 2974-2983.	1.4	237
1065	An internet-based approach for lifestyle changes in patients with NAFLD: Two-year effects on weight loss and surrogate markers. Journal of Hepatology, 2018, 69, 1155-1163.	1.8	80
1066	Clinical relevance of reporting fatty liver on ultrasound in asymptomatic patients during routine health checkups. Journal of International Medical Research, 2018, 46, 4447-4454.	0.4	20
1067	Cell-Free Circulating Nucleic Acids as Early Biomarkers for NAFLD and NAFLD-Associated Disorders. Frontiers in Physiology, 2018, 9, 1256.	1.3	24
1068	Liver fat scores predict liver disease mortality in the United States population. Alimentary Pharmacology and Therapeutics, 2018, 48, 1003-1016.	1.9	35
1070	Roles of Gut-Derived Secretory Factors in the Pathogenesis of Non-Alcoholic Fatty Liver Disease and Their Possible Clinical Applications. International Journal of Molecular Sciences, 2018, 19, 3064.	1.8	16
1071	CB1 receptor blockade ameliorates hepatic fat infiltration and inflammation and increases Nrf2-AMPK pathway in a rat model of severely uncontrolled diabetes. PLoS ONE, 2018, 13, e0206152.	1.1	25
1072	Histopathological changes and onset of severe hepatic steatosis in rats fed a choline-free diet. Experimental and Therapeutic Medicine, 2018, 16, 1735-1742.	0.8	1
1073	Risk of Hepatocellular Cancer in Patients With Non-Alcoholic Fatty Liver Disease. Gastroenterology, 2018, 155, 1828-1837.e2.	0.6	490
1074	The aryl hydrocarbon receptor "cytochrome P450 1A1 pathway controls lipid accumulation and enhances the permissiveness for hepatitis C virus assembly. Journal of Biological Chemistry, 2018, 293, 19559-19571.	1.6	42
1075	The effects of metabolic status on non-alcoholic fatty liver disease-related outcomes, beyond the presence of obesity. Alimentary Pharmacology and Therapeutics, 2018, 48, 1260-1270.	1.9	70
1076	Nonalcoholic Fatty Liver Disease Is Associated with Increased Atrial Fibrillation Risk in an Elderly Chinese Population: A Cross-Sectional Study. BioMed Research International, 2018, 2018, 1-7.	0.9	24
1077	Review of referral criteria to lipid clinics and outcomes of treatment in four UK centres. International Journal of Clinical Practice, 2018, 72, e13242.	0.8	2
1078	How Much Ischemia Can the Severely Steatotic Rat Liver Tolerate?. In Vivo, 2018, 32, 1381-1386.	0.6	4
1079	Effect of Exercise Training on Metabolic Homeostasis and Some Hemodynamics (Some Hepatic and) Tj ETQq1 1 0.784314 rgBT /Over Therapy, 2018, 08, .	0.1	0

#	ARTICLE	IF	CITATIONS
1080	Magnetic Resonance Elastography of Liver. <i>Topics in Magnetic Resonance Imaging</i> , 2018, 27, 319-333.	0.7	92
1081	Pharmacological interventions for non-alcoholic fatty liver disease: a systematic review and network meta-analysis. <i>Postgraduate Medical Journal</i> , 2018, 94, 556-565.	0.9	15
1082	Relationship between obstructive lung disease and non-alcoholic fatty liver disease in the Korean population: Korea National Health and Nutrition Examination Survey, 2007–2010. <i>International Journal of COPD</i> , 2018, Volume 13, 2603-2611.	0.9	21
1083	Association between Thyroid-Stimulating Hormone Levels and Non-Alcoholic Fatty Liver Disease Is Not Independent from Metabolic Syndrome Criteria. <i>European Thyroid Journal</i> , 2018, 7, 302-307.	1.2	17
1084	Systems pharmacology-based exploration reveals mechanisms of anti-steatotic effects of Jiang Zhi Granule on non-alcoholic fatty liver disease. <i>Scientific Reports</i> , 2018, 8, 13681.	1.6	17
1085	Sex-specific differences in hepatic steatosis in obese spontaneously hypertensive (SHROB) rats. <i>Biology of Sex Differences</i> , 2018, 9, 40.	1.8	9
1086	Review article: drug-induced liver injury in the context of nonalcoholic fatty liver disease – a physiopathological and clinical integrated view. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 48, 892-913.	1.9	70
1087	Serum CK 18-M30 reflect liver pathological severity during NAFLD progression in a rat model. <i>Pathology Research and Practice</i> , 2018, 214, 1778-1786.	1.0	3
1088	Diagnosis and Characterization of Non-Alcoholic Fatty Liver Disease. , 0, , .		4
1089	Fatty Liver Disease in Children and Adolescents with Type 1 Diabetes Mellitus(Clinical and Diagnostic) Tj ETQq1 1 0,784314 rgBT /Overle	0,2	8
1090	NAFLD and cardiovascular disease. <i>Porto Biomedical Journal</i> , 2018, 3, e2.	0.4	7
1091	Production of Elastin-Derived Peptides Contributes to the Development of Nonalcoholic Steatohepatitis. <i>Diabetes</i> , 2018, 67, 1604-1615.	0.3	31
1092	Correlation between ultrasound-diagnosed non-alcoholic fatty liver and periodontal condition in a cross-sectional study in Japan. <i>Scientific Reports</i> , 2018, 8, 7496.	1.6	32
1093	The association between missing teeth and non-alcoholic fatty liver disease in adults. <i>Journal of Clinical Periodontology</i> , 2018, 45, 941-951.	2.3	14
1094	Consensus document. Management of non-alcoholic fatty liver disease (NAFLD). Clinical practice guideline. <i>GastroenterologËa Y HepatologËa (English Edition)</i> , 2018, 41, 328-349.	0.0	7
1095	Low Urine pH Is Associated with Non-alcoholic Fatty Liver Disease: A Community-based Cross-sectional Study. <i>Internal Medicine</i> , 2018, 57, 2799-2805.	0.3	6
1096	Maternal Physical Activity and Sex Impact Markers of Hepatic Mitochondrial Health. <i>Medicine and Science in Sports and Exercise</i> , 2018, 50, 2040-2048.	0.2	9
1097	Usefulness of controlled attenuation parameter for detecting increased arterial stiffness in general population. <i>Digestive and Liver Disease</i> , 2018, 50, 1062-1067.	0.4	9

#	ARTICLE	IF	CITATIONS
1098	The Morbidity and Mortality of Laparoscopic Appendectomy in Patients with Cirrhosis. <i>Clinical Medicine Insights Gastroenterology</i> , 2018, 11, 117955221774664.	1.0	9
1099	Effects of Phytosterol Supplementation on Serum Levels of Lipid Profiles, Liver Enzymes, Inflammatory Markers, Adiponectin, and Leptin in Patients Affected by Nonalcoholic Fatty Liver Disease: A Double-Blind, Placebo-Controlled, Randomized Clinical Trial. <i>Journal of the American College of Nutrition</i> , 2018, 37, 651-658.	1.1	18
1100	Validation of simple indexes for nonalcoholic fatty liver disease in western China: a retrospective cross-sectional study. <i>Endocrine Journal</i> , 2018, 65, 373-381.	0.7	22
1101	Relationship of Eating Patterns and Metabolic Parameters, and Teneiglipitin Treatment: Interim Results from Post-marketing Surveillance in Japanese Type 2 Diabetes Patients. <i>Advances in Therapy</i> , 2018, 35, 817-831.	1.3	4
1102	Dapagliflozin significantly reduced liver fat accumulation associated with a decrease in abdominal subcutaneous fat in patients with inadequately controlled type 2 diabetes mellitus. <i>Diabetes Research and Clinical Practice</i> , 2018, 142, 254-263.	1.1	48
1103	Alcohol Metabolism in the Progression of Human Nonalcoholic Steatohepatitis. <i>Toxicological Sciences</i> , 2018, 164, 428-438.	1.4	35
1104	Alcohol Dehydrogenase Isoenzymes and Aldehyde Dehydrogenase Activity in the Serum of Patients with Non-alcoholic Fatty Liver Disease. <i>Anticancer Research</i> , 2018, 38, 4005-4009.	0.5	15
1105	Combining Genetic Variants to Improve Risk Prediction for NAFLD and Its Progression to Cirrhosis: A Proof of Concept Study. <i>Canadian Journal of Gastroenterology and Hepatology</i> , 2018, 2018, 1-9.	0.8	14
1106	Integrated transcriptomics and metabolomics reveal signatures of lipid metabolism dysregulation in HepaRG liver cells exposed to PCB 126. <i>Archives of Toxicology</i> , 2018, 92, 2533-2547.	1.9	48
1107	The association of sleep duration and sleep quality with non-alcoholic fatty liver disease in a Taiwanese population. <i>Obesity Research and Clinical Practice</i> , 2018, 12, 500-505.	0.8	13
1108	Secretory Malfunction. , 2018, , 117-154.		0
1109	Epidemiology and Etiologic Associations of Non-alcoholic Fatty Liver Disease and Associated HCC. <i>Advances in Experimental Medicine and Biology</i> , 2018, 1061, 3-18.	0.8	22
1110	The Influence of Gut Microbial Metabolism on the Development and Progression of Non-alcoholic Fatty Liver Disease. <i>Advances in Experimental Medicine and Biology</i> , 2018, 1061, 95-110.	0.8	15
1111	Microbiota, Obesity and NAFLD. <i>Advances in Experimental Medicine and Biology</i> , 2018, 1061, 111-125.	0.8	63
1113	Complications of Cirrhosis in Primary Care: Recognition and Management of Hepatic Encephalopathy. <i>American Journal of the Medical Sciences</i> , 2018, 356, 296-303.	0.4	14
1114	Mechanisms of Insulin Action and Insulin Resistance. <i>Physiological Reviews</i> , 2018, 98, 2133-2223.	13.1	1,502
1115	Quality of life in patients with nonalcoholic fatty liver disease: A systematic review. <i>Journal of Psychosomatic Research</i> , 2018, 112, 73-80.	1.2	38
1116	Association of Adipokines with Development and Progression of Nonalcoholic Fatty Liver Disease. <i>Endocrinology and Metabolism</i> , 2018, 33, 33.	1.3	120

#	ARTICLE	IF	CITATIONS
1117	Nonalcoholic Fatty Liver Disease Cirrhosis: A Review of Its Epidemiology, Risk Factors, Clinical Presentation, Diagnosis, Management, and Prognosis. <i>Canadian Journal of Gastroenterology and Hepatology</i> , 2018, 2018, 1-8.	0.8	85
1118	Effects of isomaltulose on insulin resistance and metabolites in patients with non-alcoholic fatty liver disease: A metabolomic analysis. <i>Molecular Medicine Reports</i> , 2018, 18, 2033-2042.	1.1	6
1119	Inhibition of adenosine deaminase and xanthine oxidase by valproic acid abates hepatic triglyceride accumulation independent of corticosteroids in female rats treated with estrogen-progestin. <i>Canadian Journal of Physiology and Pharmacology</i> , 2018, 96, 1092-1103.	0.7	3
1120	Hepcidin levels correlate to liver iron content, but not steatohepatitis, in non-alcoholic fatty liver disease. <i>BMC Gastroenterology</i> , 2018, 18, 78.	0.8	27
1121	Sex-Specific Association between Metabolic Abnormalities and Elevated Alanine Aminotransferase Levels in a Military Cohort: The CHIEF Study. <i>International Journal of Environmental Research and Public Health</i> , 2018, 15, 545.	1.2	32
1122	Gut-liver on a chip toward an in vitro model of hepatic steatosis. <i>Biotechnology and Bioengineering</i> , 2018, 115, 2817-2827.	1.7	74
1123	Premarket Approval Through the 510(k) Process: Lessons from the Translation Process of Magnetic Resonance Elastography. <i>Clinical and Translational Science</i> , 2018, 11, 447-449.	1.5	2
1124	Overexpression of the Vitronectin V10 Subunit in Patients with Nonalcoholic Steatohepatitis: Implications for Noninvasive Diagnosis of NASH. <i>International Journal of Molecular Sciences</i> , 2018, 19, 603.	1.8	7
1125	Genetic and Epigenetic Regulation in Nonalcoholic Fatty Liver Disease (NAFLD). <i>International Journal of Molecular Sciences</i> , 2018, 19, 911.	1.8	100
1126	Insulin-Like Growth Factor (IGF) System in Liver Diseases. <i>International Journal of Molecular Sciences</i> , 2018, 19, 1308.	1.8	179
1127	Monitoring methotrexate-induced liver fibrosis in patients with psoriasis: utility of transient elastography. <i>Psoriasis: Targets and Therapy</i> , 2018, Volume 8, 21-29.	1.2	25
1128	The association of non-alcoholic fatty liver disease with thyroid peroxidase and thyroglobulin antibody: A new insight from SPECT-China study. <i>Autoimmunity</i> , 2018, 51, 238-244.	1.2	12
1129	Association of Hepatic Steatosis With Subclinical Atherosclerosis: Systematic Review and Meta-Analysis. <i>Hepatology Communications</i> , 2018, 2, 877-887.	2.0	43
1130	Microphysiological flux balance platform unravels the dynamics of drug induced steatosis. <i>Lab on A Chip</i> , 2018, 18, 2510-2522.	3.1	29
1131	Position statement for the management of comorbidities in psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2018, 32, 2058-2073.	1.3	61
1133	Establishment of an ex Vivo Model of Nonalcoholic Fatty Liver Disease Using a Tissue-Engineered Liver. <i>ACS Biomaterials Science and Engineering</i> , 2018, 4, 3016-3026.	2.6	9
1134	Curcumin supplementation mitigates NASH development and progression in female Wistar rats. <i>Physiological Reports</i> , 2018, 6, e13789.	0.7	26
1135	A randomised, double-blind, placebo-controlled phase 1 study of the safety, tolerability and pharmacodynamics of volixibat in overweight and obese but otherwise healthy adults: implications for treatment of non-alcoholic steatohepatitis. <i>BMC Pharmacology & Toxicology</i> , 2018, 19, 10.	1.0	21

#	ARTICLE	IF	CITATIONS
1136	Comparison of transcriptome responses to glyphosate, isoxaflutole, quizalofop-p-ethyl and mesotrione in the HepaRG cell line. <i>Toxicology Reports</i> , 2018, 5, 819-826.	1.6	29
1137	A Genetic Score Associates With Pioglitazone Response in Patients With Non-alcoholic Steatohepatitis. <i>Frontiers in Pharmacology</i> , 2018, 9, 752.	1.6	23
1138	Induction of Liver Steatosis in BAP31-Deficient Mice Burdened with Tunicamycin-Induced Endoplasmic Reticulum Stress. <i>International Journal of Molecular Sciences</i> , 2018, 19, 2291.	1.8	21
1139	Ischemia-modified albumin: Crosstalk between fatty acid and cobalt binding. <i>Prostaglandins Leukotrienes and Essential Fatty Acids</i> , 2018, 135, 147-157.	1.0	39
1140	Studying non-alcoholic fatty liver disease: the ins and outs of in vivo, ex vivo and in vitro human models. <i>Hormone Molecular Biology and Clinical Investigation</i> , 2020, 41, .	0.3	15
1141	Correlation between Non-Alcoholic Fatty Liver Disease and Visceral Adipose Tissue in Non-Obese Chinese Adults: A CT Evaluation. <i>Korean Journal of Radiology</i> , 2018, 19, 923.	1.5	30
1142	Clinical and histologic features of adults with alpha-1 antitrypsin deficiency in a non-cirrhotic cohort. <i>Journal of Hepatology</i> , 2018, 69, 1357-1364.	1.8	94
1143	The Role of Long Non-Coding RNAs (lncRNAs) in the Development and Progression of Fibrosis Associated with Nonalcoholic Fatty Liver Disease (NAFLD). <i>Non-coding RNA</i> , 2018, 4, 18.	1.3	42
1144	Real-world data reveal a diagnostic gap in non-alcoholic fatty liver disease. <i>BMC Medicine</i> , 2018, 16, 130.	2.3	177
1145	Data Linking Diabetes Mellitus and Atrial Fibrillation—How Strong Is the Evidence? From Epidemiology and Pathophysiology to Therapeutic Implications. <i>Canadian Journal of Cardiology</i> , 2018, 34, 1492-1502.	0.8	27
1146	Fatty liver mediated by peroxisome proliferator-activated receptor- α DNA methylation can be reversed by a methylation inhibitor and curcumin. <i>Journal of Digestive Diseases</i> , 2018, 19, 421-430.	0.7	26
1148	Differential Diagnosis of Hepatic Necrosis Encountered at Autopsy. <i>Academic Forensic Pathology</i> , 2018, 8, 256-295.	0.3	11
1149	Role of cAMP and phosphodiesterase signaling in liver health and disease. <i>Cellular Signalling</i> , 2018, 49, 105-115.	1.7	85
1150	Updates on Dietary Models of Nonalcoholic Fatty Liver Disease: Current Studies and Insights. <i>Gene Expression</i> , 2018, 18, 5-17.	0.5	95
1152	Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016–2030. <i>Journal of Hepatology</i> , 2018, 69, 896-904.	1.8	1,157
1153	NASH Leading Cause of Liver Transplant in Women: Updated Analysis of Indications For Liver Transplant and Ethnic and Gender Variances. <i>American Journal of Gastroenterology</i> , 2018, 113, 1649-1659.	0.2	401
1154	Underrated enemy – from nonalcoholic fatty liver disease to cancers of the gastrointestinal tract. <i>Clinical and Experimental Hepatology</i> , 2018, 4, 55-71.	0.6	8
1155	Metabolic support challenges with obesity during critical illness. <i>Nutrition</i> , 2019, 57, 24-31.	1.1	19

#	ARTICLE	IF	CITATIONS
1156	Effect of luseogliflozin on hepatic fat content in type 2 diabetes patients with nonalcoholic fatty liver disease: A prospective, single-arm trial (LEAD trial). <i>Hepatology Research</i> , 2019, 49, 64-71.	1.8	85
1157	The role of curcumin in liver diseases. <i>Archives of Medical Science</i> , 2019, 15, 1608-1620.	0.4	14
1158	The Pattern of Elevated Liver Function Tests in Nonalcoholic Fatty Liver Disease Predicts Fibrosis Stage and Metabolic-Associated Comorbidities. <i>Digestive Diseases</i> , 2019, 37, 69-76.	0.8	8
1159	What Does the Future Hold for Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis?. <i>Current Vascular Pharmacology</i> , 2019, 17, 425-428.	0.8	7
1160	The role of the gut microbiome in chronic liver disease: the clinical evidence revised. <i>JHEP Reports</i> , 2019, 1, 214-226.	2.6	96
1161	CONTROL: A randomized phase 2 study of obeticholic acid and atorvastatin on lipoproteins in nonalcoholic steatohepatitis patients. <i>Liver International</i> , 2019, 39, 2082-2093.	1.9	117
1162	Associations of Plasma CD36 and Body Fat Distribution. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 4016-4023.	1.8	5
1163	Vanin 1: Its Physiological Function and Role in Diseases. <i>International Journal of Molecular Sciences</i> , 2019, 20, 3891.	1.8	70
1164	The Effect of 30-minute Ischemia on the Levels of IL6, TNF α , NO, Glutathione and Lactic Acid in the Hepatic Tissue of Rats with Hepatic Steatosis. <i>Hellenike Cheirurgike Acta Chirurgica Hellenica</i> , 2019, 91, 65-74.	0.1	1
1165	Proteomics study of the effect of high-fat diet on rat liver. <i>British Journal of Nutrition</i> , 2019, 122, 1062-1072.	1.2	14
1166	Obesity, adipocyte hypertrophy, fasting glucose, and resistin are potential contributors to nonalcoholic fatty liver disease in South Asian women. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2019, Volume 12, 863-872.	1.1	9
1167	The relationship between non-alcoholic fatty liver and skeletal muscle mass to visceral fat area ratio in women with type 2 diabetes. <i>BMC Endocrine Disorders</i> , 2019, 19, 76.	0.9	20
1168	Effect of resveratrol on nonalcoholic fatty liver disease. <i>Experimental and Therapeutic Medicine</i> , 2019, 18, 559-565.	0.8	20
1169	High Prevalence of Autoimmune Gastritis in Patients with Nonalcoholic Steatohepatitis. <i>Internal Medicine</i> , 2019, 58, 2907-2913.	0.3	10
1170	Cost-comparison analysis of FIB-4, ELF and fibroscan in community pathways for non-alcoholic fatty liver disease. <i>BMC Gastroenterology</i> , 2019, 19, 122.	0.8	81
1171	The association of hepatic fat percentage with selected anthropometric and biochemical parameters at 3-Tesla magnetic resonance imaging. <i>British Journal of Biomedical Science</i> , 2019, 76, 70-76.	1.2	2
1172	Liver sympathetic denervation reverses obesity-induced hepatic steatosis. <i>Journal of Physiology</i> , 2019, 597, 4565-4580.	1.3	65
1173	The role of elastin-derived peptides in human physiology and diseases. <i>Matrix Biology</i> , 2019, 84, 81-96.	1.5	58

#	ARTICLE	IF	CITATIONS
1174	REGENERATE: Design of a pivotal, randomised, phase 3 study evaluating the safety and efficacy of obeticholic acid in patients with fibrosis due to nonalcoholic steatohepatitis. <i>Contemporary Clinical Trials</i> , 2019, 84, 105803.	0.8	105
1175	From NASH to diabetes and from diabetes to NASH: Mechanisms and treatment options. <i>JHEP Reports</i> , 2019, 1, 312-328.	2.6	251
1176	Nutrition in Gastrointestinal Disease: Liver, Pancreatic, and Inflammatory Bowel Disease. <i>Journal of Clinical Medicine</i> , 2019, 8, 1098.	1.0	17
1177	Elevated levels of circulating ITIH4 are associated with hepatocellular carcinoma with nonalcoholic fatty liver disease: from pig model to human study. <i>BMC Cancer</i> , 2019, 19, 621.	1.1	33
1178	The PNPLA3 rs738409 C>G variant influences the association between low skeletal muscle mass and NAFLD: the Shanghai Changfeng Study. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 50, 684-695.	1.9	11
1179	Extrahepatic complications of non-alcoholic fatty liver disease. <i>Revista De Gastroenterología De México (English Edition)</i> , 2019, 84, 472-481.	0.1	3
1180	Prevalence and risk factors of non-alcoholic fatty liver disease in southwest Iran: a population-based case-control study. <i>Clinical and Experimental Hepatology</i> , 2019, 5, 224-231.	0.6	16
1181	Nonalcoholic Fatty Liver Disease Among Individuals with HIV Mono-infection: A Growing Concern?. <i>Digestive Diseases and Sciences</i> , 2019, 64, 3394-3401.	1.1	6
1182	Assessment of liver marker enzymes and its association with type 2 diabetes mellitus in Northwest Ethiopia. <i>BMC Research Notes</i> , 2019, 12, 707.	0.6	51
1183	Lifestyle and Food Habits Impact on Chronic Diseases: Roles of PPARs. <i>International Journal of Molecular Sciences</i> , 2019, 20, 5422.	1.8	11
1184	Effects of Periodic Fasting on Fatty Liver Index—A Prospective Observational Study. <i>Nutrients</i> , 2019, 11, 2601.	1.7	59
1185	The impact of hepatic steatosis on portal hypertension. <i>PLoS ONE</i> , 2019, 14, e0224506.	1.1	10
1186	Should We Screen High-Risk Populations for NAFLD?. <i>Current Hepatology Reports</i> , 2019, 18, 433-443.	0.4	6
1187	Causal relationships between obesity and the leading causes of death in women and men. <i>PLoS Genetics</i> , 2019, 15, e1008405.	1.5	113
1188	Novel Lipid Long Intervening Noncoding RNA, Oligodendrocyte Maturation-Associated Long Intergenic Noncoding RNA, Regulates the Liver Steatosis Gene Stearoyl-Coenzyme A Desaturase As an Enhancer RNA. <i>Hepatology Communications</i> , 2019, 3, 1356-1372.	2.0	28
1189	Roles of the Hepatic Endocannabinoid and Apelin Systems in the Pathogenesis of Liver Fibrosis. <i>Cells</i> , 2019, 8, 1311.	1.8	27
1190	Effect of Wakame and Carob Pod Snacks on Non-Alcoholic Fatty Liver Disease. <i>Nutrients</i> , 2019, 11, 86.	1.7	7
1191	Direct comparison of the specialised blood fibrosis tests FibroMeter ^{V2G} and Enhanced Liver Fibrosis score in patients with non-alcoholic fatty liver disease from tertiary care centres. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 50, 1214-1222.	1.9	38

#	ARTICLE	IF	CITATIONS
1192	Dietary Fructose and the Metabolic Syndrome. <i>Nutrients</i> , 2019, 11, 1987.	1.7	152
1193	Nonalcoholic fatty liver disease is a risk factor for large-for-gestational-age birthweight. <i>PLoS ONE</i> , 2019, 14, e0221400.	1.1	28
1194	M3 muscarinic receptor activation reduces hepatocyte lipid accumulation via CaMKK β /AMPK pathway. <i>Biochemical Pharmacology</i> , 2019, 169, 113613.	2.0	18
1196	Cholecystectomy versus central obesity or insulin resistance in relation to the risk of nonalcoholic fatty liver disease: the third US National Health and Nutrition Examination Survey. <i>BMC Endocrine Disorders</i> , 2019, 19, 95.	0.9	11
1197	Complicaciones extrahepáticas de la enfermedad por hígado graso no alcohólico: impacto más allá del hígado. <i>Revista De Gastroenterología De México</i> , 2019, 84, 472-481.	0.4	12
1198	Cerium oxide nanoparticles display antilipogenic effect in rats with non-alcoholic fatty liver disease. <i>Scientific Reports</i> , 2019, 9, 12848.	1.6	35
1199	Circulating miRNAs as Novel Diagnostic Biomarkers in Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis. <i>Canadian Journal of Gastroenterology and Hepatology</i> , 2019, 2019, 1-11.	0.8	17
1200	Non-alcoholic fatty liver disease in lean individuals. <i>JHEP Reports</i> , 2019, 1, 329-341.	2.6	98
1201	Significant decrease in Faecalibacterium among gut microbiota in nonalcoholic fatty liver disease: a large BMI- and sex-matched population study. <i>Hepatology International</i> , 2019, 13, 748-756.	1.9	46
1202	Let my liver rather heat with wine - a review of hepatic fibrosis pathophysiology and emerging therapeutics. <i>Hepatic Medicine: Evidence and Research</i> , 2019, Volume 11, 109-129.	0.9	4
1203	Overview of the Pathogenesis, Genetic, and Non-Invasive Clinical, Biochemical, and Scoring Methods in the Assessment of NAFLD. <i>International Journal of Environmental Research and Public Health</i> , 2019, 16, 3570.	1.2	29
1204	Effect of <i>Lactobacillus paracasei</i> N1115 and fructooligosaccharides in nonalcoholic fatty liver disease. <i>Archives of Medical Science</i> , 2019, 15, 1336-1344.	0.4	40
1205	Working hours and nonalcoholic fatty liver disease according to sleep duration. <i>Chronobiology International</i> , 2019, 36, 1671-1680.	0.9	9
1207	Nr2e1 ablation impairs liver glucolipid metabolism and induces inflammation, high-fat diets amplify the damage. <i>Biomedicine and Pharmacotherapy</i> , 2019, 120, 109503.	2.5	11
1208	Coenzyme Q10 attenuates high-fat diet-induced non-alcoholic fatty liver disease through activation of the AMPK pathway. <i>Food and Function</i> , 2019, 10, 814-823.	2.1	59
1209	Nonalcoholic fatty liver disease is associated with breast cancer in nonobese women. <i>Digestive and Liver Disease</i> , 2019, 51, 1030-1035.	0.4	38
1210	Association of low skeletal muscle mass with advanced liver fibrosis in patients with non-alcoholic fatty liver disease. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2019, 34, 1633-1640.	1.4	20
1211	Decreased lung function is associated with risk of developing non-alcoholic fatty liver disease: A longitudinal cohort study. <i>PLoS ONE</i> , 2019, 14, e0208736.	1.1	23

#	ARTICLE	IF	CITATIONS
1212	A High-Calorie Diet Aggravates Mitochondrial Dysfunction and Triggers Severe Liver Damage in Wilson Disease Rats. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2019, 7, 571-596.	2.3	50
1213	L-Ornithine L-Aspartate (LOLA) as a Novel Approach for Therapy of Non-alcoholic Fatty Liver Disease. <i>Drugs</i> , 2019, 79, 39-44.	4.9	25
1214	ESPEN guideline on clinical nutrition in liver disease. <i>Clinical Nutrition</i> , 2019, 38, 485-521.	2.3	387
1215	Effect of diet-induced weight loss on cytokeratin-18 levels in overweight and obese patients with liver fibrosis. <i>Diabetes and Metabolic Syndrome: Clinical Research and Reviews</i> , 2019, 13, 989-994.	1.8	7
1216	Oophorectomy and risk of non-alcoholic fatty liver disease and primary liver cancer in the Clinical Practice Research Datalink. <i>European Journal of Epidemiology</i> , 2019, 34, 871-878.	2.5	22
1217	Aspartate transaminase to platelet ratio index (APRI) but not FIB-5 or FIB-4 is accurate in ruling out significant fibrosis in patients with non-alcoholic fatty liver disease (NAFLD) in an urban slum-dwelling population. <i>BMJ Open Gastroenterology</i> , 2019, 6, e000288.	1.1	20
1218	Understanding the Role of the Gut Microbiome and Microbial Metabolites in Obesity and Obesity-Associated Metabolic Disorders: Current Evidence and Perspectives. <i>Current Obesity Reports</i> , 2019, 8, 317-332.	3.5	182
1219	Hepato-protective effects of <i>Glossogyne tenuifolia</i> in Streptozotocin-nicotinamide-induced diabetic rats on high fat diet. <i>BMC Complementary and Alternative Medicine</i> , 2019, 19, 117.	3.7	6
1220	Autotaxin is a valuable biomarker for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease. <i>Hepatology Research</i> , 2019, 49, 1136-1146.	1.8	24
1221	Long-term metformin use may improve clinical outcomes in diabetic patients with non-alcoholic steatohepatitis and bridging fibrosis or compensated cirrhosis. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 50, 317-328.	1.9	52
1222	Non-alcoholic fatty liver disease, liver fibrosis score and cognitive function in middle-aged adults: The Framingham Study. <i>Liver International</i> , 2019, 39, 1713-1721.	1.9	68
1223	Analysis of amino acid profiles of blood over time and biomarkers associated with non-alcoholic steatohepatitis in STAM mice. <i>Experimental Animals</i> , 2019, 68, 417-428.	0.7	8
1224	Serum Ferritin level, microalbuminuria and non-alcoholic fatty liver disease in type 2 diabetic patients. <i>Diabetes and Metabolic Syndrome: Clinical Research and Reviews</i> , 2019, 13, 2226-2229.	1.8	10
1225	The effects of oleoylethanolamide, an endogenous PPAR α agonist, on risk factors for NAFLD: A systematic review. <i>Obesity Reviews</i> , 2019, 20, 1057-1069.	3.1	35
1226	Type 2 diabetes mellitus: A risk factor for progression of liver fibrosis in middle-aged patients with non-alcoholic fatty liver disease. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2019, 34, 2011-2018.	1.4	41
1227	Phosphorylation dependent proteostasis of sterol regulatory element binding proteins. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , 2019, 1864, 1145-1156.	1.2	11
1228	Fatty liver in lipodystrophy: A review with a focus on therapeutic perspectives of adiponectin and/or leptin replacement. <i>Metabolism: Clinical and Experimental</i> , 2019, 96, 66-82.	1.5	72
1229	Cardio-Metabolic Disorders in Non-Alcoholic Fatty Liver Disease. <i>International Journal of Molecular Sciences</i> , 2019, 20, 2215.	1.8	42

#	ARTICLE	IF	CITATIONS
1230	Non-alcoholic steatohepatitis, but not simple steatosis, disturbs the functional homogeneity of the liver – a human galactose positron emission tomography study. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 50, 84-92.	1.9	7
1231	ANTHROPOMETRIC AND BIOCHEMICAL CHARACTERISTICS OF ADULT PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE. <i>Asian Journal of Pharmaceutical and Clinical Research</i> , 2019, 12, 501.	0.3	3
1232	Low serum vitamin D is independently associated with unexplained elevated ALT only among non-obese men in the general population. <i>Annals of Hepatology</i> , 2019, 18, 578-584.	0.6	6
1233	Nonalcoholic fatty liver disease and steatohepatitis in people living with HIV. <i>Expert Review of Gastroenterology and Hepatology</i> , 2019, 13, 643-650.	1.4	11
1234	Lysosomal Acid Lipase as a Molecular Target of the Very Low Carbohydrate Ketogenic Diet in Morbidly Obese Patients: The Potential Effects on Liver Steatosis and Cardiovascular Risk Factors. <i>Journal of Clinical Medicine</i> , 2019, 8, 621.	1.0	24
1235	The incretin enhancer, sitagliptin, exacerbates expression of hepatic inflammatory markers in rats fed a high-cholesterol diet. <i>Inflammation Research</i> , 2019, 68, 581-595.	1.6	6
1236	Drug-induced liver steatosis in patients with HIV infection. <i>Pharmacological Research</i> , 2019, 145, 104267.	3.1	10
1237	Triplet Male Lambs Are More Susceptible than Twins to Dietary Soybean Oil-Induced Fatty Liver. <i>Journal of Nutrition</i> , 2019, 149, 989-995.	1.3	0
1238	In New-Onset Diabetes Mellitus, Metformin Reduces Fat Accumulation in the Liver, But Not in the Pancreas or Pericardium. <i>Metabolic Syndrome and Related Disorders</i> , 2019, 17, 289-295.	0.5	16
1239	Methotrexate treatment in rheumatoid arthritis and elevated liver enzymes: A long-term follow-up of predictors, surveillance, and outcome in clinical practice. <i>International Journal of Rheumatic Diseases</i> , 2019, 22, 1226-1232.	0.9	24
1240	Bi-lobar liver biopsy via EUS enhances the assessment of disease severity in patients with non-alcoholic steatohepatitis. <i>Hepatology International</i> , 2019, 13, 323-329.	1.9	28
1241	Effect of Sodium Glucose Co-Transporter 2 Inhibitors on Liver Fat Mass and Body Composition in Patients with Nonalcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus. <i>Clinical Drug Investigation</i> , 2019, 39, 631-641.	1.1	21
1242	Oxidative Stress and Non-Alcoholic Fatty Liver Disease: Effects of Omega-3 Fatty Acid Supplementation. <i>Nutrients</i> , 2019, 11, 872.	1.7	159
1243	Characteristics and risk factors for recurrence of nonalcoholic steatohepatitis following liver transplantation. <i>Scandinavian Journal of Gastroenterology</i> , 2019, 54, 233-239.	0.6	14
1244	Diet-induced hepatic steatosis abrogates cell-surface LDLR by inducing de novo PCSK9 expression in mice. <i>Journal of Biological Chemistry</i> , 2019, 294, 9037-9047.	1.6	40
1245	Free-breathing 3-D quantification of infant body composition and hepatic fat using a stack-of-radial magnetic resonance imaging technique. <i>Pediatric Radiology</i> , 2019, 49, 876-888.	1.1	10
1246	A multidisciplinary approach to the management of NAFLD is associated with improvement in markers of liver and cardio-metabolic health. <i>Frontline Gastroenterology</i> , 2019, 10, 337-346.	0.9	48
1247	Role of Tissue Biopsy in Drug Development for Nonalcoholic Fatty Liver Disease and Other Metabolic Disorders. , 2019, , 245-274.		0

#	ARTICLE	IF	CITATIONS
1248	GVS-12 attenuates non-alcoholic steatohepatitis by suppressing inflammatory responses via PPAR β /STAT3 signaling pathways. RSC Advances, 2019, 9, 9555-9564.	1.7	2
1249	Pinitol consumption improves liver health status by reducing oxidative stress and fatty acid accumulation in subjects with non-alcoholic fatty liver disease: A randomized, double-blind, placebo-controlled trial. Journal of Nutritional Biochemistry, 2019, 68, 33-41.	1.9	44
1250	The FATZO mouse, a next generation model of type 2 diabetes, develops NAFLD and NASH when fed a Western diet supplemented with fructose. BMC Gastroenterology, 2019, 19, 41.	0.8	25
1251	18F-FDG PET/CT AS AN ASSESSMENT TOOL OF HEPATOCELLULAR CARCINOMA SECONDARY TO NON-ALCOHOLIC FATTY LIVER DISEASE DEVELOPMENT IN EXPERIMENTAL MODEL. Arquivos De Gastroenterologia, 2019, 56, 45-50.	0.3	2
1252	THE CORRELATION OF NECK CIRCUMFERENCE AND INSULIN RESISTANCE IN NAFLD PATIENTS. Arquivos De Gastroenterologia, 2019, 56, 28-33.	0.3	8
1253	Diagnostic value of MRI-PDFF for hepatic steatosis in patients with non-alcoholic fatty liver disease: a meta-analysis. European Radiology, 2019, 29, 3564-3573.	2.3	140
1254	Increased risk of chronic liver disease in patients with major depressive disorder: A population-based study. Journal of Affective Disorders, 2019, 251, 180-185.	2.0	12
1255	Noninvasive Evaluation of Liver Function in Morbidly Obese Patients. Gastroenterology Research and Practice, 2019, 2019, 1-7.	0.7	12
1256	Association between ADIPOQ G276T and C11377G polymorphisms and the risk of non-alcoholic fatty liver disease: An updated meta-analysis. Molecular Genetics & Genomic Medicine, 2019, 7, e624.	0.6	11
1257	Bariatric surgery in patients with non-alcoholic fatty liver disease - from pathophysiology to clinical effects. World Journal of Hepatology, 2019, 11, 138-149.	0.8	122
1258	Increased mortality in non-alcoholic fatty liver disease with chronic kidney disease is explained by metabolic comorbidities. Clinics and Research in Hepatology and Gastroenterology, 2019, 43, 542-550.	0.7	27
1259	Prevalence of non-alcoholic fatty liver disease in patients with diabetes mellitus, hyperlipidemia, obesity and polycystic ovary syndrome: A cross-sectional study in north of Iran. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2019, 13, 1591-1596.	1.8	33
1260	High Fib4 index in patients with suspected NASH is associated with elevation of chymase-dependent angiotensin II-forming activity in circulating mononuclear leucocytes. Heart and Vessels, 2019, 34, 1559-1569.	0.5	2
1261	Effect of fish oil supplementation and restricted feeding on body fat distribution and blood lipid profile in a rabbit model of castration-induced obesity. Research in Veterinary Science, 2019, 124, 99-105.	0.9	11
1262	Serum C16:1n7/C16:0 ratio as a diagnostic marker for non-alcoholic steatohepatitis. Journal of Gastroenterology and Hepatology (Australia), 2019, 34, 1829-1835.	1.4	18
1263	Intestinal microbiome as a novel therapeutic target for local and systemic inflammation. , 2019, 199, 164-172.		49
1264	Nonalcoholic fatty liver disease and the gut microbiome: Are bacteria responsible for fatty liver?. Experimental Biology and Medicine, 2019, 244, 408-418.	1.1	19
1265	Fecal and blood microbiota profiles and presence of nonalcoholic fatty liver disease in obese versus lean subjects. PLoS ONE, 2019, 14, e0213692.	1.1	70

#	ARTICLE	IF	CITATIONS
1266	Gene Expression Analysis of the Activating Factor 3/Nuclear Protein 1 Axis in a Non-alcoholic Steatohepatitis Mouse Model. <i>Yonago Acta Medica</i> , 2019, 62, 036-046.	0.3	11
1267	Prospective evaluation of a primary care referral pathway for patients with non-alcoholic fatty liver disease. <i>Journal of Hepatology</i> , 2019, 71, 371-378.	1.8	301
1268	Steatosis Rates by Liver Biopsy and Transient Elastography With Controlled Attenuation Parameter in Clinical Experience of Hepatitis C Virus (HCV) and Human Immunodeficiency Virus/HCV Coinfection in a Large US Hepatitis Clinic. <i>Open Forum Infectious Diseases</i> , 2019, 6, ofz099.	0.4	14
1269	Non-alcoholic fatty liver disease and pregnancy complications among Sri Lankan women: A cross sectional analytical study. <i>PLoS ONE</i> , 2019, 14, e0215326.	1.1	23
1270	Effects of sleeve gastrectomy on liver enzymes, non-alcoholic fatty liver disease-related fibrosis and steatosis scores in morbidly obese patients: first year follow-up. <i>Journal of Laboratory Medicine</i> , 2019, 43, 115-122.	1.1	6
1271	Lipidomic and transcriptomic analysis of western diet-induced nonalcoholic steatohepatitis (NASH) in female <i>Ldlr</i> ^{-/-} mice. <i>PLoS ONE</i> , 2019, 14, e0214387.	1.1	45
1272	Consumption of Alcoholic and Sugar-Sweetened Beverages is Associated with Increased Liver Fat Content in Middle-Aged Men and Women. <i>Journal of Nutrition</i> , 2019, 149, 649-658.	1.3	10
1273	Stimulated hepatic stellate cell promotes progression of hepatocellular carcinoma due to protein kinase R activation. <i>PLoS ONE</i> , 2019, 14, e0212589.	1.1	14
1274	Mussel polysaccharide β -D-glucan (MP-A) protects against non-alcoholic fatty liver disease via maintaining the homeostasis of gut microbiota and regulating related gut-liver axis signaling pathways. <i>International Journal of Biological Macromolecules</i> , 2019, 130, 68-78.	3.6	40
1275	Non-alcoholic fatty liver disease: Prevalence and all-cause mortality according to sedentary behaviour and cardiorespiratory fitness. The HUNT Study. <i>Progress in Cardiovascular Diseases</i> , 2019, 62, 127-134.	1.6	38
1276	Paternal high-fat diet transgenerationally impacts hepatic immunometabolism. <i>FASEB Journal</i> , 2019, 33, 6269-6280.	0.2	15
1277	Prenatal caffeine exposure increases the susceptibility to non-alcoholic fatty liver disease in female offspring rats via activation of GR-C/EBP α -SIRT1 pathway. <i>Toxicology</i> , 2019, 417, 23-34.	2.0	29
1278	Serum ferritin as a biomarker for NAFLD: ready for prime time?. <i>Hepatology International</i> , 2019, 13, 110-112.	1.9	14
1279	Electrophilic nitro-oleic acid reverses obesity-induced hepatic steatosis. <i>Redox Biology</i> , 2019, 22, 101132.	3.9	24
1280	RLA8: A New and Highly Effective Quadruple PPAR- α and GPR40 Agonist to Reverse Nonalcoholic Steatohepatitis and Fibrosis. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2019, 369, 67-77.	1.3	16
1281	Patients With Lean Nonalcoholic Fatty Liver Disease Are Metabolically Abnormal and Have a Higher Risk for Mortality. <i>Clinical Diabetes</i> , 2019, 37, 65-72.	1.2	77
1283	Nutritional and Dietary Interventions for Nonalcoholic Fatty Liver Disease. , 2019, , 357-372.		3
1284	Nonalcoholic Fatty Liver Disease in Children with Obesity. , 2019, , 255-268.		1

#	ARTICLE	IF	CITATIONS
1285	Apoptosis signal-regulating kinase-1 as a therapeutic target in nonalcoholic fatty liver disease. <i>Expert Review of Gastroenterology and Hepatology</i> , 2019, 13, 189-191.	1.4	10
1286	A Novel Discovery: Holistic Efficacy at the Special Organ Level of Pungent Flavored Compounds from Pungent Traditional Chinese Medicine. <i>International Journal of Molecular Sciences</i> , 2019, 20, 752.	1.8	10
1287	Non-alcoholic fatty liver disease is associated with low-grade albuminuria in men without diabetes mellitus. <i>International Journal of Medical Sciences</i> , 2019, 16, 285-291.	1.1	11
1288	Association of fatty liver disease with mortality outcomes in an Eastern Finland male cohort. <i>BMJ Open Gastroenterology</i> , 2019, 6, e000219.	1.1	6
1289	LRG ameliorates steatohepatitis by activating the AMPK/mTOR/SREBP1 signaling pathway in C57BL/6J mice fed a high-fat diet. <i>Molecular Medicine Reports</i> , 2019, 20, 701-708.	1.1	5
1290	Aromatase Inhibitors and Newly Developed Nonalcoholic Fatty Liver Disease in Postmenopausal Patients with Early Breast Cancer: A Propensity Score-Matched Cohort Study. <i>Oncologist</i> , 2019, 24, e653-e661.	1.9	16
1291	Fatty liver index as a predictor of increased risk of cardiometabolic disease: finding from the Kuopio Ischaemic Heart Disease Risk Factor Study Cohort. <i>BMJ Open</i> , 2019, 9, e031420.	0.8	10
1292	Calorie Restriction in Adulthood Reduces Hepatic Disorders Induced by Transient Postnatal Overfeeding in Mice. <i>Nutrients</i> , 2019, 11, 2796.	1.7	19
1293	Pcsk9 knockout exacerbates diet-induced non-alcoholic steatohepatitis, fibrosis and liver injury in mice. <i>JHEP Reports</i> , 2019, 1, 418-429.	2.6	51
1294	Nonalcoholic steatohepatitis. <i>Medicine (United States)</i> , 2019, 98, e18221.	0.4	12
1295	Patients With Nonalcoholic Steatohepatitis Experience Severe Impairment of Health-Related Quality of Life. <i>American Journal of Gastroenterology</i> , 2019, 114, 1636-1641.	0.2	36
1296	The ZJU index is a powerful surrogate marker for NAFLD in severely obese North American women. <i>PLoS ONE</i> , 2019, 14, e0224942.	1.1	16
1297	Dietary Patterns and Components in Nonalcoholic Fatty Liver Disease (NAFLD): What Key Messages Can Health Care Providers Offer?. <i>Nutrients</i> , 2019, 11, 2878.	1.7	47
1298	Diet-Induced Rat Model of Gradual Development of Non-Alcoholic Fatty Liver Disease (NAFLD) with Lipopolysaccharides (LPS) Secretion. <i>Diagnostics</i> , 2019, 9, 205.	1.3	19
1299	Microbiota, type 2 diabetes and non-alcoholic fatty liver disease: protocol of an observational study. <i>Journal of Translational Medicine</i> , 2019, 17, 408.	1.8	7
1300	<p>Liraglutide Improves Non-Alcoholic Fatty Liver Disease In Diabetic Mice By Modulating Inflammatory Signaling Pathways<p>. <i>Drug Design, Development and Therapy</i> , 2019, Volume 13, 4065-4074.	2.0	23
1302	The Rise in the Prevalence of Nonalcoholic Fatty Liver Disease and Hepatocellular Carcinoma. , 0, , .		9
1303	Pin1 Plays Essential Roles in NASH Development by Modulating Multiple Target Proteins. <i>Cells</i> , 2019, 8, 1545.	1.8	12

#	ARTICLE	IF	CITATIONS
1304	Intrahepatic fluorine-18-fluorodeoxyglucose kinetics measured by least squares nonlinear computer modelling and Gjeddeâ€™Patlakâ€™Rutland graphical analysis. <i>Nuclear Medicine Communications</i> , 2019, 40, 675-683.	0.5	4
1305	The diagnostic performance of a simplified blood test (SteatoTest-2) for the prediction of liver steatosis. <i>European Journal of Gastroenterology and Hepatology</i> , 2019, 31, 393-402.	0.8	12
1306	Topics on quantitative liver magnetic resonance imaging. <i>Quantitative Imaging in Medicine and Surgery</i> , 2019, 9, 1840-1890.	1.1	31
1307	Tesamorelin, liver fat, and NAFLD in the setting of HIV. <i>Lancet HIV</i> , 2019, 6, e808-e809.	2.1	5
1308	Disease progression of nonalcoholic steatohepatitis in Taiwanese patients: a longitudinal study of paired liver biopsies. <i>European Journal of Gastroenterology and Hepatology</i> , 2019, 31, 224-229.	0.8	6
1309	The promising role of probiotic and synbiotic therapy in aminotransferase levels and inflammatory markers in patients with nonalcoholic fatty liver disease â€” a systematic review and meta-analysis. <i>European Journal of Gastroenterology and Hepatology</i> , 2019, 31, 703-715.	0.8	36
1310	Nonalcoholic Fatty Liver Disease: Identification and Management of High-Risk Patients. <i>American Journal of Gastroenterology</i> , 2019, 114, 579-590.	0.2	27
1311	An AGTR1 Variant Worsens Nonalcoholic Fatty Liver Disease and the Metabolic Syndrome. <i>American Journal of Gastroenterology</i> , 2019, 114, 556-559.	0.2	5
1312	Serum cytokines, adipokines and ferritin for non-invasive assessment of liver fibrosis in chronic liver disease: a systematic review. <i>Clinical Chemistry and Laboratory Medicine</i> , 2019, 57, 577-610.	1.4	22
1313	High prevalence of non-alcoholic fatty liver disease and metabolic risk factors in Guatemala: A population-based study. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2019, 29, 191-200.	1.1	17
1314	Arid1a Loss Drives Nonalcoholic Steatohepatitis in Mice Through Epigenetic Dysregulation of Hepatic Lipogenesis and Fatty Acid Oxidation. <i>Hepatology</i> , 2019, 69, 1931-1945.	3.6	19
1315	Gut peptide and neuroendocrine regulation of hepatic lipid and lipoprotein metabolism in health and disease. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , 2019, 1864, 326-334.	1.2	12
1316	Dipeptidyl peptidase-4 inhibition protects the liver of insulin-resistant female rats against triglyceride accumulation by suppressing uric acid. <i>Biomedicine and Pharmacotherapy</i> , 2019, 110, 869-877.	2.5	11
1317	Quantitative ultrasound and machine learning for assessment of steatohepatitis in a rat model. <i>European Radiology</i> , 2019, 29, 2175-2184.	2.3	33
1318	Impact of a structured lifestyle programme on patients with metabolic syndrome complicated by nonâ€™alcoholic fatty liver disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 49, 296-307.	1.9	19
1319	<scp>HOMAâ€™R</scp>: An independent predictor of advanced liver fibrosis in nondiabetic nonâ€™alcoholic fatty liver disease. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2019, 34, 1390-1395.	1.4	67
1320	Ultrasonic Adaptive Sound Speed Estimation for the Diagnosis and Quantification of Hepatic Steatosis: A Pilot Study. <i>Ultraschall in Der Medizin</i> , 2019, 40, 722-733.	0.8	48
1321	The role of macrophages in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2019, 16, 145-159.	8.2	571

#	ARTICLE	IF	CITATIONS
1322	Non-alcoholic fatty liver disease – A global public health perspective. <i>Journal of Hepatology</i> , 2019, 70, 531-544.	1.8	1,345
1323	Randomised clinical trial: emricasan versus placebo significantly decreases ALT and caspase 3/7 activation in subjects with non-alcoholic fatty liver disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 49, 64-73.	1.9	77
1324	Adult Non-alcoholic Fatty Liver Disease (NAFLD). , 2019, , 23-46.		0
1325	Non-alcoholic fatty liver disease in the first trimester and subsequent development of gestational diabetes mellitus. <i>Diabetologia</i> , 2019, 62, 238-248.	2.9	65
1326	Evaluation of hepatic function using dynamic contrast-enhanced magnetic resonance imaging in melanocortin 4 receptor-deficient mice as a model of nonalcoholic steatohepatitis. <i>Magnetic Resonance Imaging</i> , 2019, 57, 210-217.	1.0	11
1327	Combining hepatitis B core-related and surface antigens at end of nucleos(t)ide analogue treatment to predict off-therapy relapse risk. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 49, 107-115.	1.9	73
1329	Does turmeric/curcumin supplementation improve serum alanine aminotransferase and aspartate aminotransferase levels in patients with nonalcoholic fatty liver disease? A systematic review and meta-analysis of randomized controlled trials. <i>Phytotherapy Research</i> , 2019, 33, 561-570.	2.8	31
1330	Pyruvate kinase L/R is a regulator of lipid metabolism and mitochondrial function. <i>Metabolic Engineering</i> , 2019, 52, 263-272.	3.6	37
1331	High prevalence of prediabetes and metabolic abnormalities in overweight or obese schizophrenia patients treated with clozapine or olanzapine. <i>CNS Spectrums</i> , 2019, 24, 441-452.	0.7	15
1332	Lifestyle interventions for non-alcoholic fatty liver disease. <i>Saudi Journal of Biological Sciences</i> , 2019, 26, 1519-1524.	1.8	32
1333	Homeostasis of Glucose and Lipid in Non-Alcoholic Fatty Liver Disease. <i>International Journal of Molecular Sciences</i> , 2019, 20, 298.	1.8	98
1334	Serum Testosterone Level Within Normal Range Is Positively Associated with Nonalcoholic Fatty Liver Disease in Premenopausal but Not Postmenopausal Women. <i>Journal of Women's Health</i> , 2019, 28, 1077-1082.	1.5	10
1335	Molecular pathways of nonalcoholic fatty liver disease development and progression. <i>Cellular and Molecular Life Sciences</i> , 2019, 76, 99-128.	2.4	344
1336	Causality between non-alcoholic fatty liver disease and risk of cardiovascular disease and type 2 diabetes: A meta-analysis with bias analysis. <i>Liver International</i> , 2019, 39, 557-567.	1.9	62
1337	Repression of TXNIP-NLRP3 axis restores intestinal barrier function via inhibition of myeloperoxidase activity and oxidative stress in nonalcoholic steatohepatitis. <i>Journal of Cellular Physiology</i> , 2019, 234, 7524-7538.	2.0	16
1338	Longer lactation duration is associated with decreased prevalence of non-alcoholic fatty liver disease in women. <i>Journal of Hepatology</i> , 2019, 70, 126-132.	1.8	44
1339	Pegbelfermin (BMS-986036), PEGylated FGF21, in Patients with Obesity and Type 2 Diabetes: Results from a Randomized Phase 2 Study. <i>Obesity</i> , 2019, 27, 41-49.	1.5	180
1340	Wuzhi capsule (<i>Schisandra Sphenanthera</i> extract) attenuates liver steatosis and inflammation during non-alcoholic fatty liver disease development. <i>Biomedicine and Pharmacotherapy</i> , 2019, 110, 285-293.	2.5	29

#	ARTICLE	IF	CITATIONS
1341	Clinical workup of fatty liver for the primary care provider. <i>Postgraduate Medicine</i> , 2019, 131, 19-30.	0.9	4
1342	Obesity and nonalcoholic fatty liver disease: From pathophysiology to therapeutics. <i>Metabolism: Clinical and Experimental</i> , 2019, 92, 82-97.	1.5	679
1343	Dietary patterns are associated with the prevalence of nonalcoholic fatty liver disease in Korean adults. <i>Nutrition</i> , 2019, 62, 32-38.	1.1	32
1344	Longitudinal Comparison of the Effect of Gastric Bypass to Sleeve Gastrectomy on Liver Function in a Bariatric Cohort: Tehran Obesity Treatment Study (TOTS). <i>Obesity Surgery</i> , 2019, 29, 511-518.	1.1	11
1345	Non-alcoholic fatty liver disease and obesity: the role of the gut bacteria. <i>European Journal of Nutrition</i> , 2019, 58, 1771-1784.	1.8	30
1346	Prevalence and associations of non-alcoholic fatty liver disease (NAFLD) in Sri Lankan patients with type 2 diabetes: A single center study. <i>Diabetes and Metabolic Syndrome: Clinical Research and Reviews</i> , 2019, 13, 246-250.	1.8	27
1347	Clinical significance of hepatic steatosis according to coronary plaque morphology: assessment using controlled attenuation parameter. <i>Journal of Gastroenterology</i> , 2019, 54, 271-280.	2.3	21
1348	Activation of brown adipose tissue enhances the efficacy of caloric restriction for treatment of nonalcoholic steatohepatitis. <i>Laboratory Investigation</i> , 2019, 99, 4-16.	1.7	22
1349	Sodium acetate improves disrupted gluco-regulation and hepatic triglyceride content in insulin-resistant female rats: involvement of adenosine deaminase and dipeptidyl peptidase-4 activities. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2019, 392, 103-116.	1.4	5
1350	Non-alcoholic fatty liver disease and clinical outcomes in chronic kidney disease. <i>Nephrology Dialysis Transplantation</i> , 2019, 34, 449-457.	0.4	48
1351	Effect of Soothing Gan (Liver) and Invigorating Pi (Spleen) Recipes on TLR4-p38 MAPK Pathway in Kupffer Cells of Non-alcoholic Steatohepatitis Rats. <i>Chinese Journal of Integrative Medicine</i> , 2019, 25, 216-224.	0.7	14
1352	Dihydromyricetin Ameliorates Nonalcoholic Fatty Liver Disease by Improving Mitochondrial Respiratory Capacity and Redox Homeostasis Through Modulation of SIRT3 Signaling. <i>Antioxidants and Redox Signaling</i> , 2019, 30, 163-183.	2.5	107
1353	Hepatoprotective and antioxidant activity of aerial parts of <i>Moringa oleifera</i> in prevention of non-alcoholic fatty liver disease in Wistar rats. <i>South African Journal of Botany</i> , 2020, 129, 82-90.	1.2	15
1354	Ketogenic diet in combination with voluntary exercise impacts markers of hepatic metabolism and oxidative stress in male and female Wistar rats. <i>Applied Physiology, Nutrition and Metabolism</i> , 2020, 45, 35-44.	0.9	18
1355	The Nonalcoholic Fatty Liver Disease Fibrosis Score Is Related to Epicardial Fat Thickness and Complexity of Coronary Artery Disease. <i>Angiology</i> , 2020, 71, 77-82.	0.8	28
1356	The correlation between fatty liver disease and chronic kidney disease. <i>Journal of the Formosan Medical Association</i> , 2020, 119, 42-50.	0.8	16
1357	Fatty liver index (FLI) and prediction of new cases of non-alcoholic fatty liver disease: A population-based study of northern Iran. <i>Clinical Nutrition</i> , 2020, 39, 468-474.	2.3	32
1358	Multi-drug approaches to NASH: what are the challenges in the development pipeline?. <i>Expert Opinion on Investigational Drugs</i> , 2020, 29, 143-150.	1.9	18

#	ARTICLE	IF	CITATIONS
1359	Peculiarities of Cirrhosis due to Nonalcoholic Steatohepatitis (NASH). <i>Seminars in Liver Disease</i> , 2020, 40, 001-010.	1.8	7
1360	Unmasking a Stealth Killer: The Need for Increased Awareness of NASH. <i>Digestive Diseases and Sciences</i> , 2020, 65, 987-989.	1.1	2
1361	Nonalcoholic fatty liver disease in women with polycystic ovary syndrome. <i>Endocrine</i> , 2020, 67, 1-8.	1.1	150
1362	Recent Developments in Therapeutic Peptides for the Glucagon-like Peptide 1 and 2 Receptors. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 905-927.	2.9	34
1363	Risk factors for nonalcoholic fatty liver disease after gastrectomy for gastric cancer. <i>Gastric Cancer</i> , 2020, 23, 356-362.	2.7	10
1364	Characterization of biopsy proven non-alcoholic fatty liver disease in healthy non-obese and lean population of living liver donors: The impact of uric acid. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2020, 44, 572-578.	0.7	17
1365	Association between edible mushroom intake and the prevalence of newly diagnosed non-alcoholic fatty liver disease: results from the Tianjin Chronic Low-Grade Systemic Inflammation and Health Cohort Study in China. <i>British Journal of Nutrition</i> , 2020, 123, 104-112.	1.2	17
1366	Ultrasound Fatty Liver Indicator: A Simple Tool for Differentiating Steatosis From Nonalcoholic Steatohepatitis: Validity in the Average Obese Population. <i>Journal of Ultrasound in Medicine</i> , 2020, 39, 749-759.	0.8	21
1367	Chronic kidney disease in patients with non-alcoholic fatty liver disease: What the Hepatologist should know?. <i>Annals of Hepatology</i> , 2020, 19, 134-144.	0.6	27
1368	Natural History of Non-Alcoholic Fatty Liver Disease: A Study With Paired Liver Biopsies. <i>Journal of Clinical and Experimental Hepatology</i> , 2020, 10, 245-254.	0.4	24
1369	Liver Disease, Nonalcoholic Fatty. , 2020, , 408-413.		1
1370	Nonalcoholic Steatohepatitis Is Associated With Liver-Related Outcomes and All-Cause Mortality in Chronic Hepatitis B. <i>Hepatology</i> , 2020, 71, 539-548.	3.6	128
1371	Extra-Hepatic Manifestations of Nonalcoholic Fatty Liver Disease: A Review. <i>Journal of Clinical and Experimental Hepatology</i> , 2020, 10, 81-87.	0.4	35
1372	Long-term Liver-related Outcomes of Patients With Chronic Liver Diseases in Australia. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 496-504.e3.	2.4	15
1373	Increased Prevalence of Colorectal Adenomas in Patients with Nonalcoholic Fatty Liver Disease: A Cross-Sectional Study. <i>Digestive Diseases</i> , 2020, 38, 222-230.	0.8	13
1374	Cytochrome P450-derived eicosanoids and inflammation in liver diseases. <i>Prostaglandins and Other Lipid Mediators</i> , 2020, 147, 106400.	1.0	26
1375	Development of new drugs for the treatment of nonalcoholic steatohepatitis. <i>Journal of Digestive Diseases</i> , 2020, 21, 3-11.	0.7	11
1376	Atlantic salmon fed a nutrient package of surplus methionine, vitamin B12, folic acid and vitamin B6 improved growth and reduced the relative liver size, but when in excess growth reduced. <i>Aquaculture Nutrition</i> , 2020, 26, 477-489.	1.1	14

#	ARTICLE	IF	CITATIONS
1377	Posttransplant Outcome of Lean Compared With Obese Nonalcoholic Steatohepatitis in the United States: The Obesity Paradox. <i>Liver Transplantation</i> , 2020, 26, 68-79.	1.3	26
1378	Increasing Liver Fat Is Associated With Incident Cardiovascular Risk Factors. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 1884-1886.	2.4	7
1379	Comparison of murine steatohepatitis models identifies a dietary intervention with robust fibrosis, ductular reaction, and rapid progression to cirrhosis and cancer. <i>American Journal of Physiology - Renal Physiology</i> , 2020, 318, G174-G188.	1.6	49
1380	Training of Deep Convolutional Neural Networks to Identify Critical Liver Alterations in Histopathology Image Samples. <i>Applied Sciences (Switzerland)</i> , 2020, 10, 42.	1.3	20
1381	How to Identify the Patient with Nonalcoholic Steatohepatitis Who Will Progress to Cirrhosis. <i>Gastroenterology Clinics of North America</i> , 2020, 49, 45-62.	1.0	5
1383	Diet quality and its association with nonalcoholic fatty liver disease and all-cause and cause-specific mortality. <i>Liver International</i> , 2020, 40, 815-824.	1.9	26
1384	Spirolactone reversed hepato-ovarian triglyceride accumulation caused by letrozole-induced polycystic ovarian syndrome: tissue uric acid—a familiar foe. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2020, 393, 1055-1066.	1.4	13
1385	Ultrasound-based liver elastography. , 2020, , 109-133.		0
1386	Genecriviroc for the treatment of liver fibrosis in adults with nonalcoholic steatohepatitis: AURORA Phase 3 study design. <i>Contemporary Clinical Trials</i> , 2020, 89, 105922.	0.8	92
1387	A randomized, placebo-controlled trial of emricasan in patients with NASH and F1-F3 fibrosis. <i>Journal of Hepatology</i> , 2020, 72, 816-827.	1.8	165
1388	Therapeutic potential of targeting mixed lineage kinases in cancer and inflammation. , 2020, 207, 107457.		12
1389	Performance of noninvasive scores for the diagnosis of advanced liver fibrosis in morbidly obese with nonalcoholic fatty liver disease. <i>European Journal of Gastroenterology and Hepatology</i> , 2020, 32, 420-425.	0.8	22
1390	Attributable Fractions of Nonalcoholic Fatty Liver Disease for Mortality in the United States: Results From the Third National Health and Nutrition Examination Survey With 27 Years of Follow-up. <i>Hepatology</i> , 2020, 72, 430-440.	3.6	48
1391	The regulatory effects of phytosterol esters (PSEs) on gut flora and faecal metabolites in rats with NAFLD. <i>Food and Function</i> , 2020, 11, 977-991.	2.1	35
1392	Chronic hepatitis B and non-alcoholic fatty liver disease: Conspirators or competitors?. <i>Liver International</i> , 2020, 40, 496-508.	1.9	39
1393	Effect of Canagliflozin, an SGLT2 Inhibitor, in Comparison with Atorvastatin on Dexamethasone-Induced Hepatic Steatosis in Albino Rats. <i>Current Drug Therapy</i> , 2020, 15, 274-282.	0.2	2
1394	Noninvasive assessment of hepatic steatosis and fibrosis in patients with severe obesity. <i>Endocrine</i> , 2020, 67, 569-578.	1.1	7
1395	Serum soluble sialic acid-binding immunoglobulin-like lectin-7 concentration as an indicator of liver macrophage activation and advanced fibrosis in patients with non-alcoholic fatty liver disease. <i>Hepatology Research</i> , 2020, 50, 466-477.	1.8	7

#	ARTICLE	IF	CITATIONS
1396	Quantification of hepatic steatosis with ultrasound: promising role of attenuation imaging coefficient in a biopsy-proven cohort. <i>European Radiology</i> , 2020, 30, 2293-2301.	2.3	65
1397	Active vitamin D supplementation alleviates initiation and progression of nonalcoholic fatty liver disease by repressing the p53 pathway. <i>Life Sciences</i> , 2020, 241, 117086.	2.0	19
1398	Hepatic and splenic ^{18F} FDG blood clearance rates (Ki) in hepatic steatosis and diabetes mellitus. <i>Clinical Physiology and Functional Imaging</i> , 2020, 40, 99-105.	0.5	3
1399	Statin Use is Protective Against Hepatocellular Carcinoma in Patients With Nonalcoholic Fatty Liver Disease. <i>Journal of Clinical Gastroenterology</i> , 2020, 54, 733-740.	1.1	30
1400	Sphingolipids in Non-Alcoholic Fatty Liver Disease and Hepatocellular Carcinoma: Ceramide Turnover. <i>International Journal of Molecular Sciences</i> , 2020, 21, 40.	1.8	73
1401	Molecular Magnetic Resonance Imaging of Fibrin Deposition in the Liver as an Indicator of Tissue Injury and Inflammation. <i>Investigative Radiology</i> , 2020, 55, 209-216.	3.5	15
1402	The association of genetic polymorphisms with nonalcoholic fatty liver disease in a longitudinal study. <i>BMC Gastroenterology</i> , 2020, 20, 344.	0.8	2
1403	Distinct Influence of Hypercaloric Diets Predominant with Fat or Fat and Sucrose on Adipose Tissue and Liver Inflammation in Mice. <i>Molecules</i> , 2020, 25, 4369.	1.7	4
1404	GPR91 antagonist and TGF- β inhibitor suppressed collagen production of high glucose and succinate induced HSC activation. <i>Biochemical and Biophysical Research Communications</i> , 2020, 530, 362-366.	1.0	14
1405	Non-alcoholic fatty liver disease to metabolic dysfunction-associated fatty liver disease : Conceptual changes for clinicians, researchers and patients. <i>Journal of Digestive Diseases</i> , 2020, 21, 604-609.	0.7	5
1406	Accuracy of Noninvasive Fibrosis Scores to Detect Advanced Fibrosis in Patients With Type-2 Diabetes With Biopsy-proven Nonalcoholic Fatty Liver Disease. <i>Journal of Clinical Gastroenterology</i> , 2020, 54, 891-897.	1.1	25
1407	Lifestyle and Environmental Approaches for the Primary Prevention of Hepatocellular Carcinoma. <i>Clinics in Liver Disease</i> , 2020, 24, 549-576.	1.0	9
1408	Liraglutide or insulin glargine treatments improves hepatic fat in obese patients with type 2 diabetes and nonalcoholic fatty liver disease in twenty-six weeks: A randomized placebo-controlled trial. <i>Diabetes Research and Clinical Practice</i> , 2020, 170, 108487.	1.1	48
1409	A hypocaloric high-protein diet supplemented with β -cryptoxanthin improves non-alcoholic fatty liver disease: a randomized controlled trial. <i>BMC Gastroenterology</i> , 2020, 20, 349.	0.8	4
1410	Liver steatosis is a risk factor for hepatotoxicity in inflammatory bowel disease patients treated with azathioprine. <i>European Journal of Gastroenterology and Hepatology</i> , 2020, 32, 1390-1394.	0.8	3
1411	miRNA Dysregulation in the Development of Non-Alcoholic Fatty Liver Disease and the Related Disorders Type 2 Diabetes Mellitus and Cardiovascular Disease. <i>Frontiers in Medicine</i> , 2020, 7, 527059.	1.2	22
1412	High fat diet-triggered non-alcoholic fatty liver disease: A review of proposed mechanisms. <i>Chemico-Biological Interactions</i> , 2020, 330, 109199.	1.7	119
1413	Dual TBK1/IKK μ inhibitor amlexanox mitigates palmitic acid-induced hepatotoxicity and lipoapoptosis in vitro. <i>Toxicology</i> , 2020, 444, 152579.	2.0	21

#	ARTICLE	IF	CITATIONS
1414	Knockout of sulfatase 2 is associated with decreased steatohepatitis and fibrosis in a mouse model of nonalcoholic fatty liver disease. <i>American Journal of Physiology - Renal Physiology</i> , 2020, 319, G333-G344.	1.6	4
1415	High-protein diet more effectively reduces hepatic fat than low-protein diet despite lower autophagy and FGF21 levels. <i>Liver International</i> , 2020, 40, 2982-2997.	1.9	42
1416	Adult obesity complications: challenges and clinical impact. <i>Therapeutic Advances in Endocrinology and Metabolism</i> , 2020, 11, 204201882093495.	1.4	57
1417	Roles of Hepatic Innate and Innate-Like Lymphocytes in Nonalcoholic Steatohepatitis. <i>Frontiers in Immunology</i> , 2020, 11, 1500.	2.2	25
1418	A Gilbert syndrome-associated haplotype protects against fatty liver disease in humanized transgenic mice. <i>Scientific Reports</i> , 2020, 10, 8689.	1.6	8
1419	Magnetic resonance-based biomarkers in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. <i>Endocrinology, Diabetes and Metabolism</i> , 2020, 3, e00134.	1.0	11
1420	Epidemiology of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in Japan: A focused literature review. <i>JGH Open</i> , 2020, 4, 808-817.	0.7	20
1421	Nutraceutical Properties of Polyphenols against Liver Diseases. <i>Nutrients</i> , 2020, 12, 3517.	1.7	26
1422	A nomogram for estimating the probability of nonalcoholic fatty liver disease in a Chinese population. <i>Medicine (United States)</i> , 2020, 99, e23049.	0.4	1
1423	Etiology of Hepatocellular Carcinoma: Special Focus on Fatty Liver Disease. <i>Frontiers in Oncology</i> , 2020, 10, 601710.	1.3	76
1424	Association of arterial stiffness with the histological severity of nonalcoholic fatty liver disease. <i>Hepatology International</i> , 2020, 14, 1048-1056.	1.9	9
1425	Evaluation of NAFLD and fibrosis in obese patients – a comparison of histological and clinical scoring systems. <i>BMC Gastroenterology</i> , 2020, 20, 254.	0.8	25
1426	Stratification of patients in NASH clinical trials: A pitfall for trial success. <i>JHEP Reports</i> , 2020, 2, 100148.	2.6	20
1427	Granulocyte Colony Stimulating Factor Ameliorates Hepatic Steatosis Associated with Improvement of Autophagy in Diabetic Rats. <i>Canadian Journal of Gastroenterology and Hepatology</i> , 2020, 2020, 1-9.	0.8	1
1428	Prevalence of NASH/NAFLD in people with obesity who are currently classified as metabolically healthy. <i>Surgery for Obesity and Related Diseases</i> , 2020, 16, 2050-2057.	1.0	20
1429	Lipophagy Impairment Is Associated With Disease Progression in NAFLD. <i>Frontiers in Physiology</i> , 2020, 11, 850.	1.3	70
1430	Non-invasive assessment of liver fibrosis in alcoholic liver disease. <i>Clinical and Experimental Hepatology</i> , 2020, 6, 125-130.	0.6	6
1431	A novel bile acid analog, A17, ameliorated non-alcoholic steatohepatitis in high-fat diet-fed hamsters. <i>Toxicology and Applied Pharmacology</i> , 2020, 404, 115169.	1.3	1

#	ARTICLE	IF	CITATIONS
1432	Cold Press Pomegranate Seed Oil Attenuates Dietary-Obesity Induced Hepatic Steatosis and Fibrosis through Antioxidant and Mitochondrial Pathways in Obese Mice. <i>International Journal of Molecular Sciences</i> , 2020, 21, 5469.	1.8	30
1433	Collagen-targeted molecular imaging in diffuse liver diseases. <i>Abdominal Radiology</i> , 2020, 45, 3545-3556.	1.0	7
1434	Multidisciplinary Approach for Liver Transplantation in Patients with Nonalcoholic Steatohepatitis: It Takes a Village. <i>Digestive Disease Interventions</i> , 2020, 04, 019-030.	0.3	1
1435	ESPEN practical guideline: Clinical nutrition in liver disease. <i>Clinical Nutrition</i> , 2020, 39, 3533-3562.	2.3	170
1436	Higher cut-off values of non-invasive methods might be needed to detect moderate-to-severe steatosis in morbid obese patients: a pilot study. <i>Scientific Reports</i> , 2020, 10, 15007.	1.6	2
1437	Efficacy and Mechanism of a Chinese Classic Prescription of Yueju in Treating Nonalcoholic Steatohepatitis and Protecting Hepatocytes from Apoptosis. <i>Evidence-based Complementary and Alternative Medicine</i> , 2020, 2020, 1-12.	0.5	3
1438	High prevalence of elevated serum liver enzymes in Chinese children suggests metabolic syndrome as a common risk factor. <i>Journal of Paediatrics and Child Health</i> , 2020, 56, 1590-1596.	0.4	1
1439	Optimizing patients with non-alcoholic fatty liver disease pre-transplant. <i>Canadian Liver Journal</i> , 2020, 3, 237-250.	0.3	1
1440	Non-alcoholic fatty liver disease: the role of the nurse. <i>Gastrointestinal Nursing</i> , 2020, 18, S15-S21.	0.0	1
1441	Development and Validation of a Prognostic Nomogram to Predict the Long-Time Prognosis in Non-B, Non-C Hepatocellular Carcinoma. <i>Cancer Management and Research</i> , 2020, Volume 12, 7771-7781.	0.9	4
1442	Vitamin D and non-alcoholic fatty liver disease: a meta-analysis of randomized controlled trials. <i>Food and Function</i> , 2020, 11, 7389-7399.	2.1	36
1443	<i>Lactobacillus fermentum</i> CQPC06 in naturally fermented pickles prevents non-alcoholic fatty liver disease by stabilizing the gut-liver axis in mice. <i>Food and Function</i> , 2020, 11, 8707-8723.	2.1	26
1444	LPCN 1144 Resolves NAFLD in Hypogonadal Males. <i>Hepatology Communications</i> , 2020, 4, 1430-1440.	2.0	8
1445	Liver Steatosis, Gut-Liver Axis, Microbiome and Environmental Factors. A Never-Ending Bidirectional Cross-Talk. <i>Journal of Clinical Medicine</i> , 2020, 9, 2648.	1.0	93
1446	Ultrasound Assessment of Hepatic Steatosis by Using the Double Nakagami Distribution: A Feasibility Study. <i>Diagnostics</i> , 2020, 10, 557.	1.3	15
1447	Usefulness of Different Imaging Modalities in Evaluation of Patients with Non-Alcoholic Fatty Liver Disease. <i>Biomedicines</i> , 2020, 8, 298.	1.4	12
1448	ALT Trends through Childhood and Adolescence Associated with Hepatic Steatosis at 24 Years: A Population-Based UK Cohort Study. <i>Children</i> , 2020, 7, 117.	0.6	4
1449	Validating candidate biomarkers for different stages of non-alcoholic fatty liver disease. <i>Medicine (United States)</i> , 2020, 99, e21463.	0.4	3

#	ARTICLE	IF	CITATIONS
1450	New Insights into the Pathogenesis of Non-Alcoholic Fatty Liver Disease: Gut-Derived Lipopolysaccharides and Oxidative Stress. <i>Nutrients</i> , 2020, 12, 2762.	1.7	89
1451	Oxidative Stress and Pro-Inflammatory Status in Patients with Non-Alcoholic Fatty Liver Disease. <i>Antioxidants</i> , 2020, 9, 759.	2.2	44
1452	Trends in the Prevalence of Non-Alcoholic Fatty Liver Disease and Its Future Predictions in Korean Men, 1998–2035. <i>Journal of Clinical Medicine</i> , 2020, 9, 2626.	1.0	15
1453	Effects of Resveratrol Supplementation in Patients with Non-Alcoholic Fatty Liver Disease—A Meta-Analysis. <i>Nutrients</i> , 2020, 12, 2435.	1.7	31
1454	Liraglutide Alleviates Hepatic Steatosis by Activating the TFEB-Regulated Autophagy-Lysosomal Pathway. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 602574.	1.8	51
1455	Effects of Caffeine and Chlorogenic Acid on Nonalcoholic Steatohepatitis in Mice Induced by Choline-Deficient, L-Amino Acid-Defined, High-Fat Diet. <i>Nutrients</i> , 2020, 12, 3886.	1.7	15
1456	Dietary Alaska pollock protein attenuates liver steatosis and alters gut microbiota in leptin-deficient ob/ob mice. <i>Journal of Functional Foods</i> , 2020, 75, 104266.	1.6	6
1457	Triantennary GalNAc Molecular Imaging Probes for Monitoring Hepatocyte Function in a Rat Model of Nonalcoholic Steatohepatitis. <i>Advanced Science</i> , 2020, 7, 2002997.	5.6	10
1458	Clinical and Biochemical Predictors of Nonalcoholic Fatty Liver Disease among Type 2 Diabetes Mellitus Patients at Primary Health Care Level in South Western Saudi Arabia. <i>Diagnostics</i> , 2020, 10, 809.	1.3	3
1459	Effect of Adult Weight Gain on Non-Alcoholic Fatty Liver Disease and Its Association with Anthropometric Parameters in the Lean Japanese Population. <i>Diagnostics</i> , 2020, 10, 863.	1.3	1
1461	The effect of adiponectin in the pathogenesis of non-alcoholic fatty liver disease (NAFLD) and the potential role of polyphenols in the modulation of adiponectin signaling. <i>Biomedicine and Pharmacotherapy</i> , 2020, 131, 110785.	2.5	80
1462	Low-Density Lipoprotein (LDL)-Triglyceride and Its Ratio to LDL-Cholesterol as Diagnostic Biomarkers for Nonalcoholic Steatohepatitis. <i>Journal of applied laboratory medicine</i> , The, 2020, 5, 1206-1215.	0.6	4
1463	Advanced MRI of Liver Fibrosis and Treatment Response in a Rat Model of Nonalcoholic Steatohepatitis. <i>Radiology</i> , 2020, 296, 67-75.	3.6	22
1464	Editorial: how widespread and serious is non-alcoholic fatty liver disease in the real world?. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 1199-1200.	1.9	4
1465	Vitamin D supplementation for nonalcoholic fatty liver disease in type 2 diabetes mellitus. <i>Medicine (United States)</i> , 2020, 99, e20148.	0.4	7
1466	Review article: the emerging role of genetics in precision medicine for patients with non-alcoholic steatohepatitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 1305-1320.	1.9	103
1467	A Role for Gut Microbiome Fermentative Pathways in Fatty Liver Disease Progression. <i>Journal of Clinical Medicine</i> , 2020, 9, 1369.	1.0	22
1468	Pathophysiological Changes During Ischemia-reperfusion Injury in Rodent Hepatic Steatosis. <i>In Vivo</i> , 2020, 34, 953-964.	0.6	14

#	ARTICLE	IF	CITATIONS
1469	Arachidonate 12S-lipoxygenase of platelet-type in hepatic stellate cells of methionine and choline-deficient diet-fed mice. <i>Journal of Biochemistry</i> , 2020, 168, 455-463.	0.9	4
1470	The Hepatoprotective Effect of Taurisolo, a Nutraceutical Enriched in Resveratrol and Polyphenols, Involves Activation of Mitochondrial Metabolism in Mice Liver. <i>Antioxidants</i> , 2020, 9, 410.	2.2	20
1471	Quantification of liver fat content with ultrasonographic attenuation measurement function: Correlation with unenhanced multidimensional computerized tomography. <i>Clinical Imaging</i> , 2020, 65, 85-93.	0.8	21
1472	Long noncoding RNA CCAT1 inhibits miR-613 to promote nonalcoholic fatty liver disease via increasing LXR α transcription. <i>Journal of Cellular Physiology</i> , 2020, 235, 9819-9833.	2.0	13
1473	Faut-il nourrir les sujets obèses en réanimation?. <i>Praticien En Anesthesie Reanimation</i> , 2020, 24, 48-52.	0.0	1
1474	The roles and interaction of FXR and PPARs in the pathogenesis of nonalcoholic fatty liver disease. <i>Arab Journal of Gastroenterology</i> , 2020, 21, 162-168.	0.4	6
1475	Combined alcoholic and non-alcoholic steatohepatitis. <i>JHEP Reports</i> , 2020, 2, 100101.	2.6	42
1476	Similar prevalence of hepatic steatosis among patients with chronic hepatitis C with and without HIV coinfection. <i>Scientific Reports</i> , 2020, 10, 6736.	1.6	4
1477	FDG PET/CT of the non-malignant liver in an increasingly obese world population. <i>Clinical Physiology and Functional Imaging</i> , 2020, 40, 304-319.	0.5	17
1478	Lipoprotein A, combined with alanine aminotransferase and aspartate aminotransferase, contributes to predicting the occurrence of NASH: a cross-sectional study. <i>Lipids in Health and Disease</i> , 2020, 19, 134.	1.2	10
1480	Surveillance for Hepatocellular Carcinoma in Patients with Non-Alcoholic Fatty Liver Disease: Universal or Selective?. <i>Cancers</i> , 2020, 12, 1422.	1.7	41
1481	N-Acetylcysteine Reduced Ischemia and Reperfusion Damage Associated with Steatohepatitis in Mice. <i>International Journal of Molecular Sciences</i> , 2020, 21, 4106.	1.8	9
1482	PPAR β gene Pro12Ala variants reduce the risk of obese individuals to non-alcoholic fatty liver: A study in Uyghur Chinese population residing in Northwestern China. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2020, 44, 894-904.	0.7	2
1483	Serum Ferritin Correlates With Liver Fat in Male Adolescents With Obesity. <i>Frontiers in Endocrinology</i> , 2020, 11, 340.	1.5	22
1484	Bacterial antigen translocation and age as BMI-independent contributing factors on systemic inflammation in NAFLD patients. <i>Liver International</i> , 2020, 40, 2182-2193.	1.9	14
1485	Hepatic consequences of COVID-19 infection. Lapping or biting?. <i>European Journal of Internal Medicine</i> , 2020, 77, 18-24.	1.0	86
1486	NAFLD Aggravates Septic Shock Due to Inadequate Adrenal Response and 11 β -HSDs Dysregulation in Rats. <i>Pharmaceutics</i> , 2020, 12, 403.	2.0	8
1487	Assessment of risk factors, and racial and ethnic differences in hepatocellular carcinoma. <i>JGH Open</i> , 2020, 4, 351-359.	0.7	25

#	ARTICLE	IF	CITATIONS
1488	Berbamine induced AMPK activation regulates mTOR/SREBP-1c axis and Nrf2/ARE pathway to allay lipid accumulation and oxidative stress in steatotic HepG2 cells. <i>European Journal of Pharmacology</i> , 2020, 882, 173244.	1.7	27
1489	In vivo Ultrafast Quantitative Ultrasound and Shear Wave Elastography Imaging on Farm-Raised Duck Livers during Force Feeding. <i>Ultrasound in Medicine and Biology</i> , 2020, 46, 1715-1726.	0.7	12
1490	Gender differences in liver fibrosis among patients younger than 50 years: A retrospective cohort study. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2020, 44, 733-738.	0.7	5
1491	Hepamine - A Liver Disease Microarray Database, Visualization Platform and Data-Mining Resource. <i>Scientific Reports</i> , 2020, 10, 4760.	1.6	5
1492	Androgen aggravates liver fibrosis by activation of NLRP3 inflammasome in CCl ₄ -induced liver injury mouse model. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2020, 318, E817-E829.	1.8	24
1493	Laboratory Testing in Older Adults: Indications, Benefits, and Harms. , 2020, , 1-21.		0
1495	Ethnic influence on nonalcoholic fatty liver disease prevalence and lack of disease awareness in the United States, 2011-2016. <i>Journal of Internal Medicine</i> , 2020, 287, 711-722.	2.7	50
1496	Gender differences in diet-induced steatotic disease in Cyp2b-null mice. <i>PLoS ONE</i> , 2020, 15, e0229896.	1.1	19
1497	Predictive Factors and Time to Development of Hepatic Decompensation in Patients with Non-alcoholic Fatty Liver Disease. <i>Journal of General Internal Medicine</i> , 2020, 35, 1523-1529.	1.3	5
1498	A common variant in PNPLA3 is associated with age at diagnosis of NAFLD in patients from a multi-ethnic biobank. <i>Journal of Hepatology</i> , 2020, 72, 1070-1081.	1.8	35
1499	Sex-specific metabolic responses to 6 hours of fasting during the active phase in young mice. <i>Journal of Physiology</i> , 2020, 598, 2081-2092.	1.3	15
1500	All-Trans Retinoic Acid (atRA) effectively improves liver steatosis in a rabbit model of high fat induced liver steatosis. <i>Archives of Physiology and Biochemistry</i> , 2022, 128, 1010-1015.	1.0	9
1501	The Inhibition of Aldose Reductase Accelerates Liver Regeneration through Regulating Energy Metabolism. <i>Oxidative Medicine and Cellular Longevity</i> , 2020, 2020, 1-11.	1.9	5
1502	The association between patients' preferred treatment after the use of a patient decision aid and their choice of eventual treatment. <i>Health Expectations</i> , 2020, 23, 651-658.	1.1	6
1503	Obstructive Sleep Apnea and Non-alcoholic Fatty Liver Disease in Obese Patients Undergoing Bariatric Surgery. <i>Obesity Surgery</i> , 2020, 30, 2572-2578.	1.1	14
1504	Prognostic impact of concurrent nonalcoholic fatty liver disease in patients with chronic hepatitis B-related hepatocellular carcinoma. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2020, 35, 1960-1968.	1.4	13
1506	Body Fat Changes and Liver Safety in Obese and Overweight Women Supplemented with Conjugated Linoleic Acid: A 12-Week Randomised, Double-Blind, Placebo-Controlled Trial. <i>Nutrients</i> , 2020, 12, 1811.	1.7	13
1507	Fatty Liver in HIV-Infected Persons. <i>Current Infectious Disease Reports</i> , 2020, 22, 1.	1.3	0

#	ARTICLE	IF	CITATIONS
1508	Approach to prevention of non-alcoholic fatty liver disease after liver transplantation. <i>Translational Gastroenterology and Hepatology</i> , 2020, 5, 51-51.	1.5	7
1509	Association between eating speed and newly diagnosed nonalcoholic fatty liver disease among the general population. <i>Nutrition Research</i> , 2020, 80, 78-88.	1.3	6
1510	Biological Effects of Korean Red Ginseng Polysaccharides in Aged Rat Using Global Proteomic Approach. <i>Molecules</i> , 2020, 25, 3019.	1.7	11
1511	Liver disease in pregnancy. <i>Hepatology Research</i> , 2020, 50, 1015-1023.	1.8	14
1512	Protein Requirements during Hypocaloric Nutrition for the Older Patient With Critical Illness and Obesity: An Approach to Clinical Practice. <i>Nutrition in Clinical Practice</i> , 2020, 35, 617-626.	1.1	7
1513	Long-term profile of serological biomarkers, hepatic inflammation, and fibrosis in a mouse model of non-alcoholic fatty liver disease. <i>Toxicology Letters</i> , 2020, 332, 1-6.	0.4	8
1514	The Emerging Role of Hepatocellular eNOS in Non-alcoholic Fatty Liver Disease Development. <i>Frontiers in Physiology</i> , 2020, 11, 767.	1.3	10
1515	Consumption of nixtamal from a new variety of hybrid blue maize ameliorates liver oxidative stress and inflammation in a high-fat diet rat model. <i>Journal of Functional Foods</i> , 2020, 72, 104075.	1.6	14
1516	Identification of genes in hepatocellular carcinoma induced by non-alcoholic fatty liver disease. <i>Cancer Biomarkers</i> , 2020, 29, 69-78.	0.8	12
1517	Health Care Use and Costs Among Patients With Nonalcoholic Steatohepatitis With Advanced Fibrosis Using the Fibrosisâ€4 Score. <i>Hepatology Communications</i> , 2020, 4, 998-1011.	2.0	7
1518	Systemic redox imbalance in patients with nonalcoholic fatty liver disease. <i>European Journal of Clinical Investigation</i> , 2020, 50, e13211.	1.7	10
1519	Effects of obesity, metabolic syndrome, and non-alcoholic or alcoholic elevated liver enzymes on incidence of diabetes following lifestyle intervention: A subanalysis of the J-DOIT1. <i>Journal of Occupational Health</i> , 2020, 62, e12109.	1.0	4
1520	Nonalcoholic Fatty Liver Disease: Interface Between Primary Care and Hepatology Clinics. <i>Hepatology Communications</i> , 2020, 4, 518-526.	2.0	12
1521	HAV and HBV vaccination rates among biopsyâ€confirmed NAFL patients in a free access medical system: How can we improve?. <i>GastroHep</i> , 2020, 2, 31-38.	0.3	0
1522	Combined effect of <i>n</i> -3 fatty acids and phytosterol esters on alleviating hepatic steatosis in non-alcoholic fatty liver disease subjects: a double-blind placebo-controlled clinical trial. <i>British Journal of Nutrition</i> , 2020, 123, 1148-1158.	1.2	25
1523	Multiparametric MR Index for the Diagnosis of Non-Alcoholic Steatohepatitis in Patients with Non-Alcoholic Fatty Liver Disease. <i>Scientific Reports</i> , 2020, 10, 2671.	1.6	28
1524	Genetic Risk Factors and Disease Modifiers of Nonalcoholic Steatohepatitis. <i>Gastroenterology Clinics of North America</i> , 2020, 49, 25-44.	1.0	21
1525	Epidemiology of non-alcoholic and alcoholic fatty liver diseases. <i>Translational Gastroenterology and Hepatology</i> , 2020, 5, 16-16.	1.5	296

#	ARTICLE	IF	CITATIONS
1526	Nonalcoholic Fatty Liver Disease 2020: The State of the Disease. <i>Gastroenterology</i> , 2020, 158, 1851-1864.	0.6	710
1527	Long-term outcomes of non-alcoholic fatty liver disease and the risk factors for mortality and hepatocellular carcinoma in a Japanese population. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2020, 35, 1579-1589.	1.4	27
1528	Prevalence of steatosis and fibrosis in young adults in the UK: a population-based study. <i>The Lancet Gastroenterology and Hepatology</i> , 2020, 5, 295-305.	3.7	114
1529	Liver Disease in Pregnancy: What's New. <i>Hepatology Communications</i> , 2020, 4, 145-156.	2.0	31
1530	Complement C3 and Nonalcoholic Fatty Liver Disease in Chronic Kidney Disease Patients: A Pilot Study. <i>Kidney and Blood Pressure Research</i> , 2020, 45, 61-69.	0.9	8
1531	Effectiveness of phosphatidylcholine in alleviating steatosis in patients with non-alcoholic fatty liver disease and cardiometabolic comorbidities (MANPOWER study). <i>BMJ Open Gastroenterology</i> , 2020, 7, e000341.	1.1	18
1532	Liver-related long-term outcomes of thiazolidinedione use in persons with type 2 diabetes. <i>Liver International</i> , 2020, 40, 1089-1097.	1.9	14
1533	Epigenetic silencing of microRNA-125b-5p promotes liver fibrosis in nonalcoholic fatty liver disease via integrin α 8-mediated activation of RhoA signaling pathway. <i>Metabolism: Clinical and Experimental</i> , 2020, 104, 154140.	1.5	25
1534	Complications, morbidity and mortality of nonalcoholic fatty liver disease. <i>Metabolism: Clinical and Experimental</i> , 2020, 111, 154170.	1.5	278
1535	Selenium-enriched <i>Bifidobacterium longum</i> protected alcohol and high fat diet induced hepatic injury in mice. <i>Chinese Journal of Natural Medicines</i> , 2020, 18, 169-177.	0.7	16
1536	Volixibat in adults with non-alcoholic steatohepatitis: 24-week interim analysis from a randomized, phase II study. <i>Journal of Hepatology</i> , 2020, 73, 231-240.	1.8	49
1537	High Protein Intake Is Associated With Histological Disease Activity in Patients With NAFLD. <i>Hepatology Communications</i> , 2020, 4, 681-695.	2.0	28
1538	Implications of abnormal liver function in pregnancy and non-alcoholic fatty liver disease. <i>Best Practice and Research in Clinical Obstetrics and Gynaecology</i> , 2020, 68, 2-11.	1.4	9
1539	Increasing liver fat is associated with progression of cardiovascular risk factors. <i>Liver International</i> , 2020, 40, 1339-1343.	1.9	15
1540	Peri-transplant renal dysfunction in patients with non-alcoholic steatohepatitis undergoing liver transplantation. <i>Translational Gastroenterology and Hepatology</i> , 2020, 5, 18-18.	1.5	2
1541	Serum Immunoreactive Collagen IV detected by Monoclonal Antibodies as a Marker of Severe Fibrosis in Patients with Non- Alcoholic Fatty Liver Disease. <i>Journal of Gastrointestinal and Liver Diseases</i> , 2020, 24, 61-68.	0.5	9
1542	Epidemiology of Hepatocellular Carcinoma. <i>Hepatology</i> , 2021, 73, 4-13.	3.6	1,007
1543	Evaluation of the histological variability of core and wedge biopsies in nonalcoholic fatty liver disease in bariatric surgical patients. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2021, 35, 1210-1218.	1.3	19

#	ARTICLE	IF	CITATIONS
1544	Associations Between Nonalcoholic Fatty Liver Disease and Cancers in a Large Cohort in China. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 788-796.e4.	2.4	38
1545	Clinical profile of non-alcoholic fatty liver disease in nonobese patients. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 257-261.	1.4	7
1546	The efficacy of flaxseed and hesperidin on non-alcoholic fatty liver disease: an open-labeled randomized controlled trial. <i>European Journal of Clinical Nutrition</i> , 2021, 75, 99-111.	1.3	35
1547	Dietary cholesterol drives fatty liver-associated liver cancer by modulating gut microbiota and metabolites. <i>Gut</i> , 2021, 70, 761-774.	6.1	382
1548	Inflammatory Diseases and Vitamin E—What Do We Know and Where Do We Go?. <i>Molecular Nutrition and Food Research</i> , 2021, 65, e2000097.	1.5	27
1549	<sc>NAFLD</sc> in type 2 diabetes mellitus: Still many challenging questions. <i>Diabetes/Metabolism Research and Reviews</i> , 2021, 37, e3386.	1.7	18
1550	Usefulness of collagen type IV in the detection of significant liver fibrosis in nonalcoholic fatty liver disease. <i>Annals of Hepatology</i> , 2021, 20, 100253.	0.6	21
1551	Mortality in biopsy-confirmed nonalcoholic fatty liver disease: results from a nationwide cohort. <i>Gut</i> , 2021, 70, 1375-1382.	6.1	307
1552	Improvement in insulin resistance and estimated hepatic steatosis and fibrosis after endoscopic sleeve gastroplasty. <i>Gastrointestinal Endoscopy</i> , 2021, 93, 1110-1118.	0.5	45
1553	Non-alcoholic fatty liver disease in a sample of individuals with bipolar disorders: results from the FACE-BD cohort. <i>Acta Psychiatrica Scandinavica</i> , 2021, 143, 82-91.	2.2	11
1554	The Impact of Nonalcoholic Fatty Liver Disease in Primary Care: A Population Health Perspective. <i>American Journal of Medicine</i> , 2021, 134, 23-29.	0.6	14
1555	Obesity Management of Liver Transplant Waitlist Candidates and Recipients. <i>Clinics in Liver Disease</i> , 2021, 25, 1-18.	1.0	11
1556	Role of histone deacetylase on nonalcoholic fatty liver disease. <i>Expert Review of Gastroenterology and Hepatology</i> , 2021, 15, 353-361.	1.4	5
1557	Sexual dimorphism in cardiometabolic health: the role of adipose tissue, muscle and liver. <i>Nature Reviews Endocrinology</i> , 2021, 17, 47-66.	4.3	155
1558	Translational insight into prothrombotic state and hypercoagulation in nonalcoholic fatty liver disease. <i>Thrombosis Research</i> , 2021, 198, 139-150.	0.8	27
1559	Epidemiology, Pathogenesis, Diagnosis and Emerging Treatment of Nonalcoholic Fatty Liver Disease. <i>Archives of Medical Research</i> , 2021, 52, 25-37.	1.5	112
1560	Validation of fatty liver disease scoring systems for ultrasound diagnosed non-alcoholic fatty liver disease in adolescents. <i>Digestive and Liver Disease</i> , 2021, 53, 746-752.	0.4	5
1561	Development and course of diabetes according to genetic factors and diabetes treatment among patients with nonalcoholic fatty liver disease. <i>Nutrition</i> , 2021, 83, 111080.	1.1	5

#	ARTICLE	IF	CITATIONS
1562	Adherence to Ideal Cardiovascular Health Metrics Is Associated With Reduced Odds of Hepatic Steatosis. <i>Hepatology Communications</i> , 2021, 5, 74-82.	2.0	7
1563	The Natural History of NAFLD, a Community-Based Study at a Large Health Care Delivery System in the United States. <i>Hepatology Communications</i> , 2021, 5, 83-96.	2.0	15
1564	A portable single-sided magnetic-resonance sensor for the grading of liver steatosis and fibrosis. <i>Nature Biomedical Engineering</i> , 2021, 5, 240-251.	11.6	21
1565	The Liver in COVID-19-Related Death: Protagonist or Innocent Bystander?. <i>Pathobiology</i> , 2021, 88, 88-94.	1.9	28
1566	Co-Medication and Nutrition in Hepatocellular Carcinoma: Potentially Preventative Strategies in Hepatocellular Carcinoma. <i>Digestive Diseases</i> , 2021, 39, 526-533.	0.8	9
1567	Mitochondrial dysfunction in nonalcoholic fatty liver disease and alcohol related liver disease. <i>Translational Gastroenterology and Hepatology</i> , 2021, 6, 4-4.	1.5	45
1568	Improvement of the hepatic lipid status in intrauterine growth retarded pigs by resveratrol is related to the inhibition of mitochondrial dysfunction, oxidative stress and inflammation. <i>Food and Function</i> , 2021, 12, 278-290.	2.1	15
1569	Effectiveness of dietary interventions on cardio-metabolic risk factors in patients with nonalcoholic fatty liver disease: a systematic review and meta-analysis of randomized controlled trials. <i>Annals of Gastroenterology</i> , 2021, 34, 415-423.	0.4	0
1570	Narrative review of current and emerging pharmacological therapies for nonalcoholic steatohepatitis. <i>Translational Gastroenterology and Hepatology</i> , 2021, 6, 60-60.	1.5	7
1571	Esophageal, gastric, colorectal, pancreatic, hepatocellular carcinomas and cholangiocarcinomas in Northern Macedonia: A series of patients treated at the University Clinic, between 2015 and 2019. <i>Srpski Medicinski Åasopis Lekarske Komore</i> , 2021, 2, 33-42.	0.1	0
1572	Ultrasound and Clinicopathological Study of Steatohepatic Hepatocellular Carcinoma. <i>Choonpa Igaku</i> , 2021, 48, 45-55.	0.0	0
1573	Reduction of fatty liver in rats by nicotinamide via the regeneration of the methionine cycle and the inhibition of aldehyde oxidase. <i>Journal of Toxicological Sciences</i> , 2021, 46, 31-42.	0.7	5
1574	Impact of Obesity in Non-Alcoholic Fatty Liver Disease. <i>Journal of Biomedical Science and Engineering</i> , 2021, 14, 21-32.	0.2	1
1575	A nutritional intervention that promotes increased vegetable intake in Japanese with non-alcoholic fatty liver disease: a six-month trial. <i>Journal of Clinical Biochemistry and Nutrition</i> , 2022, 70, 46-53.	0.6	2
1576	Quantitative Ultrasound Radiofrequency Data Analysis for the Assessment of Hepatic Steatosis in Nonalcoholic Fatty Liver Disease Using Magnetic Resonance Imaging Proton Density Fat Fraction as the Reference Standard. <i>Korean Journal of Radiology</i> , 2021, 22, 1077.	1.5	32
1577	Bioactive lipids in metabolic liver disease. <i>Studies in Natural Products Chemistry</i> , 2021, , 263-297.	0.8	1
1578	The association between obstructive sleep apnea and non-alcoholic steatohepatitis: a retrospective nationwide inpatient sample analysis. <i>Clinical and Experimental Hepatology</i> , 2021, 7, 25-29.	0.6	3
1579	<i>H. pylori</i> is related to NAFLD but only in female: A Cross-sectional Study. <i>International Journal of Medical Sciences</i> , 2021, 18, 2303-2311.	1.1	11

#	ARTICLE	IF	CITATIONS
1580	Prediction of Nonalcoholic Fatty Liver Disease Using Noninvasive and Non-Imaging Procedures in Japanese Health Checkup Examinees. <i>Diagnostics</i> , 2021, 11, 132.	1.3	18
1581	Early kidney dysfunction in non-alcoholic fatty liver disease - is transient elastography useful as a screening method?. <i>Digestive Diseases</i> , 2021, 39, 653-662.	0.8	1
1582	Noninvasive diagnosis of fibrosis in non-alcoholic fatty liver disease: diagnostic accuracy of different scores. <i>Minerva Gastroenterologica E Dietologica</i> , 2021, 66, 301-306.	2.2	11
1583	HbA1C as a Biomarker of Non-alcoholic Fatty Liver Disease: Comparison with Anthropometric Parameters. <i>Journal of Clinical and Translational Hepatology</i> , 2021, 000, 1-7.	0.7	5
1584	Liver Function Tests: Biochemical Overview for Clinical Correlation. <i>Indian Journal of Medical Biochemistry</i> , 2021, 25, 31-37.	0.1	1
1585	Efficacy and Safety of Intra-gastric Balloon (IGB) in Non-alcoholic Fatty Liver Disease (NAFLD): a Comprehensive Review and Meta-analysis. <i>Obesity Surgery</i> , 2021, 31, 1271-1279.	1.1	26
1586	Tumeric Ethanol Extract Up-regulated the Lipolysis by Activation of Lipase Related Pathway in HepG2 Cells. <i>Food Supplements and Biomaterials for Health</i> , 2021, 1, .	0.3	0
1587	Gastroenterologische und hepatologische Erkrankungen verhindern. , 2021, , 461-465.		0
1588	Serum Bile Acid, Vitamin E, and Serotonin Metabolites Are Associated With Future Liver-Related Events in Nonalcoholic Fatty Liver Disease. <i>Hepatology Communications</i> , 2021, 5, 608-617.	2.0	15
1589	Dynamic Shifts in the Composition of Resident and Recruited Macrophages Influence Tissue Remodeling in NASH. <i>Cell Reports</i> , 2021, 34, 108626.	2.9	164
1590	Extraintestinal manifestations of inflammatory bowel disease, nitrooxidative stress and dysbiosis: What is the link between them?. <i>Biocell</i> , 2021, 45, 461-481.	0.4	5
1591	Comparison of Fibroscan with Liver biopsy in non-alcoholic fatty liver disease (NAFLD) patients for assessing fibrosis. <i>Nigerian Journal of Gastroenterology and Hepatology</i> , 2021, 13, 12.	0.2	0
1592	Liver Enzymes Correlate With Metabolic Syndrome, Inflammation, and Endothelial Dysfunction in Prepubertal Children With Obesity. <i>Frontiers in Pediatrics</i> , 2021, 9, 629346.	0.9	15
1593	Epigallocatechin-3-Gallate Dampens Non-Alcoholic Fatty Liver by Modulating Liver Function, Lipid Profile and Macrophage Polarization. <i>Nutrients</i> , 2021, 13, 599.	1.7	26
1594	Tobacco Smoke and CYP1A2 Activity in a US Population with Normal Liver Enzyme Levels. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 2225.	1.2	10
1595	Non-alcoholic fatty liver disease and heart failure with preserved ejection fraction: from pathophysiology to practical issues. <i>ESC Heart Failure</i> , 2021, 8, 789-798.	1.4	23
1596	Temperature-corrected proton density fat fraction estimation using chemical shift-encoded MRI in phantoms. <i>Magnetic Resonance in Medicine</i> , 2021, 86, 69-81.	1.9	11
1597	Prevalence of advanced liver fibrosis and steatosis in type-2 diabetics with normal transaminases: A prospective cohort study. <i>World Journal of Gastroenterology</i> , 2021, 27, 523-533.	1.4	7

#	ARTICLE	IF	CITATIONS
1598	Valoración bioquímica en la enfermedad hepática grasa asociada a la disfunción metabólica. <i>Advances in Laboratory Medicine / Avances En Medicina De Laboratorio</i> , 2021, 2, 209-219.	0.1	1
1599	coreNASH: Multi-stakeholder Consensus on Core Outcomes for Decision Making About Nonalcoholic Steatohepatitis Treatment. <i>Hepatology Communications</i> , 2021, 5, 774-785.	2.0	3
1600	Implications of Abdominal Adipose Tissue Distribution on Nonalcoholic Fatty Liver Disease and Metabolic Syndrome: A Chinese General Population Study. <i>Clinical and Translational Gastroenterology</i> , 2021, 12, e00300.	1.3	9
1601	Implication between Genetic Variants from APOA5 and ZPR1 and NAFLD Severity in Patients with Hypertriglyceridemia. <i>Nutrients</i> , 2021, 13, 552.	1.7	7
1602	Relationship between Muscle Mass and Non-Alcoholic Fatty Liver Disease. <i>Biology</i> , 2021, 10, 122.	1.3	9
1603	DYSLIPIDEMIA IN NON ALCOHOLIC FATTY LIVER DISEASE. , 2021, , 24-25.		0
1604	Serum matrix metalloproteinase 7 (MMP7) is a biomarker of fibrosis in patients with non-alcoholic fatty liver disease. <i>Scientific Reports</i> , 2021, 11, 2858.	1.6	16
1605	Increased Frequency of Dysfunctional Siglec-7 ⁺ CD57+PD-1 ⁺ Natural Killer Cells in Patients With Non-alcoholic Fatty Liver Disease. <i>Frontiers in Immunology</i> , 2021, 12, 603133.	2.2	13
1606	CD36 as a Molecular Target of Functional DNA Aptamer NAFLD01 Selected against NAFLD Cells. <i>Analytical Chemistry</i> , 2021, 93, 3951-3958.	3.2	10
1607	Imidazolylalkyl derivatives as new preclinical drug candidates for treating non-alcoholic steatohepatitis. <i>Physiological Reports</i> , 2021, 9, e14795.	0.7	1
1608	Recent Epidemiology of Nonalcoholic Fatty Liver Disease. <i>Gut and Liver</i> , 2021, 15, 206-216.	1.4	54
1609	The European Society for Clinical Nutrition and Metabolism practical guideline: Clinical nutrition in liver disease. <i>Modern Gastroenterology</i> , 2021, , .	0.1	0
1610	A Positive Relationship between Betel Nut Chewing and Significant Liver Fibrosis in NAFLD Subjects, but Not in Non-NAFLD Ones. <i>Nutrients</i> , 2021, 13, 914.	1.7	6
1611	Impact of hepatic steatosis on outcomes after left ventricular assist device implantation. <i>Journal of Cardiac Surgery</i> , 2021, 36, 2277-2283.	0.3	0
1612	Hepatic lymphocytes involved in the pathogenesis of pediatric and adult non-alcoholic fatty liver disease. <i>Scientific Reports</i> , 2021, 11, 5129.	1.6	17
1613	Gut Microbiota and Non-Alcoholic Fatty Liver Disease Severity in Type 2 Diabetes Patients. <i>Journal of Personalized Medicine</i> , 2021, 11, 238.	1.1	15
1614	Ketogenic Diet Enhances the Cholesterol Accumulation in Liver and Augments the Severity of CCl4 and TAA-Induced Liver Fibrosis in Mice. <i>International Journal of Molecular Sciences</i> , 2021, 22, 2934.	1.8	14
1615	Qinghua Fang inhibits high-fat diet-induced non-alcoholic fatty liver disease by modulating gut microbiota. <i>Annals of Palliative Medicine</i> , 2021, 10, 3219-3234.	0.5	4

#	ARTICLE	IF	CITATIONS
1616	Visceral Adipose Tissue and Non-alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes. <i>Digestive Diseases and Sciences</i> , 2022, 67, 1389-1398.	1.1	17
1617	The interplay between non-alcoholic fatty liver disease and innate immunity in hepatitis B virus patients. <i>Egyptian Liver Journal</i> , 2021, 11, .	0.3	1
1618	Biochemical assessment of metabolic associated fatty liver disease. <i>Advances in Laboratory Medicine / Avances En Medicina De Laboratorio</i> , 2021, 2, 199-208.	0.1	3
1619	Non-Alcoholic Fatty Liver Disease Is an Independent Risk Factor for LDL Cholesterol Target Level. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 3442.	1.2	5
1620	Red Meat Consumption and Risk of Nonalcoholic Fatty Liver Disease in a Population With Low Meat Consumption: The Golestan Cohort Study. <i>American Journal of Gastroenterology</i> , 2021, 116, 1667-1675.	0.2	27
1621	Caspase-Cleaved Keratin 18 Measurements Identified Ongoing Liver Injury after Bariatric Surgery. <i>Journal of Clinical Medicine</i> , 2021, 10, 1233.	1.0	8
1622	Hepatoprotective effect of Qushihuayu formula on non-alcoholic steatohepatitis induced by MCD diet in rat. <i>Chinese Medicine</i> , 2021, 16, 27.	1.6	9
1623	Functional Foods for the Management of Non-Alcoholic Fatty Liver Disease. , 0, , .		2
1624	Non-alcoholic fatty liver disease and cognitive function in middle-aged adults: the CARDIA study. <i>BMC Gastroenterology</i> , 2021, 21, 96.	0.8	26
1625	Correlation of Serum Transaminase Levels with Liver Fibrosis Assessed by Transient Elastography in Vietnamese Patients with Nonalcoholic Fatty Liver Disease. <i>International Journal of General Medicine</i> , 2021, Volume 14, 1349-1355.	0.8	10
1626	GCSF deficiency attenuates nonalcoholic fatty liver disease through regulating GCSFR-SOCS3-JAK-STAT3 pathway and immune cells infiltration. <i>American Journal of Physiology - Renal Physiology</i> , 2021, 320, G531-G542.	1.6	14
1627	A randomised placebo controlled trial of VSL#3® probiotic on biomarkers of cardiovascular risk and liver injury in non-alcoholic fatty liver disease. <i>BMC Gastroenterology</i> , 2021, 21, 144.	0.8	35
1628	A dietary ketone ester mitigates histological outcomes of NAFLD and markers of fibrosis in high-fat diet fed mice. <i>American Journal of Physiology - Renal Physiology</i> , 2021, 320, G564-G572.	1.6	10
1629	Excess Body Weight and Metabolic (Dysfunction)-Associated Fatty Liver Disease (MAFLD). <i>Visceral Medicine</i> , 2021, 37, 273-280.	0.5	21
1630	Associations between Free Sugar and Sugary Beverage Intake in Early Childhood and Adult NAFLD in a Population-Based UK Cohort. <i>Children</i> , 2021, 8, 290.	0.6	4
1631	Assessment of the association between body composition and risk of non-alcoholic fatty liver. <i>PLoS ONE</i> , 2021, 16, e0249223.	1.1	12
1632	Non-alcoholic fatty liver diseases: current challenges and future directions. <i>Annals of Translational Medicine</i> , 2021, 9, 726-726.	0.7	16
1633	Prevalence of comorbidity in chronic HCV infection. <i>Medical Alphabet</i> , 2021, , 66-70.	0.0	2

#	ARTICLE	IF	CITATIONS
1634	Expert Opinion on the Management of Non-Alcoholic Fatty Liver Disease (NAFLD) in the Middle East with a Focus on the Use of Silymarin. <i>Gastroenterology Insights</i> , 2021, 12, 155-165.	0.7	12
1635	Nonalcohol fatty liver disease: balancing supply and utilization of triglycerides. <i>Current Opinion in Lipidology</i> , 2021, 32, 200-206.	1.2	10
1636	Non-alcoholic steatohepatitis caused by oral bacteria. <i>Pediatric Dental Journal</i> , 2021, 31, 11-16.	0.3	1
1637	Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD)â€”A Condition Associated with Heightened Sympathetic Activation. <i>International Journal of Molecular Sciences</i> , 2021, 22, 4241.	1.8	21
1638	Nonalcoholic Fatty Liver Disease: Focus on New Biomarkers and Lifestyle Interventions. <i>International Journal of Molecular Sciences</i> , 2021, 22, 3899.	1.8	20
1639	Discovery, optimization, and evaluation of non-bile acid FXR/TGR5 dual agonists. <i>Scientific Reports</i> , 2021, 11, 9196.	1.6	9
1640	Exenatide Attenuates Non-Alcoholic Steatohepatitis by Inhibiting the Pyroptosis Signaling Pathway. <i>Frontiers in Endocrinology</i> , 2021, 12, 663039.	1.5	7
1641	Diagnostic Accuracy of Non-Imaging and Ultrasound-Based Assessment of Hepatic Steatosis Using Controlled Attenuation Parameter (CAP) as Reference. <i>Journal of Clinical Medicine</i> , 2021, 10, 1507.	1.0	9
1643	Metabolic analysis of early nonalcoholic fatty liver disease in humans using liquid chromatography-mass spectrometry. <i>Journal of Translational Medicine</i> , 2021, 19, 152.	1.8	25
1644	PREVALENCE OF NAFLD AMONG HEALTHY LIVER DONORS. , 2021, , 46-48.		0
1645	Non-alcoholic fatty liver disease: An overview of risk factors, pathophysiological mechanisms, diagnostic procedures, and therapeutic interventions. <i>Life Sciences</i> , 2021, 271, 119220.	2.0	38
1646	2D Gadolinium Oxide Nanoplates as T_1 Magnetic Resonance Imaging Contrast Agents. <i>Advanced Healthcare Materials</i> , 2021, 10, e2001780.	3.9	17
1647	New insights into BMP9 signaling in liver diseases. <i>Molecular and Cellular Biochemistry</i> , 2021, 476, 3591-3600.	1.4	5
1648	Hepatocytes derived increased SAA1 promotes intrahepatic platelet aggregation and aggravates liver inflammation in NAFLD. <i>Biochemical and Biophysical Research Communications</i> , 2021, 555, 54-60.	1.0	20
1649	Clinical characteristics and longitudinal changes of patients with non-alcoholic fatty liver disease in 2Âdecades: the NAGALA study. <i>BMC Gastroenterology</i> , 2021, 21, 223.	0.8	4
1650	Joint associations of adiposity and alcohol consumption with liver disease-related morbidity and mortality risk: findings from the UK Biobank. <i>European Journal of Clinical Nutrition</i> , 2022, 76, 74-83.	1.3	14
1651	Rational Design, Synthesis and Evaluation of Novel C6 âBicycloalkaneimidazole Containing Imidazo[1,2âb]pyridazines for ASK1 Inhibition. <i>Bulletin of the Korean Chemical Society</i> , 2021, 42, 872.	1.0	1
1652	Impact of a Pilot Structured Mobile Technology Based Lifestyle Intervention for Patients with Nonalcoholic Fatty Liver Disease. <i>Digestive Diseases and Sciences</i> , 2022, 67, 481-491.	1.1	11

#	ARTICLE	IF	CITATIONS
1653	Nonalcoholic Fatty Liver Disease (NAFLD). Mitochondria as Players and Targets of Therapies?. International Journal of Molecular Sciences, 2021, 22, 5375.	1.8	59
1654	Long Working Hours and Risk of Nonalcoholic Fatty Liver Disease: Korea National Health and Nutrition Examination Survey VII. Frontiers in Endocrinology, 2021, 12, 647459.	1.5	13
1655	Viscoelasticity measured by shear wave elastography in a rat model of nonalcoholic fatty liver disease: comparison with dynamic mechanical analysis. BioMedical Engineering OnLine, 2021, 20, 45.	1.3	3
1656	Ä°nflamatuvar baÄ±rsak hastalÄ±nda non-alkolik yaÄ± karaciÄ±er hastalÄ± sÄ±klÄ±. Akademik Gastroenteroloji Dergisi, 0, , .	0.0	0
1657	The European Society for Clinical Nutrition and Metabolism practical guideline: Clinical nutrition in liver disease. Part 2. Modern Gastroenterology, 2021, , .	0.1	3
1658	The therapeutic landscape of hepatocellular carcinoma. Med, 2021, 2, 505-552.	2.2	20
1659	PECULIARITIES OF THE CLINICAL COURSE OF NON-ALCOHOLIC STEATOHEPATITIS AND STEATOSIS OF THE LIVER AT COMORBID WITH CHRONIC KIDNEY DISEASE I-III STAGE. Clinical & Experimental Pathology, 2021, 20, .	0.0	0
1660	Validity of routine biochemical and ultrasound scores for prediction of hepatic fibrosis and steatosis in NAFLD. Egyptian Liver Journal, 2021, 11, .	0.3	3
1661	3D human liver spheroids for translational pharmacology and toxicology. Basic and Clinical Pharmacology and Toxicology, 2022, 130, 5-15.	1.2	25
1662	Multiplying effects of COVIDâ€19 lockdown on metabolic risk and fatty liver. European Journal of Clinical Investigation, 2021, 51, e13597.	1.7	27
1663	Ultrasound Findings and Laboratory Predictors of Early Mortality in Patients With Severe Yellow Fever. American Journal of Roentgenology, 2021, 216, 1392-1399.	1.0	1
1664	Fatal complications after an interrupted gastric bypass operation in a patient with non-alcoholic fatty liver disease and massive obesity: a case report. Journal of Surgical Case Reports, 2021, 2021, rjab247.	0.2	0
1665	Plasma and stool metabolomics to identify microbiota derived-biomarkers of metabolic dysfunction-associated fatty liver disease: effect of PNPLA3 genotype. Metabolomics, 2021, 17, 58.	1.4	10
1666	New drugs for NASH. Liver International, 2021, 41, 112-118.	1.9	34
1667	Non-alcoholic Fatty Liver and Vitamin D Levels in Extremely Obese Individuals: A Caseâ€Control Study. Open Access Macedonian Journal of Medical Sciences, 2020, 9, 541-546.	0.1	0
1668	Lipid nanoparticle formulations for targeting leukocytes with therapeutic RNA in liver fibrosis. Advanced Drug Delivery Reviews, 2021, 173, 70-88.	6.6	6
1669	The Changing Prevalence of Non-Alcoholic Fatty Liver Disease (NAFLD) in Turkey in the Last Decade. Turkish Journal of Gastroenterology, 2021, 32, 302-312.	0.4	9
1670	Serum selenium and non-alcoholic fatty liver disease (NAFLD) in U.S. adults: National Health and Nutrition Examination Survey (NHANES) 2011â€2016. Environmental Research, 2021, 197, 111190.	3.7	48

#	ARTICLE	IF	CITATIONS
1671	A nationwide population-based prospective study of cirrhosis in Iceland. <i>JHEP Reports</i> , 2021, 3, 100282.	2.6	1
1672	Role of Leptin in Non-Alcoholic Fatty Liver Disease. <i>Biomedicines</i> , 2021, 9, 762.	1.4	41
1673	Is there scope to improve the selection of patients with alcohol-related liver disease for referral to secondary care? A retrospective analysis of primary care referrals to a UK liver centre, incorporating simple blood tests. <i>BMJ Open</i> , 2021, 11, e047786.	0.8	7
1674	Telemonitoring-Supported Exercise Training in Employees With Metabolic Syndrome Improves Liver Inflammation and Fibrosis. <i>Clinical and Translational Gastroenterology</i> , 2021, 12, e00371.	1.3	6
1675	High liver stiffness values by transient elastography related to metabolic syndrome and harmful alcohol use in a large Spanish cohort. <i>United European Gastroenterology Journal</i> , 2021, 9, 892-902.	1.6	12
1676	Low skeletal muscle mass is associated with liver fibrosis in individuals with type 2 diabetes and nonalcoholic fatty liver disease. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 3204-3211.	1.4	8
1677	Chronic hepatitis B infection with concomitant hepatic steatosis: Current evidence and opinion. <i>World Journal of Gastroenterology</i> , 2021, 27, 3971-3983.	1.4	18
1678	Usefulness of FibroScan-AST (FAST) score in Japanese patients with non-alcoholic fatty liver disease: A single-center retrospective experience. <i>Acta Hepatologica Japonica</i> , 2021, 62, 393-402.	0.0	0
1679	Abnormal Metabolism in the Progression of Nonalcoholic Fatty Liver Disease to Hepatocellular Carcinoma: Mechanistic Insights to Chemoprevention. <i>Cancers</i> , 2021, 13, 3473.	1.7	12
1680	Investigating pharmacological mechanisms of andrographolide on non-alcoholic steatohepatitis (NASH): A bioinformatics approach of network pharmacology. <i>Chinese Herbal Medicines</i> , 2021, 13, 342-350.	1.2	9
1681	Associations of maternal diet and nutritional status with offspring hepatic steatosis in the Avon longitudinal study of parents and children. <i>BMC Nutrition</i> , 2021, 7, 28.	0.6	3
1682	Alcohol-associated liver disease in the United States is associated with severe forms of disease among young, females and Hispanics. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 54, 451-461.	1.9	32
1683	Non-alcoholic fatty liver disease in children and young adults is associated with increased long-term mortality. <i>Journal of Hepatology</i> , 2021, 75, 1034-1041.	1.8	57
1684	Liver stiffness quantification in biopsy-proven nonalcoholic fatty liver disease patients using shear wave elastography in comparison with transient elastography. <i>Ultrasonography</i> , 2021, 40, 407-416.	1.0	11
1685	L-citrulline inhibits body weight gain and hepatic fat accumulation by improving lipid metabolism in a rat nonalcoholic fatty liver disease model. <i>Food Science and Nutrition</i> , 2021, 9, 4893-4904.	1.5	8
1686	Duodenal mucosal resurfacing combined with glucagon-like peptide-1 receptor agonism to discontinue insulin in type 2 diabetes: a feasibility study. <i>Gastrointestinal Endoscopy</i> , 2021, 94, 111-120.e3.	0.5	21
1687	Reassessment of the Hispanic Disparity: Hepatic Steatosis Is More Prevalent in Mexican Americans Than Other Hispanics. <i>Hepatology Communications</i> , 2021, 5, 2068-2079.	2.0	12
1688	A comparison of liver fat fraction measurement on MRI at 3T and 1.5T. <i>PLoS ONE</i> , 2021, 16, e0252928.	1.1	2

#	ARTICLE	IF	CITATIONS
1689	Salidroside Activates the AMP-Activated Protein Kinase Pathway to Suppress Nonalcoholic Steatohepatitis in Mice. <i>Hepatology</i> , 2021, 74, 3056-3073.	3.6	35
1690	Reversion to regular diet with alternate day fasting can cure grade-I non-alcoholic fatty liver disease (NAFLD) in high-fructose-intake-associated metabolic syndrome. <i>Egyptian Liver Journal</i> , 2021, 11, .	0.3	4
1691	Crosstalk between beta-adrenergic and insulin signaling mediates mechanistic target of rapamycin hyperactivation in liver of high-fat diet-fed male mice. <i>Physiological Reports</i> , 2021, 9, e14958.	0.7	3
1692	Biophysical characterization and a roadmap towards the NMR solution structure of GOS2, a key enzyme in non-alcoholic fatty liver disease. <i>PLoS ONE</i> , 2021, 16, e0249164.	1.1	2
1693	Gender-specific liver aging and magnetic resonance imaging. <i>Quantitative Imaging in Medicine and Surgery</i> , 2021, 11, 2893-2904.	1.1	8
1694	Mitochondria Matter: Systemic Aspects of Nonalcoholic Fatty Liver Disease (NAFLD) and Diagnostic Assessment of Liver Function by Stable Isotope Dynamic Breath Tests. <i>International Journal of Molecular Sciences</i> , 2021, 22, 7702.	1.8	18
1695	Saroglitazar, a PPAR α/δ Agonist, for Treatment of NAFLD: A Randomized Controlled Double-Blind Phase 2 Trial. <i>Hepatology</i> , 2021, 74, 1809-1824.	3.6	163
1696	Impact of Pemafibrate in Patients with Hypertriglyceridemia and Metabolic Dysfunction-associated Fatty Liver Disease Pathologically Diagnosed with Non-alcoholic Steatohepatitis: A Retrospective, Single-arm Study. <i>Internal Medicine</i> , 2021, 60, 2167-2174.	0.3	15
1697	Metreleptin therapy for nonalcoholic steatohepatitis: Open-label therapy interventions in two different clinical settings. <i>Med</i> , 2021, 2, 814-835.e6.	2.2	12
1698	Hepatic steatosis in patients with schizophrenia: a clinical cross-sectional study. <i>Nordic Journal of Psychiatry</i> , 2021, , 1-6.	0.7	3
1699	Impact of continuous positive airway pressure therapy for nonalcoholic fatty liver disease in patients with obstructive sleep apnea. <i>World Journal of Clinical Cases</i> , 2021, 9, 5112-5125.	0.3	4
1700	Adiponectin involved in portal flow hepatic extraction of ^{13}C -methacetin in obesity and non-alcoholic fatty liver. <i>European Journal of Internal Medicine</i> , 2021, 89, 56-64.	1.0	11
1701	Relationship Between Non-Alcoholic Fatty Liver Disease and Abdominal and Pericardial Adipose Tissue in Middle-Aged and Elderly Subjects. <i>International Journal of General Medicine</i> , 2021, Volume 14, 3439-3444.	0.8	2
1702	Apprising the choice of bariatric surgery in patients with compensated cirrhosis with morbid obesity: results of a national analysis. <i>Updates in Surgery</i> , 2021, 73, 1899-1908.	0.9	3
1703	The Other Side of Malnutrition in Inflammatory Bowel Disease (IBD): Non-Alcoholic Fatty Liver Disease. <i>Nutrients</i> , 2021, 13, 2772.	1.7	11
1704	Prospective evaluation of the prevalence of non-alcoholic fatty liver disease and steatohepatitis in a large middle-aged US cohort. <i>Journal of Hepatology</i> , 2021, 75, 284-291.	1.8	124
1705	Comparison of Body Mass Index and Fat Indices in Predicting the Severity of Nonalcoholic Fatty Liver Disease Among Children Who Are Overweight and Obese. <i>Frontiers in Pediatrics</i> , 2021, 9, 724426.	0.9	3
1706	Negative interaction of fatty liver and hypertension on cardiovascular mortality in non-diabetic men: 34 years of follow-up. <i>Scandinavian Journal of Gastroenterology</i> , 2021, 56, 1096-1102.	0.6	1

#	ARTICLE	IF	CITATIONS
1707	Periodontal diseaseâ€‘related nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: An emerging concept of oralâ€‘liver axis. <i>Periodontology</i> 2000, 2021, 87, 204-240.	6.3	44
1708	Semaglutide for nonalcoholic steatohepatitis: closer to a solution?. <i>Hepatobiliary Surgery and Nutrition</i> , 2021, 10, 541-544.	0.7	4
1709	Prevalence of fatty liver disease and its associated factors among Jordanian patients with type 2 diabetes mellitus: A cross-sectional study. <i>Annals of Medicine and Surgery</i> , 2021, 68, 102677.	0.5	7
1710	Cancer Risk in Patients With Biopsyâ€‘Confirmed Nonalcoholic Fatty Liver Disease: A Populationâ€‘Based Cohort Study. <i>Hepatology</i> , 2021, 74, 2410-2423.	3.6	91
1711	Liver enzymes and fibrosis markers in patients with non-alcoholic fatty liver disease and concomitant chronic viral hepatitis. <i>Canadian Liver Journal</i> , 2021, 4, 317-321.	0.3	1
1712	Review article: nonâ€‘alcoholic fatty liver disease and cardiovascular diseases: associations and treatment considerations. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 54, 1013-1025.	1.9	47
1713	Vitamin D Level and Vitamin D Receptor Genetic Variation Were Involved in the Risk of Non-Alcoholic Fatty Liver Disease: A Case-Control Study. <i>Frontiers in Endocrinology</i> , 2021, 12, 648844.	1.5	7
1714	Systolic Blood Pressure Mediates Body Mass Index and Non-alcoholic Fatty Liver Disease: A Population-Based Study. , 2021, 32, 458-465.		4
1715	LncRNAs as Therapeutic Targets and Potential Biomarkers for Lipid-Related Diseases. <i>Frontiers in Pharmacology</i> , 2021, 12, 729745.	1.6	8
1716	Development and Validation of a Novel Scoring System for Noninvasive Nonalcoholic Steatohepatitis Detection in Bariatric Patients. <i>Obesity Facts</i> , 2021, 14, 490-500.	1.6	6
1717	Determining a healthy reference range and factors potentially influencing PRO-C3 â€‘ A biomarker of liver fibrosis. <i>JHEP Reports</i> , 2021, 3, 100317.	2.6	18
1718	Olive oil-derived nitro-fatty acids: protection of mitochondrial function in non-alcoholic fatty liver disease. <i>Journal of Nutritional Biochemistry</i> , 2021, 94, 108646.	1.9	11
1719	Epidemiology of non-alcoholic fatty liver disease and hepatocellular carcinoma. <i>JHEP Reports</i> , 2021, 3, 100305.	2.6	83
1720	Effect of 48â€‘week pemafibrate on nonâ€‘alcoholic fatty liver disease with hypertriglyceridemia, as evaluated by the <sc>FibroScanâ€‘/sc> aspartate aminotransferase score. <i>JGH Open</i> , 2021, 5, 1183-1189.	0.7	21
1721	Severe steatosis and mild colitis are important for the early occurrence of hepatocellular carcinoma. <i>Biochemical and Biophysical Research Communications</i> , 2021, 566, 36-44.	1.0	6
1722	Comparing the performance of Fibrosis-4 and Non-Alcoholic Fatty Liver Disease Fibrosis Score with transient elastography scores of people with non-alcoholic fatty liver disease. <i>Canadian Liver Journal</i> , 2021, 4, 275-282.	0.3	2
1723	MicroRNA-132 may be associated with blood pressure and liver steatosisâ€‘ preliminary observations in obese individuals. <i>Journal of Human Hypertension</i> , 2022, 36, 911-916.	1.0	8
1724	Awareness, management, and practice patterns of pediatric NAFLD by primary care physicians. <i>Paediatrics and Child Health</i> , 2022, 27, 93-98.	0.3	3

#	ARTICLE	IF	CITATIONS
1725	Effect of Coffee Consumption on Non-Alcoholic Fatty Liver Disease Incidence, Prevalence and Risk of Significant Liver Fibrosis: Systematic Review with Meta-Analysis of Observational Studies. <i>Nutrients</i> , 2021, 13, 3042.	1.7	24
1726	The Impact of NAFLD on Hospitalization Outcomes in Patients With Inflammatory Bowel Diseases: Nationwide Analysis. <i>Inflammatory Bowel Diseases</i> , 2022, 28, 878-887.	0.9	9
1727	Non-alcoholic fatty liver disease: time for changes. <i>Mã-¼narodnij Endokrinologã-¼nij Å½urnal</i> , 2021, 17, 334-345.	0.1	3
1728	Embedding assessment of liver fibrosis into routine diabetic review in primary care. <i>JHEP Reports</i> , 2021, 3, 100293.	2.6	23
1729	Non-alcoholic fatty liver disease: Update on treatment options and translational implications of sleep disruption. <i>Annals of Clinical Gastroenterology and Hepatology</i> , 2021, 5, 032-038.	0.1	1
1730	Current and Emerging Biomarkers and Imaging Modalities for Nonalcoholic Fatty Liver Disease: Clinical and Research Applications. <i>Clinical Therapeutics</i> , 2021, 43, 1505-1522.	1.1	6
1731	Baseline homeostasis model assessment of insulin resistance associated with fibrosis progression in patients with nonalcoholic fatty liver disease without diabetes: A cohort study. <i>PLoS ONE</i> , 2021, 16, e0255535.	1.1	8
1732	Obesity and metabolic abnormalities as risks of alcoholic fatty liver in men: NAGALA study. <i>BMC Gastroenterology</i> , 2021, 21, 321.	0.8	4
1733	Emerging and Established Therapeutic Approaches for Nonalcoholic Fatty Liver Disease. <i>Clinical Therapeutics</i> , 2021, 43, 1476-1504.	1.1	14
1734	Comprehensive Analysis of NAFLD and the Therapeutic Target Identified. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 704704.	1.8	13
1735	Systematic review with meta-analysis: Non-alcoholic fatty liver disease and the association with pregnancy outcomes. <i>Clinical and Molecular Hepatology</i> , 2022, 28, 52-66.	4.5	11
1736	Vitamin D levels are not associated with non-alcoholic fatty liver disease severity in a Brazilian population. <i>International Journal for Vitamin and Nutrition Research</i> , 2021, 91, 411-418.	0.6	2
1737	Retrospective analysis (2009â€“2017) of factors associated with progression and regression of non-alcoholic fatty liver disease (Hepatic steatosis) in patients with type 2 diabetes seen at a tertiary diabetes centre in Southern India. <i>Diabetes and Metabolic Syndrome: Clinical Research and Reviews</i> , 2021, 15, 102261.	1.8	2
1738	The feasibility of T2 mapping in the assessment of hepatic steatosis, inflammation, and fibrosis in patients with non-alcoholic fatty liver disease: a preliminary study. <i>Clinical Radiology</i> , 2021, 76, 709.e13-709.e18.	0.5	7
1740	Early Chronic Kidney Disease (G1-G3a) in Combination with Steatosis as a Predictor of Incident Ischemic Heart Disease: A Longitudinal Study in Non-Diabetic Koreans. <i>Biomedicines</i> , 2021, 9, 1358.	1.4	3
1741	Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis 2020. <i>Journal of Gastroenterology</i> , 2021, 56, 951-963.	2.3	114
1742	Non-alcoholic fatty liver disease and incident major adverse cardiovascular events: results from a nationwide histology cohort. <i>Gut</i> , 2022, 71, 1867-1875.	6.1	105
1743	Nonâ€“alcoholic fatty liver disease and hematologic manifestations (Review). <i>Experimental and Therapeutic Medicine</i> , 2021, 22, 1355.	0.8	4

#	ARTICLE	IF	CITATIONS
1744	Nonalcoholic Fatty Liver Disease in Women and Girls With Polycystic Ovary Syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, 258-272.	1.8	22
1745	Histopathological Features of the Steatohepatic Variant of Hepatocellular Carcinoma and Its Relationship with Fatty Liver Disease. , 0, , .		0
1746	Nonalcoholic steatohepatitis: global impact and clinical consequences. <i>Endocrine Connections</i> , 2021, 10, R240-R247.	0.8	18
1747	Therapeutic Effects of Resveratrol on Nonalcoholic Fatty Liver Disease Through Inflammatory, Oxidative Stress, Metabolic, and Epigenetic Modifications. <i>Methods in Molecular Biology</i> , 2022, 2343, 19-35.	0.4	4
1748	Mangosteen Can Improve Steatohepatitis through Modulating Inflammatory and Autophagy/Apoptosis Cell Injury: An Animal Model Study. <i>Cytology and Genetics</i> , 2021, 55, 480-490.	0.2	2
1749	Antiangiogenic Drugs in NASH: Evidence of a Possible New Therapeutic Approach. <i>Pharmaceuticals</i> , 2021, 14, 995.	1.7	9
1750	Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis 2020. <i>Hepatology Research</i> , 2021, 51, 1013-1025.	1.8	58
1752	Prevalence of non-alcoholic fatty liver disease in patients with chronic kidney disease: a cross-sectional study. <i>Nephrology Dialysis Transplantation</i> , 2022, 37, 1927-1934.	0.4	3
1753	Selective Acetyl-CoA Carboxylase 1 Inhibitor Improves Hepatic Steatosis and Hepatic Fibrosis in a Preclinical Nonalcoholic Steatohepatitis Model. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2021, 379, 280-289.	1.3	11
1754	Trimethylamine-N-Oxide Pathway: A Potential Target for the Treatment of MAFLD. <i>Frontiers in Molecular Biosciences</i> , 2021, 8, 733507.	1.6	25
1755	Dairy protein intake is inversely related to development of non-alcoholic fatty liver disease. <i>Clinical Nutrition</i> , 2021, 40, 5252-5260.	2.3	31
1756	Hepato and nephroprotective activity of methanol extract of <i>Hygrophila spinosa</i> and its antibacterial potential against multidrug resistant <i>Pandoraea sputorum</i> . <i>Environmental Research</i> , 2021, 201, 111594.	3.7	14
1757	Potential Hepatoprotective Effect of <i>Cheatomorpha gracilis</i> extract against High Fat Diet (HFD)-Induced Liver Damage, and its characterization by HPLC. <i>Brazilian Journal of Biology</i> , 2021, 82, e247102.	0.4	0
1758	Influence of other nutrients (e.g., l-arginine, taurine, and choline) on liver diseases. , 2021, , 193-208.		0
1759	Laboratory Testing in Older Adults: Indications, Benefits, and Harms. , 2021, , 1079-1098.		0
1760	Association between Nonalcoholic Fatty Liver Disease and Bone Mineral Density in HIV-Infected Patients Receiving Long-term TDF-Based Antiretroviral Therapy. <i>Current HIV Research</i> , 2021, 19, 40-46.	0.2	2
1761	Epidemiology of nonalcoholic fatty liver disease in Europe: a systematic review and meta-analysis. <i>Annals of Gastroenterology</i> , 2021, 34, 404-414.	0.4	24
1762	Awareness of non-alcoholic fatty liver disease is low in the general population of Saudi Arabia. <i>Journal of Biochemical and Clinical Genetics</i> , 0, , 899-905.	0.1	1

#	ARTICLE	IF	CITATIONS
1763	Protocols for Mitochondria as the Target of Pharmacological Therapy in the Context of Nonalcoholic Fatty Liver Disease (NAFLD). <i>Methods in Molecular Biology</i> , 2021, 2310, 201-246.	0.4	11
1764	Hepatic steatosis relates to gastrointestinal microbiota changes in obese girls with polycystic ovary syndrome. <i>PLoS ONE</i> , 2021, 16, e0245219.	1.1	14
1765	Abnormalities of Carbohydrate Metabolism and the Liver. , 2021, , 804-811.e3.		0
1766	Downregulated microRNA-129-5p by Long Non-coding RNA NEAT1 Upregulates PEG3 Expression to Aggravate Non-alcoholic Steatohepatitis. <i>Frontiers in Genetics</i> , 2020, 11, 563265.	1.1	13
1767	Phytocannabinoidsâ€™ A Green Approach toward Non-Alcoholic Fatty Liver Disease Treatment. <i>Journal of Clinical Medicine</i> , 2021, 10, 393.	1.0	13
1768	Hepatocellular Carcinoma in Kuwait. , 2021, , 237-246.		0
1770	Laboratory Tests in Older Adults: Indications, Interpretation, Issues. , 2012, , 261-269.		3
1771	Nonalcoholic Fatty Liver Disease in Adults: The Impact of Diet and Other Therapeutic Interventions on Clinical and Histological Outcomes. , 2013, , 61-73.		1
1772	Clinical Applications of Liver Magnetic Resonance Elastography: Chronic Liver Disease. , 2014, , 39-60.		2
1773	Methanobactin: A Novel Copper-Binding Compound Produced by Methanotrophs. <i>Microbiology Monographs</i> , 2019, , 205-229.	0.3	1
1774	Non-alcoholic Fatty Liver Disease (NAFLD) and Bariatric Surgery. , 2016, , 629-636.		1
1775	Management of the Obese Patient. , 2016, , 173-193.		1
1776	Non-Alcoholic Fatty Liver Disease. <i>Advances in Experimental Medicine and Biology</i> , 2017, 960, 443-467.	0.8	183
1777	Lipotoxicity in Obesity: Benefit of Olive Oil. <i>Advances in Experimental Medicine and Biology</i> , 2017, 960, 607-617.	0.8	9
1778	Clinical Epidemiology of NAFLD. , 2019, , 211-227.		3
1779	Soluble CD163 (sCD163): Biomarker of Kupffer Cell Activation in Liver Disease. <i>Biomarkers in Disease</i> , 2017, , 321-348.	0.0	1
1780	Soluble CD163 (sCD163): Biomarker of Kupffer Cell Activation in Liver Disease. <i>Biomarkers in Disease</i> , 2016, , 1-28.	0.0	2
1781	Development of a Patient-Reported Outcome Measure for Non-Alcoholic Steatohepatitis (NASH-CHECK): Results of a Qualitative Study. <i>Patient</i> , 2021, 14, 533-543.	1.1	33

#	ARTICLE	IF	CITATIONS
1782	Prognostic value of non-alcoholic fatty liver disease in the elderly patients. <i>Aging Clinical and Experimental Research</i> , 2020, 32, 2657-2665.	1.4	5
1783	Gastric banding-associated weight loss diminishes hepatic Tsukushi expression. <i>Cytokine</i> , 2020, 133, 155114.	1.4	7
1784	Herbal formulation MIT ameliorates high-fat diet-induced non-alcoholic fatty liver disease. <i>Integrative Medicine Research</i> , 2020, 9, 100422.	0.7	4
1785	Impact of super obesity on perioperative outcomes after hepatectomy: The weight of the risk. <i>Surgery</i> , 2017, 162, 1026-1031.	1.0	10
1786	Histological grading evaluation of non-alcoholic fatty liver disease after bariatric surgery: a retrospective and longitudinal observational cohort study. <i>Scientific Reports</i> , 2020, 10, 8496.	1.6	23
1787	HbA1c may contribute to the development of non-alcoholic fatty liver disease even at normal-range levels. <i>Bioscience Reports</i> , 2020, 40, .	1.1	22
1788	N-glycosylation of CREBH improves lipid metabolism and attenuates lipotoxicity in NAFLD by modulating PPAR α and SCD1. <i>FASEB Journal</i> , 2020, 34, 15338-15363.	0.2	15
1789	Polycystic Ovarian Syndrome: Impact on Adult and Fetal Health. <i>Clinical Obstetrics and Gynecology</i> , 2021, 64, 26-32.	0.6	4
1790	Disease severity predicts higher healthcare costs among hospitalized nonalcoholic fatty liver disease/nonalcoholic steatohepatitis (NAFLD/NASH) patients in Spain. <i>Medicine (United States)</i> , 2020, 99, e23506.	0.4	10
1793	Prediction of Hepatic Steatosis (Fatty Liver) using Machine Learning. , 2019, , .		5
1794	Animal Models of Steatosis (NAFLD) and Steatohepatitis (NASH) Exhibit Hepatic Lobe-Specific Gelatinases Activity and Oxidative Stress. <i>Canadian Journal of Gastroenterology and Hepatology</i> , 2019, 2019, 1-9.	0.8	17
1796	Associations between Lifestyle-Related Diseases and Transporters Involved in Intestinal Absorption and Biliary Excretion of Cholesterol. <i>Biological and Pharmaceutical Bulletin</i> , 2018, 41, 1-10.	0.6	7
1797	Serum Bilirubin in the Czech Population—Relationship to the Risk of Myocardial Infarction in Males. <i>Circulation Journal</i> , 2020, 84, 1779-1785.	0.7	8
1799	Non-Cirrhotic Liver is Associated with Poor Prognosis of Hepatocellular Carcinoma: A Literature Review. <i>Medical Science Monitor</i> , 2019, 25, 6615-6623.	0.5	9
1800	Evaluation of Plateletcrit and Platelet Distribution Width in Patients with Non-Alcoholic Fatty Liver Disease: A Retrospective Chart Review Study. <i>Medical Science Monitor</i> , 2019, 25, 9882-9886.	0.5	8
1801	Gender differences in the prevalence of nonalcoholic fatty liver disease in the Northeast of Thailand: A population-based cross-sectional study. <i>F1000Research</i> , 2017, 6, 1630.	0.8	44
1802	Gender differences in the prevalence of nonalcoholic fatty liver disease in the Northeast of Thailand: A population-based cross-sectional study. <i>F1000Research</i> , 2017, 6, 1630.	0.8	21
1803	Metabolic profiling of adolescent non-alcoholic fatty liver disease. <i>Wellcome Open Research</i> , 2018, 3, 166.	0.9	20

#	ARTICLE	IF	CITATIONS
1804	Metabolic profiling of adolescent non-alcoholic fatty liver disease. Wellcome Open Research, 2018, 3, 166.	0.9	14
1805	Prevalence of Non-alcoholic Fatty Liver Disease in the Russian Federation: the Open, Multicenter, Prospective Study, DIREG 1. American Journal of Clinical Medicine Research, 2015, 3, 31-36.	0.1	53
1806	Recent advances in understanding/management of non-alcoholic steatohepatitis. F1000prime Reports, 2015, 7, 28.	5.9	8
1807	Genetic Polymorphisms of the Human PNPLA3 Gene Are Strongly Associated with Severity of Non-Alcoholic Fatty Liver Disease in Japanese. PLoS ONE, 2012, 7, e38322.	1.1	228
1808	Gallstone Disease Is Associated with More Severe Liver Damage in Patients with Non-Alcoholic Fatty Liver Disease. PLoS ONE, 2012, 7, e41183.	1.1	51
1809	NIKEI: A New Inexpensive and Non-Invasive Scoring System to Exclude Advanced Fibrosis in Patients with NAFLD. PLoS ONE, 2013, 8, e58360.	1.1	36
1810	Incidence of Liver Damage of Uncertain Origin in HIV Patients Not Co-Infected with HCV/HBV. PLoS ONE, 2013, 8, e68953.	1.1	32
1811	A Metabolomic Analysis of Omega-3 Fatty Acid-Mediated Attenuation of Western Diet-Induced Nonalcoholic Steatohepatitis in LDLR ^{-/-} Mice. PLoS ONE, 2013, 8, e83756.	1.1	47
1812	Dual Mode Action of Mangiferin in Mouse Liver under High Fat Diet. PLoS ONE, 2014, 9, e90137.	1.1	48
1813	Genome-Wide Analysis of Copy Number Variation Identifies Candidate Gene Loci Associated with the Progression of Non-Alcoholic Fatty Liver Disease. PLoS ONE, 2014, 9, e95604.	1.1	30
1814	Weight Loss in Nonalcoholic Fatty Liver Disease Patients in an Ambulatory Care Setting Is Largely Unsuccessful but Correlates with Frequency of Clinic Visits. PLoS ONE, 2014, 9, e111808.	1.1	59
1815	Fructose Mediated Non-Alcoholic Fatty Liver Is Attenuated by HO-1-SIRT1 Module in Murine Hepatocytes and Mice Fed a High Fructose Diet. PLoS ONE, 2015, 10, e0128648.	1.1	59
1816	The Impact of PNPLA3 rs738409 Genetic Polymorphism and Weight Gain ≥ 10 kg after Age 20 on Non-Alcoholic Fatty Liver Disease in Non-Obese Japanese Individuals. PLoS ONE, 2015, 10, e0140427.	1.1	64
1817	Efficacy of Dietary Lipid Control in Healing High-Fat and High-Cholesterol Diet-Induced Fibrotic Steatohepatitis in Rats. PLoS ONE, 2016, 11, e0145939.	1.1	10
1818	The Selective SGLT2 Inhibitor Ipragliflozin Has a Therapeutic Effect on Nonalcoholic Steatohepatitis in Mice. PLoS ONE, 2016, 11, e0146337.	1.1	135
1819	Chardonnay Grape Seed Flour Ameliorates Hepatic Steatosis and Insulin Resistance via Altered Hepatic Gene Expression for Oxidative Stress, Inflammation, and Lipid and Ceramide Synthesis in Diet-Induced Obese Mice. PLoS ONE, 2016, 11, e0167680.	1.1	27
1820	Relationship of Serum Betatrophin with Nonalcoholic Fatty Liver in a Chinese Population. PLoS ONE, 2017, 12, e0170758.	1.1	26
1821	Microvesicles released from fat-laden cells promote activation of hepatocellular NLRP3 inflammasome: A pro-inflammatory link between lipotoxicity and non-alcoholic steatohepatitis. PLoS ONE, 2017, 12, e0172575.	1.1	49

#	ARTICLE	IF	CITATIONS
1822	Docosahexaenoic acid blocks progression of western diet-induced nonalcoholic steatohepatitis in obese Ldlr ^{-/-} mice. PLoS ONE, 2017, 12, e0173376.	1.1	45
1823	Association of leukocyte cell-derived chemotaxin 2 (LECT2) with NAFLD, metabolic syndrome, and atherosclerosis. PLoS ONE, 2017, 12, e0174717.	1.1	55
1824	The relationship between visceral obesity and hepatic steatosis measured by controlled attenuation parameter. PLoS ONE, 2017, 12, e0187066.	1.1	24
1825	Light alcohol consumption has the potential to suppress hepatocellular injury and liver fibrosis in non-alcoholic fatty liver disease. PLoS ONE, 2018, 13, e0191026.	1.1	32
1826	Insulin resistance in lean and overweight non-diabetic Caucasian adults: Study of its relationship with liver triglyceride content, waist circumference and BMI. PLoS ONE, 2018, 13, e0192663.	1.1	34
1827	Second harmonic generation microscopy provides accurate automated staging of liver fibrosis in patients with non-alcoholic fatty liver disease. PLoS ONE, 2018, 13, e0199166.	1.1	28
1828	Identification of Nonalcoholic Fatty Liver Disease following Pancreatic Surgery in a Western Cohort Using a Novel Radiographic Technique. Journal of Clinical and Translational Hepatology, 2015, 3, 246-253.	0.7	4
1829	Perspectives on Nonalcoholic Fatty Liver Disease: An Overview of Present and Future Therapies. Journal of Clinical and Translational Hepatology, 2017, 5, 67-75.	0.7	18
1830	Non-alcoholic Fatty Liver Disease in Lean Subjects: Characteristics and Implications. Journal of Clinical and Translational Hepatology, 2017, XX, 1-8.	0.7	73
1831	CA-125 Significance in Cirrhosis and Correlation with Disease Severity and Portal Hypertension: A Retrospective Study. Journal of Clinical and Translational Hepatology, 2018, 6, 1-6.	0.7	14
1832	Nonalcoholic Fatty Liver Disease: Epidemiology, Liver Transplantation Trends and Outcomes, and Risk of Recurrent Disease in the Graft. Journal of Clinical and Translational Hepatology, 2018, 6, 1-5.	0.7	20
1833	Effect of Exercise on NAFLD and Its Risk Factors: Comparison of Moderate versus Low Intensity Exercise. Journal of Clinical and Translational Hepatology, 2020, 8, 120-126.	0.7	16
1834	Non-alcoholic Fatty Liver Disease: Growing Burden, Adverse Outcomes and Associations. Journal of Clinical and Translational Hepatology, 2019, X, 1-11.	0.7	90
1836	Effects of Statin Use on the Development and Progression of Nonalcoholic Fatty Liver Disease: A Nationwide Nested Case-Control Study. American Journal of Gastroenterology, 2021, 116, 116-124.	0.2	63
1837	Role of Noninvasive Tests in Clinical Gastroenterology Practices to Identify Patients With Nonalcoholic Steatohepatitis at High Risk of Adverse Outcomes: Expert Panel Recommendations. American Journal of Gastroenterology, 2021, 116, 254-262.	0.2	65
1838	Macrovesicular steatosis is associated with development of lobular inflammation and fibrosis in diet-induced non-alcoholic steatohepatitis (NASH). Inflammation and Cell Signaling, 0, , .	1.6	7
1839	Effects of Pharmacologic Dose of Resveratrol Supplementation on Oxidative/Antioxidative Status Biomarkers in Nonalcoholic Fatty Liver Disease Patients: A Randomized, Double-Blind, Placebo-Controlled Trial. Advanced Pharmaceutical Bulletin, 2018, 8, 307-317.	0.6	34
1840	The Prevalence of Non-alcoholic Fatty Liver Disease and Diabetes Mellitus in an Iranian Population. Middle East Journal of Digestive Diseases, 2017, 9, 86-93.	0.2	8

#	ARTICLE	IF	CITATIONS
1841	The Association between Angiotensin II Type 1 Receptor Gene A1166C Polymorphism and Non-alcoholic Fatty Liver Disease and Its Severity. Middle East Journal of Digestive Diseases, 2018, 10, 96-104.	0.2	10
1842	Comparison of Three Different Diet-Induced Non Alcoholic Fatty Liver Disease Protocols in Rats: A Pilot Study. Pharmaceutical Sciences, 2016, 22, 9-15.	0.8	10
1843	MANAGEMENT OF ENDOCRINE DISEASE: Non-alcoholic fatty liver disease: a multidisciplinary approach towards a cardiometabolic liver disease. European Journal of Endocrinology, 2020, 183, R57-R73.	1.9	24
1844	A Potential Treatment of Non-Alcoholic Fatty Liver Disease with SIRT1 Activators. Journal of Gastrointestinal and Liver Diseases, 2020, 23, 311-319.	0.5	79
1845	Severity of Nonalcoholic Fatty Liver Disease is Associated with Development of Metabolic Syndrome: Results of a 5-Year Cohort Study. Journal of Liver Research, Disorders & Therapy, 2015, 1, .	0.1	1
1846	The Role of Non-alcoholic Fatty Liver Disease in Cardiovascular Disease. European Cardiology Review, 2014, 9, 10.	0.7	8
1847	A brief review on the rising incidence of chronic kidney diseases and non-alcoholic fatty liver disease. Physiology International, 2020, 106, 305-310.	0.8	10
1848	Zingiber officinale formulation reduces hepatic injury and weight gain in rats fed an unhealthy diet. Anais Da Academia Brasileira De Ciencias, 2019, 91, e20180975.	0.3	9
1850	Risk Factor Prevalence and Their Relative Influence on Fatty Liver and Gallstone Disease: A Cross-Ethnic Study Comparing Two High-Risk Populations from Chile and Northeast Germany. Epidemiology - Open Journal, 2016, 1, 40-52.	0.4	1
1851	Bariatric Surgery for the Treatment of Nonalcoholic Fatty Liver Disease: Is Vertical Sleeve Gastrectomy the Best Future Option?. Journal of Gastroenterology and Hepatology Research, 2016, 5, 1957-1961.	0.2	2
1852	The Association of Hispanic Ethnicity with Nonalcoholic Fatty Liver Disease in Polycystic Ovary Syndrome. Current Opinion in Gynecology and Obstetrics, 2018, 1, 24-33.	0.0	16
1853	Linking atrial fibrillation with non-alcoholic fatty liver disease: potential common therapeutic targets. Oncotarget, 2017, 8, 60673-60683.	0.8	14
1854	Prevalence, trends, outcomes, and disparities in hospitalizations for nonalcoholic fatty liver disease in the United States. Annals of Gastroenterology, 2019, 32, 504-513.	0.4	15
1855	Flavonoids and Related Compounds in Non-Alcoholic Fatty Liver Disease Therapy. Current Medicinal Chemistry, 2015, 22, 2991-3012.	1.2	41
1856	Classical and Innovative Insulin Sensitizing Drugs for the Prevention and Treatment of NAFLD. Current Pharmaceutical Design, 2013, 19, 5280-5296.	0.9	7
1857	Hepatocellular Carcinoma in Non Alcoholic Fatty Liver Disease. Current Pharmaceutical Design, 2020, 26, 3909-3914.	0.9	7
1858	Effect of Chinese Herbal Monomer Hairy Calycosin on Nonalcoholic Fatty Liver Rats and its Mechanism. Combinatorial Chemistry and High Throughput Screening, 2019, 22, 194-200.	0.6	4
1859	The link between Hepatic Vitamin A Metabolism and Nonalcoholic Fatty Liver Disease. Current Drug Targets, 2015, 16, 1281-1292.	1.0	20

#	ARTICLE	IF	CITATIONS
1860	Natural Products on Nonalcoholic Fatty Liver Disease. <i>Current Drug Targets</i> , 2015, 16, 1347-1355.	1.0	49
1861	Evaluation of Hepatic Steatosis with CT and Correlation with Anthropometric Measurements. <i>Current Medical Imaging</i> , 2020, 16, 452-458.	0.4	1
1862	Lifestyle Intervention Enabled by Mobile Technology on Weight Loss in Patients With Nonalcoholic Fatty Liver Disease: Randomized Controlled Trial. <i>JMIR MHealth and UHealth</i> , 2020, 8, e14802.	1.8	34
1863	Applicability of a Web-Based, Individualized Exercise Intervention in Patients With Liver Disease, Cystic Fibrosis, Esophageal Cancer, and Psychiatric Disorders: Process Evaluation of 4 Ongoing Clinical Trials. <i>JMIR Research Protocols</i> , 2018, 7, e106.	0.5	17
1864	Non-alcoholic fatty liver disease: prevalence, etiology, pathogenesis, approaches to the diagnosis and therapy (literature review and own data). <i>Материалы 4-го национального конгресса «Актуальные проблемы гастроэнтерологии и гепатологии»</i> , 2018, 14, 684-693.	0.1	2
1865	Non-Alcoholic Fatty Liver Disease in Cardiac Patients with Overweight and Obesity. <i>Russian Journal of Gastroenterology Hepatology Coloproctology</i> , 2019, 28, 27-37.	0.2	3
1866	Factores de riesgo asociados a hígado graso de origen no alcohólico en una población del Caribe Colombiano. <i>Revista Colombiana De Gastroenterología</i> , 2017, 31, 89.	0.1	2
1868	Pentoxifylline with metformin treatment improves biochemical parameters in patients with nonalcoholic steatohepatitis. <i>Journal of Medical Biochemistry</i> , 2019, 39, 290-298.	0.7	5
1869	Beneficial Effect of <i>Pachyrhizus erosus</i> Fiber as a Supplemental Diet to Counteract High Sugar-Induced Fatty Liver Disease in Mice. <i>Romanian Journal of Diabetes Nutrition and Metabolic Diseases</i> , 2019, 26, 353-360.	0.3	4
1870	Non-invasive imaging techniques in assessing non-alcoholic fatty liver disease: a current status of available methods. <i>Journal of Medicine and Life</i> , 2017, 10, 19-26.	0.4	32
1871	Cross-sectional analysis of the health profile and dietary intake of a sample of Canadian adults diagnosed with non-alcoholic fatty liver disease. <i>Food and Nutrition Research</i> , 2020, 64, .	1.2	5
1872	Infectious and Non-infectious Diseases of the Digestive System. Epidemiological Interrelation. <i>Epidemiologiya i Vaktsinoprofilaktika</i> , 2019, 18, 55-66.	0.2	10
1873	Cost-effectiveness of non-invasive methods for assessment and monitoring of liver fibrosis and cirrhosis in patients with chronic liver disease: systematic review and economic evaluation. <i>Health Technology Assessment</i> , 2015, 19, 1-410.	1.3	130
1874	Elevated Alanine Aminotransferase in Early Pregnancy and Subsequent Development of Gestational Diabetes and Preeclampsia. <i>Journal of Korean Medical Science</i> , 2020, 35, e198.	1.1	11
1875	Association between Atrial Fibrillation and Advanced Liver Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease. <i>Yonsei Medical Journal</i> , 2020, 61, 860.	0.9	14
1876	Severe steatohepatitis with hepatic decompensation resulting from malnutrition after pancreaticoduodenectomy. <i>Clinical and Molecular Hepatology</i> , 2012, 18, 404.	4.5	20
1877	Chasing after novel non-invasive markers to identify advanced fibrosis in NAFLD. <i>Clinical and Molecular Hepatology</i> , 2013, 19, 255.	4.5	3

#	ARTICLE	IF	CITATIONS
1878	KASL clinical practice guidelines: Management of nonalcoholic fatty liver disease. <i>Clinical and Molecular Hepatology</i> , 2013, 19, 325.	4.5	105
1879	The serum vitamin D level is inversely correlated with nonalcoholic fatty liver disease. <i>Clinical and Molecular Hepatology</i> , 2016, 22, 146-151.	4.5	51
1880	Evidence-based clinical advice for nutrition and dietary weight loss strategies for the management of NAFLD and NASH. <i>Clinical and Molecular Hepatology</i> , 2020, 26, 383-400.	4.5	50
1881	Beneficial effect of anti-diabetic drugs for nonalcoholic fatty liver disease. <i>Clinical and Molecular Hepatology</i> , 2020, 26, 430-443.	4.5	38
1882	Steatotic Rat Hepatocytes in Primary Culture Are More Susceptible to the Acute Toxic Effect of Acetaminophen. <i>Physiological Research</i> , 2012, 61, S93-S101.	0.4	18
1883	Calorie-Restricted Mediterranean and Low-Fat Diets Affect Fatty Acid Status in Individuals with Nonalcoholic Fatty Liver Disease. <i>Nutrients</i> , 2021, 13, 15.	1.7	45
1884	Perspectives of nonalcoholic fatty liver disease research: a personal point of view. , 2020, 1, 85-107.		23
1885	A comparison of survival and pathologic features of non-alcoholic steatohepatitis and hepatitis C virus patients with hepatocellular carcinoma. <i>World Journal of Gastroenterology</i> , 2012, 18, 4145.	1.4	29
1886	Genetic and epigenetic variants influencing the development of nonalcoholic fatty liver disease. <i>World Journal of Gastroenterology</i> , 2012, 18, 6546.	1.4	73
1887	Have guidelines addressing physical activity been established in nonalcoholic fatty liver disease?. <i>World Journal of Gastroenterology</i> , 2012, 18, 6790.	1.4	61
1888	Prevalence and features of fatty liver detected by physical examination in Guangzhou. <i>World Journal of Gastroenterology</i> , 2013, 19, 5334.	1.4	22
1889	Non-alcoholic fatty liver disease and liver transplantation: Outcomes and advances. <i>World Journal of Gastroenterology</i> , 2013, 19, 9146.	1.4	36
1890	Lack of association between apolipoprotein C3 gene polymorphisms and risk of nonalcoholic fatty liver disease in a Chinese Han population. <i>World Journal of Gastroenterology</i> , 2014, 20, 3655.	1.4	31
1891	Liver transplantation for nonalcoholic fatty liver disease: New challenges and new opportunities. <i>World Journal of Gastroenterology</i> , 2014, 20, 5320.	1.4	96
1892	Role of autophagy in the pathophysiology of nonalcoholic fatty liver disease: A controversial issue. <i>World Journal of Gastroenterology</i> , 2014, 20, 7325.	1.4	88
1893	Proteomic and genomic studies of non-alcoholic fatty liver disease - clues in the pathogenesis. <i>World Journal of Gastroenterology</i> , 2014, 20, 8325.	1.4	33
1894	Epidemiology of fatty liver: an update. <i>World Journal of Gastroenterology</i> , 2014, 20, 9050-4.	1.4	71
1895	Non-alcoholic fatty liver disease and obesity: biochemical, metabolic and clinical presentations. <i>World Journal of Gastroenterology</i> , 2014, 20, 9330-7.	1.4	328

#	ARTICLE	IF	CITATIONS
1896	Non-alcoholic fatty liver disease: What has changed in the treatment since the beginning?. World Journal of Gastroenterology, 2014, 20, 14219.	1.4	38
1897	Liver transplantation and non-alcoholic fatty liver disease. World Journal of Gastroenterology, 2014, 20, 15532.	1.4	134
1898	Ghrelin-ghrelin<i>O</i>-acyltransferase system in the pathogenesis of nonalcoholic fatty liver disease. World Journal of Gastroenterology, 2015, 21, 3214-3222.	1.4	21
1899	Liver disease in menopause. World Journal of Gastroenterology, 2015, 21, 7613.	1.4	93
1900	Endocrine causes of nonalcoholic fatty liver disease. World Journal of Gastroenterology, 2015, 21, 11053.	1.4	69
1901	Central obesity and nonalcoholic fatty liver disease risk after adjusting for body mass index. World Journal of Gastroenterology, 2015, 21, 1650.	1.4	135
1902	Fatty liver index<i>vs</i>waist circumference for predicting non-alcoholic fatty liver disease. World Journal of Gastroenterology, 2016, 22, 3023.	1.4	82
1903	Iron and non-alcoholic fatty liver disease. World Journal of Gastroenterology, 2016, 22, 8112.	1.4	108
1904	Outcomes of abdominal surgery in patients with liver cirrhosis. World Journal of Gastroenterology, 2016, 22, 2657.	1.4	59
1905	Urinary metabolomics analysis identifies key biomarkers of different stages of nonalcoholic fatty liver disease. World Journal of Gastroenterology, 2017, 23, 2771.	1.4	53
1906	New botanical drug, HL tablet, reduces hepatic fat as measured by magnetic resonance spectroscopy in patients with nonalcoholic fatty liver disease: A placebo-controlled, randomized, phase II trial. World Journal of Gastroenterology, 2017, 23, 5977.	1.4	8
1907	Fatty liver in hepatitis C patients post-sustained virological response with direct-acting antivirals. World Journal of Gastroenterology, 2018, 24, 1269-1277.	1.4	55
1908	Mild drinking habit is a risk factor for hepatocarcinogenesis in non-alcoholic fatty liver disease with advanced fibrosis. World Journal of Gastroenterology, 2018, 24, 1440-1450.	1.4	54
1909	C-peptide as a key risk factor for non-alcoholic fatty liver disease in the United States population. World Journal of Gastroenterology, 2018, 24, 3663-3670.	1.4	24
1910	Quantitative and noninvasive assessment of chronic liver diseases using two-dimensional shear wave elastography. World Journal of Gastroenterology, 2018, 24, 957-970.	1.4	38
1911	Hepatocellular carcinoma in the post-hepatitis C virus era: Should we change the paradigm?. World Journal of Gastroenterology, 2019, 25, 3929-3940.	1.4	29
1912	Nonalcoholic fatty liver disease in patients with inflammatory bowel disease: Beyond the natural history. World Journal of Gastroenterology, 2019, 25, 5676-5686.	1.4	44
1913	Tumor necrosis factor alpha receptor 1 deficiency in hepatocytes does not protect from non-alcoholic steatohepatitis, but attenuates insulin resistance in mice. World Journal of Gastroenterology, 2020, 26, 4933-4944.	1.4	8

#	ARTICLE	IF	CITATIONS
1914	Non-alcoholic fatty liver disease: A major challenge in type 2 diabetes mellitus (Review). <i>Experimental and Therapeutic Medicine</i> , 2020, 20, 2387-2391.	0.8	8
1915	Effect of Antioxidant Status and Oxidative Stress Products in Pre-menopausal Women after Treatment with Date Seed Powder (<i>Phoenix dactylifera L.</i>): A Study on Women in Indonesia. <i>Pakistan Journal of Nutrition</i> , 2017, 16, 477-481.	0.2	16
1916	Assessing liver fibrosis without biopsy in patients with HCV or NAFLD. <i>Cleveland Clinic Journal of Medicine</i> , 2019, 86, 179-186.	0.6	10
1917	Increased risk of colorectal polyps in patients with non-alcoholic fatty liver disease undergoing liver transplant evaluation. <i>Journal of Gastrointestinal Oncology</i> , 2015, 6, 459-68.	0.6	22
1918	Recent advances in the development of farnesoid X receptor agonists. <i>Annals of Translational Medicine</i> , 2015, 3, 5.	0.7	115
1919	Non-Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Mellitus: A Position Statement of the Fatty Liver Research Group of the Korean Diabetes Association. <i>Diabetes and Metabolism Journal</i> , 2020, 44, 382.	1.8	46
1920	Nonalcoholic Fatty Liver Disease: A Drug Revolution Is Coming. <i>Diabetes and Metabolism Journal</i> , 2020, 44, 640-657.	1.8	16
1921	Cardiovascular dysfunction and liver transplantation. <i>Korean Journal of Anesthesiology</i> , 2018, 71, 85-91.	0.9	37
1922	Outcome of phlebotomy for treating nonalcoholic fatty liver disease: A systematic review and meta-analysis. <i>Saudi Journal of Gastroenterology</i> , 2016, 22, 407.	0.5	11
1923	Do symbiotic and Vitamin E supplementation have favorable effects in nonalcoholic fatty liver disease? A randomized, double-blind, placebo-controlled trial. <i>Journal of Research in Medical Sciences</i> , 2016, 21, 106.	0.4	32
1924	The Global Nonalcoholic Fatty Liver Disease Epidemic: What a Radiologist Needs to Know. <i>Journal of Clinical Imaging Science</i> , 2015, 5, 32.	0.4	21
1925	Profile of liver enzymes in non-alcoholic fatty liver disease in patients with impaired glucose tolerance and newly detected untreated type 2 diabetes. <i>Indian Journal of Endocrinology and Metabolism</i> , 2015, 19, 597.	0.2	96
1926	Effects of cumin on nonalcoholic steatohepatitis: A double blind, randomised, controlled trial. <i>Advanced Biomedical Research</i> , 2015, 4, 212.	0.2	12
1927	Non-alcoholic fatty liver disease associated with hepatocellular carcinoma: An increasing concern. <i>Indian Journal of Medical Research</i> , 2019, 149, 9.	0.4	74
1928	Correlational Study of Nonalcoholic Fatty Liver Disease Diagnosed by Ultrasonography with Lipid Profile and Body Mass Index in Adult Nepalese Population. <i>Journal of Medical Ultrasound</i> , 2019, 27, 19-25.	0.2	10
1929	Insomnia and risk of nonalcoholic fatty liver disease. <i>Journal of Postgraduate Medicine</i> , 2017, 63, 226-231.	0.2	18
1930	Non-Alcoholic Fatty Steatohepatitis an Inflammatory Disorder Beyond the Liver. <i>Journal of Clinical & Cellular Immunology</i> , 2013, 04, .	1.5	1
1931	Vitamin D Deficiency, A Noninvasive Marker of Steatohepatitis in Patients with Obesity and Biopsy Proven Nonalcoholic Fatty Liver Disease. <i>Acta Endocrinologica</i> , 2018, 14, 76-84.	0.1	3

#	ARTICLE	IF	CITATIONS
1932	Vitamin D levels do not predict the stage of hepatic fibrosis in patients with non-alcoholic fatty liver disease: A PRISMA compliant systematic review and meta-analysis of pooled data. World Journal of Hepatology, 2018, 10, 142-154.	0.8	28
1933	One in five hepatocellular carcinoma patients in the United States are Hispanic while less than 40% were eligible for liver transplantation. World Journal of Hepatology, 2018, 10, 956-965.	0.8	3
1934	Liver failure caused by prolonged state of malnutrition following bariatric surgery. World Journal of Hepatology, 2018, 10, 396-399.	0.8	15
1935	Rise of sodium-glucose cotransporter 2 inhibitors in the management of nonalcoholic fatty liver disease. World Journal of Hepatology, 2019, 11, 562-573.	0.8	8
1936	Non-alcoholic steatohepatitis and the risk of myocardial infarction: A population-based national study. World Journal of Hepatology, 2020, 12, 378-388.	0.8	9
1937	Association between nonalcoholic fatty liver disease and acute ischemic stroke severity and outcome. World Journal of Hepatology, 2013, 5, 621.	0.8	26
1938	Transient elastography: Kill two birds with one stone?. World Journal of Hepatology, 2013, 5, 264.	0.8	77
1939	Pathogenesis and therapeutic approaches for non-alcoholic fatty liver disease. World Journal of Hepatology, 2014, 6, 800.	0.8	64
1940	Obesity and non-alcoholic fatty liver disease: Disparate associations among Asian populations. World Journal of Hepatology, 2014, 6, 263.	0.8	99
1941	Epigenetic mechanisms in non-alcoholic fatty liver disease: An emerging field. World Journal of Hepatology, 2015, 7, 2497.	0.8	38
1942	Role of pentoxifylline in non-alcoholic fatty liver disease in high-fat diet-induced obesity in mice. World Journal of Hepatology, 2015, 7, 2551.	0.8	12
1943	Non-invasive methods for the diagnosis of nonalcoholic fatty liver disease. World Journal of Hepatology, 2015, 7, 638.	0.8	68
1944	Influence of cirrhosis in cardiac surgery outcomes. World Journal of Hepatology, 2015, 7, 753.	0.8	36
1945	Metabonomic window into hepatitis B virus-related hepatic diseases. World Journal of Hepatology, 2016, 8, 1.	0.8	3
1946	Egg consumption and risk of non-alcoholic fatty liver disease. World Journal of Hepatology, 2017, 9, 503.	0.8	30
1947	Clinical applications, limitations and future role of transient elastography in the management of liver disease. World Journal of Gastrointestinal Pharmacology and Therapeutics, 2016, 7, 91.	0.6	54
1948	Management of Hepatocellular Carcinoma: Bangladesh Perspective. Euroasian Journal of Hepato-gastroenterology, 2018, 8, 52-53.	0.1	8
1949	Genetic Polymorphisms of PNPLA3 and SAMM50 Are Associated with Nonalcoholic Fatty Liver Disease in a Korean Population. Gut and Liver, 2018, 12, 316-323.	1.4	45

#	ARTICLE	IF	CITATIONS
1950	Extrahepatic Manifestations of Nonalcoholic Fatty Liver Disease. <i>Gut and Liver</i> , 2020, 14, 168-178.	1.4	63
1951	Epidemiology of non-alcoholic fatty liver disease and risk of hepatocellular carcinoma progression. <i>Clinical and Experimental Hepatology</i> , 2020, 6, 289-294.	0.6	20
1952	The relationship between insulin resistance, metabolic syndrome and nonalcoholic fatty liver disease in non-obese non-diabetic Turkish individuals: A pilot study. <i>Turkish Journal of Gastroenterology</i> , 2015, 25, 63-68.	0.4	9
1953	Anthropometric and Biochemical Characteristics of Patients with Nonalcoholic Fatty Liver Diagnosed by Non-Invasive Diagnostic Methods. <i>Medicinski Arhiv = Medical Archives = Archives De Médecine</i> , 2014, 68, 22.	0.4	11
1954	Gene expression profiling reveals key genes and pathways related to the development of non-alcoholic fatty liver disease. <i>Annals of Hepatology</i> , 2016, 15, 190-9.	0.6	28
1955	The product of triglycerides and glucose as biomarker for screening simple steatosis and NASH in asymptomatic women. <i>Annals of Hepatology</i> , 2016, 15, 715-20.	0.6	38
1956	Effect of coffee and green tea consumption on liver enzyme and metabolic syndrome in Korean. <i>Journal of the Korea Academia-Industrial Cooperation Society</i> , 2012, 13, 2570-2578.	0.0	7
1957	Predictive Factors of Steatosis and Non-Alcoholic Steatohepatitis in Morbidly Obese Patients Undergoing Bariatric Surgery. <i>Hepatitis Monthly</i> , 2017, 17, .	0.1	1
1958	Association Between Platelet Count as a Noninvasive Marker and Ultrasonographic Grading in Patients With Nonalcoholic Fatty Liver Disease. <i>Hepatitis Monthly</i> , 2015, 15, e24449.	0.1	22
1959	Prevalence of Non-Alcoholic Fatty Liver Disease in Morbidly Obese Patients Undergoing Sleeve Bariatric Surgery in Iran and Association With Other Comorbid Conditions. <i>Jundishapur Journal of Chronic Disease Care</i> , 2015, 4, .	0.1	3
1960	Gender-based differences in the relationship between fatty liver disease and atherosclerosis. <i>Cardiovascular Journal of Africa</i> , 2016, 27, 281-286.	0.2	17
1961	Non-alcoholic steatohepatitis-related liver cirrhosis is increasing in China: A ten-year retrospective study. <i>Clinics</i> , 2015, 70, 563-568.	0.6	22
1962	Steatosis and steatohepatitis found in adults after death due to non-burn trauma. <i>Clinics</i> , 2019, 74, e1070.	0.6	2
1963	The genetic architecture of NAFLD among inbred strains of mice. <i>ELife</i> , 2015, 4, e05607.	2.8	96
1964	Sarcopenia Is Significantly Associated with Presence and Severity of Nonalcoholic Fatty Liver Disease. <i>Journal of Obesity and Metabolic Syndrome</i> , 2019, 28, 129-138.	1.5	36
1965	Effects of voluntary exercise training on liver fat accumulation - Measurement of over time CT imaging - <i>Japanese Journal of Physical Fitness and Sports Medicine</i> , 2017, 66, 283-291.	0.0	1
1966	Vitamin E as an Adjuvant Treatment for Non-alcoholic Fatty Liver Disease in Adults: A Systematic Review of Randomized Controlled Trials. <i>Cureus</i> , 2020, 12, e9018.	0.2	6
1967	The Association between Nuts Intake and Non-Alcoholic Fatty Liver Disease (NAFLD) Risk: a Case-Control Study. <i>Clinical Nutrition Research</i> , 2020, 9, 195.	0.5	9

#	ARTICLE	IF	CITATIONS
1968	Insulin Resistance in Egyptian Nonalcoholic Fatty Liver Disease patients. <i>British Journal of Medicine and Medical Research</i> , 2015, 6, 463-473.	0.2	1
1969	Nonalcoholic Fatty Liver Disease (NAFLD) in Saudi Patients with T2DM in Jazan Region: Prevalence and Associated Factors. <i>British Journal of Medicine and Medical Research</i> , 2015, 5, 872-879.	0.2	11
1971	Nonalcoholic fatty liver disease and early prediction of gestational diabetes mellitus using machine learning methods. <i>Clinical and Molecular Hepatology</i> , 2022, 28, 105-116.	4.5	9
1972	Sexual Dimorphisms in Nonalcoholic Fatty Liver Disease. <i>Current Hepatology Reports</i> , 2021, 20, 97-107.	0.4	2
1973	Acetyl-CoA carboxylase inhibitors in non-alcoholic steatohepatitis: Is there a benefit?. <i>World Journal of Gastroenterology</i> , 2021, 27, 6522-6526.	1.4	4
1974	Electrical impedance tomography for non-invasive identification of fatty liver infiltrate in overweight individuals. <i>Scientific Reports</i> , 2021, 11, 19859.	1.6	6
1975	Effects of glucagon-like peptide-1 receptor agonists on histopathological and secondary biomarkers of non-alcoholic steatohepatitis: A systematic review and meta-analysis. <i>Diabetes, Obesity and Metabolism</i> , 2022, 24, 337-342.	2.2	4
1976	Association of anti-oxidative capacity of HDL with subclinical atherosclerosis in subjects with and without non-alcoholic fatty liver disease. <i>Diabetology and Metabolic Syndrome</i> , 2021, 13, 121.	1.2	14
1977	Weight loss interventions and nonalcoholic fatty liver disease: Optimizing liver outcomes. <i>Diabetes, Obesity and Metabolism</i> , 2022, 24, 44-54.	2.2	18
1978	Metabolic effects of ramipril and indapamide in hypertensive patients with non-alcoholic fatty liver disease. <i>Arterial Hypertension (Russian Federation)</i> , 2021, 27, 472-481.	0.1	0
1979	An Efficient Model of Non-alcoholic Fatty Liver Disease (NAFLD) Versus Current Experimental Models: Effects of Fructose, Fat, and Carbon Tetrachloride on NAFLD. <i>Hepatitis Monthly</i> , 2021, 21, .	0.1	2
1980	Focus on the Type 2 Diabetes Patient with Liver Disease: Emphasis on Nonalcoholic Fatty Liver Disease (NAFLD). <i>Endocrine Practice</i> , 2011, 17, 9-13.	1.1	0
1981	Nonalcoholic Fatty Liver Disease (NAFLD) and Nonalcoholic Steatohepatitis (NASH). , 2012, , 399-407.		0
1982	Oils rich in alpha-linolenic acid independently protect against characteristics of fatty liver disease in the delta-6-desaturase null mouse. <i>FASEB Journal</i> , 2012, 26, 266.1.	0.2	0
1983	Alcohol and Nutrition as Risk Factors for Chronic Liver Disease. , 2013, , 497-506.		1
1984	Noninvasive markers: a double-edged sword that stratifies nonalcoholic steatohepatitis. <i>Clinical and Molecular Hepatology</i> , 2013, 19, 116.	4.5	0
1986	Pharmacologic Therapy for Nonalcoholic Fatty Liver Disease. <i>Korean Journal of Medicine</i> , 2014, 86, 425.	0.1	1
1987	Alarming Rise in Chronic Liver Disease and Challenges Ahead. <i>International Journal of Medical and Dental Sciences</i> , 2015, 3, 242.	0.1	0

#	ARTICLE	IF	CITATIONS
1988	Fructose, High Fructose Corn Syrup, Sucrose, and Nonalcoholic Fatty Liver Disease. , 2014, , 325-339.		1
1990	Clinical Aspects of Nonalcoholic Fatty Liver Disease. Oxidative Stress and Disease, 2014, , 3-24.	0.3	0
1991	VITAMIN B12 DEFICIENCY IN NONALCOHOLIC FATTY LIVER DISEASE. Journal of Evolution of Medical and Dental Sciences, 2014, 3, 8281-8285.	0.1	1
1992	Unusual presentation of nonalcoholic steatohepatitis-related cirrhosis in a patient with celiac disease and microscopic colitis. Journal of Translational Internal Medicine, 2014, 2, 172-174.	1.0	2
1993	Gut Flora in the Development and Progression of Nonalcoholic Fatty Liver Disease. Journal of Liver: Disease & Transplantation, 2015, 04, .	0.0	0
1994	Nonalcoholic Steatohepatitis in Children: The Modern Day Pediatric Epidemic. Journal of Gastroenterology and Hepatology Research, 2015, 4, 1663-1670.	0.2	0
1995	Nonalcoholic Fatty Liver Disease (NAFLD) after Liver Transplantation: A Mini-Review. Journal of Liver: Disease & Transplantation, 2015, 04, .	0.0	0
1996	NASH, The Ethical Dilemma. , 2015, , 1-16.		0
1997	Gambaran NAFLD pada Pasien dengan Sindrom Metabolik di Poliklinik Penyakit Dalam RSUP Dr. M. Djamil Padang. Jurnal Kesehatan Andalas, 2015, 4, .	0.1	0
1998	Obesity and nonalcoholic fatty liver disease: metabolic risks and their correction. Obesity and Metabolism, 2015, 12, 35-39.	0.4	1
1999	Correction of Hormonal-Metabolic Disturbances in Patients with Diabetes Mellitus Type 2 and Non-Alcoholic Steatohepatitis. LĀ-ki UkraĀ-ni, 2015, .	0.0	0
2000	A Review of Pharmacological Treatments of NASH. Gastroenterology & Hepatology (Bartlesville, Okla) Tj ETQq1 1 0,784314 rgBT /Ove	0.0	0
2002	High-intensity circuit weight training versus aerobic training in patients with nonalcoholic fatty liver disease. Bulletin of Faculty of Physical Therapy, 2015, 20, 181-192.	0.2	1
2003	Prevalence and Predictor of Nonalcoholic Steatohepatitis (NASH) in Nonalcoholic Fatty Liver Disease (NAFLD). Journal of Bangladesh College of Physicians & Surgeons, 2015, 32, 71-77.	0.0	3
2004	Hepatic Lipogenesis: Nutritional Control and Pathophysiological Relevance. , 2016, , 211-234.		1
2005	Association Between Statin Use and Hepatocellular Carcinoma: A Meta-Analysis of Observational Studies. Science Journal of Public Health, 2016, 4, 81.	0.1	0
2006	Are Hypothyroidism and Obstructive Sleep Apnea Independent Risk Factors for the Development of Non-Alcoholic Fatty Liver Disease?. Journal of Hepatology and Gastrointestinal Disorders, 2016, 02, .	0.0	0
2007	Non-alcoholic Fatty Liver Disease in Obesity. , 2016, , 159-179.		0

#	ARTICLE	IF	CITATIONS
2008	Type 2 Diabetes and Developmental Origin of Non-Alcohol Fatty Liver Disease and Future Directions of Treatment. <i>Clinical & Experimental Pharmacology</i> , 2016, 6, .	0.3	0
2009	Lipids, Low-Grade Chronic Inflammation and NAFLD. , 2016, , 731-759.		1
2010	Statins for the Treatment of Non Alcoholic Fatty Liver Disease in Patients with Metabolic Syndrome. <i>Journal of Diabetes, Metabolic Disorders & Control</i> , 2016, 3, .	0.2	0
2011	NASH, The Ethical Dilemma. , 2016, , 1-16.		0
2012	Nonneoplastic Hepatobiliary Disease. , 2016, , 1969-2030.		0
2013	Is vitamin e or ursodeoxycholic acid a valid treatment option for nonalcoholic fatty liver disease in 2016?. <i>Saudi Journal of Gastroenterology</i> , 2016, 22, 169.	0.5	1
2015	A COMPARATIVE STUDY OF NON-ALCOHOLIC FATTY LIVER DISEASE IN RURAL AND URBAN POPULATION WITH TYPE 2 DIABETES MELLITUS. <i>Journal of Evolution of Medical and Dental Sciences</i> , 2016, 5, 2805-2808.	0.1	0
2016	Anti-Lipogenic Effect of Functional Cereal Samples on High Sucrose Diet-Induced Non-Alcoholic Fatty Liver Disease in Mice. <i>Journal of the Korean Society of Food Science and Nutrition</i> , 2016, 45, 789-796.	0.2	3
2017	The Role of Sexual Dimorphism in the Development of Non-Alcoholic Fatty Liver Disease. <i>Gastroenterologia</i> , 2016, .	0.0	0
2018	A STUDY OF NONALCOHOLIC FATTY LIVER DISEASE AND FATTY LIVER INDEX IN TYPE 2 DIABETES MELLITUS PATIENTS. <i>Journal of Evidence Based Medicine and Healthcare</i> , 2016, 3, 3001-3006.	0.0	0
2019	Estimation of thyroid hormones and liver enzymes levels in hypo and hyperthyroidism in iraqi women. <i>International Journal of Pharma and Bio Sciences</i> , 2016, 7, .	0.1	1
2022	Hepatobiliary dysfunction in Type-2 diabetes mellitus. <i>Journal of Family Medicine and Primary Care</i> , 2017, 6, 563.	0.3	2
2024	METABOLIC SURGERY IN CORRECTION OF FATTY LIVER DISEASE. <i>Vestnik Khirurgii Imeni I I Grekova</i> , 2017, 176, 34-41.	0.0	1
2026	The new combined parameter of hepatic and splenic elastography in patients with non-alcoholic fatty liver disease. <i>Klinicheskaia Meditsina</i> , 2017, 94, 935-940.	0.2	0
2027	TM6SF2 rs58542926 Polymorphism is not Associated With Risk of Steatosis or Fibrosis in Chilean Patients With Chronic Hepatitis C. <i>Hepatitis Monthly</i> , 2017, 17, .	0.1	2
2028	Rising Rate of Liver Transplantation in the Baby Boomer Generation with Non-alcoholic Steatohepatitis in the United States. <i>Journal of Clinical and Translational Hepatology</i> , 2017, XX, 1-4.	0.7	6
2029	Choline-Deficient-Diet-Induced Fatty Liver Is A Metastasis-Resistant Microenvironment. <i>Anticancer Research</i> , 2017, 37, 3429-3434.	0.5	5
2030	Which Method is Superior in the Diagnosis of Nonalcoholic Fatty Liver and Steatohepatitis in Children?. <i>Hepatitis Monthly</i> , 2017, 17, .	0.1	0

#	ARTICLE	IF	CITATIONS
2032	Noninvasive diagnosis of liver fibrosis in patients with nonalcoholic fatty liver disease. <i>Gastroenterologia</i> , 2017, 51, 188-195.	0.0	4
2033	Development of a non-invasive model to improve the accuracy of determining liver fibrosis stage in Nonalcoholic fatty liver disease. <i>Gastroenterologia</i> , 2017, 51, 256-271.	0.0	1
2034	Relationship between the Lipid Accumulation Product Index and Alanine Aminotransferase in Korean Adult Men. <i>Korean Journal of Clinical Laboratory Science</i> , 2017, 49, 374-381.	0.1	0
2035	Current approaches to diagnosing and treating nonalcoholic fatty liver disease. <i>Profilakticheskaya Meditsina</i> , 2018, 21, 62.	0.2	6
2036	Noninvasive quantification of liver fat content by different gradient echo magnetic resonance imaging sequences in patients with nonalcoholic fatty liver disease. <i>Journal of Medical Signals and Sensors</i> , 2018, 8, 244.	0.5	0
2037	Non-Alcoholic Fatty Liver Disease. <i>The Egyptian Journal of Hospital Medicine</i> , 2018, 70, 570-576.	0.0	0
2038	<i>Epidemiology and Comorbidities.</i> , 2018, , 1-83.		0
2039	Prevalence, patterns and predictive factors of non-alcoholic fatty liver disease among morbidly obese patients undergoing sleeve gastrectomy. <i>Australasian Medical Journal</i> , 2018, 11, .	0.1	0
2040	Clinical Manifestations of Liver Disease in Diabetes Mellitus. <i>Clinical Gastroenterology</i> , 2018, , 275-315.	0.0	0
2042	Dynamic thiol-disulfide homeostasis is disturbed in patients with non-alcoholic fatty liver disease. <i>Laboratoriums Medizin</i> , 2018, 42, 31-38.	0.1	3
2043	Nonalcoholic Fatty Liver Disease and Liver Fibrosis in Bariatric Patients: Tehran Obesity Treatment Study (TOTS). <i>Hepatitis Monthly</i> , 2018, 18, .	0.1	1
2044	Features of clinical and biochemical values in patients with various types of non-alcoholic fatty liver disease. <i>Bukovinian Medical Herald</i> , 2018, 22, 138-143.	0.1	0
2045	Tamoxifen-Induced Non-alcoholic Steatohepatitis Cirrhosis. <i>Soonchunhyang Medical Science</i> , 2018, 24, 81-84.	0.0	1
2046	Effect of Exercise Training on Metabolic Homeostasis and Some Hepatic and Cardiovascular Functions in a Rat Model of High Fat Diet Induced Obesity. <i>Medical Journal of the University of Cairo Faculty of Medicine</i> , 2018, 86, 1983-1994.	0.0	0
2047	Diabetes mellitus and non-alcoholic fatty liver disease. <i>Scientia Sinica Vitae</i> , 2018, 48, 876-881.	0.1	0
2048	The role of adipocytokines in the development of non-alcoholic fatty liver disease in patients with hypertension and obesity. <i>MAĀĀnarodnij EndokrinologĀĀĀnij ĀĀĀurnal</i> , 2018, 14, 339-343.	0.1	0
2049	Ceramide as a risk factor of nonalcoholic fatty liver disease. <i>Family Medicine</i> , 2018, .	0.1	0
2050	The pathogenetic role of large intestine dysbiosis in the pathogenesis of the mutually burdened non-alcoholic fatty liver disease and chronic kidney disease. <i>Ukrainian Therapeutical Journal</i> , 2018, .	0.0	1

#	ARTICLE	IF	CITATIONS
2051	Selection of hepatoprotector in multimorbid diseases of hepatobiliary system. Modern Gastroenterology, 2018, .	0.1	0
2052	Some causes of poor adherence to long-term statin therapy and their solution. Vnitri Lekarstvi, 2018, 64, 923-927.	0.1	2
2053	The peculiarities of liver damage markers and lipid blood spectrum in patients with nonalcoholic steatohepatitis, osteoarthritis and obesity. Ukrainian Therapeutical Journal, 2018, .	0.0	1
2054	The Severity of Non-Alcoholic Fatty Liver in Type II Diabetes. Medicina Interna (Bucharest, Romania: TJ ETQq1 1 0.784314 rgBT /Overl	0.1	1
2055	Diagnostic and prognostic biomarkers for the screening of patients with metabolic liver disease risk. Germs, 2018, 8, 175-177.	0.5	0
2056	Metabolic Syndrome and Nonalcoholic Fatty Liver Disease. Medicina Interna (Bucharest, Romania: 1991), 2019, 16, 51-58.	0.1	1
2057	ANTHROPOMETRIC AND BIOCHEMICAL CHARACTERISTICS OF ADULT PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE. Asian Journal of Pharmaceutical and Clinical Research, 2019, 12, 501.	0.3	0
2058	Endothelial dysfunction in adolescents and young adults with nonalcoholic liver disease. Journal of Mind and Medical Sciences, 0, , 58-63.	0.1	0
2059	The Association Between Risk Factors And Ultrasound-Based Grades Of Non-Alcoholic Fatty Liver Disease In Type-2 Diabetes Patients. Jurnal Widya Medika, 2019, 5, 47-59.	0.0	0
2060	Practical Use of Transient Elastography in Screening for Nonalcoholic Steatohepatitis in a Japanese Population. Journal of Clinical and Translational Hepatology, 2019, 7, 1-5.	0.7	0
2062	Non-Alcoholic Fatty Liver Disease. Vnitri Lekarstvi, 2019, 65, 571-575.	0.1	4
2063	Evaluation of Thyroid Function in Obese Adults with Non-Alcoholic Fatty Liver Disease Attending Tanta University Hospital. Medical Journal of the University of Cairo Faculty of Medicine, 2019, 87, 3267-3275.	0.0	0
2064	The impact of scoring system in the evaluation of Nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH). Gastroenterology & Hepatology (Bartlesville, Okla), 2019, 10, 262-266.	0.0	2
2065	Factors Associated with the Severity of Findings on Hepatic Transient Elastography among Persons with Type 2 Diabetes and Fatty Live. Journal of the ASEAN Federation of Endocrine Societies, 2019, 34, 134-143.	0.1	4
2066	Introductory Chapter: Nonalcoholic Fatty Liver Disease - What Should We Know?. , 0, ,		0
2067	Non-viral liver diseases: pathogenetic approaches to therapy. Medical Alphabet, 2019, 3, 30-36.	0.0	0
2068	Selank and semax as potential hepatoprotectors in medical treatment of tuberculosis. Research Results in Pharmacology, 2019, 5, 33-39.	0.1	0
2069	Clinical and Metabolic Profiles of Patients with Lean Non-Alcoholic Fatty Liver Diseases (NAFLD) Attending a Tertiary Health Care Centre of North-Eastern Region. Journal of Evidence Based Medicine and Healthcare, 2019, 6, 3192-3196.	0.0	0

#	ARTICLE	IF	CITATIONS
2070	Semi-quantitative ultrasound assessment of nonalcoholic fatty liver disease highlightens early subclinical atherosclerotic vascular damage: From risk factors to vascular damage. Polish Annals of Medicine, 2020, , .	0.3	1
2072	Perforin Acts as an Immune Regulator to Prevent the Progression of NAFLD. Frontiers in Immunology, 2020, 11, 846.	2.2	3
2073	Utility of Liver Function Tests and Fatty Liver Index to Categorize Metabolic Phenotypes in a Mediterranean Population. International Journal of Environmental Research and Public Health, 2020, 17, 3518.	1.2	6
2074	Autopsy incidence rate of fatty liver disease in the Irkutsk region. Eksperimental'naya I Klinicheskaya Gastroenterologiya, 2020, 174, 72-76.	0.1	2
2075	Current Status of Research on the Role of Circular RNAs in Hepatocellular Carcinoma and Clinical Implications. Medical Science Monitor, 2020, 26, e923832.	0.5	0
2076	Role of molecular genetic factors in pathogenesis and diagnosis of non-alcoholic fatty liver disease (literature review and own data). Medical Alphabet, 2020, , 13-19.	0.0	1
2077	Incidence of nonalcoholic fatty liver diseases and their associated risk factors among the type-2 diabetic population. Journal of Applied Pharmaceutical Science, 0, , .	0.7	0
2078	Efficacy and safety of endoscopic sleeve gastroplasty versus laparoscopic sleeve gastrectomy in obese subjects with Non-Alcoholic SteatoHepatitis (NASH): study protocol for a randomized controlled trial (TESLA-NASH study). Trials, 2021, 22, 756.	0.7	15
2079	Assessment of the inter-platform reproducibility of ultrasound attenuation examination in nonalcoholic fatty liver disease. Ultrasonography, 2022, 41, 355-364.	1.0	11
2080	The Gutâ€œLiver Axis in Chronic Liver Disease: A Macrophage Perspective. Cells, 2021, 10, 2959.	1.8	18
2081	SPECIFIC FEATURES OF METABOLIC DISORDERS IN MALES AND FEMALES WITH NON-ALCOHOLIC FATTY LIVER DISEASE. Juvenis Scientia, 2020, 6, 18-32.	0.1	0
2082	Detection of NAFLD/NASH in the General Population and in Primary Care Clinics. , 2020, , 11-27.		0
2083	Overall clinical and economic impact of non-alcoholic fatty liver disease. Revista Espanola De Enfermedades Digestivas, 2020, 113, 396-403.	0.1	0
2085	A Mineralocorticoid Receptor Deficiency in Myeloid Cells Reduces Liver Steatosis by Impairing Activation of CD8+ T Cells in a Nonalcoholic Steatohepatitis Mouse Model. Frontiers in Immunology, 2020, 11, 563434.	2.2	16
2086	Free-breathing 3D stack-of-radial MRI quantification of liver fat and R2* in adults with fatty liver disease. Magnetic Resonance Imaging, 2022, 85, 141-152.	1.0	7
2087	Pharmacokinetic Considerations for Organ Dysfunction Clinical Trials in Early Drug Development. , 2020, , 313-342.		0
2088	Evaluation of the Relationship between Insulin Resistance and HBV DNA Level in Patients with HBeAg-negative Chronic HBV Infection (Natural Course Phase 3). Euroasian Journal of Hepato-gastroenterology, 2021, 10, 85-91.	0.1	4
2090	MedikamentÃ¶s-toxischer Leberschaden (DILI). Pathologie, 2020, , 117-157.	0.0	0

#	ARTICLE	IF	CITATIONS
2093	Pharmacological Options for NASH. , 2020, , 309-327.		0
2094	Beneficial Effects of Honey Flavonoids in Nonalcoholic Fatty Liver Disease: An Update. , 2020, , 365-377.		0
2095	The Incidence and Risk Factors of Non-Alcoholic Fatty Liver Disease: A Cohort Study from Iran. Hepatitis Monthly, 2020, 20, .	0.1	7
2096	Nonalcoholic fatty liver disease: The role of quercetin and its therapeutic implications. Saudi Journal of Gastroenterology, 2021, 27, 319-330.	0.5	10
2097	Non alcoholic fatty liver disease and Chronic kidney Disease- pathophysiological connecting link. Gastroenterology & Hepatology (Bartlesville, Okla), 2020, 11, 89-92.	0.0	0
2098	Molecular Regulation of Bile Acid Homeostasis. Drug Metabolism and Disposition, 2022, 50, 425-455.	1.7	25
2099	The Role of Gut-Derived Lipopolysaccharides and the Intestinal Barrier in Fatty Liver Diseases. Journal of Gastrointestinal Surgery, 2022, 26, 671-683.	0.9	58
2100	Translatomics Probes Into the Role of Lycopene on Improving Hepatic Steatosis Induced by High-Fat Diet. Frontiers in Nutrition, 2021, 8, 727785.	1.6	4
2101	A short report on NGM282/aldafermin for the treatment of nonalcoholic steatohepatitis (NASH). Expert Opinion on Therapeutic Targets, 2021, 25, 889-895.	1.5	6
2102	Association of Incidence between Pancreatic Adipose Infiltration and Metabolic Syndrome: A Literature Review and Meta-analysis. Computational and Mathematical Methods in Medicine, 2021, 2021, 1-10.	0.7	1
2103	Non-alcoholic steatohepatitis and the risk of myocardial infarction: A population-based national study. World Journal of Hepatology, 2020, 12, 379-389.	0.8	0
2106	The evaluation of complications and mortality in non-alcoholic steatohepatitis related cirrhosis. Marmara Medical Journal, 0, , 130-135.	0.2	0
2107	Estimation of visceral fat is useful for the diagnosis of significant fibrosis in patients with non-alcoholic fatty liver disease. World Journal of Gastroenterology, 2020, 26, 6658-6668.	1.4	12
2108	Evaluation of Cytotoxic Activity of Lavandula stoechas Aerial Parts Fractions against HepG2 Cell Lines. Current Bioactive Compounds, 2020, 16, 1281-1289.	0.2	6
2111	Protective effect of xanthohumol on toxin-induced liver inflammation and fibrosis. International Journal of Clinical and Experimental Pathology, 2012, 5, 29-36.	0.5	28
2112	Fatty liver in lean patients: is it a different disease?. Annals of Gastroenterology, 2012, 25, 1-2.	0.4	39
2113	Liver disease in women: the influence of gender on epidemiology, natural history, and patient outcomes. Gastroenterology and Hepatology, 2013, 9, 633-9.	0.2	73
2114	Cardiovascular disorders in the context of non-alcoholic Fatty liver disease: a literature review. The Journal of Tehran Heart Center, 2014, 9, 1-8.	0.3	3

#	ARTICLE	IF	CITATIONS
2115	Sonographic assessment of fatty liver: intraobserver and interobserver variability. <i>International Journal of Clinical and Experimental Medicine</i> , 2014, 7, 5453-60.	1.3	31
2116	Fibroscan versus simple noninvasive screening tools in predicting fibrosis in high-risk nonalcoholic fatty liver disease patients from Western India. <i>Annals of Gastroenterology</i> , 2015, 28, 281-286.	0.4	17
2117	Protective effect of salvianolic acid B on NASH rat liver through restoring intestinal mucosal barrier function. <i>International Journal of Clinical and Experimental Pathology</i> , 2015, 8, 5203-9.	0.5	12
2118	Metabolic derangements mediate cognitive impairment and Alzheimer's disease: role of peripheral insulin-resistance diseases. <i>Panminerva Medica</i> , 2012, 54, 171-8.	0.2	32
2119	Non-invasive imaging techniques in assessing non-alcoholic fatty liver disease: a current status of available methods. <i>Journal of Medicine and Life</i> , 2017, 10, 19-26.	0.4	12
2121	Clinicopathological and immunological characteristics and outcome of concomitant coeliac disease and non-alcoholic fatty liver disease in adults: a large prospective longitudinal study. <i>BMJ Open Gastroenterology</i> , 2018, 5, e000150.	1.1	6
2122	New insights into Nod-like receptors (NLRs) in liver diseases. <i>International Journal of Physiology, Pathophysiology and Pharmacology</i> , 2018, 10, 1-16.	0.8	9
2123	A Case-control Study to Evaluate the Prevalence of Nonalcoholic Fatty Liver Disease Among Patients with Moderate-to-severe Psoriasis. <i>Journal of Clinical and Aesthetic Dermatology</i> , 2018, 11, 33-37.	0.1	24
2124	Hepato-splenic axis: hepatic and splenic metabolic activities are linked. <i>American Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 8, 228-238.	1.0	5
2125	The Association of Hispanic Ethnicity with Nonalcoholic Fatty Liver Disease in Polycystic Ovary Syndrome. , 2018, 1, 24-33.		3
2126	Clinical, Epidemiological and Histopathological Aspects in Patients with Hepatocellular Carcinoma Undergoing Liver Transplantation. <i>Asian Pacific Journal of Cancer Prevention</i> , 2018, 19, 2795-2802.	0.5	5
2127	Implications of Nonalcoholic Fatty Liver Disease on Pregnancy and Maternal and Child Outcomes. <i>Gastroenterology and Hepatology</i> , 2019, 15, 221-228.	0.2	3
2129	Preclinical cardiac disease in nonalcoholic fatty liver disease with and without metabolic syndrome. <i>American Journal of Cardiovascular Disease</i> , 2019, 9, 65-77.	0.5	5
2130	Comorbidity of metabolic syndrome components in a population-based screening program: A latent class analysis. <i>Medical Journal of the Islamic Republic of Iran</i> , 2020, 34, 69.	0.9	1
2131	Higher non-HDL-cholesterol to HDL-cholesterol ratio is linked to increase in non-alcoholic fatty liver disease: secondary analysis based on a longitudinal study. <i>International Journal of Clinical and Experimental Pathology</i> , 2020, 13, 2569-2575.	0.5	0
2132	The therapeutic effects of berberine plus sitagliptin in a rat model of fatty liver disease. <i>Iranian Journal of Basic Medical Sciences</i> , 2021, 24, 451-459.	1.0	1
2133	Targeting the eicosanoid pathway in hepatocellular carcinoma. <i>American Journal of Cancer Research</i> , 2021, 11, 2456-2476.	1.4	1
2134	Association of non-alcoholic fatty liver disease with coronary artery calcification progression: a systematic review and meta-analysis. <i>Przegląd Gastroenterologiczny</i> , 2021, 16, 196-206.	0.3	1

#	ARTICLE	IF	CITATIONS
2135	Sleep Duration, Sleep Quality, and the Development of Nonalcoholic Fatty Liver Disease: A Cohort Study. <i>Clinical and Translational Gastroenterology</i> , 2021, 12, e00417.	1.3	1
2136	Sleep Duration, Sleep Quality, and the Development of Nonalcoholic Fatty Liver Disease: A Cohort Study. <i>Clinical and Translational Gastroenterology</i> , 2021, 12, e00417.	1.3	13
2137	The Role of Notch Signaling Pathway in Non-Alcoholic Fatty Liver Disease. <i>Frontiers in Molecular Biosciences</i> , 2021, 8, 792667.	1.6	11
2138	Nonalcoholic fatty liver disease is associated with worse intestinal complications in patients hospitalized for <i>Clostridioides difficile</i> infection. <i>World Journal of Hepatology</i> , 2021, 13, 1777-1790.	0.8	2
2140	Liver pathology in pregnancy. <i>Pathology International</i> , 2022, 72, 1-13.	0.6	8
2141	Prevalence and outcomes of chronic liver disease in patients receiving dialysis: systematic review and meta-analysis. <i>CKJ: Clinical Kidney Journal</i> , 2022, 15, 747-757.	1.4	4
2142	Activation and Functional Priming of Blood Neutrophils in Non-Alcoholic Fatty Liver Disease Increases in Non-Alcoholic Steatohepatitis. <i>Clinical and Experimental Gastroenterology</i> , 2021, Volume 14, 441-449.	1.0	7
2143	Potential relation between non-alcoholic fatty liver disease and glycemic and metabolic parameters in subjects without diabetes. <i>Egyptian Liver Journal</i> , 2021, 11, .	0.3	2
2144	The Leg Fat to Total Fat Ratio Is Associated with Lower Risks of Non-Alcoholic Fatty Liver Disease and Less Severe Hepatic Fibrosis: Results from Nationwide Surveys (KNHANES 2008-2011). <i>Endocrinology and Metabolism</i> , 2021, 36, 1232-1242.	1.3	2
2145	Evaluation of fibrosis in patients with nonalcoholic fatty liver disease. <i>Revista De Gastroenterología De México (English Edition)</i> , 2021, 87, 1-1.	0.1	0
2147	Systematic Review and Meta-analysis: The Role of Diet in the Development of Nonalcoholic Fatty Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2023, 21, 1462-1474.e24.	2.4	20
2148	m6A mRNA methylation-directed myeloid cell activation controls progression of NAFLD and obesity. <i>Cell Reports</i> , 2021, 37, 109968.	2.9	53
2149	Subclinical steatohepatitis and advanced liver fibrosis in health examinees with nonalcoholic fatty liver disease (NAFLD) in 10 South Korean cities: A retrospective cross-sectional study. <i>PLoS ONE</i> , 2021, 16, e0260477.	1.1	2
2150	Effect of Long-Term Exercise on Liver Lipid Metabolism in Chinese Patients With NAFLD: A Systematic Review and Meta-Analysis. <i>Frontiers in Physiology</i> , 2021, 12, 748517.	1.3	5
2151	Assessment of non-alcoholic fatty liver disease (NAFLD) severity with novel serum-based markers: A pilot study. <i>PLoS ONE</i> , 2021, 16, e0260313.	1.1	16
2152	Concerted regulation of non-alcoholic fatty liver disease progression by microRNAs in apolipoprotein E-deficient mice. <i>DMM Disease Models and Mechanisms</i> , 2021, 14, .	1.2	5
2153	Sex-Specific Differences in the Association Between Race/Ethnicity and NAFLD Among US Population. <i>Frontiers in Medicine</i> , 2021, 8, 795421.	1.2	12
2154	Biochemical Parameters as Predictors of Underlying Liver Disease in Patients with Chronic Kidney Disorders. <i>Acta Informatica Medica</i> , 2021, 29, 260.	0.5	2

#	ARTICLE	IF	CITATIONS
2155	Reducing the Risk of and Screening for Liver Cancer. , 2021, , 1-20.		0
2156	Machine Learning Approach to Classify Cardiovascular Disease in Patients With Nonalcoholic Fatty Liver Disease in the UK Biobank Cohort. Journal of the American Heart Association, 2022, 11, e022576.	1.6	8
2157	The advantages of physical exercise as a preventive strategy against NAFLD in postmenopausal women. European Journal of Clinical Investigation, 2022, 52, e13731.	1.7	8
2159	Evaluation and impact of different biomarkers for early detection of hepatocellular carcinoma. Hepatoma Research, 0, 2020, .	0.6	0
2160	Portrait of Regional Trends in Liver Transplantation for Nonalcoholic Steatohepatitis in the United States. American Journal of Gastroenterology, 2022, 117, 433-444.	0.2	10
2161	Is there a role of lipid-lowering therapies in the management of fatty liver disease?. World Journal of Hepatology, 2022, 14, 119-139.	0.8	13
2162	Association between thyroid function and assessment of hepatic fat and iron contents by magnetic resonance imaging. Endocrine Connections, 2022, , .	0.8	2
2164	The triglyceride-glucose index as a clinical useful marker for metabolic associated fatty liver disease (MAFLD): a population-based study among Iranian adults. Journal of Diabetes and Metabolic Disorders, 2022, 21, 97-107.	0.8	8
2165	The effect of polypharmacy on quality of life in adult patients with nonalcoholic fatty liver disease in the United States. Quality of Life Research, 2022, 31, 2481-2491.	1.5	6
2166	Recapitulating lipid accumulation and related metabolic dysregulation in human liver-derived organoids. Journal of Molecular Medicine, 2022, 100, 471-484.	1.7	9
2167	Lipid droplets associated perilipins protein insights into finding a therapeutic target approach to cure non-alcoholic fatty liver disease (NAFLD). Future Journal of Pharmaceutical Sciences, 2022, 8, .	1.1	11
2168	Exploring New Drug Targets for Type 2 Diabetes: Success, Challenges and Opportunities. Biomedicines, 2022, 10, 331.	1.4	17
2169	Fermented field water-dropwort (<i>Oenanthe javanica</i>) alleviates diet-induced non-alcoholic steatohepatitis. Food and Agricultural Immunology, 2022, 33, 20-34.	0.7	0
2170	Association between bedtime at night and nonalcoholic fatty liver disease diagnosed by liver ultrasound transient elastography. Diabetes Research and Clinical Practice, 2022, 184, 109195.	1.1	6
2171	Effects of magnesium picolinate, zinc picolinate, and selenomethionine co-supplementation on reproductive hormones, and glucose and lipid metabolism-related protein expressions in male rats fed a high-fat diet. Food Chemistry Molecular Sciences, 2022, 4, 100081.	0.9	2
2172	A problem of proportions: estimates of metabolic associated fatty liver disease and liver fibrosis in Australian adults in the nationwide 2012 AusDiab Study. Scientific Reports, 2022, 12, 1956.	1.6	6
2174	Diagnostic Modalities of Non-Alcoholic Fatty Liver Disease: From Biochemical Biomarkers to Multi-Omics Non-Invasive Approaches. Diagnostics, 2022, 12, 407.	1.3	22
2175	Effect of Omega-3 Polyunsaturated Fatty Acids on Lipid Metabolism in Patients With Metabolic Syndrome and NAFLD. Hepatology Communications, 2022, 6, 1336-1349.	2.0	22

#	ARTICLE	IF	CITATIONS
2176	Sarcopenia in liver cirrhosis: Prevalence, pathophysiology and therapeutic strategies. <i>Analytical Biochemistry</i> , 2022, 647, 114581.	1.1	8
2177	The Translational Bridge between Inflammation and Hepatocarcinogenesis. <i>Cells</i> , 2022, 11, 533.	1.8	9
2178	Cholesterol metabolism in aging simultaneously altered in liver and nervous system. <i>Aging</i> , 2022, 14, 1549-1561.	1.4	17
2179	Noninvasive biomarkers of non-alcoholic fatty liver disease in patients with metabolic syndrome: insights from the RESOLVE Study. <i>Minerva Gastroenterology</i> , 2024, 69, .	0.3	0
2180	Non-Alcoholic Fatty Liver Disease (NAFLD) in Patients with Psoriasis: A Review of the Hepatic Effects of Systemic Therapies. <i>Psoriasis: Targets and Therapy</i> , 2021, Volume 11, 151-168.	1.2	10
2181	Intestinal Barrier and Permeability in Health, Obesity and NAFLD. <i>Biomedicines</i> , 2022, 10, 83.	1.4	71
2182	Testosterone, Sex Hormone-Binding Globulin and Nonalcoholic Fatty Liver Disease: a Systematic Review and Meta-Analysis. <i>Annals of Hepatology</i> , 2017, 16, 382-394.	0.6	66
2183	Risk factors and pathogenic mechanismâ€“associated hepatocellular carcinoma. , 2022, , 33-49.		0
2184	Positive Pattern Recognition System Using Alanine Aminotransferase, Type IV Collagen 7s, and E Value (Liver Stiffness) for the Diagnosis of Nonalcoholic Steatohepatitis Based on Natural History. <i>JMA Journal</i> , 2022, 5, .	0.6	1
2185	Prevalence of Metabolic-associated Fatty Liver Disease in Mexico and Development of a Screening Tool: The MAFLD-S Score. , 2022, 1, 352-358.		5
2187	Antisense Oligonucleotide Technologies to Combat Obesity and Fatty Liver Disease. <i>Frontiers in Physiology</i> , 2022, 13, 839471.	1.3	4
2188	Nonalcoholic Fatty Liver Disease in Lean Chinese: The Public Health Crisis We Can No Longer Ignore. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
2190	Non-alcoholic fatty liver disease (NAFLD): a significant predictor of gestational diabetes mellitus (GDM) and early pregnancy miscarriagesâ€”prospective study in Rajarata Pregnancy Cohort (RaPCo). <i>BMJ Open Gastroenterology</i> , 2022, 9, e000831.	1.1	7
2191	The impact of metabolic health on non-alcoholic fatty liver disease (NAFLD). A single center experience. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2022, 46, 101896.	0.7	2
2192	Nuclear Receptors Linking Metabolism, Inflammation, and Fibrosis in Nonalcoholic Fatty Liver Disease. <i>International Journal of Molecular Sciences</i> , 2022, 23, 2668.	1.8	42
2193	Organ meat consumption and risk of nonalcoholic fatty liver disease: the TCLSIH study. <i>British Journal of Nutrition</i> , 2022, , 1-21.	1.2	0
2194	Dietary Patterns and Prevalent NAFLD at Year 25 from the Coronary Artery Risk Development in Young Adults (CARDIA) Study. <i>Nutrients</i> , 2022, 14, 854.	1.7	5
2195	Platelets in Non-alcoholic Fatty Liver Disease. <i>Frontiers in Pharmacology</i> , 2022, 13, 842636.	1.6	9

#	ARTICLE	IF	CITATIONS
2196	Synergistic and Detrimental Effects of Alcohol Intake on Progression of Liver Steatosis. <i>International Journal of Molecular Sciences</i> , 2022, 23, 2636.	1.8	11
2197	Prevalence and risk factors of metabolic-associated fatty liver disease during 2014–2018 from three cities of Liaoning Province: an epidemiological survey. <i>BMJ Open</i> , 2022, 12, e047588.	0.8	4
2198	Gene expression signature of exercise and change of diet on non-alcoholic fatty liver disease in mice. <i>Comparative Exercise Physiology</i> , 2022, 18, 143-154.	0.3	0
2199	Deciphering the role of aquaporins in metabolic diseases: A mini review. <i>American Journal of the Medical Sciences</i> , 2022, 364, 148-162.	0.4	3
2200	Comparative Studies on Blood Serum Profiles of Liver Enzymes, Proteins, Total Bilirubin and Liver Organ Morphometry of Muscovy Ducks. <i>Black Sea Journal of Agriculture</i> , 2022, 5, 167-171.	0.1	0
2201	Nonalcoholic Fatty Liver Disease and Endocrine Axes—A Scoping Review. <i>Metabolites</i> , 2022, 12, 298.	1.3	19
2202	Operative and long-term oncologic outcomes of laparoscopic versus open major liver resection in patients with a high body mass index (>25 kg/m ²): a propensity score matching analysis. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2022, 36, 5772-5783.	1.3	2
2203	Transarterial Chemoembolization Combined With Tyrosine Kinase Inhibitors for Intermediate-Stage Hepatocellular Carcinoma, What Else Can We Do?. <i>Frontiers in Oncology</i> , 2022, 12, 824799.	1.3	3
2204	Dual roles of B lymphocytes in mouse models of diet-induced nonalcoholic fatty liver disease. <i>Hepatology</i> , 2022, 76, 1135-1149.	3.6	17
2205	Association between non-alcoholic fatty liver disease and the risk of dementia: A nationwide cohort study. <i>Liver International</i> , 2022, 42, 1027-1036.	1.9	23
2206	The association between dietary acid load and odds of non-alcoholic fatty liver disease: A case-control study. <i>Nutrition and Health</i> , 2023, 29, 637-644.	0.6	5
2207	Role of XBP1 in regulating the progression of non-alcoholic steatohepatitis. <i>Journal of Hepatology</i> , 2022, 77, 312-325.	1.8	49
2208	Prospective Evaluation of Virtual MR Elastography With Diffusion-Weighted Imaging in Subjects With Nonalcoholic Fatty Liver Disease. <i>Journal of Magnetic Resonance Imaging</i> , 2022, 56, 1448-1456.	1.9	2
2209	Recent Epidemiology and Risk Factors of Nonalcoholic Fatty Liver Disease. <i>Journal of Obesity and Metabolic Syndrome</i> , 2022, 31, 17-27.	1.5	39
2210	Fibromax and inflammatory markers cannot replace liver biopsy in the evaluation of non-alcoholic fatty liver disease. <i>Minerva Gastroenterology</i> , 2022, 68, .	0.3	5
2211	The role of microbiota in nonalcoholic fatty liver disease. <i>European Journal of Clinical Investigation</i> , 2022, 52, e13768.	1.7	22
2212	Explore the Mechanism of Astragalus mongholicus Bunge against Nonalcoholic Fatty Liver Disease Based on Network Pharmacology and Experimental Verification. <i>Gastroenterology Research and Practice</i> , 2022, 2022, 1-17.	0.7	3
2213	Investigation of the protective and therapeutic effects of thiamine in thioacetamide-induced liver injury. , 2022, 77, 1953-1964.		1

#	ARTICLE	IF	CITATIONS
2214	Predicting NAFLD prevalence in the United States using National Health and Nutrition Examination Survey 2017–2018 transient elastography data and application of machine learning. <i>Hepatology Communications</i> , 2022, 6, 1537-1548.	2.0	33
2215	mTOR as an eligible molecular target for possible pharmacological treatment of nonalcoholic steatohepatitis. <i>European Journal of Pharmacology</i> , 2022, 921, 174857.	1.7	6
2216	Enhanced lipogenesis through Ppar β helps cavefish adapt to food scarcity. <i>Current Biology</i> , 2022, 32, 2272-2280.e6.	1.8	23
2217	Association of Non-Alcoholic Fatty Liver Disease With in-Hospital Outcomes in Primary Heart Failure Hospitalizations With Reduced or Preserved Ejection Fraction. <i>Current Problems in Cardiology</i> , 2023, 48, 101199.	1.1	12
2218	Effect of physical activity on the development and the resolution of nonalcoholic fatty liver in relation to body mass index. <i>BMC Public Health</i> , 2022, 22, 655.	1.2	4
2219	Identification cholesterol metabolites altered before the onset of nonalcoholic steatohepatitis by targeted metabolomics. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , 2022, 1867, 159135.	1.2	5
2220	Nonalcoholic Fatty Liver Disease – Cardiovascular Risk Factor in Patients with Type 2 Diabetes Mellitus. <i>Medicina Interna (Bucharest, Romania)</i> , 2021, 18, 21-27.	0.1	0
2221	Cell Models and Omics Techniques for the Study of Nonalcoholic Fatty Liver Disease: Focusing on Stem Cell-Derived Cell Models. <i>Antioxidants</i> , 2022, 11, 86.	2.2	3
2222	Factors That Predict the Progression of Non-alcoholic Fatty Liver Disease (NAFLD). <i>Cureus</i> , 2021, 13, e20776.	0.2	6
2223	Elevated serum ferritin in non-alcoholic fatty liver disease is not predictive of fibrosis. <i>Canadian Liver Journal</i> , 2022, 5, 152-159.	0.3	5
2224	Gender-specific prevalence of metabolic-associated fatty liver disease among government employees in Tianjin, China: a cross-sectional study. <i>BMJ Open</i> , 2021, 11, e056260.	0.8	8
2225	THE POSSIBILITIES OF COMPLEX VISUAL DIAGNOSTICS OF LIVER PATHOLOGY IN PATIENTS WITH DIFFUSE LIVER DISEASES ASSOCIATED WITH COVID-19.. <i>Computational Geophysics</i> , 2021, 4, 41-45.	0.0	0
2226	Sulforaphane Attenuates Nonalcoholic Fatty Liver Disease by Inhibiting Hepatic Steatosis and Apoptosis. <i>Nutrients</i> , 2022, 14, 76.	1.7	21
2227	Nitro Fatty Acids (NO ₂ -FAs): An Emerging Class of Bioactive Fatty Acids. <i>Molecules</i> , 2021, 26, 7536.	1.7	9
2228	Non-alcoholic fatty liver disease: a multidisciplinary clinical practice approach—the institutional adaptation to existing Clinical Practice Guidelines. <i>Emergency and Critical Care Medicine</i> , 2022, 2, 12-22.	0.1	2
2229	Fibrogenesis Marker PRO-C3 Is Higher in Advanced Liver Fibrosis and Improves in Patients Undergoing Bariatric Surgery. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, e1356-e1366.	1.8	6
2230	Association of non-alcoholic fatty liver disease with coronary artery calcification progression: a systematic review and meta-analysis. <i>Przegląd Gastroenterologiczny</i> , 2021, 16, 196-206.	0.3	4
2231	Emerging advances in the pharmacologic treatment of nonalcoholic steatohepatitis and related cirrhosis. <i>Annals of Gastroenterology</i> , 2022, , .	0.4	4

#	ARTICLE	IF	CITATIONS
2232	DNA Methylation Patterns According to Fatty Liver Index and Longitudinal Changes from the Korean Genome and Epidemiology Study (KoGES). <i>Current Issues in Molecular Biology</i> , 2022, 44, 1149-1168.	1.0	4
2233	Lifestyle as well as metabolic syndrome and non-alcoholic fatty liver disease: an umbrella review of evidence from observational studies and randomized controlled trials. <i>BMC Endocrine Disorders</i> , 2022, 22, 95.	0.9	5
2234	SPP1 and CXCL9 Promote Non-alcoholic Steatohepatitis Progression Based on Bioinformatics Analysis and Experimental Studies. <i>Frontiers in Medicine</i> , 2022, 9, 862278.	1.2	7
2235	Clinical Progression of Metabolic-Associated Fatty Liver Disease Is Rare in a Danish Tertiary Liver Center. <i>Journal of Clinical Medicine</i> , 2022, 11, 2271.	1.0	0
2247	Clinicopathological and immunological characteristics and outcome of concomitant coeliac disease and non-alcoholic fatty liver disease in adults: a large prospective longitudinal study. <i>BMJ Open Gastroenterology</i> , 2018, 5, e000150.	1.1	9
2249	Other aspects of bariatric surgery: liver steatosis, ferritin and cholesterol metabolism. <i>Nutricion Hospitalaria</i> , 2013, 28 Suppl 2, 104-8.	0.2	7
2250	Vitamin D levels and bone turnover markers are not related to non-alcoholic fatty liver disease in severely obese patients. <i>Nutricion Hospitalaria</i> , 2014, 30, 1256-62.	0.2	10
2251	NUTRITIONAL STATUS, DIET AND NON-ALCOHOLIC FATTY LIVER DISEASE IN ELDERS. <i>Nutricion Hospitalaria</i> , 2015, 32, 2038-45.	0.2	4
2253	Obesity-Related Gastrointestinal Disorders. , 2022, , 207-219.		1
2254	Correlation between Fibroscan and laboratory tests in non-alcoholic fatty liver disease/non-alcoholic steatohepatitis patients for assessing liver fibrosis. <i>World Journal of Hepatology</i> , 2022, 14, 744-753.	0.8	2
2255	Effect of a Six-Month Lifestyle Intervention on the Physical Activity and Fitness Status of Adults with NAFLD and Metabolic Syndrome. <i>Nutrients</i> , 2022, 14, 1813.	1.7	19
2256	Clinical Differences and Non-Alcoholic Fatty Liver Disease-Related Factors of Lean and Non-Lean Patients with Metabolic Syndrome. <i>Journal of Clinical Medicine</i> , 2022, 11, 2445.	1.0	0
2257	Hepatorenal Index by Bâ€Mode Ratio Versus Imaging and Fatty Liver Index to Diagnose Steatosis in Alcoholâ€Related and Nonalcoholic Fatty Liver Disease. <i>Journal of Ultrasound in Medicine</i> , 2022, , .	0.8	5
2258	Circulating bile acid concentrations and nonâ€alcoholic fatty liver disease in Guatemala. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 56, 321-329.	1.9	12
2259	Additional treatment of vitamin D for improvement of insulin resistance in non-alcoholic fatty liver disease patients: a systematic review and meta-analysis. <i>Scientific Reports</i> , 2022, 12, 7716.	1.6	17
2260	An examination of eating behavior in patients with non-alcoholic fatty liver disease: A cross-sectional study in a Japanese population. <i>Human Nutrition and Metabolism</i> , 2022, 28, 200150.	0.8	1
2261	Croatian guidelines for the diagnosis and treatment of nonalcoholic fatty liver disease. <i>Acta Clinica Croatica</i> , 2021, 60, 36-52.	0.1	0
2262	Diagnostic Feasibility of Magnetic Resonance Elastography Radiomics Analysis for the Assessment of Hepatic Fibrosis in Patients With Nonalcoholic Fatty Liver Disease. <i>Journal of Computer Assisted Tomography</i> , 2022, Publish Ahead of Print, .	0.5	3

#	ARTICLE	IF	CITATIONS
2263	Prolonged effects of DPP-4 inhibitors on steato-hepatic changes in Sprague-Dawley rats fed a high-cholesterol diet. <i>Inflammation Research</i> , 2022, , .	1.6	0
2264	Comparison of reader agreement, correlation with liver biopsy, and time-burden sampling strategies for liver proton density fat fraction measured using magnetic resonance imaging in patients with obesity: a secondary cross-sectional study. <i>BMC Medical Imaging</i> , 2022, 22, 92.	1.4	1
2265	Postmortem survey of haemoglobin A1c, non-alcoholic steatohepatitis and liver fibrosis within a general population. <i>Journal of Clinical Pathology</i> , 2023, 76, 606-611.	1.0	4
2267	Point-of-care magnetic resonance technology to measure liver fat: Phantom and first human pilot study. <i>Magnetic Resonance in Medicine</i> , 2022, 88, 1794-1805.	1.9	6
2268	Natural PPARs agonists for the treatment of nonalcoholic fatty liver disease. <i>Biomedicine and Pharmacotherapy</i> , 2022, 151, 113127.	2.5	10
2269	Applications of Quantitative Systems Pharmacology (QSP) in Drug Development for NAFLD and NASH and Its Regulatory Application. <i>Pharmaceutical Research</i> , 2022, 39, 1789-1802.	1.7	4
2270	Does Hepatic Steatosis Influence the Virological Response with Chronic Hepatitis B Patients Treated with Entecavir or Tenofovir Disoproxil Fumarate?. , 2022, 33, 587-595.		0
2271	The Role of Thiazolidinediones in the Amelioration of Nonalcoholic Fatty Liver Disease: A Systematic Review. <i>Cureus</i> , 2022, , .	0.2	3
2272	Inulin may prevent steatosis by suppressing cannabinoid receptor-1 and patatin-like phospholipase-3 expression in liver. <i>Nutrition</i> , 2022, 103-104, 111742.	1.1	2
2273	Pregnancy and Metabolic-associated Fatty Liver Disease: A Clinical Update. <i>Journal of Clinical and Translational Hepatology</i> , 2022, 10, 947-954.	0.7	7
2274	Ethyl glucuronide in hair detects a high rate of harmful alcohol consumption in presumed non-alcoholic fatty liver disease. <i>Journal of Hepatology</i> , 2022, 77, 918-930.	1.8	68
2275	Osteopontin Promotes Macrophage M1 Polarization by Activation of the JAK1/STAT1/HMGB1 Signaling Pathway in Nonalcoholic Fatty Liver Disease. <i>Journal of Clinical and Translational Hepatology</i> , 2022, 000, 000-000.	0.7	3
2276	A diet-induced murine model for non-alcoholic fatty liver disease with obesity and insulin resistance that rapidly develops steatohepatitis and fibrosis. <i>Laboratory Investigation</i> , 2022, 102, 1150-1157.	1.7	4
2277	Population-specific cut-off points of fatty liver index: a study based on the National Health and Nutrition Examination Survey data. <i>BMC Gastroenterology</i> , 2022, 22, .	0.8	3
2278	Quantification of liver fat deposition in obese and diabetic patients: A pilot study on the correlation with myocardium and periapical fat content†. <i>Liver Research</i> , 2022, , .	0.5	1
2280	Short-term outcome of bariatric surgery on nonalcoholic fatty liver disease: a Korean perspective. <i>Annals of Surgical Treatment and Research</i> , 2022, 102, 353.	0.4	2
2281	Validity of fatty liver disease indices in the presence of alcohol consumption. <i>Scandinavian Journal of Gastroenterology</i> , 2022, 57, 1349-1360.	0.6	2
2282	Pituitary Tumor-Transforming Gene 1/Delta like Non-Canonical Notch Ligand 1 Signaling in Chronic Liver Diseases. <i>International Journal of Molecular Sciences</i> , 2022, 23, 6897.	1.8	5

#	ARTICLE	IF	CITATIONS
2283	The Determinants of Liver Fibrosis in Patients with Nonalcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus. <i>Biomedicines</i> , 2022, 10, 1487.	1.4	9
2284	Impact of Physical Activity Differences Due to COVID-19 Pandemic Lockdown on Non-Alcoholic Fatty Liver Parameters in Adults with Metabolic Syndrome. <i>Nutrients</i> , 2022, 14, 2370.	1.7	5
2285	Risk factors associated with nonalcoholic fatty liver disease evaluated by elastography in patients with type 2 diabetes. <i>Archives of Endocrinology and Metabolism</i> , 2022, , .	0.3	1
2286	Combinations of an acetyl CoA carboxylase inhibitor with hepatic lipid modulating agents do not augment antifibrotic efficacy in preclinical models of NASH and fibrosis. <i>Hepatology Communications</i> , 2022, 6, 2298-2309.	2.0	6
2287	Prevalence estimation of significant fibrosis because of <sc>NASH</sc> in Spain combining transient elastography and histology. <i>Liver International</i> , 2022, 42, 1783-1792.	1.9	10
2288	Efficacy and safety of oral semaglutide in patients with non-€ alcoholic fatty liver disease complicated by type 2 diabetes mellitus: A pilot study. <i>JGH Open</i> , 2022, 6, 503-511.	0.7	10
2289	Relation of Dietary Patterns and Nutritional Profile to Hepatic Fibrosis in a Sample of Lebanese Non-Alcoholic Fatty Liver Disease Patients. <i>Nutrients</i> , 2022, 14, 2554.	1.7	1
2290	Effect of Aerobic Exercise on Lipid Metabolism in Rats With NAFLD. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	2
2291	Amycenone reduces excess body weight and attenuates hyperlipidaemia by inhibiting lipogenesis and promoting lipolysis and fatty acid Î²-oxidation in KK- <i>A</i> ^y / _{obese} diabetic mice. <i>Journal of Nutritional Science</i> , 2022, 11, .	0.7	2
2292	Statins in Alcoholic and Non-Alcoholic Fatty Liver Disease and Chronically Elevated Liver Enzymes. <i>International Journal of Clinical Medicine</i> , 2022, 13, 229-252.	0.1	1
2293	<i>Gryllus bimaculatus</i> extract ameliorates high-fat diet-induced hyperglycemia and hyperlipidemia by inhibiting hepatic lipogenesis through AMPK activation. <i>Food Science and Biotechnology</i> , 0, , .	1.2	0
2294	Correlation between nonalcoholic fatty liver disease by ultrasound with hepatic veins spectral doppler and aminotransferases. <i>International Journal of Health Sciences</i> , 0, , 2439-2450.	0.0	0
2295	Pharmacological Treatment of Nonalcoholic Fatty Liver Disease: Antidiabetic Agents. <i>Journal of Korean Diabetes</i> , 2022, 23, 83-88.	0.1	0
2296	Transforming growth factor-€beta 1: A new factor reducing hepatic SHBG production in liver fibrosis. <i>Journal of Cellular Physiology</i> , 0, , .	2.0	1
2297	A Non-Invasive Scoring System for Liver Fibrosis in Patients with Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD). , 2022, , .		0
2298	Effects of licorice root supplementation on liver enzymes, hepatic steatosis, metabolic and oxidative stress parameters in women with nonalcoholic fatty liver disease: A randomized double-€blind clinical trial. <i>Phytotherapy Research</i> , 2022, 36, 3949-3956.	2.8	5
2299	Divergent trajectories of lean <i>vs </i>obese non-alcoholic steatohepatitis patients from listing to post-transplant: A retrospective cohort study. <i>World Journal of Gastroenterology</i> , 2022, 28, 3218-3231.	1.4	2
2300	Semaglutide might be a key for breaking the vicious cycle of metabolically associated fatty liver disease spectrum?. <i>World Journal of Clinical Cases</i> , 2022, 10, 6759-6768.	0.3	3

#	ARTICLE	IF	CITATIONS
2301	Predictors of patient survival following liver transplant in non-alcoholic steatohepatitis: A systematic review and meta-analysis. <i>EClinicalMedicine</i> , 2022, 50, 101534.	3.2	7
2302	<i>Phyllanthus emblica</i> aqueous extract retards hepatic steatosis and fibrosis in NAFLD mice in association with the reshaping of intestinal microecology. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	12
2303	<i>Akkermansia Muciniphila</i> Suppressing Nonalcoholic Steatohepatitis Associated Tumorigenesis Through Natural Killer T Cells. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
2304	Non-alcoholic Fatty Liver Disease and Steatohepatitis: Risk Factors and Pathophysiology. <i>Middle East Journal of Digestive Diseases</i> , 2022, 14, 167-181.	0.2	2
2305	<i>Salvia-Nelumbinis naturalis</i> improves lipid metabolism of NAFLD by regulating the SIRT1/AMPK signaling pathway. <i>BMC Complementary Medicine and Therapies</i> , 2022, 22, .	1.2	4
2306	A cross-sectional study assessing the relationship between non-alcoholic fatty liver disease and periodontal disease. <i>Scientific Reports</i> , 2022, 12, .	1.6	8
2307	Comparison of Clinical, Biochemical, and Histopathologic Profiles between NAFLD in Asian-Indians and United States Adults. <i>Euroasian Journal of Hepato-gastroenterology</i> , 2022, 12, S15-S18.	0.1	2
2308	Single-cell transcriptome and cell type-specific molecular pathways of human non-alcoholic steatohepatitis. <i>Scientific Reports</i> , 2022, 12, .	1.6	11
2309	Novel insights into the pathogenic impact of diabetes on the gastrointestinal tract. <i>European Journal of Clinical Investigation</i> , 2022, 52, .	1.7	6
2310	Detangling the interrelations between MAFLD, insulin resistance, and key hormones. <i>Hormones</i> , 2022, 21, 573-589.	0.9	16
2311	Thyroid hormones as a disease modifier and therapeutic target in nonalcoholic steatohepatitis. <i>Expert Review of Endocrinology and Metabolism</i> , 2022, 17, 425-434.	1.2	17
2312	Perinatal exposure to environmental endocrine disruptor bisphenol A aggravates the onset of non-alcoholic fatty liver disease (NAFLD) in weanling F1 offspring of obese rats. <i>Environmental Science and Pollution Research</i> , 2023, 30, 3146-3165.	2.7	6
2313	Undiagnosed Abnormal Alanine Transaminase Levels in Vulnerable Populations: Impact of Sex, Race/ethnicity, and Body Mass. <i>Obesity Science and Practice</i> , 0, , .	1.0	1
2314	Proteomic analysis of the effect of high-fat-diet and voluntary physical activity on mouse liver. <i>PLoS ONE</i> , 2022, 17, e0273049.	1.1	2
2315	The triglyceride glucose-body mass index: a non-invasive index that identifies non-alcoholic fatty liver disease in the general Japanese population. <i>Journal of Translational Medicine</i> , 2022, 20, .	1.8	16
2316	Growing challenge of post-liver transplantation non-alcoholic fatty liver disease. <i>World Journal of Transplantation</i> , 2022, 12, 281-287.	0.6	4
2317	Metformin, pioglitazone, dapagliflozin and their combinations ameliorate manifestations associated with NAFLD in rats via anti-inflammatory, anti-fibrotic, anti-oxidant and anti-apoptotic mechanisms. <i>Life Sciences</i> , 2022, 308, 120956.	2.0	14
2318	Kombucha tea improves glucose tolerance and reduces hepatic steatosis in obese mice. <i>Biomedicine and Pharmacotherapy</i> , 2022, 155, 113660.	2.5	8

#	ARTICLE	IF	CITATIONS
2319	Integrated analysis of effect of daisaikoto, a traditional Japanese medicine, on the metabolome and gut microbiome in a mouse model of nonalcoholic fatty liver disease. <i>Gene</i> , 2022, 846, 146856.	1.0	2
2320	Plasma MicroRNA (miRNA)s as Novel Markers of Nonalcoholic Fatty Liver Disease. <i>Biomarkers in Disease</i> , 2022, , 1-18.	0.0	0
2321	Fluid Mechanics Approach to Perfusion Quantification: Vasculature Computational Fluid Dynamics Simulation, Quantitative Transport Mapping (QTM) Analysis of Dynamics Contrast Enhanced MRI, and Application in Nonalcoholic Fatty Liver Disease Classification. <i>IEEE Transactions on Biomedical Engineering</i> , 2023, 70, 980-990.	2.5	2
2322	Impact of NAFLD on clinical outcomes in hepatocellular carcinoma treated with sorafenib: an international cohort study. <i>Therapeutic Advances in Gastroenterology</i> , 2022, 15, 175628482211001.	1.4	5
2323	Long non-coding RNA in Non-alcoholic fatty liver disease. <i>Advances in Clinical Chemistry</i> , 2022, , 1-35.	1.8	4
2324	Reducing the Risk of and Screening for Liver Cancer. , 2022, , 105-123.		0
2325	Liver Disease Among Mexican Americans Aged 67 Years and Older. <i>Journal of Primary Care and Community Health</i> , 2022, 13, 215013192211162.	1.0	0
2326	Obesity and cancers of the liver, gallbladder, and pancreas. , 2023, , 155-177.		1
2327	Estimating global prevalence, incidence, and outcomes of non-alcoholic fatty liver disease from 2000 to 2021: systematic review and meta-analysis. <i>Chinese Medical Journal</i> , 2022, 135, 1682-1691.	0.9	16
2328	Stress-Induced Premature Senescence Related to Oxidative Stress in the Developmental Programming of Nonalcoholic Fatty Liver Disease in a Rat Model of Intrauterine Growth Restriction. <i>Antioxidants</i> , 2022, 11, 1695.	2.2	3
2329	Hepatic Fibrosis Is a Risk Factor for Greater Severity and Worse Outcome of Acute Ischemic Stroke. <i>Journal of Clinical Medicine</i> , 2022, 11, 5141.	1.0	2
2330	A poor perspective of self weight significantly increases adverse outcomes in non-alcoholic fatty liver disease (NAFLD). <i>Frontiers in Medicine</i> , 0, 9, .	1.2	3
2331	Inflammasome-Mediated Cytokines: A Key Connection between Obesity-Associated NASH and Liver Cancer Progression. <i>Biomedicines</i> , 2022, 10, 2344.	1.4	3
2333	INVESTIGATION OF 2548G>A LEPTINE GENE POLYMORPHIC VARIANT IMPACT ON RISK OF NON-ALCOHOLIC FATTY LIVER DISEASE IN PATIENTS WITH TYPE 2 DIABETES MELLITUS. <i>Problemi Endokrinnoi Patologii</i> , 2022, 79, 42-52.	0.0	0
2334	Hepatocellular carcinoma surveillance in patients with non-alcoholic fatty liver disease. <i>Clinical and Molecular Hepatology</i> , 2023, 29, S207-S219.	4.5	8
2335	Racial/ethnic differences in fibrosis prevalence and progression in biopsy-proven steatosis: A focus on the Asian American population. <i>Hepatology Communications</i> , 2022, 6, 3024-3035.	2.0	1
2337	Immunotherapy for nonalcoholic fatty liver disease-related hepatocellular carcinoma: Lights and shadows. <i>World Journal of Gastrointestinal Oncology</i> , 2022, 14, 1622-1636.	0.8	6
2338	Nonalcoholic Fatty Liver Disease and Adverse Pregnancy Outcomes in Women With Normal Prepregnant Weight. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2023, 108, 463-471.	1.8	5

#	ARTICLE	IF	CITATIONS
2339	Role of non-invasive methods in detecting liver impairment in familial Mediterranean fever adult patients with persistent hepatic cytolysis. <i>Scientific Reports</i> , 2022, 12, .	1.6	1
2340	Validation and Comparison of Two Dietary Indexes for Predicting Nonalcoholic Fatty Liver Disease in US Adults. <i>Journal of Nutrition</i> , 2022, 152, 2865-2876.	1.3	7
2341	Features of the course of non-alcoholic liver steatosis in women of reproductive age and in menopause. <i>Meditinskiy Sovet</i> , 2022, , 62-69.	0.1	3
2342	The Global, Regional, and National Burden and Trends of NAFLD in 204 Countries and Territories: An Analysis From Global Burden of Disease 2019. <i>JMIR Public Health and Surveillance</i> , 2022, 8, e34809.	1.2	12
2343	Plasma MicroRNA (miRNA)s as Novel Markers of Nonalcoholic Fatty Liver Disease. <i>Biomarkers in Disease</i> , 2022, , 517-534.	0.0	0
2344	Regulation of Iron Metabolism in NAFLD/NASH. , 0, , .		0
2345	The crosstalk between insulin resistance and nonalcoholic fatty liver disease/metabolic dysfunction-associated fatty liver disease: a culprit or a consequence?. <i>Cardiovascular Prevention and Pharmacotherapy</i> , 2022, 4, 132-141.	0.0	0
2346	Noninvasive Staging of Hepatic Steatosis Using Calibrated 2D US with Liver Biopsy as the Reference Standard. <i>Radiology</i> , 2023, 306, .	3.6	3
2347	En masse organoid phenotyping informs metabolic-associated genetic susceptibility to NASH. <i>Cell</i> , 2022, 185, 4216-4232.e16.	13.5	28
2348	Nonalcoholic fatty liver disease in adolescents with phenylketonuria. <i>Jornal De Pediatria</i> , 2022, , .	0.9	0
2349	Hepatic Lipid Homeostasis in NAFLD. , 0, , .		0
2350	The New FibroScan-AST (FAST) Score: Enhancing Diabetes Mellitus Impact on Metabolic-Associated Fatty Liver Disease. <i>GE Portuguese Journal of Gastroenterology</i> , 2023, 30, 422-429.	0.3	1
2352	Prevalence and risk factors of nonalcoholic fatty liver disease in a general population, the HUNT study. <i>Scandinavian Journal of Gastroenterology</i> , 2023, 58, 505-511.	0.6	1
2353	MGAT2 inhibitor decreases liver fibrosis and inflammation in murine NASH models and reduces body weight in human adults with obesity. <i>Cell Metabolism</i> , 2022, 34, 1732-1748.e5.	7.2	12
2354	MRI Quantification of Placebo Effect in Nonalcoholic Steatohepatitis Clinical Trials. <i>Radiology</i> , 2023, 306, .	3.6	3
2355	Tapered Graded Index Lens Antenna With Enhanced Penetration for Near-Field Torso Imaging. <i>IEEE Transactions on Antennas and Propagation</i> , 2023, 71, 78-88.	3.1	4
2356	Outcome of Phlebotomy on Improvement of Liver Enzymes and Steatosis in Non-Alcoholic Fatty Liver Disease: A Randomized, Controlled Trial. <i>Journal of Advances in Medical and Biomedical Research</i> , 2022, 30, 493-500.	0.1	1
2357	The NAFLD Decompensation Risk Score: External Validation and Comparison to Existing Models to Predict Hepatic Events in a Retrospective Cohort Study. <i>Journal of Clinical and Experimental Hepatology</i> , 2023, 13, 233-240.	0.4	3

#	ARTICLE	IF	CITATIONS
2358	The Effect of the Restrictive Ketogenic Diet on the Body Composition, Haematological and Biochemical Parameters, Oxidative Stress and Advanced Glycation End-Products in Young Wistar Rats with Diet-Induced Obesity. <i>Nutrients</i> , 2022, 14, 4805.	1.7	4
2359	The lipid accumulation product is a powerful tool to diagnose metabolic dysfunction-associated fatty liver disease in the United States adults. <i>Frontiers in Endocrinology</i> , 0, 13, .	1.5	4
2360	Clinical Impact of Glucagon-Like Peptide-1 Receptor Analogs on the Complications of Obesity. <i>Obesity Facts</i> , 2023, 16, 149-163.	1.6	4
2362	Chronic high-fat diet induces galectin-3 and TLR4 to activate NLRP3 inflammasome in NASH. <i>Journal of Nutritional Biochemistry</i> , 2023, 112, 109217.	1.9	4
2364	Utility of Indices Obtained During Medical Checkups for Predicting Fatty Liver Disease in Non-obese People. <i>Internal Medicine</i> , 2023, , .	0.3	2
2365	Three segments sampling strategy for the assessment of liver steatosis using magnetic resonance imaging proton density fat fraction. <i>European Journal of Radiology</i> , 2023, 159, 110653.	1.2	1
2366	Emerging role of aging in the progression of NAFLD to HCC. <i>Ageing Research Reviews</i> , 2023, 84, 101833.	5.0	21
2367	Silica nanoparticles aggravated the metabolic associated fatty liver disease through disturbed amino acid and lipid metabolisms-mediated oxidative stress. <i>Redox Biology</i> , 2023, 59, 102569.	3.9	20
2368	Non-alcoholic Steatohepatitis Diagnosis and Treatment Medical and Surgery, Based on Guideline Updates: A Mini Review. , 2022, 8, .		0
2369	Age patterns of nonalcoholic fatty liver disease incidence: heterogeneous associations with metabolic changes. <i>Diabetology and Metabolic Syndrome</i> , 2022, 14, .	1.2	9
2370	HÃgado graso: una epidemia silente. , 2022, 44, 386-395.		0
2371	Correlation between long-term use of metformin and incidence of NAFLD among patients with type 2 diabetes mellitus: A real-world cohort study. <i>Frontiers in Endocrinology</i> , 0, 13, .	1.5	9
2372	Hepatocellular cancer of non-viral etiology: more questions than answers?. <i>Medical Alphabet</i> , 2022, , 7-12.	0.0	0
2373	Effectiveness of Grape Seed Extract in Patients with Nonalcoholic Fatty Liver: A Randomized Double-Blind Clinical Study. <i>Hepatitis Monthly</i> , 2022, 22, .	0.1	2
2374	Uncertainty-aware physics-driven deep learning network for free-breathing liver fat and R ² * quantification using self-gated stack-of-radial MRI. <i>Magnetic Resonance in Medicine</i> , 2023, 89, 1567-1585.	1.9	3
2375	Nonalcoholic Fatty Liver Disease in Lean/Nonobese and Obese Individuals: A Comprehensive Review on Prevalence, Pathogenesis, Clinical Outcomes, and Treatment. <i>Journal of Clinical and Translational Hepatology</i> , 2022, 000, 000-000.	0.7	3
2376	A phase I/II study of ARO-HSD, an RNA interference therapeutic, for the treatment of non-alcoholic steatohepatitis. <i>Journal of Hepatology</i> , 2023, 78, 684-692.	1.8	14
2377	Screening Patterns of Nonalcoholic Fatty Liver Disease in Children with Obesity in Canadian Primary Care: A Cross-Sectional Study. <i>Canadian Journal of Gastroenterology and Hepatology</i> , 2022, 2022, 1-9.	0.8	3

#	ARTICLE	IF	CITATIONS
2378	S100A6 Activates Kupffer Cells via the p-P38 and p-JNK Pathways to Induce Inflammation, Mononuclear/macrophage Infiltration Sterile Liver Injury in Mice. <i>Inflammation</i> , 2023, 46, 534-554.	1.7	4
2380	Association of PNPLA3 rs738409 and TM6SF2 rs58542926 Polymorphisms with Non-alcoholic Fatty Liver Disease in the Iranian Population. <i>Hepatitis Monthly</i> , 2022, In Press, .	0.1	0
2381	NAFLD in Indians: A Myopic Yet Alarming Perspective. <i>Journal of Clinical and Experimental Hepatology</i> , 2022, , .	0.4	0
2382	Akkermansia muciniphila suppressing nonalcoholic steatohepatitis associated tumorigenesis through CXCR6+ natural killer T cells. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	8
2383	The importance of liver function assessment before cardiac surgery: A narrative review. <i>Frontiers in Surgery</i> , 0, 9, .	0.6	3
2384	A new serotonin 2A receptor antagonist with potential benefits in Non-Alcoholic Fatty Liver Disease. <i>Life Sciences</i> , 2023, 314, 121315.	2.0	3
2385	Enzymatically-epoxidized docosahexaenoic acid, 19,20-EpDPE, suppresses hepatic crown-like structure formation and nonalcoholic steatohepatitis fibrosis through GPR120. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , 2023, 1868, 159275.	1.2	1
2386	NAFLD and NASH biomarker qualification in the LITMUS consortium “Lessons learned. <i>Journal of Hepatology</i> , 2023, 78, 852-865.	1.8	14
2387	Expression of p-STAT3 and c-Myc correlates with P2-HNF4 β expression in nonalcoholic fatty liver disease (NAFLD). <i>Oncotarget</i> , 2022, 13, 1308-1313.	0.8	1
2388	Valeric Acid Promotes Adipocyte Differentiation, Adiponectin Production, and Glucose Uptake via Its PPAR γ Ligand Activity. <i>ACS Omega</i> , 2022, 7, 48113-48120.	1.6	1
2389	Serum glycolipids mediate the relationship of urinary bisphenols with NAFLD: analysis of a population-based, cross-sectional study. <i>Environmental Health</i> , 2022, 21, .	1.7	4
2390	Prevalence of non-alcoholic fatty liver disease and its association with lifestyle habits in adults in Chile: a cross-sectional study from the National Health Survey 2016-2017. <i>British Journal of Nutrition</i> , 2023, 130, 1036-1046.	1.2	3
2391	Identification of patients with type 2 diabetes with non-alcoholic fatty liver disease who are at increased risk of progressing to advanced fibrosis: a cross-sectional study. <i>BMJ Open</i> , 2023, 13, e063959.	0.8	0
2392	The association between hepatic steatosis and incident cardiovascular disease, cancer, and all-cause mortality in a US multicohort study. <i>Hepatology</i> , 2023, 77, 2063-2072.	3.6	9
2393	Management of obesity across women's life course: FIGO Best Practice Advice. <i>International Journal of Gynecology and Obstetrics</i> , 2023, 160, 35-49.	1.0	7
2394	The Relation of Biomarkers in Serum Non-Alcohol Fatty Liver Disease with Diabetes Mellitus Type 2 and NAFLD Obese among Adults in Basrah Governorate. , 2023, 2, .		0
2395	Exploring the Validity of Available Markers and Indices in the Diagnosis of Nonalcoholic Fatty Liver Disease (NAFLD) in People with Type 2 Diabetes in Saudi Arabia. <i>Diseases (Basel, Switzerland)</i> , 2023, 11, 10.	1.0	1
2396	Prevalence and clinical determinants of non-alcoholic fatty liver disease by liver scores in adults with type 1 diabetes. <i>Journal of Diabetes and Its Complications</i> , 2023, 37, 108405.	1.2	1

#	ARTICLE	IF	CITATIONS
2397	HÃgado graso (parte 1): aspectos generales, epidemiologÃa, fisiopatologÃa e historia natural. Revista Colombiana De Gastroenterologia, 2022, 37, 420-433.	0.1	1
2398	Risk of New-Onset Liver Injuries Due to COVID-19 in Preexisting Hepatic Conditionsâ€”Review of the Literature. Medicina (Lithuania), 2023, 59, 62.	0.8	3
2399	Improving diagnostic accuracy of ultrasound texture features in detecting and quantifying hepatic steatosis using various beamforming sound speeds. Physics in Medicine and Biology, 2023, 68, 04NT02.	1.6	1
2400	Dietary inflammatory index and risk of non-alcoholic fatty liver disease and advanced hepatic fibrosis in US adults. Frontiers in Nutrition, 0, 10, .	1.6	2
2402	Inhibition of Diacylglycerol Acyltransferase 2 Versus Diacylglycerol Acyltransferase 1: Potential Therapeutic Implications of Pharmacology. Clinical Therapeutics, 2023, 45, 55-70.	1.1	9
2403	Impaired Function of Solute Carrier Family 19 Leads to Low Folate Levels and Lipid Droplet Accumulation in Hepatocytes. Biomedicines, 2023, 11, 337.	1.4	0
2404	AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology, 2023, 77, 1797-1835.	3.6	358
2406	A bibliometric analysis and visualization of nonalcoholic fatty liver disease from 2012 to 2021. Clinical and Experimental Medicine, 2023, 23, 1961-1971.	1.9	2
2407	Oxidized Low-Density Lipoproteins Trigger Hepatocellular Oxidative Stress with the Formation of Cholesteryl Ester Hydroperoxide-Enriched Lipid Droplets. International Journal of Molecular Sciences, 2023, 24, 4281.	1.8	3
2408	The triglycerides and glucose index is highly associated with non-alcoholic fatty liver disease in overweight and obese women. Irish Journal of Medical Science, 0, , .	0.8	0
2409	Does opioid agonist treatment reduce overdose mortality risk in people who are older or have physical comorbidities? Cohort study using linked administrative health data in New South Wales, Australia, 2002â€”17. Addiction, 2023, 118, 1527-1539.	1.7	5
2410	Effects of Monacolin K in Nondiabetic Patients with NAFLD: A Pilot Study. Nutrients, 2023, 15, 1887.	1.7	0
2411	The Role Bariatric Surgery and Endobariatric Therapies in Nonalcoholic Steatohepatitis. Clinics in Liver Disease, 2023, 27, 413-427.	1.0	2
2412	Changes in liver enzymes are associated with changes in insulin resistance, inflammatory biomarkers and leptin in prepubertal children with obesity. Italian Journal of Pediatrics, 2023, 49, .	1.0	1
2414	A qualitative patient interview study to understand the experience of patients with nonalcoholic steatohepatitis. Hepatology Communications, 2023, 7, e0036-e0036.	2.0	2
2416	Noninvasive tests predict liverâ€”related events and mortality in patients with nonalcoholic fatty liver disease: subâ€”analysis of the CLIONEâ€”Asia study. Journal of Gastroenterology and Hepatology (Australia), 0, , .	1.4	0
2417	NAFLD, MAFLD, and beyond: one or several acronyms for better comprehension and patient care. Internal and Emergency Medicine, 2023, 18, 993-1006.	1.0	10
2418	Non-Parenchymal Cells and the Extracellular Matrix in Hepatocellular Carcinoma in Non-Alcoholic Fatty Liver Disease. Cancers, 2023, 15, 1308.	1.7	3

#	ARTICLE	IF	CITATIONS
2419	Semaglutide in the treatment of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. <i>Journal of Education, Health and Sport</i> , 2023, 13, 123-131.	0.0	0
2420	Dairy product consumption was associated with a lower likelihood of non-alcoholic fatty liver disease: A systematic review and meta-analysis. <i>Frontiers in Nutrition</i> , 0, 10, .	1.6	5
2422	Serum <sc>MFAP4</sc> , a novel potential biomarker for liver cirrhosis screening, correlates with transient elastography in <sc>NAFLD</sc> patients. <i>JGH Open</i> , 2023, 7, 197-203.	0.7	0
2423	Nonalcoholic Fatty Liver Disease and Cardiovascular Disease: Causation or Association. <i>Cardiology in Review</i> , 0, Publish Ahead of Print, .	0.6	1
2424	Prevalence of non-alcoholic fatty liver disease in patients with nephrotic syndrome: A population-based study. <i>World Journal of Hepatology</i> , 0, 15, 265-273.	0.8	2
2425	Effects of additive interactions among obesity, visceral adiposity, and sarcopenia on nonalcoholic fatty liver disease. <i>Scientific Reports</i> , 2023, 13, .	1.6	3
2426	Frequency of Liver Fibrosis by Non Invasive Marker in Patients with Non-Alcohol Fatty Liver Diseases. , 0, , 99-102.		0
2427	Hepatic COX1 loss leads to impaired autophagic flux and exacerbates nonalcoholic steatohepatitis. <i>Acta Pharmaceutica Sinica B</i> , 2023, , .	5.7	0
2428	Does Type 2 Diabetes Increase the Risk of Hepatocellular Carcinoma in Nonalcoholic Fatty Liver Disease Patients: A Systematic Review. <i>Cureus</i> , 2023, , .	0.2	0
2429	Chronic hepatitis B infection and diabetes mellitus: a double liver trouble?. <i>Minerva Medica</i> , 2023, 114, .	0.3	1
2430	Mouse strain-dependent variation in metabolic associated fatty liver disease (MAFLD): a comprehensive resource tool for pre-clinical studies. <i>Scientific Reports</i> , 2023, 13, .	1.6	2
2431	Development and implementation of a continuing medical education program on non-alcoholic fatty liver disease for primary care practitioners in Europe. <i>Frontiers in Medicine</i> , 0, 10, .	1.2	2
2432	The monocyte-to-high-density lipoprotein ratio is associated with the occurrence of atrial fibrillation among NAFLD patients: A propensity-matched analysis. <i>Frontiers in Endocrinology</i> , 0, 14, .	1.5	1
2434	Cardiovascular Disease Risk and Statin Use Among Adults with Metabolic Dysfunction Associated Fatty Liver Disease. <i>American Journal of Medicine</i> , 2023, 136, 669-676.e1.	0.6	3
2435	Liver steatosis as a predictor of incident diabetes in adults: a prospective evaluation in the Brazilian Longitudinal Study of Adult Health (ELSA-Brasil). <i>Cadernos De Saude Publica</i> , 2023, 39, .	0.4	0
2436	ĐžĐđĐ'Đ•Đ"ĐžĐœĐ•Đ•ĐĐĐžĐđĐĐ- Đ'ĐĐĐĐšĐ•Đ™ Đž Đ-Đ~ĐĐžĐ'ĐžĐœ Đ"Đ•ĐŸĐĐĐĐžĐ-Đ•. <i>Vestnik OĀĭjskogo Oāudarstœennogo</i>		
2437	Polycystic ovary syndrome and nonalcoholic fatty liver disease. , 2024, , 92-99.		0
2438	Effects of <sc><i>MBOAT7</i></sc> polymorphism and steatosis on liver function assessed by methacetin breath test. <i>European Journal of Clinical Investigation</i> , 2023, 53, .	1.7	0

#	ARTICLE	IF	CITATIONS
2439	Artificial Intelligence (AI)-Enhanced Ultrasound Techniques Used in Non-Alcoholic Fatty Liver Disease: Are They Ready for Prime Time?. Applied Sciences (Switzerland), 2023, 13, 5080.	1.3	0
2444	Nonalcoholic Steatohepatitis (NASH). , 2023, , 95-103.		0
2479	Natural History of Nonalcoholic Fatty Liver Disease. , 2023, , 19-43.		0
2491	Nonalcoholic Fatty Liver Disease and Psoriasis. , 2023, , 229-241.		0
2507	Tissue-derived extracellular vesicles in cancer progression: mechanisms, roles, and potential applications. Cancer and Metastasis Reviews, 0, , .	2.7	1
2516	Advantages and Disadvantages of Nutraceuticals. , 2023, , 245-286.		0
2524	ALCOHOLIC AND NON-ALCOHOLIC FATTY LIVER DISEASES. , 2024, , 101-132.e4.		0
2526	Metabolic-Associated Fatty Liver Disease: Opportunistic Screening at CT Colonography. , 2023, , 277-290.		0
2548	Updates in Pediatric Hepatology and Pancreatology. , 2023, , 399-425.		0